

**Funding Opportunities Monthly Edition  
June 2021 Due Dates**

## Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in June 2021. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                          | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---------------------------------------|----------------|---------------|----------------|
| 081353  | <a href="#">International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)</a>   | Fogarty International Center/NIH/DHHS | PAR-19-244     | 04-Jun-2021   | 1,150,000 USD  |
|         | <p>Contact Name   Barbara Sina, Ph.D.</p> <p>Contact Telephone   301-402-9467</p> <p>Contact Email   <a href="mailto:sinab@mail.nih.gov">sinab@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   04-Jun-2021</p> <p>Synopsis   The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. Courses for Skills Development Mentoring Activities Curriculum or Methods Development The goal of this initiative is to support educational activities that foster a better understanding of the ethics of international biomedical, behavioral and clinical research and enhance the application of research ethics principles in low- and middle-income countries (LMICs). This program aims to increase the number of LMIC research intensive institutions that can provide advanced education in international research ethics. Education programs supported by this initiative will equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international clinical and public health research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their institutions, governments and international research organizations. To accomplish this goal, this FOA will support innovative LMIC masters level research ethics education programs proposing integrated activities to develop curriculum, courses for skills development, including practicum experiences, and creative mentoring approaches.</p> |                                       |                |               |                |
| 081350  | <a href="#">International Bioethics Research Training Program (D43 Clinical Trial Optional)</a>   | Fogarty International Center/NIH/DHHS | PAR-19-243     | 04-Jun-2021   | 1,150,000 USD  |
|         | <p>Contact Name   Barbara Sina, Ph.D.</p> <p>Contact Telephone   301-402-9467</p> <p>Contact Email   <a href="mailto:sinab@mail.nih.gov">sinab@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>   |                                       |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Deadline Dates (ALL) 04-Jun-2021</p> <p>Synopsis The overall goal of this initiative is to support the development of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate didactic, mentored research and training components to prepare multiple individuals with ethics expertise for positions of scholarship and leadership in health research institutions in the LMIC. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary study to an existing trial; or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p> |                                    |                |                                     |                |
| 085437  | <p><a href="#">RFA-CA-19-049 -- Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed)</a></p> <p>Contact Name Laurence (Austin) Doyle, MD</p> <p>Contact Telephone 240-276-6112</p> <p>Contact Email <a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p>   | National Cancer Institute/NIH/DHHS | RFA-CA-19-049  | 23-May-2021 [Optional][LOI/Pre-App] | 750,000 USD    |
| 075883  | <p><a href="#">Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)</a></p> <p>Contact Name Huiming Zhang, Ph.D.</p> <p>Contact Telephone 240-276-5979</p> <p>Contact Email <a href="mailto:zhanghui@mail.nih.gov">zhanghui@mail.nih.gov</a></p>   | National Cancer Institute/NIH/DHHS | PAR-18-841     | 14-Jun-2021                         | 2,500,000 USD  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2021</p> <p>Synopsis<br/>National Cancer Institute (NCI) invites applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients' malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource. This FOA will use the NIH U24 Resource-Related Research Projects – Cooperative Agreements award mechanism.</p> |                                    |                |                                     |                |
| 100992  | <p><a href="#">RFA-CA-21-013 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)</a></p>   | National Cancer Institute/NIH/DHHS | RFA-CA- 21-013 | 09-May-2021 [Optional][LOI/Pre-App] | 275,000 USD    |
|         | <p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 301-480-5778</p> <p>Contact Email <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis<br/>The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that</p>  |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.

|        |  |                                    |                |                                     |             |
|--------|--|------------------------------------|----------------|-------------------------------------|-------------|
| 100999 | <a href="#">RFA-CA-21-017 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)</a> | National Cancer Institute/NIH/DHHS | RFA-CA- 21-017 | 09-May-2021 [Optional][LOI/Pre-App] | 200,000 USD |
|--------|--|------------------------------------|----------------|-------------------------------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Juli Klemm, Ph.D.   |
| Contact Telephone    | 301-480-5778  |
| Contact Email        | <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021   |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery. |

|        |  |                                    |                |                                     |               |
|--------|--|------------------------------------|----------------|-------------------------------------|---------------|
| 100995 | <a href="#">RFA-CA-21-016 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | RFA-CA- 21-016 | 09-May-2021 [Optional][LOI/Pre-App] | Not Specified |
|--------|--|------------------------------------|----------------|-------------------------------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Juli Klemm, Ph.D.  |
| Contact Telephone | 301-480-5778   |
| Contact Email     | <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a> |
| Sponsor Website   |  |
| Program URL       | <a href="#">Link to program URL</a>                        |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Deadline Dates (ALL) 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.</p> |                                    |                |                                     |                |
| 100993  | <a href="#">RFA-CA-21-014 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | RFA-CA-21-014  | 09-May-2021 [Optional][LOI/Pre-App] | 900,000 USD    |
|         | <p>Contact Name Juli Klemm, Ph.D.</p> <p>Contact Telephone 301-480-5778</p> <p>Contact Email <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed</p>   |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount  |
|---------|--|--|----------------|-------------------------------------|---|
|         |  |  |                |                                     | technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. |
| 100994  | <a href="#">RFA-CA-21-015 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)</a>             | National Cancer Institute/NIH/DHHS   | RFA-CA- 21-015 | 09-May-2021 [Optional][LOI/Pre-App] | 3,000,000 USD   |
|         | Contact Name   | Juli Klemm, Ph.D.  |                |                                     |   |
|         | Contact Telephone  | 301-480-5778   |                |                                     |   |
|         | Contact Email  | <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>   |                |                                     |   |
|         | Sponsor Website  |  |                |                                     |   |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |                                     |   |
|         | Deadline Dates (ALL)   | 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021  |                |                                     |   |
|         | Synopsis   | <p>The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.</p> |                |                                     |   |
| 101003  | <a href="#">RFA-CA-21-018 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)</a> | National Cancer Institute/NIH/DHHS   | RFA-CA- 21-018 | 09-May-2021 [Optional][LOI/Pre-App] | 200,000 USD   |
|         | Contact Name   | Juli Klemm, Ph.D.  |                |                                     |   |
|         | Contact Telephone  | 301-480-5778   |                |                                     |   |
|         | Contact Email  | <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>   |                |                                     |   |
|         | Sponsor Website  |  |                |                                     |   |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |                                     |   |
|         | Deadline Dates (ALL)   | 09-May-2021 [Optional][LOI/Pre-App], 08-Jun-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021  |                |                                     |   |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |                 |  |  |  |  |
|--|-----------------|--|--|--|--|
|  | <p>Synopsis</p> | <p>The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.</p> |  |  |  |
|--|-----------------|--|--|--|--|

|        |   |                                    |                |                                     |             |
|--------|---|------------------------------------|----------------|-------------------------------------|-------------|
| 101004 | <a href="#">RFA-CA-21-019 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | RFA-CA- 21-019 | 10-May-2021 [Optional][LOI/Pre-App] | 200,000 USD |
|--------|---|------------------------------------|----------------|-------------------------------------|-------------|

|  |                      |   |  |  |  |
|--|----------------------|---|--|--|--|
|  | Contact Name         | Juli Klemm, Ph.D.   |  |  |  |
|  | Contact Telephone    | 301-480-5778  |  |  |  |
|  | Contact Email        | <a href="mailto:juli.klemm@nih.gov">juli.klemm@nih.gov</a>  |  |  |  |
|  | Sponsor Website      |   |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>   |  |  |  |
|  | Deadline Dates (ALL) | 10-May-2021 [Optional][LOI/Pre-App], 09-Jun-2021 , 19-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 |  |  |  |

|  |                 |  |  |  |  |
|--|-----------------|--|--|--|--|
|  | <p>Synopsis</p> | <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U24 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.</p> |  |  |  |
|--|-----------------|--|--|--|--|

|        |  |                                    |                |                                     |             |
|--------|--|------------------------------------|----------------|-------------------------------------|-------------|
| 085444 | <a href="#">RFA-CA-19-052 -- Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)</a> | National Cancer Institute/NIH/DHHS | RFA-CA- 19-052 | 23-May-2021 [Optional][LOI/Pre-App] | 750,000 USD |
|--------|--|------------------------------------|----------------|-------------------------------------|-------------|

|  |              |                             |  |  |  |
|--|--------------|-----------------------------|--|--|--|
|  | Contact Name | Laurence (Austin) Doyle, MD |  |  |  |
|--|--------------|-----------------------------|--|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-6112</p> <p>Contact Email   <a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p> |                                    |                |               |                |
| 075930  | <a href="#">Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | PAR-18-845     | 15-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Ron Johnson, PhD</p> <p>Contact Telephone   240-276-6228</p> <p>Contact Email   <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2021</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs. This FOA will use the NIH Research Project (R01) award mechanism.</p>   |                                    |                |               |                |
| 082219  | <a href="#">Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-277     | 08-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Dr. Mukesh Verma, Ph.D.</p> <p>Contact Telephone   240-276-6889</p> <p>Contact Email   <a href="mailto:vermam@mail.nih.gov">vermam@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | Deadline Dates (ALL)   | 08-Jun-2021 , 08-Oct-2021   |                |               |                |
|         | Synopsis   | This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations. |                |               |                |
| 084813  | <a href="#">Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS  | PAR-19-339     | 09-Jun-2021   | 275,000 USD    |
|         | Contact Name   | Todd S Horowitz, Ph.D   |                |               |                |
|         | Contact Telephone  | 240-276-6963  |                |               |                |
|         | Contact Email  | <a href="mailto:todd.horowitz@mail.nih.gov">todd.horowitz@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022   |                |               |                |
|         | Synopsis   | This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.   |                |               |                |
| 084812  | <a href="#">Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS  | PAR-19-340     | 09-Jun-2021   | Not Specified  |
|         | Contact Name   | Todd S Horowitz, Ph.D   |                |               |                |
|         | Contact Telephone  | 240-276-6963  |                |               |                |
|         | Contact Email  | <a href="mailto:todd.horowitz@mail.nih.gov">todd.horowitz@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022   |                |               |                |
|         | Synopsis   | This FOA encourages the integration of cognitive neuroscience approaches to improve traditional assessment of acute and chronic cognitive changes following cancer treatment for non-central nervous system malignancies.   |                |               |                |
| 084969  | <a href="#">Innovative Approaches to Studying Cancer Communication in the New</a>  | National Cancer   | PAR-19-        | 09-Jun-2021   | 275,000        |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <a href="#">Information Ecosystem (R21 Clinical Trial Optional)</a>  | Institute/NIH/DHHS                 | 350            |               | USD            |
|         | <p>Contact Name   Kelly D. Blake, ScD</p> <p>Contact Telephone   240-281-5934</p> <p>Contact Email   <a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022</p> <p>Synopsis   Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p> |                                    |                |               |                |
| 075931  | <a href="#">Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed)</a>   | National Cancer Institute/NIH/DHHS | PAR-18-846     | 25-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Ron Johnson, PhD</p> <p>Contact Telephone   240-276-6228</p> <p>Contact Email   <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jun-2021</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>  |                                    |                |               |                |
| 075939  | <a href="#">Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 - Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-18-848     | 25-Jun-2021   | 275,000 USD    |
|         | Contact Name   Rachel Grana Mayne, PhD, MPH  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-5899</p> <p>Contact Email   <a href="mailto:rachel.mayne@nih.gov">rachel.mayne@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jun-2021</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>                                  |                                    |                |               |                |
| 075934  | <a href="#">Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01 - Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-18-847     | 15-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Rachel Grana Mayne, PhD, MPH</p> <p>Contact Telephone   240-276-5899</p> <p>Contact Email   <a href="mailto:rachel.mayne@nih.gov">rachel.mayne@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2021</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. This FOA will use the NIH R01 Research Project Grant award mechanism.</p> |                                    |                |               |                |
| 079335  | <a href="#">Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-149     | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name   Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone   240-276-5714</p> <p>Contact Email   <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | Deadline Dates (ALL)   | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |                |               |                |
|         | Synopsis   | The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.  |                |               |                |
| 082214  | <a href="#">Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS   | PAR-19-274     | 07-May-2021   | Not Specified  |
|         | Contact Name   | Gila Neta, Ph.D.   |                |               |                |
|         | Contact Telephone  | 240-276-6785   |                |               |                |
|         | Contact Email  | <a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022  |                |               |                |
|         | Synopsis   | The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above. |                |               |                |
| 102330  | <a href="#">RFA-CA-21-030 -- Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS   | RFA-CA-21-030  | 05-Jun-2021   | 2,375,000 USD  |
|         | Contact Name   | Paul C. Pearlman, Ph.D.  |                |               |                |
|         | Contact Telephone  | 240-276-5354   |                |               |                |
|         | Contact Email  | <a href="mailto:paul.pearlman@nih.gov">paul.pearlman@nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |                 |  |  |  |  |
|--|-----------------|--|--|--|--|
|  | <p>Synopsis</p> | <p>May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.</p> |  |  |  |
|--|-----------------|--|--|--|--|

|        |  |                                    |                |                                     |             |
|--------|--|------------------------------------|----------------|-------------------------------------|-------------|
| 085445 | <a href="#">RFA-CA-19-053 -- Revision Applications for Mechanisms of Cancer Drug Resistance (P50 Clinical Trial Not Allowed)</a> | National Cancer Institute/NIH/DHHS | RFA-CA- 19-053 | 23-May-2021 [Optional][LOI/Pre-App] | 750,000 USD |
|--------|--|------------------------------------|----------------|-------------------------------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Laurence (Austin) Doyle, MD                                    |
| Contact Telephone    | 240-276-6112   |
| Contact Email        | <a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a> |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>                            |
| Deadline Dates (ALL) | 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021               |

|  |                 |   |  |  |  |
|--|-----------------|---|--|--|--|
|  | <p>Synopsis</p> | <p>This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded P50 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p> |  |  |  |
|--|-----------------|---|--|--|--|

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 087000 | <a href="#">Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)</a> | National Cancer Institute/NIH/DHHS | PAR-20-053 | 05-Jun-2021 | Not Specified |
|--------|---|------------------------------------|------------|-------------|---------------|

|              |                                  |
|--------------|----------------------------------|
| Contact Name | Sudhir Srivastava, Ph.D., M.P.H. |
|--------------|----------------------------------|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-7028</p> <p>Contact Email   <a href="mailto:srivasts@mail.nih.gov">srivasts@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.</p>  |                                    |                |               |                |
| 079076  | <a href="#">Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PA-19-111      | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Nonniekaye Shelburne, MS, CRNP, AOCN</p> <p>Contact Telephone   240-276-6897</p> <p>Contact Email   <a href="mailto:nshelburne@mail.nih.gov">nshelburne@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).</p> |                                    |                |               |                |
| 086487  | <a href="#">Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-20-034     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Rebecca A Ferrer, Ph.D.</p>   |                                    |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-6963</p> <p>Contact Email   <a href="mailto:ferrerra@mail.nih.gov">ferrerra@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.</p> |                                    |                |               |                |
| 086964  | <a href="#">NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-20-052     | 07-May-2021   | 100,000 USD    |
|         | <p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email  </p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 24-Jun-2021 , 07-Sep-2021 , 20-Oct-2021 , 07-Jan-2022 , 24-Feb-2022 , 07-May-2022 , 24-Jun-2022 , 07-Sep-2022 , 20-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>  |                                    |                |               |                |
| 086149  | <a href="#">Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-19-387     | 05-Jun-2021   | Not Specified  |
|         | Contact Name   Todd S. Horowitz, Ph.D.   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-6963</p> <p>Contact Email   <a href="mailto:todd.horowitz@nih.gov">todd.horowitz@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.</p>  |                                    |                |               |                |
| 097239  | <p><a href="#">Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)</a></p>  | National Cancer Institute/NIH/DHHS | PAR-20-276     | 05-Jun-2021   | 1,750,000 USD  |
|         | <p>Contact Name   Melissa Rotunno, Ph.D.</p> <p>Contact Telephone   240-276-7245</p> <p>Contact Email   <a href="mailto:rotunnom@mail.nih.gov">rotunnom@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis   Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.</p> |                                    |                |               |                |
| 079067  | <p><a href="#">Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)</a></p>   | National Cancer Institute/NIH/DHHS | PA-19-112      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Nonniekaye Shelburne, MS, CRNP, AOCN</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-6897</p> <p>Contact Email   <a href="mailto:nshelburne@mail.nih.gov">nshelburne@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).</p>                        |                                    |                |               |                |
| 076579  | <a href="#">Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | PA-18-876      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Dr. Roberto Flores</p> <p>Contact Telephone   240-276-7119</p> <p>Contact Email   <a href="mailto:floresr2@mail.nih.gov">floresr2@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.</p> |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
| 085330  | <a href="#">Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-19-360     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Sarah Kobrin, Ph.D., MPH</p> <p>Contact Telephone   240-276-6931</p> <p>Contact Email   <a href="mailto:kobrins@mail.nih.gov">kobrins@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p> |                                    |                |               |                |
| 085257  | <a href="#">Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-19-352     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone   240-276-7621</p> <p>Contact Email   <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.</p>   |                                    |                |               |                |
| 085422  | <a href="#">Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-363     | 07-May-2021   | 499,999 USD    |
|         | <p>Contact Name   Anne Menkens, Ph.D.</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-6510</p> <p>Contact Email   <a href="mailto:menkensa@mail.nih.gov">menkensa@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>   |                                    |                |               |                |
| 087228  | <a href="#">Co-infection and Cancer (R01 Clinical Trial Not Allowed)</a>   | National Cancer Institute/NIH/DHHS | PAR-20-062     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone   240-276-6967</p> <p>Contact Email   <a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment</p> |                                    |                |               |                |
| 100707  | <a href="#">National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)</a>  | National Cancer Institute/NIH/DHHS | PAR-21-033     | 07-May-2021   | 2,499,995 USD  |
|         | <p>Contact Name   Lori A. Henderson, Ph.D.</p> <p>Contact Telephone   240-276-5930</p> <p>Contact Email   <a href="mailto:hendersonlori@mail.nih.gov">hendersonlori@mail.nih.gov</a></p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.</p> |                                    |                |               |                |
| 101162  | <a href="#">Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways</a>  | National Cancer Institute/NIH/DHHS | NOT-CA-21-019  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023</p> <p>Synopsis The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences’ interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways. Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.</p>  |                                    |                |               |                |
| 079767  | <a href="#">Biology of Bladder Cancer (R01 Clinical Trial Optional)</a>   | National Cancer                    | PAR-19-        | 05-Jun-2021   | Not            |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         |   | Institute/NIH/DHHS                 | 183            |               | Specified      |
|         | <p>Contact Name Ron Johnson, Ph. D.</p> <p>Contact Telephone 240-276-6250</p> <p>Contact Email <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.</p> |                                    |                |               |                |
| 099622  | <a href="#">Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-20-302     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Bob Vollinger, DrPH, MSPH</p> <p>Contact Telephone 240-276-6919</p> <p>Contact Email <a href="mailto:Bob.Vollinger@nih.gov">Bob.Vollinger@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

ensure that the research projects align with NIH mission priorities in health economics research.

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 077667 | <a href="#">Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PA-18-932 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Erica S. Breslau, PhD, MPH  |
| Contact Telephone    | 240-276-6773  |
| Contact Email        | <a href="mailto:breslaue@mail.nih.gov">breslaue@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022   |
| Synopsis             | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. This FOA will use the NIH Research Project (R01) award mechanism. |

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 076909 | <a href="#">Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PA-18-902 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Gabriela Riscuta, MD, CNS   |
| Contact Telephone    | 240-276-7118  |
| Contact Email        | <a href="mailto:gabriela.riscuta@nih.gov">gabriela.riscuta@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021   |
| Synopsis             | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. The purpose |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

of this funding opportunity announcement (FOA) is twofold: 1) to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2) to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA will use the NIH Research Project (R01) award mechanism.

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 076805 | <a href="#">Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-18-893 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|------------|-------------|---------------|

Contact Name | Frank M. Perna, Ed.D., Ph.D.  
 Contact Telephone | 240-276-6782  
 Contact Email | [pernafm@mail.nih.gov](mailto:pernafm@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021

Synopsis | National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R01 Research Project Grant award mechanism.

|        |   |                                    |            |             |             |
|--------|---|------------------------------------|------------|-------------|-------------|
| 079769 | <a href="#">Biology of Bladder Cancer (R21 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-19-184 | 05-Jun-2021 | 275,000 USD |
|--------|---|------------------------------------|------------|-------------|-------------|

Contact Name | Ron Johnson, Ph. D.  
 Contact Telephone | 240-276-6250

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.</p>  |                                    |                |               |                |
| 100708  | <a href="#">Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)</a>   | National Cancer Institute/NIH/DHHS | PAR-21-035     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-7048</p> <p>Contact Email <a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of</p> |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         |  | cancer diagnosis and/or oncologic therapy in patients.   |                |               |                |
| 092626  | <a href="#">RFA-CA-20-031 -- Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)</a> | National Cancer Institute/NIH/DHHS   | RFA-CA-20-031  | 07-May-2021   | 1,250,000 USD  |
|         | Contact Name   | Sudha Sivaram, DrPH, MPH   |                |               |                |
|         | Contact Telephone  | 240-276-5804   |                |               |                |
|         | Contact Email  | <a href="mailto:nciglobaltraining@nih.gov">nciglobaltraining@nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022  |                |               |                |
|         | Synopsis   | <p>The purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the United States (U.S.)-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p> |                |               |                |
| 079077  | <a href="#">Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)</a>                | National Cancer Institute/NIH/DHHS   | PAR-19-113     | 05-Jun-2021   | 2,000,000 USD  |
|         | Contact Name   | Nastaran Z. Kuhn, Ph.D.  |                |               |                |
|         | Contact Telephone  | 240-276-7610   |                |               |                |
|         | Contact Email  | <a href="mailto:nas.zahir@nih.gov">nas.zahir@nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 05-Jun-2021 , 05-Oct-2021  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |          |  |  |  |  |
|--|----------|--|--|--|--|
|  | Synopsis | <p>This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.</p> |  |  |  |
|--|----------|--|--|--|--|

|        |   |                                    |            |             |             |
|--------|---|------------------------------------|------------|-------------|-------------|
| 083680 | <a href="#">Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-19-309 | 07-May-2021 | 275,000 USD |
|--------|---|------------------------------------|------------|-------------|-------------|

|  |                      |   |  |  |  |
|--|----------------------|---|--|--|--|
|  | Contact Name         | Tanya Agurs-Collins, Ph.D   |  |  |  |
|  | Contact Telephone    | 240-276-6956  |  |  |  |
|  | Contact Email        | <a href="mailto:collinsta@mail.nih.gov">collinsta@mail.nih.gov</a>  |  |  |  |
|  | Sponsor Website      |   |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>   |  |  |  |
|  | Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022   |  |  |  |
|  | Synopsis             | <p>The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.</p> |  |  |  |

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 085337 | <a href="#">Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-19-358 | 16-Jun-2021 | 275,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

|  |                   |                          |  |  |  |
|--|-------------------|--------------------------|--|--|--|
|  | Contact Name      | Sarah Kobrin, Ph.D., MPH |  |  |  |
|  | Contact Telephone | 240-276-6931             |  |  |  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Contact Email <a href="mailto:kobrins@mail.nih.gov">kobrins@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p>                                     |                                    |                |                                     |                |
| 085275  | <a href="#">Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-355     | 16-Jun-2021                         | 275,000 USD    |
|         | <p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes</p> |                                    |                |                                     |                |
| 090518  | <a href="#">RFA-CA-20-028 -- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | RFA-CA-20-028  | 30-Jun-2021 [Optional][LOI/Pre-App] | 275,000 USD    |
|         | <p>Contact Name Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.,</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website</p>  |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.</p>   |                                    |                |                                     |                |
| 090505  | <a href="#">RFA-CA-20-027 -- Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | RFA-CA-20-027  | 30-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.,</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.</p> |                                    |                |                                     |                |
| 085441  | <a href="#">RFA-CA-19-051 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U54 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | RFA-CA-19-051  | 23-May-2021 [Optional][LOI/Pre-App] | 750,000 USD    |
|         | <p>Contact Name Laurence (Austin) Doyle, MD</p> <p>Contact Telephone 240-276-6112</p>   |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U54 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p>   |                                    |                |               |                |
| 082216  | <a href="#">Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | PAR-19-276     | 07-May-2021   | 50,000 USD     |
|         | <p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email <a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.</p> |                                    |                |               |                |
| 102278  | <a href="#">Notice of Special Interest (NOSI): Translation of Quantitative ImagingTools and Methods for the Academic Industrial Partnership</a>   | National Cancer Institute/NIH/DHHS | NOT-CA-21-032  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Robert J. Nordstrom, Ph.D.</p> <p>Contact Telephone 240-276-5934</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Contact Email <a href="mailto:nordstrr@mail.nih.gov">nordstrr@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This NOSI highlights the NCI Cancer Imaging Program's interest in receiving investigator-initiated grant applications focused on the translation of mature well-developed and optimized quantitative imaging (QI) tools and methods for prediction and/or measurement of response to cancer therapies, or for planning and translating radiation therapy treatment strategies in clinical trials and workflow.</p>  |                                    |                |                                     |                |
| 085440  | <a href="#">RFA-CA-19-050 -- Revision Applications for Mechanisms of Cancer Drug Resistance (U01 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | RFA-CA-19-050  | 23-May-2021 [Optional][LOI/Pre-App] | 750,000 USD    |
|         | <p>Contact Name Laurence (Austin) Doyle, MD</p> <p>Contact Telephone 240-276-6112</p> <p>Contact Email <a href="mailto:Doylela@mail.nih.gov">Doylela@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U01 Research Project grants on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.</p> |                                    |                |                                     |                |
| 079333  | <a href="#">Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-150     | 07-May-2021                         | 275,000 USD    |
|         | <p>Contact Name Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>   |                                    |                |                                     |                |



## NIH Funding Opportunities

| SPIN ID   | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---|---|------------------------------------|----------------|---------------|----------------|
| Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022<br><br>Synopsis   The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.  |   |                                    |                |               |                |
| 097241  | <a href="#">Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)</a> | National Cancer Institute/NIH/DHHS | PAR-20-277     | 16-Jun-2021   | 400,000 USD    |
| Contact Name   Melissa Rotunno, Ph.D.<br>Contact Telephone   240-276-7245<br>Contact Email   <a href="mailto:rotunnom@mail.nih.gov">rotunnom@mail.nih.gov</a><br>Sponsor Website  <br>Program URL   <a href="#">Link to program URL</a><br>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022<br><br>Synopsis   Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. |   |                                    |                |               |                |
| 099631  | <a href="#">Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-20-303     | 16-Jun-2021   | 275,000 USD    |
| Contact Name   Bob Vollinger, DrPH, MSPH<br>Contact Telephone   240-276-6919<br>Contact Email   <a href="mailto:Bob.Vollinger@nih.gov">Bob.Vollinger@nih.gov</a><br>Sponsor Website  <br>Program URL   <a href="#">Link to program URL</a>  |   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.</p>   |                                    |                |               |                |
| 101459  | <a href="#">Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities</a>  | National Cancer Institute/NIH/DHHS | NOT-CA-21-020  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Kathy Cronin, Ph.D.</p> <p>Contact Telephone   240-276-6836</p> <p>Contact Email   <a href="mailto:cronink@mail.nih.gov">cronink@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis   The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that efficiently use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely collected by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic status, income, insurance status, age, education level, or geographic area. The Surveillance, Epidemiology, and End Results (SEER) Program and the National Program of Cancer Registries (NPCR) are uniquely positioned to support research to assess health disparities in the United States (US) population because they contain information on all cases diagnosed within geographically defined areas. The goal of these hypothesis-driven studies should be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.</p> |                                    |                |               |                |
| 087229  | <a href="#">Co-infection and Cancer (R21 Clinical Trial Not Allowed)</a>   | National Cancer Institute/NIH/DHHS | PAR-20-061     | 16-Jun-2021   | 275,000 USD    |
|         | Contact Name   Tram Kim Lam, Ph.D., MPH  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-276-6967</p> <p>Contact Email   <a href="mailto:lamt@mail.nih.gov">lamt@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p> |                                    |                |               |                |
| 085343  | <a href="#">Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-359     | 16-Jun-2021   | 100,000 USD    |
|         | <p>Contact Name   Sarah Kobrin, Ph.D., MPH</p> <p>Contact Telephone   240-276-6931</p> <p>Contact Email   <a href="mailto:kobrins@mail.nih.gov">kobrins@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p>   |                                    |                |               |                |
| 086150  | <a href="#">Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional)</a>  | National Cancer Institute/NIH/DHHS | PAR-19-389     | 16-Jun-2021   | 400,000 USD    |
|         | <p>Contact Name   Todd S. Horowitz, Ph.D.</p> <p>Contact Telephone   240-276-6963</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:todd.horowitz@nih.gov">todd.horowitz@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.</p>  |                                    |                |               |                |
| 102778  | <a href="#">The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)</a>  | National Cancer Institute/NIH/DHHS | PAR-21-111     | 12-Jun-2021   | 450,000 USD    |
|         | <p>Contact Name Sonia B. Jakowlew, Ph.D.</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial must apply to the "Independent Clinical Trial Not Allowed companion FOA (PAR-21-128).</p> |                                    |                |               |                |
| 102781  | <a href="#">The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)</a>  | National Cancer Institute/NIH/DHHS | PAR-21-128     | 12-Jun-2021   | 450,000 USD    |
|         | <p>Contact Name Sonia B. Jakowlew, Ph.D.</p> <p>Contact Telephone 240-276-5630</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants proposing a clinical trial, a clinical trial feasibility study, or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOAs (PAR-21-111 or PAR-21-318).</p>   |                                    |                |               |                |
| 102792  | <a href="#">The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)</a>   | National Cancer Institute/NIH/DHHS | PAR-21-318     | 12-Jun-2021   | 450,000 USD    |
|         | <p>Contact Name Sonia B. Jakowlew, Ph.D.</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email <a href="mailto:jakowles@mail.nih.gov">jakowles@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables)</p> |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
| 103024  | <a href="#">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-21-206     | 05-Jun-2021   | 2,495,000 USD  |

and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants planning studies with specific application toward processes or products in mind should submit under the "Independent Clinical Trial Required" companion FOA (PAR-21-111). Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial or independent basic experimental study with humans, must apply to the "Independent Clinical Trial Not Allowed" companion FOA (PAR-21-128).

|                      |  |
|----------------------|--|
| Contact Name         | Miguel Ossandon MS   |
| Contact Telephone    | 240-276-5714   |
| Contact Email        | <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023  |
| Synopsis             | <p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support straight clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA. This FOA does not propose to support</p> |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

commercial production or basic research projects.

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 098641 | <a href="#">NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-20-292 | 21-Jun-2021 | 275,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

|   |   |
|---|---|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>William C. Timmer, Ph.D</p> <p>240-276-6130</p> <p><a href="mailto:william.timmer@nih.gov">william.timmer@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021 , 17-Dec-2021 , 22-Feb-2022 , 21-Jun-2022 , 21-Jun-2022 , 20-Jul-2022</p> <p>This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).</p> |
|---|---|

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 102905 | <a href="#">Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)</a> | National Cancer Institute/NIH/DHHS | PAR-21-061 | 15-Jun-2021 | 275,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

Contact Name | Mauricio Rangel-Gomez, Ph.D.

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   240-620-0534</p> <p>Contact Email   <a href="mailto:Mauricio.Rangel-Gomez@nih.gov">Mauricio.Rangel-Gomez@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2021 , 17-Nov-2021 , 14-Jun-2022 , 17-Nov-2022 , 14-Jun-2023 , 17-Nov-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This FOA will fund investigators to develop a larger research project grant application.</p> |                                    |                |               |                |
| 080277  | <a href="#">Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | PAR-19-199     | 10-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Young S. Kim, PhD</p> <p>Contact Telephone   240-276-7115</p> <p>Contact Email   <a href="mailto:yk47s@nih.gov">yk47s@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   10-Jun-2021 , 08-Nov-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.</p>   |                                    |                |               |                |
| 092676  | <a href="#">New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-20-170     | 06-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Angela B. Mariotto, PhD</p> <p>Contact Telephone   240-276-6698</p> <p>Contact Email   <a href="mailto:mariotta@mail.nih.gov">mariotta@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>  |                                    |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                          | Funding Amount |
|---------|---|------------------------------------|----------------|--|----------------|
|         | <p>Deadline Dates (ALL)   06-Jun-2021 , 18-Nov-2021 , 06-Jun-2022 , 18-Nov-2022 , 06-Jun-2023</p> <p>Synopsis   The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration of cancer registry data to expand the data items collected. Applications proposed must be based on partnership with at a minimum of two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research. The scientific scope of this FOA includes but is not limited to Development, validation, evaluation of scalable tools/methods to facilitate automatic/unsupervised extraction and consolidation of specific data from various types of unstructured medical records as for example, pathology reports, diagnostic imaging, laboratory, hospital discharge forms and clinical visits; Supplementation of cancer registries with new or more detailed data items, from existing data sources or from linkages with novel data sources, e.g. electronic medical records (EMR) Funds will be made available through the U01 cooperative agreement award mechanism.</p> |                                    |                |  |                |
| 080274  | <a href="#">Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-198     | 10-Jun-2021                            | Not Specified  |
|         | <p>Contact Name   Young S. Kim, PhD</p> <p>Contact Telephone   240-276-7115</p> <p>Contact Email   <a href="mailto:yk47s@nih.gov">yk47s@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   10-Jun-2021 , 08-Nov-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.</p>  |                                    |                |  |                |
| 103296  | <a href="#">RFA-RM-21-020 -- Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | RFA-RM-21-020  | 15-Jun-2021<br>[Optional][LOI/Pre-App] | 600,000 USD    |
|         | Contact Name   Jerry Li, M.D.,Ph.D.   |                                    |                |  |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Contact Telephone    | 240-276-6210  |
| Contact Email        | <a href="mailto:DruggableGenome@mail.nih.gov">DruggableGenome@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 15-Jun-2021 [Optional][LOI/Pre-App], 15-Jul-2021  |
| Synopsis             | <p>The overarching goal of this funding opportunity announcement (FOA) for the Common Fund program "Illuminating the Druggable Genome" (IDG;<a href="https://commonfund.nih.gov/idg/">https://commonfund.nih.gov/idg/</a>) is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the IDG consortium's Knowledge Management Center (KMC) as well as the broader IDG Consortium. Awards will support the IDG Consortium by: (1) developing and deploying tools to enhance the community's ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to be incorporated into Pharos(<a href="https://pharos.nih.gov/idg/index">https://pharos.nih.gov/idg/index</a>) that will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developing methods to prioritize IDG-eligible understudied proteins for deeper study using experimental assays both developed within the IDG pipeline or by the larger community. The IDG consortium's purpose is to facilitate the unveiling of the functions of selected understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), and a Resource Dissemination and Outreach Center (RDOC). This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<a href="http://commonfund.nih.gov/">http://commonfund.nih.gov/</a>) through the NIH Office of the NIH Director, Office of Strategic Coordination (<a href="https://dpcpsi.nih.gov/">https://dpcpsi.nih.gov/</a>). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Cancer Institute (NCI/NIH), (<a href="https://www.cancer.gov">https://www.cancer.gov</a>) on behalf of the NIH.</p> |

|        |  |                                    |               |             |               |
|--------|--|------------------------------------|---------------|-------------|---------------|
| 103489 | <a href="#">Notice of Special Interest (NOSI): Telehealth in Cancer Care</a> | National Cancer Institute/NIH/DHHS | NOT-CA-21-043 | 05-Jun-2021 | Not Specified |
|--------|--|------------------------------------|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Gurvaneet Randhawa, M.D., M.P.H.  |
| Contact Telephone    | 240-276-6940  |
| Contact Email        | <a href="mailto:Gurvaneet.Randhawa@nih.gov">Gurvaneet.Randhawa@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May- |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date                          | Funding Amount |
|---------|--|--|----------------|--|----------------|
|         | <p>Synopsis</p>  | <p>2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024</p> <p>The purpose of this Notice of Special Interest (NOSI) is to highlight the interest of the NCI's Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged. This NOSI for R01 and R21 applications is a companion announcement to the RFA titled "Centers on Telehealth Research and Cancer-Related Care" (RFA-CA-21-029).</p>  |                |  |                |
| 084968  | <p><a href="#">Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)</a></p>                       | National Cancer Institute/NIH/DHHS   | PAR-19-348     | 09-Jun-2021                            | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>            | <p>Kelly D. Blake, ScD</p> <p>240-281-5934</p> <p><a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>09-Jun-2021 , 13-Oct-2021 , 08-Jun-2022</p> <p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.</p> |                |  |                |
| 103287  | <p><a href="#">RFA-CA-21-023 -- Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)</a></p> | National Cancer Institute/NIH/DHHS   | RFA-CA-21-023  | 31-May-2021<br>[Optional][LOI/Pre-App] | 3,750,000 USD  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>  | <p>Henry Rodriguez, MS, PhD, MBA</p> <p>240-781-3370</p> <p><a href="mailto:rodriguez@mail.nih.gov">rodriguez@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p>  |                |  |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Deadline Dates (ALL)   31-May-2021 [Optional][LOI/Pre-App], 30-Jun-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science. This FOA solicits applications for multidisciplinary Proteome Characterization Centers (PCCs). PCC awardees will be expected to work as an interactive group and use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically-characterized samples. These samples (human biospecimens and preclinical models) will be provided by the NCI. PCCs will interact with additional CPTAC Centers that include: Proteogenomic Data Analysis Centers (PGDACs, to be supported by RFA-CA-21-024; U24) that will conduct integrative analyses of data across the entire proteomes and genomes of human tumors to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-21-025; U01) that will apply state-of-the-art proteomic and proteogenomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a patient's tumor.</p> |                                    |                |                                     |                |
| 103284  | <p><a href="#">RFA-CA-21-025 -- Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed)</a></p>   | National Cancer Institute/NIH/DHHS | RFA-CA-21-025  | 30-Jun-2021 [Optional][LOI/Pre-App] | 3,750,000 USD  |
|         | <p>Contact Name   Henry Rodriguez, MS, PhD, MBA</p> <p>Contact Telephone   240-781-3370</p> <p>Contact Email   <a href="mailto:rodriguez@mail.nih.gov">rodriguez@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and</p>   |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science. This FOA solicits applications for multidisciplinary Proteogenomic Translational Research Centers (PTRCs). PTRCs are intended to function as an interactive group focused on applying standardized state-of-the-art proteomic and genomic approaches to understand tumor biology in clinically relevant research projects related to treatment response. Projects should focus on the proteogenomic aspects of understanding drug response and resistance by generating and testing hypothesis using preclinical cancer models and/or human cancer samples, followed by validation using human biospecimens from clinical trials. Proposed projects are expected to be conducted in collaboration with clinical researchers, including molecular oncologists. It is envisioned that these projects will facilitate a rational approach to target cancer-related pathways and improve outcomes for patients with cancer. PTRCs will interact with additional CPTAC Centers that include: Proteogenomic Data Analysis Centers (PGDACs, to be supported by RFA-CA-21-024; U24) that will conduct integrative analyses of data across the entire proteomes and genomes of human tumors to elucidate how distinct changes at the proteome level are related to abnormalities in cancer genomes and/or changes at the functional level; and Proteome Characterization Centers (PCCs, to be supported by RFA-CA-21-023; U24) that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically characterized samples. These samples (human biospecimens and preclinical models) will be provided by the NCI.

|        |   |                                    |                |                                     |               |
|--------|---|------------------------------------|----------------|-------------------------------------|---------------|
| 103288 | <a href="#">RFA-CA-21-024 -- Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)</a> | National Cancer Institute/NIH/DHHS | RFA-CA- 21-024 | 31-May-2021 [Optional][LOI/Pre-App] | 2,750,000 USD |
|--------|---|------------------------------------|----------------|-------------------------------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Henry Rodriguez, MS, PhD, MBA   |
| Contact Telephone    | 240-781-3370  |
| Contact Email        | <a href="mailto:rodriguez@h@mail.nih.gov">rodriguez@h@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 31-May-2021 [Optional][LOI/Pre-App], 30-Jun-2021  |
| Synopsis             | This Funding Opportunity Announcement (FOA) supports the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>accelerate research in these areas by disseminating resources for the scientific community. The program will continue to 1) support an increased understanding of cancer through comprehensive proteogenomic approaches, 2) expand support for the development of novel cancer diagnostics and therapeutics by implementing proteogenomic strategies to understand drug response and development of resistance in the context of a clinical trial, and 3) accelerate its translation through public resources (such as data, assays, images and reagents) that catalyze hypothesis-driven science. This FOA solicits applications for multidisciplinary Proteogenomic Data Analysis Centers (PGDACs), which will provide data analysis and biological and clinical interpretation of CPTAC data. PGDAC awardees will be expected to develop computational tools for data analysis, data integration and visualization and apply these tools to CPTAC data. PGDACs will interact with additional CPTAC Centers that include: Proteome Characterization Centers (PCC, to be supported by RFA-CA-21-023; U24), that will use various standardized proteomic analysis technologies for the systematic and comprehensive proteome-wide characterization of defined sets of genomically characterized samples. These samples (human biospecimens and preclinical models) will be provided by the NCI; and Proteogenomic Translational Research Centers (PTRCs, to be supported under RFA-CA-21-025; U01) that will apply state-of-the-art proteomic and proteogenomic approaches to elucidate responses to cancer therapeutic agents, e.g., in order to predict which therapeutic agents are likely to be effective against a patient's tumor.</p> |  |                |               |                |
| 090364  | <a href="#">Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS   | PAR-20-131     | 05-Jun-2021   | 1,350,000 USD  |
|         | Contact Name  | Joanna Watson, Ph.D.   |                |               |                |
|         | Contact Telephone   | 240-276-6230   |                |               |                |
|         | Contact Email   | <a href="mailto:Joanna.Watson@nih.gov">Joanna.Watson@nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023  |                |               |                |
|         | Synopsis  | <p>The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored</p> |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 076806 | <a href="#">Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-18-892 | 07-May-2021 | 275,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Frank M. Perna, Ed.D., Ph.D.   |
| Contact Telephone    | 240-276-6782   |
| Contact Email        | <a href="mailto:pernafm@mail.nih.gov">pernafm@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021  |
| Synopsis             | National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism. |

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 081348 | <a href="#">Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)</a> | National Cancer Institute/NIH/DHHS | PAR-19-242 | 17-Jun-2021 | Not Specified |
|--------|---|------------------------------------|------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Mark Damico, Ph.D., Program Director                             |
| Contact Telephone | 240-276-5630   |
| Contact Email     | <a href="mailto:damicomw@mail.nih.gov">damicomw@mail.nih.gov</a> |
| Sponsor Website   |  |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Jun-2021</p> <p>Synopsis The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p>  |                                    |                |               |                |
| 082215  | <a href="#">Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)</a>   | National Cancer Institute/NIH/DHHS | PAR-19-275     | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email <a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.</p> |                                    |                |               |                |
| 103478  | <a href="#">3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)</a>  | National Cancer Institute/NIH/DHHS | RFA-CA-21-037  | 30-Jun-2021   | 500,000 USD    |
|         | <p>Contact Name Philipp Oberdoerffer, Ph.D.</p> <p>Contact Telephone 240-760-6681</p> <p>Contact Email <a href="mailto:Philipp.Oberdoerffer@nih.gov">Philipp.Oberdoerffer@nih.gov</a></p> <p>Sponsor Website</p>  |                                    |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 , 22-Nov-2021</p> <p>Synopsis<br/>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: Generation of Human Tumor Atlases. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, <a href="http://humantumoratlas.org">humantumoratlas.org</a>) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data Coordinating Center.</p>   |   |                |               |                |
| 091405  | <p><a href="#">Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)</a></p>   | National Center for Complementary and Integrative Health/NIH/DHHS | PAR-20-154     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Lanay Mudd, Ph.D</p> <p>Contact Telephone 301-594-9346</p> <p>Contact Email <a href="mailto:lanay.mudd@mail.nih.gov">lanay.mudd@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis<br/>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications must have sufficient preliminary data that includes: demonstration of feasibility of remote recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety of the intervention; and</p> |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

|        |  |   |           |             |               |
|--------|--|---|-----------|-------------|---------------|
| 080314 | <a href="#">Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)</a> | National Center for Complementary and Integrative Health/NIH/DHHS | PA-19-200 | 05-Jun-2021 | Not Specified |
|--------|--|---|-----------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Inna Belfer, M.D., Ph.D.   |
| Contact Telephone    | 301-435-1573   |
| Contact Email        | <a href="mailto:inna.belfer@nih.gov">inna.belfer@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022  |
| Synopsis             | The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA. |

|        |  |   |           |             |             |
|--------|--|---|-----------|-------------|-------------|
| 080324 | <a href="#">Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)</a> | National Center for Complementary and Integrative Health/NIH/DHHS | PA-19-201 | 16-Jun-2021 | 275,000 USD |
|--------|--|---|-----------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Inna Belfer, M.D., Ph.D.  |
| Contact Telephone    | 301-435-1573  |
| Contact Email        | <a href="mailto:inna.belfer@nih.gov">inna.belfer@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022   |
| Synopsis             | The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

|        |  |   |               |             |               |
|--------|--|---|---------------|-------------|---------------|
| 102903 | <a href="#">Notice of Special Interest (NOSI): Fundamental Science Research on Complementary and Integrative Health Approaches</a> | National Center for Complementary and Integrative Health/NIH/DHHS | NOT-AT-21-006 | 05-Jun-2021 | Not Specified |
|--------|--|---|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Wen Chen, M.M.Sc., Ph.D.  |
| Contact Telephone    | 301-451-3989  |
| Contact Email        | <a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 |
| Synopsis             | The purpose of this Notice of Special Interest (NOSI) is to describe NCCIH priorities in innovative basic and mechanistic research or technology/method development research relevant to complementary and integrative health approaches.   |

|        |  |                                 |            |             |               |
|--------|--|---------------------------------|------------|-------------|---------------|
| 100970 | <a href="#">NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)</a> | National Eye Institute/NIH/DHHS | PAR-21-073 | 09-Jun-2021 | Not Specified |
|--------|--|---------------------------------|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Neeraj Agarwal, Ph.D.  |
| Contact Telephone    | 301-451-2020   |
| Contact Email        | <a href="mailto:agarwalnee@nei.nih.gov">agarwalnee@nei.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 09-Jun-2021 , 09-Jun-2022 , 09-Jun-2023  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs which prepare clinically trained vision scientists for |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

independent research careers. This initiative is intended to expand and strengthen the community of clinician investigators engaged in clinical research. Such an increase in the number of well-trained clinical researchers is necessary to achieve a pool of scientists with contemporary, multidisciplinary expertise able to leverage recent advances in ocular genetics, artificial intelligence, computational modelling, ocular therapeutics, bioengineering, and bio-behavioral research in order to enhance patient treatment and to increase scientific momentum in these fields. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing a separate ancillary study to an existing trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. For this career development program scholars are limited to clinical trials that are mechanistic and/or minimal risk. The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for either a mechanistic or minimal risk trial. A mechanistic trial is designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. For this career development program, scholars are limited to clinical trials that are mechanistic and/or minimal risk. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

|        |   |                                 |               |             |               |
|--------|---|---------------------------------|---------------|-------------|---------------|
| 101324 | <a href="#">Notice of Special Interest (NOSI): NEI Anterior Segment Initiative (ASI): Identification and Development of New Biomarkers and Effective Methods to Diagnose Dry Eye Disease.</a> | National Eye Institute/NIH/DHHS | NOT-EY-21-007 | 07-May-2021 | Not Specified |
|--------|---|---------------------------------|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         |   |
| Contact Telephone    |   |
| Contact Email        |   |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 05-Sep-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 |
| Synopsis             | The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response. |

|        |   |                                 |         |             |         |
|--------|---|---------------------------------|---------|-------------|---------|
| 081744 | <a href="#">NEI Research Grant for Vision-Related Secondary Data Analysis (R21)</a> | National Eye Institute/NIH/DHHS | PAR-19- | 07-May-2021 | 275,000 |
|--------|---|---------------------------------|---------|-------------|---------|

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                    | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---------------------------------|----------------|---------------|----------------|
|         | <a href="#">Clinical Trial Not Allowed</a>   |                                 | 260            |               | USD            |
|         | <p>Contact Name   Donald Everett, M.A.</p> <p>Contact Telephone   301-451-2020</p> <p>Contact Email   <a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis   This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.</p> |                                 |                |               |                |
| 081084  | <a href="#">NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)</a>  | National Eye Institute/NIH/DHHS | PAR-19-231     | 07-May-2021   | 300,000 USD    |
|         | <p>Contact Name   Donald Everett, MA</p> <p>Contact Telephone   301-451-2020</p> <p>Contact Email   <a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis   The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-</p>  |                                 |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         |   | <p>documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.</p>  |                |               |                |
| 101704  | <a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)</a> | National Heart, Lung, and Blood Institute/NIH/DHHS   | PAR-21-119     | 04-Jun-2021   | Not Specified  |
|         | Contact Name  | Traci Heath Mondoro, Ph.D.   |                |               |                |
|         | Contact Telephone   | 301-435-0065   |                |               |                |
|         | Contact Email   | <a href="mailto:xxxx@mail.nih.gov">xxxx@mail.nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 04-Jun-2021 , 07-Sep-2021 , 02-Oct-2021 , 07-Jan-2022 , 04-Jun-2022 , 07-Sep-2022 , 02-Oct-2022 , 07-Jan-2023 , 04-Jun-2023 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-2024  |                |               |                |
|         | Synopsis  | <p>The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.</p> |                |               |                |
| 101703  | <a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)</a>     | National Heart, Lung, and Blood Institute/NIH/DHHS   | PAR-21-118     | 04-Jun-2021   | 4,545,000 USD  |
|         | Contact Name  | Traci Heath Mondoro, Ph.D.   |                |               |                |
|         | Contact Telephone   | 301-435-0050   |                |               |                |
|         | Contact Email   | <a href="mailto:mondorot@nhlbi.nih.gov">mondorot@nhlbi.nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   04-Jun-2021 , 07-Sep-2021 , 02-Oct-2021 , 07-Jan-2022 , 04-Jun-2022 , 07-Sep-2022 , 02-Oct-2022 , 07-Jan-2023 , 04-Jun-2023 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion FOA, PAR-21-119, which utilizes an R61/R33 phased approach.</p>                                     |  |                |               |                |
| 078369  | <a href="#">New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed)</a>   | National Heart, Lung, and Blood Institute/NIH/DHHS | PA-19-049      | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Ravi Chandra Balijepalli, Ph.D.</p> <p>Contact Telephone   301-435-0504</p> <p>Contact Email   <a href="mailto:ravi.balijepalli@nih.gov">ravi.balijepalli@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis   The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain “resilience” – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.</p> |  |                |               |                |
| 100447  | <a href="#">Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders</a>  | National Heart, Lung, and Blood Institute/NIH/DHHS | NOT-HL-20-815  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Rebecca A. Roper, MS, MPH</p> <p>Contact Telephone   301-496-1051</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:Rebecca.Roper@nih.gov">Rebecca.Roper@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.</p>   |  |                |               |                |
| 079552  | <a href="#">Implementation of Shared Decision Making for HLBS Diseases and Conditions (R01 Clinical Trial Optional)</a>  | National Heart, Lung, and Blood Institute/NIH/DHHS | PA-19-166      | 07-May-2021   | 2,499,995 USD  |
|         | <p>Contact Name Susan T. Shero, BSN, MS</p> <p>Contact Telephone 301-496-1051</p> <p>Contact Email <a href="mailto:sheros@nih.gov">sheros@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this initiative is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lung, blood, and sleep (HLBS) diseases and conditions; and to address barriers and facilitators related to SDM strategies used to improve quality of care, adherence, and informed consent; reduce health disparities; and deliver treatments best suited for individual patients. Investigators and multidisciplinary research teams with expertise in clinical implementation research, health information technology, behavioral science, behavioral economics, workflow design, and organizational engineering are encouraged to apply.</p> |  |                |               |                |
| 099803  | <a href="#">Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases</a>   | National Heart, Lung, and Blood Institute/NIH/DHHS | NOT-HL-20-737  | 07-May-2021   | Not Specified  |
|         | Contact Name Lora Reineck, MD, MS  |  |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Contact Telephone    | 301-435-0222  |
| Contact Email        | <a href="mailto:lora.reineck@nih.gov">lora.reineck@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023   |
| Synopsis             | <p>Providing care that is consistent with a patient’s values, preferences, and goals is a cornerstone of palliative care, an interdisciplinary patient-centered approach that aims to improve quality of life for persons with advanced illness and their families. Palliative care focuses on several objectives including relief of symptoms and suffering, communication of prognosis and treatment options in the context of patients’ goals, and coordination of care within and across healthcare settings. Palliative care is not synonymous with hospice or end-of-life care. Rather, palliative care addresses the spectrum of care for serious illness from diagnosis through terminal stages of diseases. Moreover, palliative care does not necessarily entail withholding or curbing treatment. Relief of symptoms, enhancing quality of life, and many other specific aspects of goal-concordant care may, in fact, involve optimal medical or surgical treatment of diseases. The expected outcome of integrating palliative care into the management of the patient’s disease is a better quality of life, a realistic understanding of risks and benefits of treatment and interventions, and medical treatment decisions that align with the patient’s goals, preferences, and values. Many heart, lung, blood, and sleep (HLBS) diseases, including heart failure, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary hypertension, cystic fibrosis, myelodysplastic syndromes, and aplastic anemia are life-limiting, non-curable illnesses. These and other HLBS diseases may benefit from care focused on improvement of symptoms and quality of life, in addition to care focused on slowing or halting progression of diseases. Integration of palliative care into cardiology, pulmonary, hematology, and critical care practice is recommended by multiple professional societies. Additionally, symptoms of HLBS diseases such as cough, shortness of breath, and fatigue may be especially burdensome, even in diseases that are not life-limiting. Research to improve burdensome symptoms has the potential to greatly improve the quality of life for all patients with HLBS diseases, not just those with life-limiting disease.</p> |

|        |  |  |               |             |               |
|--------|--|--|---------------|-------------|---------------|
| 100825 | <a href="#">Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)</a> | National Heart, Lung, and Blood Institute/NIH/DHHS | NOT-HL-20-823 | 07-May-2021 | Not Specified |
|--------|--|--|---------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Weiniu Gan, Ph.D.  |
| Contact Telephone | 301-435-0202   |
| Contact Email     | <a href="mailto:ganw2@mail.nih.gov">ganw2@mail.nih.gov</a> |
| Sponsor Website   |  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other “omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.</p> |  |                |               |                |
| 100811  | <a href="#">NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)</a>   | National Heart, Lung, and Blood Institute/NIH/DHHS | PAR-21-079     | 07-May-2021   | 450,000 USD    |
|         | <p>Contact Name Patrice Desvigne-Nickens, MD</p> <p>Contact Telephone 301-435-0504</p> <p>Contact Email <a href="mailto:gweinmann@nih.gov">gweinmann@nih.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan</p>  |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at <https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization>), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 084638 | <a href="#">Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</a> | National Heart, Lung, and Blood Institute/NIH/DHHS | PAR-19-329 | 11-May-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|   |   |
|---|---|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Nancy DiFronzo, PhD</p> <p>301-435-0065</p> <p><a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015) . For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC) ( PAR-19-330 ). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.</p> |
|---|---|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 084646 | <a href="#">Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)</a> | National Heart, Lung, and Blood Institute/NIH/DHHS | PAR-19-330 | 11-May-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Nancy DiFronzo, PhD  |
| Contact Telephone    | 301-435-0065   |
| Contact Email        | <a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022  |
| Synopsis             | <p>This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA ( PAR-19-329 ) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.</p> |

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 084637 | <a href="#">Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)</a> | National Heart, Lung, and Blood Institute/NIH/DHHS | PAR-19-328 | 11-May-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Nahed El Kassar, MD  |
| Contact Telephone | 301-435-0065   |
| Contact Email     | <a href="mailto:nahed.elkassar@nih.gov">nahed.elkassar@nih.gov</a> |
| Sponsor Website   |  |
| Program URL       | <a href="#">Link to program URL</a>                                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.</p>  |  |                |               |                |
| 086465  | <p><a href="#">RFA-HL-20-029 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23 Recipients (R03 - Clinical Trial Optional)</a></p>   | National Heart, Lung, and Blood Institute/NIH/DHHS | RFA-HL-20-029  | 10-May-2021   | 100,000 USD    |
|         | <p>Contact Name   Roya Kalantari, PhD</p> <p>Contact Telephone   301-480-1989</p> <p>Contact Email   <a href="mailto:roya.kalantari@nih.gov">roya.kalantari@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   10-May-2021 , 08-Jun-2021 , 08-Sep-2021 , 08-Oct-2021 , 10-Jan-2022</p> <p>Synopsis   The purpose of this FOA is to solicit current or recently completed NHLBI K01, K08, and K23 awardees for grant support to expand their current research objectives or to branch out to a study that resulted from the research conducted under the K award. Active NHLBI K01, K08, and K23 awardees may apply for R03 support to run concurrently with the final two years of their K award. Recently completed NHLBI K01, K08, and K23 awardees are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. Thus, this FOA is intended to enhance the capability of NHLBI K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects</p> |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         |   | that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application.  |                |               |                |
| 102820  | <a href="#">Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)</a>  | National Heart, Lung, and Blood Institute/NIH/DHHS   | NOT-HL-21-007  | 05-Jun-2021   | Not Specified  |
|         | Contact Name  | James Luo, Ph.D.   |                |               |                |
|         | Contact Telephone   | 301-435-0533   |                |               |                |
|         | Contact Email   | <a href="mailto:luoja@nih.gov">luoja@nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023  |                |               |                |
|         | Synopsis  | <p>The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other “omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.</p> |                |               |                |
| 085485  | <a href="#">RFA-HL-20-028 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)</a> | National Heart, Lung, and Blood Institute/NIH/DHHS   | RFA-HL-20-028  | 11-May-2021   | 500,000 USD    |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--|----------------|-------------------------------------|----------------|
|         | <p>Contact Name   Kathleen Rousche, Ph.D.</p> <p>Contact Telephone   301-827-7981</p> <p>Contact Email   <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p> |  |                |                                     |                |
| 085483  | <a href="#">RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)</a>  | National Heart, Lung, and Blood Institute/NIH/DHHS | RFA-HL-20-027  | 11-May-2021                         | 700,000 USD    |
|         | <p>Contact Name   Kathleen Rousche, Ph.D.</p> <p>Contact Telephone   301-827-7981</p> <p>Contact Email   <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.</p>                           |  |                |                                     |                |
| 102465  | <a href="#">RFA-HL-22-002 -- Lung Transplant Consortium - Data Coordinating Center (U24 - Clinical Trial Not Allowed)</a>  | National Heart, Lung, and Blood Institute/NIH/DHHS | RFA-HL-22-003  | 15-May-2021 [Optional][LOI/Pre-App] | 3,500,000 USD  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|   |  |
|---|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Matt Craig, PhD</p> <p>301-827-7841</p> <p><a href="mailto:matt.craig@nih.gov">matt.craig@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>This Funding Opportunity Announcement (FOA) invites applications to serve as the Data Coordinating Center (DCC) that will support the research activities of a cooperative multi-site Lung Transplant Consortium (LTC). The primary responsibility of the DCC will be to oversee the conduct of multiple observational and complementary mechanistic clinical research studies involving lung transplantation performed under a common research protocol by awarded Clinical Centers (CCs) within the LTC. The NHLBI anticipates that the DCC will collaborate strategically with the CCs to provide support for regulatory and administrative activities, common research protocol development, statistical data analysis, data and biospecimen collection and storage, the reporting of study results through publication in a timely manner, and the dissemination of datasets and biospecimens for secondary analyses by the broader research community at the conclusion of the program. The DCC will promote collaboration and communication among LTC investigators and will coordinate outreach activities including engaging foundations, societies, and other entities with a shared interest in lung transplantation. The DCC will be responsible for integrating the efforts of 8 Clinical Center awards consisting of approximately 24 sites performing local site-specific observational research studies to identify factors that impact donor lung utilization and early post-transplant outcomes such as primary and acute lung allograft dysfunction in lung transplant recipients. In addition, the DCC, in partnership with the LTC Steering Committee, will oversee the creation and implementation of a common research protocol to enroll participants for collection of a core set of data and biospecimens across all participating consortium sites. By leveraging this shared longitudinal resource, LTC investigators will have the tools to identify and answer additional important research questions involving lung transplantation. This FOA runs in parallel with the LTC Clinical Centers (see RFA-HL-22-002).</p> |
|---|--|

|        |  |  |               |             |             |
|--------|--|--|---------------|-------------|-------------|
| 085482 | <p><a href="#">RFA-HL-20-024 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)</a></p> | National Heart, Lung, and Blood Institute/NIH/DHHS | RFA-HL-20-024 | 11-May-2021 | 500,000 USD |
|--------|--|--|---------------|-------------|-------------|

|   |  |
|---|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> | <p>Kathleen Rousche, Ph.D.</p> <p>301-827-7981</p> <p><a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> |
|---|--|



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>  |  |                |               |                |
| 085480  | <a href="#">RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)</a>  | National Heart, Lung, and Blood Institute/NIH/DHHS | RFA-HL-20-022  | 11-May-2021   | 600,000 USD    |
|         | <p>Contact Name Margaret Ochocinska, PhD</p> <p>Contact Telephone 301-827-8285</p> <p>Contact Email <a href="mailto:ochocinm@mail.nih.gov">ochocinm@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.</p> |  |                |               |                |
| 085481  | <a href="#">RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)</a>   | National Heart, Lung, and Blood Institute/NIH/DHHS | RFA-HL-20-023  | 11-May-2021   | 700,000 USD    |
|         | <p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p>  |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--|----------------|-------------------------------------|----------------|
|         | <p>Contact Email <a href="mailto:kathleen.rousche@nih.gov">kathleen.rousche@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>  |  |                |                                     |                |
| 102462  | <a href="#">RFA-HL-22-002 -- Lung Transplant Consortium - Clinical Centers (U01 - Clinical Trial Not Allowed)</a>  | National Heart, Lung, and Blood Institute/NIH/DHHS | RFA-HL-22-002  | 15-May-2021 [Optional][LOI/Pre-App] | 1,375,000 USD  |
|         | <p>Contact Name Matt Craig, PhD</p> <p>Contact Telephone 301-827-7841</p> <p>Contact Email <a href="mailto:matt.craig@nih.gov">matt.craig@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks applications from lung transplant clinical centers (CCs) to form a cooperative multi-site Lung Transplant Consortium (LTC). The LTC will support CCs in conducting observational and complementary mechanistic clinical research studies that aim to understand the impact of site-specific lung transplant selection criteria and clinical management strategies on donor lung utilization and/or early post-transplant outcomes such as the development of primary graft dysfunction (PGD) and acute lung allograft dysfunction (ALAD) in recipients. Each CC application must consist of a multidisciplinary investigative team that includes a lung transplant surgeon and a lung transplant pulmonologist, and be comprised of primary and subsites that have a combined annual lung transplant volume of at least 100 transplants. Each CC application should propose hypothesis-driven scientific questions to assess certain donor and/or recipient clinical practices and their impact on donor lung utilization, PGD, ALAD or other relevant short-term outcomes that can be addressed through observational data and/or biospecimen collection and analysis at the sites included in their application. In addition, the CCs will be expected to enroll participants and contribute to a core set of data and biospecimens to be collected across all participating consortium sites through the implementation of a common research</p> |  |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

protocol under the auspices of a centralized Data Coordinating Center (DCC) and a Steering Committee (SC). By leveraging this shared longitudinal resource, LTC investigators will have the tools to identify and answer additional important research questions involving lung transplantation. This FOA runs in parallel with the LTC Data Coordinating Center (see RFA-HL-22-003).

|        |   |  |           |             |               |
|--------|---|--|-----------|-------------|---------------|
| 074657 | <a href="#">The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)</a> | National Heart, Lung, and Blood Institute/NIH/DHHS | PA-18-784 | 07-May-2021 | Not Specified |
|--------|---|--|-----------|-------------|---------------|

Contact Name | Lis Caler, Ph.D.  
 Contact Telephone | 301-435-0222  
 Contact Email | [lis.caler@mail.nih.gov](mailto:lis.caler@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021

Synopsis

National Heart, Lung, and Blood Institute (NHLBI) invites applications for functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.

|        |  |   |           |             |               |
|--------|--|---|-----------|-------------|---------------|
| 076415 | <a href="#">Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed)</a> | National Human Genome Research Institute/NIH/DHHS | PA-18-868 | 05-Jun-2021 | Not Specified |
|--------|--|---|-----------|-------------|---------------|

Contact Name | Lisa D. Brooks, Ph.D.  
 Contact Telephone | 301-547-1387  
 Contact Email | [Lisa.Brooks@nih.gov](mailto:Lisa.Brooks@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                      | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis National Human Genome Research Institute (NHGRI) invites applications for the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically. This FOA will use the NIH Research Project (R01) award mechanism.</p>  |   |                |               |                |
| 076417  | <a href="#">Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed)</a>  | National Human Genome Research Institute/NIH/DHHS | PA-18-867      | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name Lisa D. Brooks, Ph.D.</p> <p>Contact Telephone 301-547-1387</p> <p>Contact Email <a href="mailto:Lisa.Brooks@nih.gov">Lisa.Brooks@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021</p> <p>Synopsis National Human Genome Research Institute (NHGRI) invites applications for the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>                          |   |                |               |                |
| 101174  | <a href="#">Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application</a>   | National Human Genome Research Institute/NIH/DHHS | NOT-HG-21-018  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Michael W. Smith, Ph.D.</p> <p>Contact Telephone 301-480-3413</p> <p>Contact Email <a href="mailto:smithmw@mail.nih.gov">smithmw@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024</p> |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|---|----------------|-------------------------------------|----------------|
|         | Synopsis   | The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and clinical applications in human genomics.   |                |                                     |                |
| 101030  | <a href="#">Notice of Special Interest (NOSI): High-throughput Molecular and Cellular Phenotyping</a>  | National Human Genome Research Institute/NIH/DHHS   | NOT-HG-21-004  | 07-May-2021                         | Not Specified  |
|         | Contact Name   | Colin Fletcher, Ph.D.   |                |                                     |                |
|         | Contact Telephone  | 301-496-7531  |                |                                     |                |
|         | Contact Email  | <a href="mailto:fletcher2@mail.nih.gov">fletcher2@mail.nih.gov</a>  |                |                                     |                |
|         | Sponsor Website  |   |                |                                     |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |                                     |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 08-Jan-2022 , 05-Feb-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Oct-2023 , 07-Jan-2024 |                |                                     |                |
|         | Synopsis   | The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.  |                |                                     |                |
| 103144  | <a href="#">RFA-HG-21-006 -- Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)</a> | National Human Genome Research Institute/NIH/DHHS   | RFA-HG-21-006  | 26-May-2021 [Optional][LOI/Pre-App] | 2,800,000 USD  |
|         | Contact Name   | Michael W. Smith, Ph.D.   |                |                                     |                |
|         | Contact Telephone  | 301-480-3413  |                |                                     |                |
|         | Contact Email  | <a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a>  |                |                                     |                |
|         | Sponsor Website  |   |                |                                     |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |                                     |                |
|         | Deadline Dates (ALL)   | 26-May-2021 [Optional][LOI/Pre-App], 25-Jun-2021 , 30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022 , 02-Jan-2023 [Optional][LOI/Pre-App], 01-Feb-2023  |                |                                     |                |
|         | Synopsis   | This Funding Opportunity Announcement (FOA) solicits R01 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2)  |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--|----------------|-------------------------------------|----------------|
|         |  | <p>methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals.</p>  |                |                                     |                |
| 103150  | <a href="#">RFA-HG-21-007 -- Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed)</a>     | National Human Genome Research Institute/NIH/DHHS  | RFA-HG-21-007  | 26-May-2021 [Optional][LOI/Pre-App] | 400,000 USD    |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>  | <p>Michael W. Smith, Ph.D.</p> <p>301-480-3413</p> <p><a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>26-May-2021 [Optional][LOI/Pre-App], 25-Jun-2021 , 30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022 , 02-Jan-2023 [Optional][LOI/Pre-App], 01-Feb-2023</p> <p>This Funding Opportunity Announcement (FOA) solicits R21 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals.</p> |                |                                     |                |
| 103218  | <a href="#">RFA-HG-21-008 -- Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)</a> | National Human Genome Research Institute/NIH/DHHS  | RFA-HG-21-008  | 26-May-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name</p>  | <p>Michael W. Smith, Ph.D.</p>   |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                      | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|---|----------------|-------------------------------------|----------------|
|         | <p>Contact Telephone   301-480-3413</p> <p>Contact Email   <a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   26-May-2021 [Optional][LOI/Pre-App], 25-Jun-2021 , 30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022 , 02-Jan-2023 [Optional][LOI/Pre-App], 01-Feb-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to innovate and develop the early stages of novel commercial technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by the business sector with cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance commercial DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals.</p> |   |                |                                     |                |
| 097524  | <a href="#">Investigator-Initiated Research on Genetic Counseling Processes and Practices (R21 Clinical Trial Optional)</a>   | National Human Genome Research Institute/NIH/DHHS | RFA-HG-20-049  | 08-Jun-2021 [Optional][LOI/Pre-App] | 400,000 USD    |
|         | <p>Contact Name   Nicole Lockhart</p> <p>Contact Telephone   301-385-1622</p> <p>Contact Email   <a href="mailto:lockhani@mail.nih.gov">lockhani@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021</p> <p>Synopsis   The purpose of this initiative is to support targeted studies on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Applications will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems; and the challenges of effective and efficient communication of genomic findings to clinicians, patients, and families.</p>   |   |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--|----------------|-------------------------------------|----------------|
| 100671  | <a href="#">Notice of Special Interest (NOSI): Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | NOT-AI-21-002  | 11-Jun-2021                         | Not Specified  |
|         | <p>Contact Name Erik Stemmy, Ph.D.</p> <p>Contact Telephone 240-627-3380</p> <p>Contact Email <a href="mailto:NIAIDCOVID19P01@niaid.nih.gov">NIAIDCOVID19P01@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jun-2021</p> <p>Synopsis NIAID is issuing this Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains.</p> |  |                |                                     |                |
| 101626  | <a href="#">RFA-AI-20-077 -- Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | RFA-AI-20-077  | 05-May-2021 [Optional][LOI/Pre-App] | 2,500,000 USD  |
|         | <p>Contact Name Mercy PrabhuDas, Ph.D., M.B.A.</p> <p>Contact Telephone 240-627-3534</p> <p>Contact Email <a href="mailto:mprabhudas@niaid.nih.gov">mprabhudas@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the</p>                             |  |                |                                     |                |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                          | Funding Amount   |
|---------|--|---|----------------|--|------------------|
|         |  | developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population.   |                |  |                  |
| 101637  | <a href="#">RFA-AI-20-078 -- Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | RFA-AI-20-078  | 05-May-2021<br>[Optional][LOI/Pre-App] | 5,000,000<br>USD |
|         | Contact Name   | Mercy PrabhuDas, Ph.D., M.B.A.  |                |  |                  |
|         | Contact Telephone  | 240-627-3534  |                |  |                  |
|         | Contact Email  | <a href="mailto:mprabhudas@niaid.nih.gov">mprabhudas@niaid.nih.gov</a>  |                |  |                  |
|         | Sponsor Website  |   |                |  |                  |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |  |                  |
|         | Deadline Dates (ALL)   | 05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021  |                |  |                  |
|         | Synopsis   | The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development, and maintenance of immunity throughout childhood (from birth to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens, and environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists, neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections or treat/prevent immune-mediated diseases in this vulnerable population. |                |  |                  |
| 101499  | <a href="#">RFA-AI-21-001 -- Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed)</a> | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | RFA-AI-21-001  | 16-May-2021<br>[Optional][LOI/Pre-App] | 3,000,000<br>USD |
|         | Contact Name   | Lakshmi Ramachandra, MSc, PhD   |                |  |                  |
|         | Contact Telephone  | 301-669-5061  |                |  |                  |
|         | Contact Email  | <a href="mailto:Lakshmi.ramachandra@mail.nih.gov">Lakshmi.ramachandra@mail.nih.gov</a>  |                |  |                  |
|         | Sponsor Website  |   |                |  |                  |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |  |                  |
|         | Deadline Dates (ALL)   | 16-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021  |                |  |                  |
|         | Synopsis   | The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis  |                |  |                  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.

|        |  |  |           |             |             |
|--------|--|--|-----------|-------------|-------------|
| 078717 | <a href="#">Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R21 Clinical Trial Not Allowed)</a> | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-19-083 | 07-May-2021 | 275,000 USD |
|--------|--|--|-----------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Dona Love, Ph.D.   |
| Contact Telephone    | 301-761-7788   |
| Contact Email        | <a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |
| Synopsis             | The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses. |

|        |  |  |            |             |             |
|--------|--|--|------------|-------------|-------------|
| 078719 | <a href="#">Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)</a> | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PAR-19-079 | 16-Jun-2021 | 275,000 USD |
|--------|--|--|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Frosso Voulgaropoulou, PhD  |
| Contact Telephone    | 240-627-3205  |
| Contact Email        | <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a>                                    |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021   |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|---|----------------|-------------------------------------|----------------|
|         |  | characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.  |                |                                     |                |
| 078714  | <a href="#">Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)</a>                         | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | PA-19-081      | 16-Jun-2021                         | 275,000 USD    |
|         | Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis   | Dona Love, Ph.D.<br>301-761-7788<br><a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a><br><br><a href="#">Link to program URL</a><br>16-Jun-2021 , 16-Oct-2021<br>The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).  |                |                                     |                |
| 102326  | <a href="#">RFA-AI-21-007 -- Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)</a> | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | RFA-AI-21-007  | 31-May-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis   | Katrin Eichelberg, MSc, PhD<br>240-669-2921<br><a href="mailto:keichelberg@nih.gov">keichelberg@nih.gov</a><br><br><a href="#">Link to program URL</a><br>31-May-2021 [Optional][LOI/Pre-App], 30-Jun-2021<br>To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones. |                |                                     |                |
| 078718  | <a href="#">Molecular and Genetic Characterization of Inborn Errors of Immunity</a>  | National Institute of Allergy and   | PAR-19-        | 05-Jun-2021                         | Not            |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name | Sponsor Number   | Deadline Date | Funding Amount |               |
|---------|---|--------------|--|---------------|----------------|---------------|
|         | <a href="#">(R01 Clinical Trial Not Allowed)</a>  |              | Infectious Diseases/NIH/DHHS                                   | 078           | Specified      |               |
|         | <p>Contact Name   Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone   240-627-3205</p> <p>Contact Email   <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.</p>   |              |  |               |                |               |
| 078715  | <a href="#">Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R01 Clinical Trial Not Allowed)</a>  |              | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-19-082     | 05-Jun-2021    | Not Specified |
|         | <p>Contact Name   Dona Love, Ph.D.</p> <p>Contact Telephone   301-761-7788</p> <p>Contact Email   <a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.</p> |              |  |               |                |               |
| 078710  | <a href="#">Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)</a>   |              | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-19-077     | 05-Jun-2021    | Not Specified |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Contact Name   Annie Mo, Ph.D.</p> <p>Contact Telephone   240-627-3320</p> <p>Contact Email   <a href="mailto:moa@niaid.nih.gov">moa@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation. This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially <i>P. falciparum</i> and <i>P. vivax</i>.</p>   |  |                |               |                |
| 078788  | <a href="#">Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (R01 Clinical Trial Not Allowed)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-19-096      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Leah R. Vincent, Ph.D.</p> <p>Contact Telephone   301-761-7365</p> <p>Contact Email   <a href="mailto:leah.vincent@nih.gov">leah.vincent@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to advance the understanding of natural history of infection for three sexually transmitted infections (STIs): gonorrhea, syphilis, and chlamydia. This research opportunity encourages studies that address the natural history of infection in the context of either: 1) correlates of protection, 2) host response to infection, 3) clinical endpoints of disease, or 4) biological and clinical factors that influence clearance rather than persistence of infection.</p> |  |                |               |                |
| 078712  | <a href="#">Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-19-080      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Dona Love, Ph.D.</p> <p>Contact Telephone   301-761-7788</p>  |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).</p>  |  |                |               |                |
| 076258  | <a href="#">Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-18-859      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Diane Post, Ph.D.</p> <p>Contact Telephone 240-627-3348</p> <p>Contact Email <a href="mailto:postd@niaid.nih.gov">postd@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA will use the NIH Research Project (R01) award mechanism.</p> |  |                |               |                |
| 076434  | <a href="#">Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-18-873      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Barbara Mulach, Ph.D.</p> <p>Contact Telephone 240-627-3322</p> <p>Contact Email <a href="mailto:bmulach@niaid.nih.gov">bmulach@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 07-Sep-2021</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p style="text-align: center;">Synopsis</p> <p>The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH Research Project (R01) award mechanism.</p> |  |                |               |                |
| 102013  | <a href="#">Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS | NOT-AI-21-008  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Cheryl Lapham, Ph.D.</p> <p>Contact Telephone   240-627-3490</p> <p>Contact Email   <a href="mailto:clapham@niaid.nih.gov">clapham@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL  </p> <p>Deadline Dates (ALL)   05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.</p>  |  |                |               |                |
| 076260  | <a href="#">Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-18-858      | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Diane Post, Ph.D.</p> <p>Contact Telephone   240-627-3348</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:postd@niaid.nih.gov">postd@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021</p> <p>Synopsis National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>  |  |                |               |                |
| 094378  | <a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PAR-20-209     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Deborah Philip, Ph.D.</p> <p>Contact Telephone 301-761-7776</p> <p>Contact Email <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-210).</p> |  |                |               |                |
| 099832  | <a href="#">Limited Competition: Exploratory and Developmental Research Grant</a>  | National Institute of Allergy and                              | PAR-20-        | 07-May-2021   | 275,000        |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <a href="#">Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)</a>  | Infectious Diseases/NIH/DHHS                                   | 291            |               | USD            |
|         | <p>Contact Name Timothy A. Gondré-Lewis, Ph.D.</p> <p>Contact Telephone 240-627-3566</p> <p>Contact Email <a href="mailto:tglewis@mail.nih.gov">tglewis@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.</p> |  |                |               |                |
| 099831  | <a href="#">Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PAR-20-290     | 07-May-2021   | 100,000 USD    |
|         | <p>Contact Name Stacy E. Ferguson, Ph.D.</p> <p>Contact Telephone 240-627-3504</p> <p>Contact Email <a href="mailto:fergusont@niaid.nih.gov">fergusont@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23</p>  |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | <p>award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>  |                |               |                |
| 094380  | <a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</a>                               | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | PAR-20-210     | 07-May-2021   | Not Specified  |
|         | Contact Name   | Shawn Drew Gaillard, Ph.D.  |                |               |                |
|         | Contact Telephone  | 301-761-7776  |                |               |                |
|         | Contact Email  | <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023   |                |               |                |
|         | Synopsis   | <p>The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-20-209).</p> |                |               |                |
| 081206  | <a href="#">Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)</a> | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | PA-19-237      | 07-May-2021   | 275,000 USD    |
|         | Contact Name   | Chao Jiang, Ph.D.   |                |               |                |
|         | Contact Telephone  | 301-761-7802  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|--|----------------|-------------------------------------|----------------|
|         | <p>Contact Email <a href="mailto:chao.jiang@nih.gov">chao.jiang@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.</p>   |  |                |                                     |                |
| 085477  | <a href="#">NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PAR-19-371     | 07-May-2021                         | Not Specified  |
|         | <p>Contact Name Shawn Drew Gaillard, Ph.D.</p> <p>Contact Telephone 240-627-3857</p> <p>Contact Email <a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Allergy and Infectious Diseases (NIAID) provides support for the NIAID Research Scholar Development Award (RSDA), which is intended to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) will utilize the NIH Career Transition Award (K22) mechanism.</p> |  |                |                                     |                |
| 102076  | <a href="#">RFA-AI-20-079 -- Human Immunology Project Consortium (HIPC) (U19 Clinical Trial Optional)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | RFA-AI-20-079  | 05-May-2021 [Optional][LOI/Pre-App] | 7,500,000 USD  |
|         | <p>Contact Name Alison Deckhut Augustine, Ph.D.</p> <p>Contact Telephone 240-627-3475</p> <p>Contact Email <a href="mailto:NIAIDHPCU19@mail.nih.gov">NIAIDHPCU19@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021</p>  |  |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|---|----------------|-------------------------------------|----------------|
|         | <p>Synopsis</p>   | <p>This Funding Opportunity Announcement (FOA) for the Human Immunology Project Consortium (HIPC) solicits applications from single institutions, or consortia of institutions, to participate in a network of human immunology profiling research groups in the area of infectious diseases, including HIV. The purpose of this FOA is to characterize human immune responses/mechanisms elicited by vaccinations, vaccine adjuvants or natural infections by capitalizing on recent advances in immune profiling technologies. Studies supported under this FOA will measure the diversity and commonalities of human immune responses under a variety of conditions and longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The resulting data will be used to develop molecular signatures that define immune response profiles and identify biomarkers that correlate with the outcomes of vaccinations, vaccine adjuvants or natural infections in humans. An additional goal of this program is to promote rapid public access to HIPC-supported data and meta-data through public portals such as ImmPort. A companion FOA will support development and operation of a HIPC Coordinating Center that will be responsible for fostering collaborations amongst HIPC-funded investigators; facilitating public dissemination of integrated HIPC findings and knowledge; and supporting development or adoption of new, robust methods for data integration, analysis, presentation, and visualization to further research and development in this field.</p> |                |                                     |                |
| 102629  | <p><a href="#">RFA-AI-21-005 -- Tropical Medicine Research Centers Coordinating Center (U01 Clinical Trial Not Allowed)</a></p>                         | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | RFA-AI-21-005  | 19-May-2021 [Optional][LOI/Pre-App] | 2,500,000 USD  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Malla Rao, Ph.D.</p> <p>240-627-3352</p> <p><a href="mailto:mrao@niaid.nih.gov">mrao@niaid.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>19-May-2021 [Optional][LOI/Pre-App], 18-Jun-2021</p> <p>This Funding Opportunity Announcement (FOA) solicits applications for a Tropical Medicine Research Centers Coordinating Center (TMRC CC) for the Tropical Medicine Research Centers (TMRC). The TMRC CC will oversee and coordinate efforts across the TMRCs related to data management, data and specimen sharing, scientific collaboration, creation and maintenance of a virtual sample repository, organizing annual meetings, managing an Opportunity Fund to support research by junior and early-stage investigators, and liaising with United States Government (USG) counterparts and other stakeholders.</p>  |                |                                     |                |
| 102836  | <p><a href="#">RFA-AI-21-020 -- Early-Stage Development of Data Science Technologies</a></p>  | National Institute of Allergy and   | RFA-AI-        | 02-Jun-2021                         | 900,000        |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|--|----------------|-------------------------------------|----------------|
|         | <a href="#">for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)</a>  | Infectious Diseases/NIH/DHHS                                   | 21-020         | [Optional][LOI/Pre-App]             | USD            |
|         | <p>Contact Name   Steve Tsang, PhD</p> <p>Contact Telephone   240-627-3330</p> <p>Contact Email   <a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Jun-2021 [Optional][LOI/Pre-App], 02-Jul-2021 , 18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p> |  |                |                                     |                |
| 102837  | <a href="#">RFA-AI-21-035-- Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS | RFA-AI-21-035  | 02-Jun-2021 [Optional][LOI/Pre-App] | 275,000 USD    |
|         | <p>Contact Name   Steve Tsang, PhD</p> <p>Contact Telephone   240-627-3330</p> <p>Contact Email   <a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   02-Jun-2021 [Optional][LOI/Pre-App], 02-Jul-2021 , 18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022</p>  |  |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                          | Funding Amount |
|---------|---|--|----------------|--|----------------|
|         | <p>Synopsis</p>   | <p>[Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge. This contrasts with early-stage development (U01) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p>  |                |  |                |
| 102838  | <p><a href="#">RFA-AI-21-021 -- Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed)</a></p> | National Institute of Allergy and Infectious Diseases/NIH/DHHS   | RFA-AI-21-021  | 02-Jun-2021<br>[Optional][LOI/Pre-App] | 3,000,000 USD  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>               | <p>Steve Tsang, PhD</p> <p>240-627-3330</p> <p><a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>02-Jun-2021 [Optional][LOI/Pre-App], 02-Jul-2021 , 18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge. This contrasts with early-stage development</p> |                |  |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|---|----------------|-------------------------------------|----------------|
|         |  | (U01) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs. |                |                                     |                |
| 102961  | <a href="#">Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | NOT-AI-21-032  | 05-Jun-2021                         | Not Specified  |
|         | <p>Contact Name   Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone   240-627-3205</p> <p>Contact Email   <a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) is to support the discovery and characterization of Inborn Errors of Immunity, also referred to as Primary Immunodeficiencies, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.</p> |   |                |                                     |                |
| 102077  | <a href="#">RFA-AI-20-080 -- Human Immunology Project Consortium (HIPC) Coordinating Center (U01 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | RFA-AI-20-080  | 05-May-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name   Alison Deckhut Augustine, Ph.D.</p> <p>Contact Telephone   240-627-3475</p> <p>Contact Email   <a href="mailto:NIAIDHPCU19@mail.nih.gov">NIAIDHPCU19@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021</p> <p>Synopsis   The goal of this FOA is to support a Coordinating Center for the Human Immunology Project Consortium (HIPC) program. The HIPC program, supported through a separate FOA, will consist of 5-8 multi-project cooperative agreement (U19) awardees that will measure the diversity and commonalities of human immune responses under a variety of conditions and</p>   |   |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                          | Funding Amount   |
|---------|--|---|----------------|--|------------------|
|         |  | <p>longitudinally using high-throughput systems immunology approaches coupled with detailed clinical phenotyping in well-characterized human cohorts. The HIPC Coordinating Center supported by this FOA will be responsible for: coordinating cross-HIPC data integration, analysis, and visualization; developing and maintaining a public HIPC website and knowledgebase to support cross-HIPC data analysis and visualization; and fostering collaborations amongst HIPC-funded investigators by managing the HIPC subcommittees and an Infrastructure and Opportunity Fund to support collaborative studies.</p> |                |  |                  |
| 102623  | <a href="#">RFA-AI-21-004 -- Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | RFA-AI-21-004  | 19-May-2021<br>[Optional][LOI/Pre-App] | 2,500,000<br>USD |
|         | <p>Contact Name   Malla Rao, Ph.D.</p> <p>Contact Telephone   240-627-3352</p> <p>Contact Email   <a href="mailto:mrao@niaid.nih.gov">mrao@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   19-May-2021 [Optional][LOI/Pre-App], 18-Jun-2021</p> <p>Synopsis   This funding opportunity announcement (FOA) solicits research applications focused on the etiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, treatment and control of select Neglected Tropical Diseases (NTDs) in endemic areas. The Tropical Medicine Research Centers (TMRCs) are intended to advance NIAID's global research effort by targeting research endeavors to: develop novel diagnostic, prevention and therapeutic strategies adapted for the unique needs of low and middle-income countries (LMICs), as classified by the World Bank; create and sustain in-country research capacity; stimulate scientific collaboration and global partnerships; provide opportunities for junior and early-stage investigators to conduct research on NTDs; and facilitate sample sharing to support translational research to develop or evaluate new drugs, diagnostics, vaccines, therapeutics, and/or vector control strategies.</p> |   |                |  |                  |
| 103116  | <a href="#">RFA-AI-21-009 -- Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed)</a>  | National Institute of Allergy and Infectious Diseases/NIH/DHHS  | RFA-AI-21-009  | 30-Jun-2021<br>[Optional][LOI/Pre-App] | Not Specified    |
|         | <p>Contact Name   Stephen Smiley, PhD</p> <p>Contact Telephone   240-627-3071</p> <p>Contact Email   <a href="mailto:stephen.smiley@nih.gov">stephen.smiley@nih.gov</a></p> <p>Sponsor Website  </p>   |   |                |  |                  |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis This funding opportunity announcement (FOA) encourages multidisciplinary teams to characterize mechanisms that impact resistance to HIV broadly neutralizing antibodies (bNAbs) and develop strategies to prevent and overcome HIV resistance to bNAbs.</p>   |  |                |               |                |
| 081410  | <a href="#">Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R21 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PAR-19-247     | 18-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name M. Chelsea Lane, Ph.D.</p> <p>Contact Telephone 240-627-3741</p> <p>Contact Email <a href="mailto:lanemc@niaid.nih.gov">lanemc@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jun-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.</p>   |  |                |               |                |
| 076435  | <a href="#">Research to Advance Vaccine Safety (R21 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS | PA-18-872      | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name Barbara Mulach, Ph.D.</p> <p>Contact Telephone 240-627-3322</p> <p>Contact Email <a href="mailto:bmulach@niaid.nih.gov">bmulach@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1)</p> |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p> |  |                |               |                |
| 081406  | <a href="#">Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R01 Clinical Trial Not Allowed)</a>   | National Institute of Allergy and Infectious Diseases/NIH/DHHS                 | PAR-19-248     | 10-Jun-2021   | 2,499,995 USD  |
|         | <p>Contact Name   M. Chelsea Lane, Ph.D.<br/>           Contact Telephone   240-627-3741<br/>           Contact Email   <a href="mailto:lanemc@niaid.nih.gov">lanemc@niaid.nih.gov</a><br/>           Sponsor Website  <br/>           Program URL   <a href="#">Link to program URL</a><br/>           Deadline Dates (ALL)   10-Jun-2021<br/>           Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.</p>   |  |                |               |                |
| 073322  | <a href="#">Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21 Clinical Trial Not Allowed)</a>  | National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS | PA-18-718      | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Ricardo R. Cibotti, Ph.D.<br/>           Contact Telephone   301-451-5888<br/>           Contact Email   <a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a><br/>           Sponsor Website  <br/>           Program URL   <a href="#">Link to program URL</a></p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   16-Jun-2021</p> <p>Synopsis   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>   |  |                |               |                |
| 073320  | <a href="#">Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)</a>  | National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS | PA-18-719      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Ricardo R. Cibotti, Ph.D.</p> <p>Contact Telephone   301-451-5888</p> <p>Contact Email   <a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021</p> <p>Synopsis   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. This FOA will use the NIH Research Project (R01) award mechanism.</p> |  |                |               |                |
| 101494  | <a href="#">Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases</a>  | National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS | NOT-AR-21-012  | 07-May-2021   | Not Specified  |
|         | Contact Name   Marie Mancini, Ph.D.   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number  | Deadline Date                       | Funding Amount |
|---------|---|--|---|-------------------------------------|----------------|
|         |   | Contact Telephone  | 301-594-5032  |                                     |                |
|         |   | Contact Email  | <a href="mailto:mancinim2@mail.nih.gov">mancinim2@mail.nih.gov</a>  |                                     |                |
|         |   | Sponsor Website  |   |                                     |                |
|         |   | Program URL  | <a href="#">Link to program URL</a>   |                                     |                |
|         |   | Deadline Dates (ALL)   | 07-May-2021 , 15-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021   |                                     |                |
|         |   | Synopsis   | The purpose of this Notice is to announce to potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) an interest in research on the impact of COVID-19 as related to diseases and conditions within the NIAMS mission.  |                                     |                |
| 100387  | <a href="#">Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)</a> | National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS | PAR-21-054  | 20-Jun-2021 [Optional][LOI/Pre-App] | 400,000 USD    |
|         |   | Contact Name   | Heiyoung Park, Ph.D.  |                                     |                |
|         |   | Contact Telephone  | 301-594-5032  |                                     |                |
|         |   | Contact Email  | <a href="mailto:parkh1@mail.nih.gov">parkh1@mail.nih.gov</a>  |                                     |                |
|         |   | Sponsor Website  |   |                                     |                |
|         |   | Program URL  | <a href="#">Link to program URL</a>   |                                     |                |
|         |   | Deadline Dates (ALL)   | 20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022  |                                     |                |
|         |   | Synopsis   | This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease. |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|--|----------------|-------------------------------------|----------------|
| 100388  | <a href="#">Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)</a>   | National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS | PAR-21-055     | 20-Jun-2021 [Optional][LOI/Pre-App] | 1,200,000 USD  |
|         | <p>Contact Name   Heiyoung Park, Ph.D.</p> <p>Contact Telephone   301-594-5032</p> <p>Contact Email   <a href="mailto:parkh1@mail.nih.gov">parkh1@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p> |  |                |                                     |                |
| 081513  | <a href="#">Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03)</a>   | National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS | PAR-19-257     | 21-Jun-2021                         | 100,000 USD    |
|         | <p>Contact Name   Su-Yau Mao, Ph.D.</p> <p>Contact Telephone   301-594-5032</p> <p>Contact Email   <a href="mailto:maos2@mail.nih.gov">maos2@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>   |  |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   21-Jun-2021 , 19-Oct-2021 , 21-Feb-2022</p> <p>Synopsis   The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K08 and K23 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$50,000 direct costs per year for each of two years, the NIAMS is seeking to enhance the capability of its clinical scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.</p> |  |                |               |                |
| 079367  | <a href="#">Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)</a>   | National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS | PAR-19-156     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone   301-451-4577</p> <p>Contact Email   <a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.</p>                                      |  |                |               |                |
| 088092  | <a href="#">NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)</a>   | National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS | PAR-20-084     | 07-May-2021   | 400,000 USD    |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Contact Name         | Randy King, Ph.D.   |
| Contact Telephone    | 301-451-0707  |
| Contact Email        | <a href="mailto:Randy.King@nih.gov">Randy.King@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023   |
| Synopsis             | This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators ( <a href="https://grants.nih.gov/policy/early-investigators/index.htm">https://grants.nih.gov/policy/early-investigators/index.htm</a> ) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review. |

|        |  |   |           |                                     |             |
|--------|--|---|-----------|-------------------------------------|-------------|
| 097282 | <a href="#">Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed)</a> | National Institute of Child Health and Human Development/NIH/DHHS | PA-20-282 | 19-May-2021 [Optional][LOI/Pre-App] | 275,000 USD |
|--------|--|---|-----------|-------------------------------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Susan Taymans, PhD   |
| Contact Telephone    | 301-496-6517   |
| Contact Email        | <a href="mailto:Taymanss@mail.nih.gov">Taymanss@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 19-May-2021 [Optional][LOI/Pre-App], 19-Jun-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 19-Feb-2022 , 19-Sep-2022 [Optional][LOI/Pre-App], 19-Oct-2022 , 19-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023  |
| Synopsis             | National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and Office of Disease Prevention (ODP) invite applications for exploratory/developmental research that explores the |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

|        |   |   |           |  |               |
|--------|---|---|-----------|--|---------------|
| 097283 | <a href="#">Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional)</a> | National Institute of Child Health and Human Development/NIH/DHHS | PA-20-281 | 19-May-2021<br>[Optional][LOI/Pre-App] | Not Specified |
|--------|---|---|-----------|--|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Susan Taymans, PhD   |
| Contact Telephone    | 301-496-6517   |
| Contact Email        | <a href="mailto:Taymanss@mail.nih.gov">Taymanss@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 19-May-2021 [Optional][LOI/Pre-App], 19-Jun-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 19-Feb-2022 , 19-Sep-2022 [Optional][LOI/Pre-App], 19-Oct-2022 , 19-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023  |
| Synopsis             | National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), and Office of Disease Prevention (ODP) invite applications for exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program. |

|        |  |   |               |  |             |
|--------|--|---|---------------|--|-------------|
| 102078 | <a href="#">RFA-RM-21-011 -- Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)</a> | National Institute of Child Health and Human Development/NIH/DHHS | RFA-RM-21-011 | 18-May-2021<br>[Optional][LOI/Pre-App] | 200,000 USD |
|--------|--|---|---------------|--|-------------|



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

App]

|   |  |
|---|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 18-May-2021 [Optional][LOI/Pre-App], 18-Jun-2021<br><br>Synopsis | The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community. Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions. This FOA is a Common Fund initiative (Common Fund) through the NIH Office of the Director, Office of Strategic Coordination ( <a href="https://dpcpsi.nih.gov/">https://dpcpsi.nih.gov/</a> ). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by a trans-NIH team led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
|---|--|

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 079181 | <a href="#">Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Required)</a> | National Institute of Child Health and Human Development/NIH/DHHS | PAR-19-133 | 07-May-2021 | 300,000 USD |
|--------|--|---|------------|-------------|-------------|

|  |   |
|--|---|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 07-May-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Oct-2021 , 07-Jan-2022<br>Synopsis | Mahua Mukhopadhyay, PhD<br>301-435-6886<br><a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a><br><br><a href="#">Link to program URL</a><br>The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support |
|--|---|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         |   | <p>small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.</p>   |                |               |                |
| 099263  | <a href="#">Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract</a>                 | National Institute of Child Health and Human Development/NIH/DHHS   | NOT-HD-20-021  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Stuart B. Moss, PhD</p> <p>301-435-6979</p> <p><a href="mailto:mossstua@mail.nih.gov">mossstua@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>05-Jun-2021 , 16-Jun-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Feb-2022 , 16-Feb-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Feb-2023 , 16-Feb-2023 , 05-Jun-2023 , 16-Jun-2023</p> <p>The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.</p> |                |               |                |
| 100064  | <a href="#">Notice of Special Interest (NOSI): Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens</a>                    | National Institute of Child Health and Human Development/NIH/DHHS   | NOT-HD-20-022  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p>  | <p>Regina Bures, PhD</p> <p>301-496-9485</p>  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis This Notice of Special Interest (NOSI) encourages applications that propose to conduct secondary analyses using publicly available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost-effective research utilizing data and biospecimens collected with NICHD resources.</p>   |   |                |               |                |
| 101700  | <a href="#">Notice of Special Interest (NOSI): Biophysical and Biomechanical Aspects of Embryonic Development (R21)</a>  | National Institute of Child Health and Human Development/NIH/DHHS | NOT-HD-21-004  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Mahua Mukhopadhyay, PhD</p> <p>Contact Telephone 301-435-6886</p> <p>Contact Email <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022</p> <p>Synopsis The Notice of Scientific Interest (NOSI) is intended to encourage innovative and high risk/impact research in the area of physics/mechanics of embryonic development to be explored in model organisms. The research proposed under this program can explore approaches and concepts new to the area of developmental tissue mechanics, research and development of new technologies, or initial research and development of data upon which significant future research may be built. The focus of this NOSI is to promote research aimed at generating new and critical information about tissue mechanics relevant to vertebrate development and understanding the basis for developmental disorders.</p> |   |                |               |                |
| 075841  | <a href="#">Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional)</a>  | National Institute of Child Health and Human Development/NIH/DHHS | PA-18-839      | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name Ravi Ravindranath, PhD</p> <p>Contact Telephone 301-435-6889</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:ravindr@nih.gov">ravindr@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p> |   |                |               |                |
| 074839  | <p><a href="#">Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)</a></p>  | National Institute of Child Health and Human Development/NIH/DHHS | PA-18-791      | 07-May-2021   | 100,000 USD    |
|         | <p>Contact Name Marion Koso-Thomas, M.D, MPH</p> <p>Contact Telephone 301-435-6873</p> <p>Contact Email <a href="mailto:kosomari@nih.gov">kosomari@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH R03 Small</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| Grant Program award mechanism.

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 087243 | <a href="#">Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 Clinical Trial Not Allowed)</a> | National Institute of Child Health and Human Development/NIH/DHHS | PAR-20-065 | 16-Jun-2021 | 150,000 USD |
|--------|--|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Reiko Toyama, PhD   |
| Contact Telephone    | 301-435-2723  |
| Contact Email        | <a href="mailto:toyamar@mail.nih.gov">toyamar@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022   |
| Synopsis             | The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician-scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects. |

|        |   |   |            |             |             |
|--------|---|---|------------|-------------|-------------|
| 087240 | <a href="#">Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)</a> | National Institute of Child Health and Human Development/NIH/DHHS | PAR-20-064 | 07-May-2021 | 100,000 USD |
|--------|---|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Regina Bures, Ph.D.   |
| Contact Telephone    | 301-496-9485  |
| Contact Email        | <a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--|----------------|-------------------------------------|----------------|
|         | Synopsis   | The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.  |                |                                     |                |
| 085590  | <a href="#">Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)</a> | National Institute of Child Health and Human Development/NIH/DHHS  | PAR-19-375     | 07-May-2021                         | 200,000 USD    |
|         | Contact Name   | James N. Coulombe, Ph.D.   |                |                                     |                |
|         | Contact Telephone  | 301-451-1390   |                |                                     |                |
|         | Contact Email  | <a href="mailto:CoulombeJ@mail.nih.gov">CoulombeJ@mail.nih.gov</a>   |                |                                     |                |
|         | Sponsor Website  |  |                |                                     |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |                                     |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023  |                |                                     |                |
|         | Synopsis   | The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The goal of the Gabriella Miller Kids First Pediatric Data Resource is to build a collection of curated genomic and phenotypic data from childhood cancer and birth defects cohorts and provide a central portal where data and analysis tools will be readily accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed. |                |                                     |                |
| 102942  | <a href="#">RFA-HD-22-006 -- Pediatric Scientist Development Program (K12 Independent Clinical Trial Not Allowed)</a>                      | National Institute of Child Health and Human Development/NIH/DHHS  | RFA-HD-22-006  | 29-Jun-2021 [Optional][LOI/Pre-App] | 7,000,000 USD  |
|         | Contact Name   | Karen K. Winer   |                |                                     |                |
|         | Contact Telephone  | 301-435-6877   |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|---|----------------|-------------------------------------|----------------|
|         | <p>Contact Email <a href="mailto:winerk@mail.nih.gov">winerk@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021</p> <p>Synopsis This funding opportunity announcement (FOA) invites applications for the pediatric scientist development program (PSDP). This program constitutes a national network of mentors and scholars, in contrast to K12 programs that are based solely at a single applicant institution. The program will be responsible for identifying pediatricians who have completed their clinical training and who have promising research potential, and for matching them with established mentors with strong records of mentoring and research productivity. The program will develop guidelines for mentoring and career development in order to promote the successful transition of the candidates into independent research careers in academic settings.</p>  |   |                |                                     |                |
| 103217  | <a href="#">RFA-HD-22-010 -- Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)</a>   | National Institute of Child Health and Human Development/NIH/DHHS | RFA-HD-22-010  | 29-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name Esther Eisenberg, MD, MPH</p> <p>Contact Telephone 301-496-6516</p> <p>Contact Email <a href="mailto:eisenbes@mail.nih.gov">eisenbes@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to encourage the small business community to collaborate with scientists and clinicians in the fields of female and male reproductive medicine, infertility, andrology/urology, and gynecology to develop, adapt and validate discoveries in genomics, epigenomics, metabolomics and biomarkers to the clinical diagnosis and treatment of women and men with infertility, and diseases and disorders that affect fertility. The ultimate goal is to advance the application of precision medicine to reproductive health through the development of new procedures, assays, digital apps, devices or technologies that improve the specificity, accuracy and rapidity of diagnosis and enhance the individualization, safety and convenience of clinical care.</p> |   |                |                                     |                |
| 103462  | <a href="#">RFA-HD-22-013 -- Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed)</a>  | National Institute of Child Health and Human Development/NIH/DHHS | RFA-HD-22-013  | 29-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|---|----------------|-------------------------------------|----------------|
|         | <p>Contact Name   Rosalind B. King, PhD</p> <p>Contact Telephone   301-435-6986</p> <p>Contact Email   <a href="mailto:rozking@mail.nih.gov">rozking@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021</p> <p>Synopsis   The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.</p> |   |                |                                     |                |
| 103463  | <a href="#">RFA-HD-22-014 -- Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program FY 2022 (R24 Clinical Trial Not Allowed)</a>  | National Institute of Child Health and Human Development/NIH/DHHS | RFA-HD-22-014  | 29-Jun-2021 [Optional][LOI/Pre-App] | 600,000 USD    |
|         | <p>Contact Name   Rosalind B. King, PhD</p> <p>Contact Telephone   301-435-6986</p> <p>Contact Email   <a href="mailto:rozking@mail.nih.gov">rozking@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021</p> <p>Synopsis   The purpose of this funding announcement is to support a coordinating center for the NICHD Population Dynamics Centers Research Infrastructure Programs.</p>  |   |                |                                     |                |
| 075633  | <a href="#">The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)</a>   | National Institute of Child Health and Human Development/NIH/DHHS | PAR-18-831     | 03-Jun-2021                         | 275,000 USD    |
|         | <p>Contact Name   Stuart B. Moss, PhD</p> <p>Contact Telephone   301-435-6979</p> <p>Contact Email   <a href="mailto:mossstua@mail.nih.gov">mossstua@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>  |   |                |                                     |                |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL) 03-Jun-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.</p>  |   |                |               |                |
| 075836  | <a href="#">Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)</a>   | National Institute of Child Health and Human Development/NIH/DHHS | PA-18-838      | 07-May-2021   | 2,499,995 USD  |
|         | <p>Contact Name Ravi Ravindranath, PhD</p> <p>Contact Telephone 301-435-6889</p> <p>Contact Email <a href="mailto:ravindr@n@mail.nih.gov">ravindr@n@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH Research Project (R01) award mechanism.</p> |   |                |               |                |
| 074832  | <a href="#">Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01 - Clinical Trial Optional)</a>  | National Institute of Child Health and Human Development/NIH/DHHS | PA-18-790      | 07-May-2021   | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Contact Name         | Marion Koso-Thomas, M.D, MPH  |
| Contact Telephone    | 301-435-6873  |
| Contact Email        | <a href="mailto:kosomari@mail.nih.gov">kosomari@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021   |
| Synopsis             | National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH Research Project (R01) award mechanism. |

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 075624 | <a href="#">The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)</a> | National Institute of Child Health and Human Development/NIH/DHHS | PAR-18-830 | 03-Jun-2021 | 499,999 USD |
|--------|--|---|------------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Stuart B. Moss, PhD  |
| Contact Telephone    | 301-435-6979   |
| Contact Email        | <a href="mailto:mossstua@mail.nih.gov">mossstua@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 03-Jun-2021  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs. |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|---|----------------|-------------------------------------|----------------|
| 074138  | <a href="#">Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01 - Clinical Trial Optional)</a>   | National Institute of Child Health and Human Development/NIH/DHHS | PAR-18-766     | 07-May-2021                         | Not Specified  |
|         | <p>Contact Name Tracy King, MD, MPH</p> <p>Contact Telephone 301-402-1822</p> <p>Contact Email <a href="mailto:tracy.king@nih.gov">tracy.king@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis<br/>National Institute of Child Health and Human Development (NICHD) invites applications focusing on identification and management of behavioral symptoms and mental health conditions in individuals with intellectual disabilities (ID). Specific areas of interest for this funding opportunity are (1) applications to develop and validate assessment tools that reliably identify behavioral symptoms or diagnose mental health conditions in individuals with ID, and (2) applications studying the pharmacokinetics, safety and efficacy of specific psychotropic medications for treatment of behavioral symptoms or mental health conditions in individuals with ID. This FOA will use the NIH Research Project (R01) award mechanism.</p> |   |                |                                     |                |
| 103524  | <a href="#">RFA-HD-22-018 -- Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional)</a>   | National Institute of Child Health and Human Development/NIH/DHHS | RFA-HD-22-018  | 29-Jun-2021 [Optional][LOI/Pre-App] | 259,613 USD    |
|         | <p>Contact Name Christopher C. Lindsey, PhD</p> <p>Contact Telephone 301-435-6907</p> <p>Contact Email <a href="mailto:chris.lindsey@mail.nih.gov">chris.lindsey@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 29-Jun-2021 [Optional][LOI/Pre-App], 29-Jul-2021</p> <p>Synopsis<br/>The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved clinical biomarkers and companion biomarker diagnostics (e.g., point of care and/or direct-to-consumer tests, DTC) to support the clinical development of non-hormonal contraceptive product(s) for men and women.</p>  |   |                |                                     |                |
| 101831  | <a href="#">Notice of Special Interest (NOSI): NIDCR Support for Research on the</a>  | National Institute of Dental and                                  | NOT-DE-        | 05-Jun-2021                         | Not            |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <a href="#">Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)</a>  | Craniofacial Research/NIH/DHHS                                  | 21-001         |               | Specified      |
|         | <p>Contact Name   Amanda Melillo, Ph.D.</p> <p>Contact Telephone   301-529-7217</p> <p>Contact Email   <a href="mailto:amanda.melillo@nih.gov">amanda.melillo@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis   The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies focused on the physiological involvement of oral cavity and oral manifestations related to SARS-CoV-2 and/or Coronavirus Disease 2019 (COVID-19). Globally, the death toll for COVID-19 caused by the coronavirus SARS-CoV-2 has surpassed 1.9 million, and in the United States, more than 375,000 individuals have succumbed to the disease as of January 2021. Synergizing with a myriad of initiatives across NIH and responding to a palpable sense of public health urgency, NIDCR is positioned to address COVID-19 research knowledge gaps unique to our mission, as well as to facilitate broad and rapid dissemination of research findings. Outcomes from this NOSI are expected to strengthen the knowledge base of COVID-19 disease mechanisms and presentations in the oral cavity.</p> |   |                |               |                |
| 079343  | <a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-152     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Leslie A. Frieden, PhD</p> <p>Contact Telephone   301-496-4263</p> <p>Contact Email   <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent</p>  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | <p>research funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion 'Clinical Trial Required' FOA (PAR-18-360). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants" should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19-151).</p>   |                |               |                |
| 079337  | <a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS   | PAR-19-151     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>        | <p>Leslie A. Frieden, PhD</p> <p>301-496-4263</p> <p><a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should apply to the companion 'Clinical Trial Required' FOA (PAR-18-360). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-152).</p> |                |               |                |
| 087115  | <a href="#">Improving Oral Health and Reducing Disparities in Adolescents (R21 Clinical Trial Not Allowed)</a>   | National Institute of Dental and Craniofacial Research/NIH/DHHS   | PAR-20-059     | 07-May-2021   | 275,000 USD    |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|---|----------------|-------------------------------------|----------------|
|         | <p>Contact Name   Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone   301-594-5394</p> <p>Contact Email   <a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</p>  |   |                |                                     |                |
| 086963  | <a href="#">NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-20-046     | 07-May-2021                         | 200,000 USD    |
|         | <p>Contact Name   Lu Wang, Ph.D.</p> <p>Contact Telephone   301-594-4846</p> <p>Contact Email   <a href="mailto:wanglu@nidcr.nih.gov">wanglu@nidcr.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML).</p> |   |                |                                     |                |
| 102397  | <a href="#">RFA-DE-22-001 -- NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | RFA-DE-22-001  | 08-Jun-2021 [Optional][LOI/Pre-App] | 5,200,000 USD  |
|         | <p>Contact Name   Lillian Shum, PhD</p> <p>Contact Telephone   301-594-0618</p>  |   |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:ShumL@mail.nih.gov">ShumL@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021 , 26-Jul-2021</p> <p>Synopsis The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.</p> |   |                |               |                |
| 079222  | <p><a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Basic Experimental Studies with Humans Required)</a></p>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-141     | 07-May-2021   | Not Specified  |

|  |   |  |  |  |  |
|--|---|--|--|--|--|
|  | <p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications</p> |  |  |  |  |
|--|---|--|--|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' FOA (PAR-18-432). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA ( PAR-19-144 ).

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
| 079369 | <a href="#">NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Basic Experimental Studies with Humans Required)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-161 | 07-May-2021 | Not Specified |
|--------|---|---|------------|-------------|---------------|

Contact Name | Lynn Mertens King, Ph.D.  
 Contact Telephone | 301-594-5006  
 Contact Email | [lynn.king@nih.gov](mailto:lynn.king@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022

Synopsis | The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trial Required' NIDCR K01 PAR-18-359). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NIDCR K01 PAR-19-160 Clinical Trial Not Allowed.

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 079322 | <a href="#">NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-145 | 07-May-2021 | 200,000 USD |
|--------|--|---|------------|-------------|-------------|

Contact Name | Darien Weatherspoon, DDS, MPH  
 Contact Telephone | 301-594-5394



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.</p>  |   |                |               |                |
| 096097  | <p><a href="#">Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)</a></p>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-20-233     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Orlando Lopez, PhD</p> <p>Contact Telephone 301-402-4243</p> <p>Contact Email <a href="mailto:orlando.lopez@nih.gov">orlando.lopez@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.</p> |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID              | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|----------------------|---|---|----------------|---------------|----------------|--------------|-------------------------------|-------------------|--------------|---------------|--|-----------------|--|-------------|-------------------------------------|----------------------|---|----------|--|
| 076573               | <a href="#">Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 - Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-18-875     | 07-May-2021   | Not Specified  |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Darien Weatherspoon, DDS, MPH</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-594-5394</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-May-2021 , 05-Jun-2021 , 07-Sep-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH Research Project (R01) award mechanism.</td> </tr> </table> |   |                |               |                | Contact Name | Darien Weatherspoon, DDS, MPH | Contact Telephone | 301-594-5394 | Contact Email | <a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a> | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021   | Synopsis | National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH Research Project (R01) award mechanism. |
| Contact Name         | Darien Weatherspoon, DDS, MPH   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Telephone    | 301-594-5394  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Email        | <a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a>  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Sponsor Website      |   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Program URL          | <a href="#">Link to program URL</a>   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Synopsis             | National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH Research Project (R01) award mechanism.  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| 087114               | <a href="#">Improving Oral Health and Reducing Disparities in Adolescents (R01 Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-20-058     | 07-May-2021   | Not Specified  |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Darien Weatherspoon, DDS, MPH</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-594-5394</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</td> </tr> </table>                                   |   |                |               |                | Contact Name | Darien Weatherspoon, DDS, MPH | Contact Telephone | 301-594-5394 | Contact Email | <a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a>           | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 | Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.   |
| Contact Name         | Darien Weatherspoon, DDS, MPH   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Telephone    | 301-594-5394  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Email        | <a href="mailto:darien.weatherspoon@nih.gov">darien.weatherspoon@nih.gov</a>  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Sponsor Website      |   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Program URL          | <a href="#">Link to program URL</a>   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023   |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| 074728               | <a href="#">Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)</a>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-18-787     | 07-May-2021   | Not Specified  |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Chiayeng Wang, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-4647</td> </tr> </table>   |   |                |               |                | Contact Name | Chiayeng Wang, Ph.D.          | Contact Telephone | 301-827-4647 |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Name         | Chiayeng Wang, Ph.D.  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Telephone    | 301-827-4647  |   |                |               |                |              |                               |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Contact Email        | <a href="mailto:chiayeng.wang@nih.gov">chiayeng.wang@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021   |
| Synopsis             | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH Research Project (R01) award mechanism. |

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
| 083076 | <a href="#">Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-292 | 07-May-2021 | Not Specified |
|--------|---|---|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Kathryn Stein, Ph.D.   |
| Contact Telephone    | 301-827-4653   |
| Contact Email        | <a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022  |
| Synopsis             | This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic investigation of the interplay of genes/gene networks and environmental factors in dental, oral, craniofacial (DOC), and other diseases and conditions. |

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
| 100184 | <a href="#">National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-20-306 | 07-May-2021 | Not Specified |
|--------|---|---|------------|-------------|---------------|

|                   |                            |
|-------------------|----------------------------|
| Contact Name      | Dena Fischer, DDS, MSD, MS |
| Contact Telephone | 301-594-4876               |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |  |
|----------------------|--|
| Contact Email        | <a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 09-Feb-2022 , 07-May-2022 , 09-Jun-2022 , 07-Jul-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023  |
| Synopsis             | <p>The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational studies to be conducted in the National Dental PBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the National Dental PBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, consideration of the dental PBRN as an appropriate venue for conduct of the research, NIDCR program priorities, and availability of funds. The main goals of the dental PBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice. This FOA encourages applications proposing research studies that align with the goals of the dental PBRN.</p> |

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
| 079225  | <a href="#">NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-144     | 07-May-2021   | Not Specified  |

|                      |   |
|----------------------|---|
| Contact Name         | Leslie A. Frieden, PhD  |
| Contact Telephone    | 301-496-4263  |
| Contact Email        | <a href="mailto:leslie.frieden@nih.gov">leslie.frieden@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>                                 |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
|        | <p>Synopsis</p>   | <p>This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19- 141). The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.</p> |            |             |               |
| 079378 | <p><a href="#">NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Clinical Trial Not Allowed)</a></p> | National Institute of Dental and Craniofacial Research/NIH/DHHS   | PAR-19-160 | 07-May-2021 | Not Specified |

|                      |   |
|----------------------|---|
| Contact Name         | Lynn Mertens King, Ph.D.  |
| Contact Telephone    | 301-594-5006  |
| Contact Email        | <a href="mailto:lynn.king@nih.gov">lynn.king@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022   |
| Synopsis             | <p>The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor . This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-18-359).</p> |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
| 083077  | <a href="#">Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-293     | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name: Kathryn Stein, Ph.D.</p> <p>Contact Telephone: 301-827-4653</p> <p>Contact Email: <a href="mailto:kathryn.stein@nih.gov">kathryn.stein@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications to develop novel and robust experimental systems that offer approaches complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.</p>   |   |                |               |                |
| 086959  | <a href="#">NIDCR Research Grants for Analyses of Existing Genomics Data (R01 Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-20-045     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name: Lu Wang, Ph.D.</p> <p>Contact Telephone: 301-594-4846</p> <p>Contact Email: <a href="mailto:wanglu@nidcr.nih.gov">wanglu@nidcr.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis: The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed</p> |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         |  | analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.   |                |               |                |
| 079633  | <a href="#">Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS  | PAR-19-173     | 16-Jun-2021   | 275,000 USD    |
|         | Contact Name   | Preethi Chander, PhD   |                |               |                |
|         | Contact Telephone  | 301-827-4620   |                |               |                |
|         | Contact Email  | <a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022  |                |               |                |
|         | Synopsis   | This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan. |                |               |                |
| 096105  | <a href="#">Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)</a>      | National Institute of Dental and Craniofacial Research/NIH/DHHS  | PAR-20-232     | 07-May-2021   | Not Specified  |
|         | Contact Name   | Orlando Lopez, PhD   |                |               |                |
|         | Contact Telephone  | 301-402-4243   |                |               |                |
|         | Contact Email  | <a href="mailto:orlando.lopez@nih.gov">orlando.lopez@nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023  |                |               |                |
|         | Synopsis   | This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 100931 | <a href="#">NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-21-084 | 07-May-2021 | 200,000 USD |
|--------|--|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Preethi Chander, PhD  |
| Contact Telephone    | 301-827-4620  |
| Contact Email        | <a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024   |
| Synopsis             | This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application. |

|        |  |   |            |             |               |
|--------|--|---|------------|-------------|---------------|
| 102596 | <a href="#">NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-21-160 | 08-Jun-2021 | Not Specified |
|--------|--|---|------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Dena Fischer, DDS, MSD, MS                                     |
| Contact Telephone | 301-594-4876   |
| Contact Email     | <a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a> |
| Sponsor Website   |  |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 04-Oct-2022 , 07-Jan-2023 , 07-Feb-2023 , 07-May-2023 , 06-Jun-2023 , 07-Sep-2023 , 03-Oct-2023 , 07-Jan-2024 , 06-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this FOA are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-regulated product. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase (UH3) of up to five years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, NIDCR program priorities, and availability of funds. The UG3/UH3 application must be submitted as a single application with the final design of the UH3 clinical trial described in the application, following the instructions described in this FOA. The UG3 planning phase permits both scientific and operational planning activities, though the planning phase cannot be used to test for intervention safety or efficacy. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. Applications designed to test behavior change interventions or those used as tools to understand mechanisms of behavior change will not be supported by this FOA.</p> |   |                |               |                |
| 103255  | <p><a href="#">NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)</a></p>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-21-197     | 09-Jun-2021   | Not Specified  |
|         | <p>Contact Name Melissa W. Riddle, PhD</p> <p>Contact Telephone 301-451-3888</p> <p>Contact Email <a href="mailto:riddleme@mail.nih.gov">riddleme@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2021 , 07-Sep-2021 , 06-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 04-Oct-2022 , 07-Jan-2023 , 07-Feb-2023 , 07-May-2023 , 06-Jun-2023 , 07-Sep-2023 , 03-Oct-2023 , 07-Jan-2024 , 06-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | <p>conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years. Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and cost-effectiveness research (Stages IV/V).</p> |                |               |                |
| 069114  | <a href="#">NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)</a> | National Institute of Dental and Craniofacial Research/NIH/DHHS   | PAR-18-360     | 07-May-2021   | Not Specified  |
|         | Contact Name   | Leslie A. Frieden, PhD  |                |               |                |
|         | Contact Telephone  | 301-496-4263  |                |               |                |
|         | Contact Email  | <a href="mailto:leslie.frieden@mail.nih.gov">leslie.frieden@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022   |                |               |                |
|         | Synopsis   | <p>National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program. provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K22 Career Transition Award mechanism.</p>   |                |               |                |
| 081268  | <a href="#">Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical</a>                                 | National Institute of Dental and  | PAR-19-        | 07-May-2021   | Not            |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number                     | Deadline Date | Funding Amount |
|---------|--|---|------------------------------------|---------------|----------------|
|         | <a href="#">Trial Not Allowed</a>  |   | Craniofacial Research/NIH/DHHS 239 |               | Specified      |
|         | <p>Contact Name   Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone   301-594-5394</p> <p>Contact Email   <a href="mailto:darien.weatherspoon@mail.nih">darien.weatherspoon@mail.nih</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.</p> |   |                                    |               |                |
| 076575  | <a href="#">Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 - Clinical Trial Not Allowed)</a>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PA-18-874                          | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name   Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone   301-594-5394</p> <p>Contact Email   <a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>                           |   |                                    |               |                |
| 079632  | <a href="#">Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed)</a>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-172                         | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Preethi Chander, PhD</p> <p>Contact Telephone   301-827-4620</p>   |   |                                    |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:preethi.chander@nih.gov">preethi.chander@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.</p>   |   |                |               |                |
| 069107  | <a href="#">NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)</a>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-18-359     | 07-May-2021   | 625,000 USD    |
|         | <p>Contact Name Lynn Mertens King, PhD</p> <p>Contact Telephone 301-594-5006</p> <p>Contact Email <a href="mailto:lynn.king@nih.gov">lynn.king@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K01 Research Scientist Development Award - Research &amp; Training award mechanism.</p> |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
| 087123  | <a href="#">NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-20-060     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Dena Fischer, DDS, MSD, MS</p> <p>Contact Telephone   301-594-4876</p> <p>Contact Email   <a href="mailto:dena.fischer@nih.gov">dena.fischer@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected as part of a previous NIDCR award.</p>  |   |                |               |                |
| 081272  | <a href="#">Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed)</a>  | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-240     | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name   Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone   301-594-5394</p> <p>Contact Email   <a href="mailto:darien.weatherspoon@mail.nih.gov">darien.weatherspoon@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines “older adults” as those individuals age 65 years and older.</p> |   |                |               |                |
| 053538  | <a href="#">Precision Imaging of Oral Lesions (R21-Clinical Trial Not Allowed)</a>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-18-788     | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name   Chiayeng Wang, Ph.D.</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-827-4647</p> <p>Contact Email   <a href="mailto:chiayeng.wang@nih.gov">chiayeng.wang@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p> |   |                |               |                |
| 081212  | <p><a href="#">Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)</a></p>   | National Institute of Dental and Craniofacial Research/NIH/DHHS | PAR-19-238     | 07-May-2021   | Not Specified  |

|  |   |  |  |  |  |
|--|---|--|--|--|--|
|  | <p>Contact Name   Lynn Mertens King, PhD</p> <p>Contact Telephone   301-594-5006</p> <p>Contact Email   <a href="mailto:Lynn.King@nih.gov">Lynn.King@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial (DOC) research with a focus on behavioral and social sciences, and on genetics, genomics, bioinformatics and computational biology research. The intent of this program is to provide mid-career and senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field, in order to enrich their existing DOC research program; and (b) established investigators in other fields who seek training with DOC research investigators in order to facilitate the introduction of DOC research into an existing research program. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p> |  |  |  |  |
|--|---|--|--|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|---|----------------|-------------------------------------|----------------|
| 101371  | <a href="#">NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)</a>   | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-21-101     | 09-Jun-2021                         | 450,000 USD    |
|         | <p>Contact Name   Tracy Rankin, Ph.D., M.P.H.</p> <p>Contact Telephone   301-594-4748</p> <p>Contact Email   <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   09-Jun-2021 , 17-Feb-2022 , 13-Oct-2022 , 08-Jun-2023 , 15-Feb-2024</p> <p>Synopsis   NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.</p> |   |                |                                     |                |
| 101487  | <a href="#">RFA-DK-20-032 -- Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)</a>  | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | RFA-DK-20-032  | 22-May-2021 [Optional][LOI/Pre-App] | 600,000 USD    |
|         | <p>Contact Name   Henry B. Burch, M.D</p> <p>Contact Telephone   301-827-0827</p> <p>Contact Email   <a href="mailto:henry.burch@nih.gov">henry.burch@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 22-May-2022 [Optional][LOI/Pre-App], 22-Jun-2022 , 22-May-2023 [Optional][LOI/Pre-App], 22-Jun-2023</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy</p>  |   |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 080703 | <a href="#">Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)</a> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-19-222 | 07-May-2021 | 375,000 USD |
|--------|--|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Lawrence Agodoa, M.D.   |
| Contact Telephone    | 301-594-1932  |
| Contact Email        | <a href="mailto:SmallGrant4Diversity@niddk.nih.gov">SmallGrant4Diversity@niddk.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021   |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators: (1) from diverse backgrounds, including from groups nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Human Genome Research Institute (NHGRI) and (2) who at the time of award under this FOA will have/have had less than \$125,000 direct cost of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. |

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 076246 | <a href="#">Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)</a> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-18-857 | 07-May-2021 | 275,000 USD |
|--------|--|---|------------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Mary Evans, Ph.D.  |
| Contact Telephone    | 301-594-4578   |
| Contact Email        | <a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a> |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>                                  |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021                              |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |          |  |  |  |  |
|--|----------|--|--|--|--|
|  | Synopsis | <p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p> |  |  |  |
|--|----------|--|--|--|--|

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
| 101372 | <a href="#">NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)</a> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-21-102 | 07-May-2021 | Not Specified |
|--------|---|---|------------|-------------|---------------|

|  |                      |  |  |  |  |
|--|----------------------|--|--|--|--|
|  | Contact Name         | Tracy Rankin, Ph.D., M.P.H.  |  |  |  |
|  | Contact Telephone    | 301-594-4748   |  |  |  |
|  | Contact Email        | <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a>   |  |  |  |
|  | Sponsor Website      |  |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>  |  |  |  |
|  | Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024  |  |  |  |
|  | Synopsis             | <p>This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.</p> |  |  |  |

|        |  |   |            |             |               |
|--------|--|---|------------|-------------|---------------|
| 101373 | <a href="#">NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)</a> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-21-103 | 07-May-2021 | Not Specified |
|--------|--|---|------------|-------------|---------------|

|  |                   |                             |  |  |  |
|--|-------------------|-----------------------------|--|--|--|
|  | Contact Name      | Tracy Rankin, Ph.D., M.P.H. |  |  |  |
|  | Contact Telephone | 301-594-4748                |  |  |  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:rankint@mail.nih.gov">rankint@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.</p>   |   |                |               |                |
| 081339  | <a href="#">Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)</a>   | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAS-19-241     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Tamara G. Bavendam, MD, MS</p> <p>Contact Telephone 301-594-4733</p> <p>Contact Email <a href="mailto:tamara.bavendam@nih.gov">tamara.bavendam@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational and clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. Specific research topic areas supported by the SUITOR program, as outlined below, will change over time and will be updated annually through the NIH Guide to Grants and Contracts.</p> |   |                |               |                |
| 079079  | <a href="#">Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)</a>   | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAS-19-105     | 05-Jun-2021   | Not Specified  |
|         | Contact Name Terry Rogers Bishop, Ph.D.  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Contact Telephone 301-594-7726</p> <p>Contact Email <a href="mailto:terry.bishop@nih.gov">terry.bishop@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.</p>   |   |                |               |                |
| 085472  | <p><a href="#">Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)</a></p>  | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-19-365     | 07-May-2021   | 150,000 USD    |
|         | <p>Contact Name Lisa M. Spain, Ph.D.</p> <p>Contact Telephone 301-451-9871</p> <p>Contact Email <a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to provide NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p> |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID   | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---|---|--|----------------|-------------------------------------|----------------|
| This program will use the NIH Small Research Grant (R03) award mechanism. |   |  |                |                                     |                |
| 080580  | <a href="#">RFA-DK-19-004 -- Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)</a>   | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS  | RFA-DK-19-004  | 01-Jun-2021 [Optional][LOI/Pre-App] | 3,750,000 USD  |
|   | Contact Name  | Peter J. Perrin, Ph.D.   |                |                                     |                |
|   | Contact Telephone   | 301-451-3759   |                |                                     |                |
|   | Contact Email   | <a href="mailto:Peter.Perrin@nih.gov">Peter.Perrin@nih.gov</a>   |                |                                     |                |
|   | Sponsor Website   |  |                |                                     |                |
|   | Program URL   | <a href="#">Link to program URL</a>  |                |                                     |                |
|   | Deadline Dates (ALL)  | 01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021   |                |                                     |                |
|   | Synopsis  | <p>This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.</p> |                |                                     |                |
| 102917  | <a href="#">RFA-DK-20-034 -- Program to Advance the Career Development of Scientists from Diverse Backgrounds Conducting Nutrition, Obesity, Diabetes, and Related Research (U24 Clinical Trial Optional)</a> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS  | RFA-DK-20-034  | 14-Jun-2021 [Optional][LOI/Pre-App] | 2,650,000 USD  |
|   | Contact Name  | Mary E. Evans, Ph.D.   |                |                                     |                |
|   | Contact Telephone   | 301-594-4578   |                |                                     |                |
|   | Contact Email   | <a href="mailto:evansmary@niddk.nih.gov">evansmary@niddk.nih.gov</a>   |                |                                     |                |
|   | Sponsor Website   |  |                |                                     |                |
|   | Program URL   | <a href="#">Link to program URL</a>  |                |                                     |                |
|   | Deadline Dates (ALL)  | 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021   |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |                 |   |  |  |  |
|--|-----------------|---|--|--|--|
|  | <p>Synopsis</p> | <p>The purpose of this Funding Opportunity Announcement is to enhance the diversity of the research workforce who are available to successfully compete for independent research funding from NIH in the areas of nutrition, obesity, diabetes, and related conditions. This program will establish a consortium providing professional development, mentoring, networking, pilot and feasibility funds, and other opportunities designed to advance the career development of post-doctoral scholars and early career faculty from diverse backgrounds, including those from groups nationally underrepresented in biomedical and behavioral research, who intend to pursue a research career focused on nutrition, obesity, diabetes, and/or related conditions. The program will be administered through research institutions with substantial existing NIH funding within the research mission of NIDDK.</p> |  |  |  |
|--|-----------------|---|--|--|--|

|        |  |   |            |             |               |
|--------|--|---|------------|-------------|---------------|
| 084473 | <p><a href="#">NIDDK Central Repositories Non-renewable Sample Access (X01 Clinical Trial Not Allowed)</a></p> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-19-319 | 29-Jun-2021 | Not Specified |
|--------|--|---|------------|-------------|---------------|

|  |   |  |  |  |  |
|--|---|--|--|--|--|
|  | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Lisa M. Spain, Ph.D</p> <p>301-451-9871</p> <p><a href="mailto:SpainL@niddk.nih.gov">SpainL@niddk.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>29-Jun-2021 , 26-Oct-2021 , 01-Mar-2022 , 28-Jun-2022</p> <p>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at <a href="http://www.niddkrepository.org">www.niddkrepository.org</a>. Applicants must provide information from the NIDDK Central Repositories documenting sample availability. This FOA will utilize the NIH X01 Resource Access Award mechanism.</p> |  |  |  |
|--|---|--|--|--|--|

|        |   |   |            |             |             |
|--------|---|---|------------|-------------|-------------|
| 090534 | <p><a href="#">Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)</a></p> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-20-140 | 07-May-2021 | 275,000 USD |
|--------|---|---|------------|-------------|-------------|

|  |   |   |  |  |  |
|--|---|---|--|--|--|
|  | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> | <p>Daniel Gossett, Ph.D.</p> <p>301-594-7723</p> <p><a href="mailto:daniel.gossett@nih.gov">daniel.gossett@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> |  |  |  |
|--|---|---|--|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | Deadline Dates (ALL)  | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023  |                |               |                |
|         | Synopsis  | The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.  |                |               |                |
| 078518  | <a href="#">Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development (R01 Clinical Trial Not Allowed)</a> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS  | PA-19-065      | 07-May-2021   | Not Specified  |
|         | Contact Name  | Jose Serrano, M.D., Ph.D.  |                |               |                |
|         | Contact Telephone   | 301-594-8871   |                |               |                |
|         | Contact Email   | <a href="mailto:serranoj@mail.nih.gov">serranoj@mail.nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022  |                |               |                |
|         | Synopsis  | The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop “virtual coaches” by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate). |                |               |                |
| 080282  | <a href="#">High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)</a>  | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS  | PAR-19-202     | 01-Jun-2021   | Not Specified  |
|         | Contact Name  | Corinne M. Silva, Ph.D.  |                |               |                |
|         | Contact Telephone   | 301-451-7335   |                |               |                |
|         | Contact Email   | <a href="mailto:silvacm@mail.nih.gov">silvacm@mail.nih.gov</a>   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 , 02-Nov-2021</p> <p>Synopsis The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of NIDDK.</p>   |   |                |               |                |
| 076879  | <a href="#">Elucidating the Role of the Autonomic Nervous System in Peripheral Metabolism and Metabolic Disease through the Application of Novel Tools and Methodologies (RC2 Clinical Trial Optional)</a>  | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-18-898     | 01-Jun-2021   | Not Specified  |
|         | <p>Contact Name Karen Teff, Ph.D.</p> <p>Contact Telephone 301-594-8803</p> <p>Contact Email <a href="mailto:karen.teff@nih.gov">karen.teff@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for scientific advancements addressing the role of the autonomic nervous system in the regulation of peripheral metabolism and its role in diabetes, obesity and related metabolic disease. Interdisciplinary teams may propose to develop resources in the form of novel tools or methodologies that when applied to the autonomic nervous system will contribute to elucidating its functional role in metabolism. Alternatively, teams may focus on novel approaches to address specific knowledge gaps or scientific questions that will significantly contribute to our understanding of role of the autonomic nervous system in metabolism with the goal of accelerating scientific progress in the treatment and prevention of metabolic disease. This FOA will use the NIH RC2 High Impact Research and Research Infrastructure Programs award mechanism.</p> |   |                |               |                |
| 076166  | <a href="#">Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</a>   | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAR-18-854     | 10-May-2021   | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |  |
|----------------------|--|
| Contact Name         | Mary Evans, Ph.D.  |
| Contact Telephone    | 301-594-4578   |
| Contact Email        | <a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 10-May-2021 , 11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021  |
| Synopsis             | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism. |

|        |   |   |            |             |             |
|--------|---|---|------------|-------------|-------------|
| 091518 | <a href="#">Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)</a> | National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS | PAS-20-160 | 07-May-2021 | 600,000 USD |
|--------|---|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Susan Mendley, M.D.   |
| Contact Telephone    | 301- 827-1861   |
| Contact Email        | <a href="mailto:susan.mendley@nih.gov">susan.mendley@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023   |
| Synopsis             | This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.

|        |  |  |            |             |             |
|--------|--|--|------------|-------------|-------------|
| 102785 | <a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)</a> | National Institute of Environmental Health Sciences/NIH/DHHS | PAR-21-170 | 12-Jun-2021 | 375,000 USD |
|--------|--|--|------------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Carol Shreffler, PhD   |
| Contact Telephone    | 984-287-3322   |
| Contact Email        | <a href="mailto:shreffl1@niehs.nih.gov">shreffl1@niehs.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024  |
| Synopsis             | The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion ‘Independent Clinical Trial Required’ PAR 18-261. |

|        |  |  |            |             |             |
|--------|--|--|------------|-------------|-------------|
| 102787 | <a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)</a> | National Institute of Environmental Health Sciences/NIH/DHHS | PAR-21-171 | 12-Jun-2021 | 375,000 USD |
|--------|--|--|------------|-------------|-------------|

Contact Name | Carol Shreffler, PhD

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Contact Telephone   984-287-3322</p> <p>Contact Email   <a href="mailto:shreffl1@niehs.nih.gov">shreffl1@niehs.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis   The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial trial, as part of their research and career development. Applicants proposing basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants", must apply to companion FOA, PAR-21-170. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-21-172.</p> |  |                |               |                |
| 102788  | <p><a href="#">Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)</a></p>   | National Institute of Environmental Health Sciences/NIH/DHHS | PAR-21-172     | 12-Jun-2021   | 375,000 USD    |
|         | <p>Contact Name   Carol Shreffler, PhD</p> <p>Contact Telephone   984-287-3322</p> <p>Contact Email   <a href="mailto:shreffl1@niehs.nih.gov">shreffl1@niehs.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024</p> <p>Synopsis   The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

ancillary study to a clinical trial. Applicants to this FOA are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-171. Applicants proposing basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants”, should apply to the companion FOA PAR-21-170)

|        |  |  |               |             |             |
|--------|--|--|---------------|-------------|-------------|
| 084593 | <a href="#">RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)</a> | National Institute of Environmental Health Sciences/NIH/DHHS | RFA-ES-19-011 | 03-May-2021 | 275,000 USD |
|--------|--|--|---------------|-------------|-------------|

|   |   |
|---|---|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Martha I. Barnes, MS</p> <p>919-541-3335</p> <p><a href="mailto:barnes@niehs.nih.gov">barnes@niehs.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>03-May-2021 , 01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022</p> <p>This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.</p> |
|---|---|

|        |  |   |               |             |               |
|--------|--|---|---------------|-------------|---------------|
| 099774 | <a href="#">Notice of Special Interest (NOSI): Training Modules for Creating Safe, Inclusive, and Supportive Research Environments</a> | National Institute of General Medical Sciences/NIH/DHHS | NOT-GM-20-047 | 18-Jun-2021 | Not Specified |
|--------|--|---|---------------|-------------|---------------|

|   |  |
|---|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> | <p>Patrick H. Brown, Ph.D.</p> <p></p> <p><a href="mailto:patrick.brown@nih.gov">patrick.brown@nih.gov</a></p> |
|---|--|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | Sponsor Website   |   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 18-Jun-2021   |                |               |                |
|         | Synopsis  | The purpose of this Notice is to inform applicants of the topic areas for the June 18, 2021 due date of the NIGMS funding opportunity announcement (FOA) PAR-20-296 "Modules for Enhancing Biomedical Research Workforce Training (R25 - Clinical Trial Not Allowed)".  |                |               |                |
| 081443  | <a href="#">Exploratory Research for Technology Development (R21 - Clinical Trial Not Allowed)</a>            | National Institute of General Medical Sciences/NIH/DHHS   | PAR-19-254     | 16-Jun-2021   | 275,000 USD    |
|         | Contact Name  | Paul Sammak, Ph.D.  |                |               |                |
|         | Contact Telephone   |   |                |               |                |
|         | Contact Email   | <a href="mailto:paul.sammak@nih.gov">paul.sammak@nih.gov</a>  |                |               |                |
|         | Sponsor Website   |   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022   |                |               |                |
|         | Synopsis  | This Funding Opportunity Announcement (FOA) will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high-risk approaches with potential for significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been developed in the literature or with preliminary data. Published data can be used to establish the current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely-available preprints that have a Digital Object Identifier (DOI) are acceptable. |                |               |                |
| 083521  | <a href="#">Limited Competition: NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)</a> | National Institute of General Medical Sciences/NIH/DHHS   | PAR-19-301     | 15-Jun-2021   | 3,750,000 USD  |
|         | Contact Name  | Peter C. Preusch, Ph.D.   |                |               |                |
|         | Contact Telephone   |   |                |               |                |
|         | Contact Email   | <a href="mailto:preuschp@nigms.nih.gov">preuschp@nigms.nih.gov</a>  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for support of national or regional resources that will provide access to state-of-the-art facilities, equipment, technologies, research tools, software, and/or service to a substantial user base at institutions across multiple states (regional) or the country (national). These resources should already be established, although new resources formed through consolidation of multiple local or regional facilities are also eligible. They should be poised to achieve or already have achieved significant economies of scale and should be able to significantly increase access to the supported technologies or services for researchers across one or more regions or the country. Major new research and development efforts should not be included. For this FOA, a resource is defined as an activity that provides research capabilities and expertise to a large number of investigators and is available to any qualified investigator as a service. The intent is to provide access to investigators without regard to the particular biomedical focus of their research, but not to duplicate or replace resources supported by other NIH Institutes and Centers (ICs) or host institutions. Only those resources whose technical capabilities fall within the program areas supported by NIGMS will be supported. It is expected that the resource will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support. Stand-alone data resources and databases are not eligible for funding through this FOA. This FOA is limited to applications requesting support for resources that have been developed through previous NIGMS funding.</p> |   |                |               |                |
| 099764  | <p><a href="#">Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed)</a></p>   | National Institute of General Medical Sciences/NIH/DHHS | PAR-20-296     | 18-Jun-2021   | 250,000 USD    |
|         | <p>Contact Name Patrick H. Brown, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:patrick.brown@nih.gov">patrick.brown@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jun-2021 , 20-Jun-2022 , 19-Jun-2023</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Specifically, this FOA will support the development of training modules designed to be freely available, at no cost to the broader community to enhance training of the biomedical research workforce. Responsive topics will be indicated through Notices of Special Interest (NOSIs) released annually by NIGMS.

|        |  |   |            |             |               |
|--------|--|---|------------|-------------|---------------|
| 081442 | <a href="#">Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)</a> | National Institute of General Medical Sciences/NIH/DHHS | PAR-19-253 | 05-Jun-2021 | Not Specified |
|--------|--|---|------------|-------------|---------------|

Contact Name | Paul Sammak, Ph.D.  
 Contact Telephone |  
 Contact Email | [paul.sammak@nih.gov](mailto:paul.sammak@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022

Synopsis | This Funding Opportunity Announcement (FOA) will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact. The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. Proof of concept for the technology must have already been demonstrated, but there should still be significant technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three-year R01 application with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four-year duration (five years for Early Stage Investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive.

|        |   |  |               |                                     |             |
|--------|---|--|---------------|-------------------------------------|-------------|
| 087255 | <a href="#">RFA-MH-20-506 -- Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | RFA-MH-20-506 | 01-Jun-2021 [Optional][LOI/Pre-App] | 450,000 USD |
|--------|---|--|---------------|-------------------------------------|-------------|

Contact Name | Matthew Rudorfer, M.D.  
 Contact Telephone | 301-443-1111  
 Contact Email | [mrudorfe@mail.nih.gov](mailto:mrudorfe@mail.nih.gov)

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                 | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--|----------------|-------------------------------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis<br/>The purpose of this Funding Opportunity Announcement (FOA) is to encourage practice-based research aimed at refining and pilot testing developmentally-focused, theory-based efficacious prevention interventions that may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. This FOA is published in parallel to a companion FOA ( RFA-MH-20-505 ) that uses the R01 funding mechanism to support larger-scale, fully powered trials with this focus.</p>  |  |                |                                     |                |
| 087253  | <a href="#">RFA-MH-20-505 -- Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional)</a>  | National Institute of Mental Health/NIH/DHHS | RFA-MH-20-505  | 01-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name Matthew Rudorfer, M.D.</p> <p>Contact Telephone 301-443-1111</p> <p>Contact Email <a href="mailto:mrudorfe@mail.nih.gov">mrudorfe@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [Optional][LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis<br/>The purpose of this Funding Opportunity Announcement (FOA) is to encourage practice-based research aimed at testing the effectiveness of developmentally-focused theory-based efficacious prevention interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. The research should test prevention approaches that are both scalable and sustainable for implementation in pediatric-serving primary care settings, with an emphasis on populations experiencing mental health disparities. This FOA seeks to support clinical trials to establish the effectiveness of scalable prevention interventions when implemented using available resources within pediatric-serving primary care settings. This FOA is published in parallel to a companion R34 FOA (RFA-MH-20-506) that supports pilot effectiveness studies in preparation for the larger-scale, fully powered studies described in this FOA.</p> |  |                |                                     |                |
| 087198  | <a href="#">RFA-MH-20-351 -- Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)</a>   | National Institute of Mental Health/NIH/DHHS | RFA-MH-20-351  | 10-Jun-2021                         | 275,000 USD    |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |  |
|----------------------|--|
| Contact Name         | David McMullen, M.D.   |
| Contact Telephone    | 301-451-0180   |
| Contact Email        | <a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 10-Jun-2021  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies is outside the scope of this FOA. This FOA uses the R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity ( RFA-MH-20-350) seeks R01 grant applications. |

|        |  |  |               |             |               |
|--------|--|--|---------------|-------------|---------------|
| 087196 | <a href="#">RFA-MH-20-350 -- Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)</a> | National Institute of Mental Health/NIH/DHHS | RFA-MH-20-350 | 10-Jun-2021 | Not Specified |
|--------|--|--|---------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | David McMullen, M.D.   |
| Contact Telephone    | 301-451-0180   |
| Contact Email        | <a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 10-Jun-2021  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies is outside the scope of this FOA. This FOA uses the R01 grant mechanism, encouraging longer-term projects, whereas its companion funding opportunity RFA-MH-20-351 seeks R21 grant applications encouraging shorter, higher-risk applications.

|        |  |  |           |             |             |
|--------|--|--|-----------|-------------|-------------|
| 078787 | <a href="#">Emotion Regulation, Aging and Mental Disorder (R21 Clinical Trial Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS | PA-19-095 | 16-Jun-2021 | 275,000 USD |
|--------|--|--|-----------|-------------|-------------|

Contact Name | Jovier Evans, PhD  
 Contact Telephone | 301-443-1369  
 Contact Email | [jevans1@mail.nih.gov](mailto:jevans1@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021

Synopsis | This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

|        |  |  |            |             |             |
|--------|--|--|------------|-------------|-------------|
| 077729 | <a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional)</a> | National Institute of Mental Health/NIH/DHHS | PAR-18-941 | 16-Jun-2021 | 275,000 USD |
|--------|--|--|------------|-------------|-------------|

Contact Name | David McMullen, M.D.  
 Contact Telephone | 301-451-0180  
 Contact Email | [david.mcmullen@nih.gov](mailto:david.mcmullen@nih.gov)

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021</p> <p>Synopsis<br/>National Institute of Mental Health (NIMH) invites applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA will utilize the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p> |  |                |               |                |
| 077725  | <p><a href="#">Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Optional)</a></p>  | National Institute of Mental Health/NIH/DHHS | PAR-18-942     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name David McMullen, M.D.</p> <p>Contact Telephone 301-451-0180</p> <p>Contact Email <a href="mailto:david.mcmullen@nih.gov">david.mcmullen@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis<br/>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the</p>  |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         |   | <p>effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA may propose hypothesis-driven research , but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA.</p> |                |               |                |
| 077665  | <a href="#">Development and Optimization of Tasks and Measures for Functional Domains of Behavior (R01 Clinical Trial Not Allowed)</a>  | National Institute of Mental Health/NIH/DHHS   | PAR-18-930     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Sarah Morris, Ph.D.</p> <p>Contact Telephone   301-443-9233</p> <p>Contact Email   <a href="mailto:sarah.morris@nih.gov">sarah.morris@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis   National Institute of Mental Health (NIMH) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for the development and optimization of tasks and/or measures for constructs pertaining to functional aspects of behavior or cognitive/affective processes, for use in laboratory or population-based studies, clinical trials outcomes, or related research. This FOA encourages research that will result in the availability of tasks and measures that demonstrate: (1) good validity as a measure of a specific construct; (2) robust measurement properties; and (3) suitability for use across diverse participants. This FOA will use the NIH Research Project (R01) award mechanism.</p> |  |                |               |                |
| 078784  | <a href="#">Emotion Regulation, Aging and Mental Disorder (R01 Clinical Trial Not Allowed)</a>  | National Institute of Mental Health/NIH/DHHS   | PA-19-094      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Jovier Evans, PhD</p> <p>Contact Telephone   301-443-1369</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.</p> |  |                |               |                |
| 097908  | <a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)</a>  | National Institute of Mental Health/NIH/DHHS | PAR-20-263     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name David Panchision</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms,</p>  |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         |   | <p>these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established.</p> |                |               |                |
| 078030  | <a href="#">Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)</a>  | National Institute of Mental Health/NIH/DHHS  | PAR-19-027     | 05-Jun-2021   | 2,500,000 USD  |
|         | Contact Name  | Bettina Buhring   |                |               |                |
|         | Contact Telephone   | 301-443-1576  |                |               |                |
|         | Contact Email   | <a href="mailto:neurodevelopmentpar@mail.nih.gov">neurodevelopmentpar@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website   |   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 05-Jun-2021 , 05-Oct-2021   |                |               |                |
|         | Synopsis  | <p>This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion funding opportunity seeks shorter, higher-risk R21 grant applications.</p>   |                |               |                |
| 082860  | <a href="#">Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS  | PAR-19-289     | 05-Jun-2021   | Not Specified  |
|         | Contact Name  | Lois Winsky, Ph.D.  |                |               |                |
|         | Contact Telephone   | 301-443-5288  |                |               |                |
|         | Contact Email   | <a href="mailto:lwinsky@mail.nih.gov">lwinsky@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses. The objectives of the FOA will be accomplished by supporting basic and translational neuroscientists who are committed to improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivophysiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. As such, this FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p> |  |                |               |                |
| 083168  | <a href="#">Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)</a>  | National Institute of Mental Health/NIH/DHHS | PAR-19-297     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Anjené Addington</p> <p>Contact Telephone 301-443-6653</p> <p>Contact Email <a href="mailto:anjene.addington@nih.gov">anjene.addington@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.

|        |   |  |           |             |               |
|--------|---|--|-----------|-------------|---------------|
| 077196 | <a href="#">New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 (Collab) Clinical Trial Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS | PA-18-907 | 07-May-2021 | Not Specified |
|--------|---|--|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Alexander Arguello, PhD   |
| Contact Telephone    | 301-827-3547  |
| Contact Email        | <a href="mailto:alexander.arguello@nih.gov">alexander.arguello@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022   |
| Synopsis             | National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA should be used when two or more sites are needed to complete the study. For a linked set of collaborative R01s, each site must have its own Program Director/Principal Investigator and the set of linked applications provide a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA will use the NIH Research Project (R01) award mechanism. |

|        |  |  |           |             |               |
|--------|--|--|-----------|-------------|---------------|
| 077195 | <a href="#">New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS | PA-18-908 | 07-May-2021 | Not Specified |
|--------|--|--|-----------|-------------|---------------|

|              |                         |
|--------------|-------------------------|
| Contact Name | Alexander Arguello, PhD |
|--------------|-------------------------|

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-827-3547</p> <p>Contact Email   <a href="mailto:alexander.arguello@nih.gov">alexander.arguello@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA will use the NIH Research Project (R01) award mechanism.</p>  |  |                |               |                |
| 076937  | <p><a href="#">Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 (Collab) Clinical Trial Not Allowed)</a></p>  | National Institute of Mental Health/NIH/DHHS | PAR-18-905     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Anjené Addington</p> <p>Contact Telephone   301-443-6653</p> <p>Contact Email   <a href="mailto:anjene.addinton@nih.gov">anjene.addinton@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021</p> <p>Synopsis   National Institute of Mental Health (NIMH) invites applications for collaborative R01 projects from multidisciplinary teams that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address research projects that go beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and</p> |  |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

contributions. This FOA will use the NIH Research Project (R01) award mechanism.

|        |   |  |            |             |               |
|--------|---|--|------------|-------------|---------------|
| 076934 | <a href="#">Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 Clinical Trial Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS | PAR-18-904 | 05-Jun-2021 | Not Specified |
|--------|---|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Anjené Addington  |
| Contact Telephone    | 301-443-6653  |
| Contact Email        | <a href="mailto:anjene.addinton@nih.gov">anjene.addinton@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021   |
| Synopsis             | National Institute of Mental Health (NIMH) invites applications for projects that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. This FOA will use the NIH Research Project (R01) award mechanism. |

|        |   |  |            |             |               |
|--------|---|--|------------|-------------|---------------|
| 081132 | <a href="#">Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-19-236 | 05-Jun-2021 | Not Specified |
|--------|---|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Susan T. Azrin, Ph.D.   |
| Contact Telephone    | 301-443-3267  |
| Contact Email        | <a href="mailto:susan.azrin@nih.gov">susan.azrin@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022   |
| Synopsis             | Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         |   | <p>care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP in the U.S. by eliminating bottlenecks or closing gaps in the pathway to CSC services. Alternatively, applicants whose work in this area is at a developmental stage should consider applying to the companion R34 FOA PAR-19-235.</p> |                |               |                |
| 078035  | <a href="#">Basic Neurodevelopmental Biology of Brain Circuits and Behavior (R21 Clinical Trial Not Allowed)</a>  | National Institute of Mental Health/NIH/DHHS   | PAR-19-028     | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Bettina Buhring</p> <p>Contact Telephone   301-443-1576</p> <p>Contact Email   <a href="mailto:neurodevelopmentpar@mail.nih.gov">neurodevelopmentpar@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change during pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity seeks R01 grant applications.</p> |  |                |               |                |
| 077664  | <a href="#">High-Priority Areas for Research Leveraging EHR and Large-Scale Data (R01 Clinical Trial Not Allowed)</a>   | National Institute of Mental Health/NIH/DHHS   | PAR-18-929     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Farris Tuma, ScD</p> <p>Contact Telephone   301-443-9232</p> <p>Contact Email   <a href="mailto:ftuma@mail.nih.gov">ftuma@mail.nih.gov</a></p> <p>Sponsor Website  </p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis<br/>National Institutes of Health (NIH) and its participating Institutes and Centers, along with Department of Veterans Affairs (VA) invite applications to leverage large-scale, real-world data from electronic health records (EHRs) from a variety of systems (e.g., the Department of Defense (DOD), Department of Veterans Affairs (VA), Centers for Medicare and Medicaid Services administrative claims, as well as public or private health care systems and networks) to understand risk, onset, course, and impact of treatments and services for mental and neurological disorders and to identify promising new mental health and neurological disorders research. There is particular interest in leveraging EHRs and administrative data to 1) understand and improve the treatment of post traumatic psychopathology, including posttraumatic stress disorder, depression, traumatic brain injury (TBI), and risk for suicide; and 2) characterize post-trauma multi-symptom recovery trajectory patterns of TBI, that may include post traumatic stress disorder, depression, cognitive impairment, pain, substance abuse disorder and risk for suicide. NIMH also invites innovative approaches to use EHR and administrative data to understand risk, onset, course, and impact of treatments and services for mental disorders more broadly. This FOA will use the NIH Research Project (R01) award mechanism.</p> |  |                |               |                |
| 079331  | <a href="#">Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)</a>   | National Institute of Mental Health/NIH/DHHS | PAR-19-146     | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name Enrique Michelotti, PhD</p> <p>Contact Telephone 301-443-5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis<br/>This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA.</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| Applicants with preliminary data may wish to apply to the companion R01 mechanism ( PAR-19-147)

|        |  |  |            |             |             |
|--------|--|--|------------|-------------|-------------|
| 097912 | <a href="#">Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS | PAR-20-264 | 16-Jun-2021 | 275,000 USD |
|--------|--|--|------------|-------------|-------------|

|   |  |
|---|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>David Panchision</p> <p>301-443-5288</p> <p><a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023</p> <p>This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data.</p> |
|---|--|

|        |   |  |            |             |               |
|--------|---|--|------------|-------------|---------------|
| 079325 | <a href="#">Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS | PAR-19-147 | 07-May-2021 | Not Specified |
|--------|---|--|------------|-------------|---------------|

|  |  |
|--|--|
| <p>Contact Name</p> <p>Contact Telephone</p> | <p>Enrique Michelotti, PhD</p> <p>301-443-5415</p> |
|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.</p>  |  |                |               |                |
| 080146  | <a href="#">Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)</a>  | National Institute of Mental Health/NIH/DHHS | PAR-19-189     | 16-Jun-2021   | 450,000 USD    |
|         | <p>Contact Name Denise Juliano-Bult, M.S.W.</p> <p>Contact Telephone 301-443-1638</p> <p>Contact Email <a href="mailto:djuliano@mail.nih.gov">djuliano@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis The purpose of this funding announcement is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials. These areas include: 1) studies to identify mutable factors that impact access, continuity, utilization, quality, value, outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future intervention development 2) development and testing of new research tools, measures, or methods 3) testing the feasibility of integrating existing data sets to understand factors affecting access, quality or outcomes of care 4) pilot work on the learning mental health care system model as a means to enable practical studies of the value and effectiveness of services and treatments Studies focused on the development or preliminary testing of services interventions should be submitted under RFA-MH-18-706 (SPIN # 68982).</p> |  |                |               |                |
| 092681  | <a href="#">RFA-MH-20-500 -- Post-Acute Interventions for the Treatment of Anorexia</a>  | National Institute of Mental                 | RFA-MH-        | 15-May-2021   | 450,000        |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                 | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--|----------------|-------------------------------------|----------------|
|         | <a href="#">Nervosa (R34 Clinical Trial Required)</a>  | Health/NIH/DHHS                              | 20-500         | [Optional][LOI/Pre-App]             | USD            |
|         | <p>Contact Name   Mary Rooney, Ph.D., ABPP</p> <p>Contact Telephone   301-827-1325</p> <p>Contact Email   <a href="mailto:mary.rooney@nih.gov">mary.rooney@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>Synopsis   NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of interventions targeting sustained and enhanced treatment response following acute treatment for anorexia nervosa (AN). An emphasis is placed on trials that go beyond seeking incremental gains in intervention effects, and instead take a theory-driven, empirical approach to developing and testing interventions that will have a significant impact on weight restoration and psychological symptoms associated with AN. Consistent with an effectiveness framework, studies should take a deployment-focused approach to intervention development and testing, acknowledging that many patients will receive post-acute treatment from community providers unaffiliated with specialty eating disorder centers.</p> |  |                |                                     |                |
| 092121  | <a href="#">RFA-MH-20-525 -- NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)</a>  | National Institute of Mental Health/NIH/DHHS | RFA-MH-20-525  | 21-May-2021 [Optional][LOI/Pre-App] | 2,500,000 USD  |
|         | <p>Contact Name   Eric R. Murphy, Ph.D.</p> <p>Contact Telephone   301-443-9230 ?</p> <p>Contact Email   <a href="mailto:eric.murphy@nih.gov">eric.murphy@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   21-May-2021 [Optional][LOI/Pre-App], 20-Jun-2021 , 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022</p> <p>Synopsis   The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders.</p>  |  |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| The NIMH BRAINS program will focus on the research priorities and gap areas identified in the NIMH Strategic Plan.

|        |  |  |           |             |               |
|--------|--|--|-----------|-------------|---------------|
| 102818 | <a href="#">Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Required)</a> | National Institute of Mental Health/NIH/DHHS | PA-21-195 | 12-Jun-2021 | Not Specified |
|--------|--|--|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Ashlee Van't Veer   |
| Contact Telephone    | 301-443-3107  |
| Contact Email        | <a href="mailto:dnbbsstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a>   |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024   |
| Synopsis             | The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PA-21-194. |

|        |   |  |           |             |               |
|--------|---|--|-----------|-------------|---------------|
| 102817 | <a href="#">Mentored Career Transition Award for Intramural Fellows (K22 Clinical Trials Not Allowed)</a> | National Institute of Mental Health/NIH/DHHS | PA-21-194 | 12-Jun-2021 | Not Specified |
|--------|---|--|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Ashlee Van't Veer   |
| Contact Telephone    | 301-443-3107  |
| Contact Email        | <a href="mailto:dnbbsstrainingbranch@mail.nih.gov">dnbbstrainingbranch@mail.nih.gov</a>                                     |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 12-Jun-2021 , 12-Oct-2021 , 12-Feb-2022 , 12-Jun-2022 , 12-Oct-2022 , 12-Feb-2023 , 12-Jun-2023 , 12-Oct-2023 , 12-Feb-2024 |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |                 |   |  |  |  |
|--|-----------------|---|--|--|--|
|  | <p>Synopsis</p> | <p>The Mentored Career Transition Award for NIMH Intramural Fellows (K22) is a two-phase, mentored career development award program that is intended to facilitate a timely transition of qualified postdoctoral fellows in the NIMH Division of Intramural Programs (DIRP) from intramural postdoctoral research positions to extramural, academic tenure-track or equivalent faculty positions at eligible U.S. institutions. Both the intramural and extramural phases will be mentored, and the award will provide research support during the extramural phase to help awardees launch competitive, independent research programs. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion FOA, PA-21-195.</p> |  |  |  |
|--|-----------------|---|--|--|--|

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 102908 | <a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-175 | 05-Jun-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Andrew Rossi, Ph.D.   |
| Contact Telephone    | 301-443-1576  |
| Contact Email        | <a href="mailto:andrew.rossi@nih.gov">andrew.rossi@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 |

|  |                 |   |  |  |  |
|--|-----------------|---|--|--|--|
|  | <p>Synopsis</p> | <p>A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include</p> |  |  |  |
|--|-----------------|---|--|--|--|



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R01 grant mechanism, whereas its companion FOA, PAR-21-176, seeks shorter, higher-risk R21 grant applications.

|        |  |  |               |             |               |
|--------|--|--|---------------|-------------|---------------|
| 102537 | <a href="#">Notice of Special Interest (NOSI): Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings</a> | National Institute of Mental Health/NIH/DHHS | NOT-MH-21-090 | 05-Jun-2021 | Not Specified |
|--------|--|--|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Andrea Horvath Marques, MD, MPH, PhD  |
| Contact Telephone    | 301-646-7320  |
| Contact Email        | <a href="mailto:andrea.horvathmarques@nih.gov">andrea.horvathmarques@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024   |
| Synopsis             | The National Institute of Mental Health is issuing this Notice of Special Interest (NOSI) to highlight interest in developing and implementing prevention strategies to reduce suicide risk (suicide ideation and behavior, including acts of self-harm/suicide) and promote resilience among young people, age 10-24 years, in low-and middle-income countries (LMICs)and low-resources settings. NIMH welcomes applicants from LMICs and strongly encourages applicants from the United States or upper middle-income countries to partner with sites in LMICs. |

|        |   |  |            |             |               |
|--------|---|--|------------|-------------|---------------|
| 102513 | <a href="#">Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-135 | 15-Jun-2021 | Not Specified |
|--------|---|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Alexander Talkovsky, Ph.D.  |
| Contact Telephone    | 301-827-7614  |
| Contact Email        | <a href="mailto:alexander.talkovsky@nih.gov">alexander.talkovsky@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024 |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |          |  |  |  |  |
|--|----------|--|--|--|--|
|  | Synopsis | <p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p> |  |  |  |
|--|----------|--|--|--|--|

|        |   |  |            |             |             |
|--------|---|--|------------|-------------|-------------|
| 102507 | <a href="#">Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-131 | 15-Jun-2021 | 450,000 USD |
|--------|---|--|------------|-------------|-------------|

|  |                      |   |  |  |  |
|--|----------------------|---|--|--|--|
|  | Contact Name         | Joel Sherrill, Ph.D.  |  |  |  |
|  | Contact Telephone    | 301-443-2477  |  |  |  |
|  | Contact Email        | <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a>  |  |  |  |
|  | Sponsor Website      |   |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>   |  |  |  |
|  | Deadline Dates (ALL) | 15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024   |  |  |  |
|  | Synopsis             | <p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with</p> |  |  |  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------|----------------|---------------|----------------|
|         | <p>broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.). In this pilot effectiveness phase of research, NIMH places highest priority on intervention and service delivery approaches that can be justified in terms of their potential to substantially impact practice and public health. This FOA supports pilot studies and provides resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, pragmatic trial). Support for fully-powered effectiveness studies is provided through separate FOAs that utilize the R01 mechanism for single-site effectiveness trials (PAR-21-130; "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01).") and collaborative R01 mechanism for multi-site effectiveness trials (PAR-21-129;"Clinical Trials to Test the Effectiveness of Treatment, Prevention, and Services Interventions (Collaborative R01 Clinical Trial Required)"). Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p> |              |                |               |                |

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 102505 | <a href="#">Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-129 | 15-Jun-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Joel Sherrill, Ph.D.  |
| Contact Telephone    | 301-443-2477  |
| Contact Email        | <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024   |
| Synopsis             | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. Support for fully-powered effectiveness studies via a single R01 grant is provided through a separate FOA, PAR-21-130, "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01)." This FOA is designed for applicants seeking funding for multi-site collaborative clinical trials to establish the effectiveness of interventions. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 102509 | <a href="#">First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-133 | 15-Jun-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Margaret Grabb, Ph.D.  |
| Contact Telephone    | 301-443-3563   |
| Contact Email        | <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024  |
| Synopsis             | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         |   | <p>evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development. This FOA is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should consider one of the companion FOAs.</p>  |                |               |                |
| 102508  | <a href="#">Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS  | PAR-21-132     | 15-Jun-2021   | Not Specified  |
|         | Contact Name  | Adam Haim, Ph.D.  |                |               |                |
|         | Contact Telephone   | 301-435-3593  |                |               |                |
|         | Contact Email   | <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website   |   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024   |                |               |                |
|         | Synopsis  | <p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants pursuing other stages of the clinical trial</p> |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| pipeline should consider one of the companion FOAs

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 102506 | <a href="#">Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-130 | 15-Jun-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Joel Sherrill, Ph.D.   |
| Contact Telephone    | 301-443-2477   |
| Contact Email        | <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024  |
| Synopsis             | <p>NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA uses the R01 grant mechanism to support trials that are adequately powered and of sufficient scope to test effectiveness and examine mediators and moderators of response. Support for multi-site trials that require participation of two or more collaborative sites for completion of the study (e.g., in order to increase sample size, accelerate recruitment, or increase sample diversity and representation) is provided through a separate FOA, PAR-21-129 "Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01)." This FOA is designed for applicants seeking funding for single-site clinical trials to establish the effectiveness of interventions. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p> |

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 102530 | <a href="#">Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-137 | 15-Jun-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

Contact Name | Margaret Grabb, Ph.D.

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024</p> <p>Synopsis   NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-21-136 . Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.</p> |              |                |               |                |

|        |   |  |            |             |               |
|--------|---|--|------------|-------------|---------------|
| 102528 | <a href="#">Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-136 | 15-Jun-2021 | Not Specified |
|--------|---|--|------------|-------------|---------------|

|  |   |  |  |  |  |
|--|---|--|--|--|--|
|  | <p>Contact Name   Margaret Grabb, Ph.D.</p> <p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024</p> <p>Synopsis   NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in human, early testing of new interventions, confirmatory efficacy trials,</p> |  |  |  |  |
|--|---|--|--|--|--|



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

through to effectiveness trials. The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single-phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, PAR-21-137 or PAR-21-133.

|        |   |  |            |             |               |
|--------|---|--|------------|-------------|---------------|
| 102511 | <a href="#">Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-134 | 15-Jun-2021 | Not Specified |
|--------|---|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Alexander Talkovsky, Ph.D.  |
| Contact Telephone    | 301-827-7614  |
| Contact Email        | <a href="mailto:alexander.talkovsky@nih.gov">alexander.talkovsky@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 15-Jun-2021 , 15-Oct-2021 , 15-Feb-2022 , 15-Jun-2022 , 14-Oct-2022 , 15-Feb-2023 , 15-Jun-2023 , 17-Oct-2023 , 15-Feb-2024   |
| Synopsis             | NIMH solicits clinical trial applications through a series of Funding Opportunity Announcements (FOAs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. They may also be standalone interventions or augmentations of efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to 3 years for studies to replicate previous target |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

engagement findings, and to relate change in the intervention target/mechanism to clinical benefit. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support “go/no-go” decisions about further development and/or testing of the intervention. This FOA is designed for applicants seeking to fund pilot stages of research. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion FOAs.

|        |  |  |            |             |             |
|--------|--|--|------------|-------------|-------------|
| 102910 | <a href="#">Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)</a> | National Institute of Mental Health/NIH/DHHS | PAR-21-176 | 16-Jun-2021 | 275,000 USD |
|--------|--|--|------------|-------------|-------------|

|   |   |
|---|---|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Andrew Rossi, Ph.D.</p> <p>301-443-1576</p> <p><a href="mailto:andrew.rossi@nih.gov">andrew.rossi@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024</p> <p>A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA uses the R21 exploratory grant mechanism, whereas its companion FOA, PAR-21-175, seeks R01 grant applications for larger research applications that have an established premise.</p> |
|---|---|

## NIH Funding Opportunities

| SPIN ID              | Program Title  | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|----------------------|--|--|----------------|---------------|----------------|--------------|------------------|-------------------|--------------|---------------|--|-----------------|--|-------------|-------------------------------------|----------------------|---|----------|--|
| 103214               | <a href="#">Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 Clinical Trial Required)</a>  | National Institute of Mental Health/NIH/DHHS | PAR-21-211     | 16-Jun-2021   | 450,000 USD    |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Adam Haim, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-435-3593</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01, PAR-21-210.</td> </tr> </table> |  |                |               |                | Contact Name | Adam Haim, Ph.D. | Contact Telephone | 301-435-3593 | Contact Email | <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a> | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024 | Synopsis | NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01, PAR-21-210. |
| Contact Name         | Adam Haim, Ph.D.   |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Telephone    | 301-435-3593   |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Email        | <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>   |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Sponsor Website      |  |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Program URL          | <a href="#">Link to program URL</a>  |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024  |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Synopsis             | NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01, PAR-21-210.   |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| 103213               | <a href="#">Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)</a>  | National Institute of Mental Health/NIH/DHHS | PAR-21-210     | 05-Jun-2021   | Not Specified  |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Adam Haim, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-435-3593</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-</td> </tr> </table>   |  |                |               |                | Contact Name | Adam Haim, Ph.D. | Contact Telephone | 301-435-3593 | Contact Email | <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a> | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-     |          |  |
| Contact Name         | Adam Haim, Ph.D.   |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Telephone    | 301-435-3593   |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Email        | <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a>   |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Sponsor Website      |  |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Program URL          | <a href="#">Link to program URL</a>  |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-  |  |                |               |                |              |                  |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                 | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
| 080474  | <a href="#">Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)</a> | National Institute of Mental Health/NIH/DHHS | PAR-19-214     | 21-Jun-2021   | Not Specified  |

2024

NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support trials that are statistically powered to provide a definitive answer regarding the effectiveness of the post-acute phase intervention. Support for pilot effectiveness trials designed to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of post-acute phase intervention approaches is provided via the R34, PAR-21-211.

Contact Name | Lois Winsky, Ph.D.  
 Contact Telephone | 301-443-5288  
 Contact Email | [lwinsky@mail.nih.gov](mailto:lwinsky@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 21-Jun-2021 , 20-Oct-2021 , 21-Feb-2022

The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to specific chemical, physiological, or behavioral manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.   |                |               |                |
| 102539  | <a href="#">Notice of Special Interest (NOSI): Advancing Health Communication Research on HIV Prevention, Treatment and Cure</a> | National Institute of Mental Health/NIH/DHHS  | NOT-MH-21-105  | 25-May-2021   | Not Specified  |
|         | Contact Name   | Collene Lawhorn, Ph.D.  |                |               |                |
|         | Contact Telephone  | 301-828-7186  |                |               |                |
|         | Contact Email  | <a href="mailto:collene.lawhorn@nih.gov">collene.lawhorn@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 25-May-2021 , 05-Jun-2021 , 12-Jun-2021 , 16-Jun-2021 , 25-Jun-2021 , 08-Aug-2021 , 07-Sep-2021 , 25-Sep-2021 , 05-Oct-2021 , 12-Oct-2021 , 16-Oct-2021 , 25-Oct-2021 , 08-Dec-2021 , 07-Jan-2022 , 25-Jan-2022 , 05-Feb-2022 , 12-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 08-Apr-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024 |                |               |                |
|         | Synopsis   | The National Institute of Mental Health is issuing this Notice to highlight interest in research applications to optimize health communication strategies that advance HIV prevention, treatment and cure.  |                |               |                |
| 081133  | <a href="#">Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)</a>                  | National Institute of Mental Health/NIH/DHHS  | PAR-19-235     | 16-Jun-2021   | 450,000 USD    |
|         | Contact Name   | Susan T. Azrin, Ph.D.   |                |               |                |
|         | Contact Telephone  | 301-443-3267  |                |               |                |
|         | Contact Email  | <a href="mailto:susan.azrin@nih.gov">susan.azrin@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |                 |  |  |  |  |
|--|-----------------|--|--|--|--|
|  | <p>Synopsis</p> | <p>Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. Alternatively, applicants who have already completed significant developmental or pilot work in this area are encouraged to apply to the companion R01 FOA PAR-19-236.</p> |  |  |  |
|--|-----------------|--|--|--|--|

|        |  |  |               |                                     |               |
|--------|--|--|---------------|-------------------------------------|---------------|
| 078105 | <p><a href="#">RFA-NS-19-006 -- BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)</a></p> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | RFA-NS-19-006 | 28-May-2021 [Optional][LOI/Pre-App] | Not Specified |
|--------|--|--|---------------|-------------------------------------|---------------|

|   |  |
|---|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Stephanie Fertig</p> <p>301-469-1779</p> <p><a href="mailto:BRAIN-FOAs@nih.gov">BRAIN-FOAs@nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>28-May-2021 [Optional][LOI/Pre-App], 27-Jun-2021</p> <p>This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report</p> |
|---|--|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

that are otherwise unavailable or impractical in their current form.

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 100818 | <a href="#">Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-21-058 | 04-May-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Mary Ann Pellemounter, PhD  |
| Contact Telephone    | 301-496-1779  |
| Contact Email        | <a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023   |
| Synopsis             | The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. |

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 100816 | <a href="#">Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-21-056 | 04-May-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Mary Ann Pellemounter, PhD   |
| Contact Telephone    | 301-496-1779   |
| Contact Email        | <a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023  |
| Synopsis             | The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 086929 | <a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 - No Independent Clinical Trial Allowed)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-20-049 | 07-May-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Stephen Korn, PhD  |
| Contact Telephone    |  |
| Contact Email        | <a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023  |
| Synopsis             | The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent small clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent small clinical trial as lead investigator, should apply to the companion FOA (PAR-20-050). |

|        |   |  |           |             |               |
|--------|---|--|-----------|-------------|---------------|
| 071756 | <a href="#">Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (R01 Clinical Trial Not Allowed)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PA-18-622 | 07-May-2021 | Not Specified |
|--------|---|--|-----------|-------------|---------------|

|                   |                       |
|-------------------|-----------------------|
| Contact Name      | Jill A. Morris, Ph.D. |
| Contact Telephone | 301-496-5745          |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name         | Sponsor Number  | Deadline Date | Funding Amount |
|---------|---------------|----------------------|---|---------------|----------------|
|         |               | Contact Email        | <a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a>  |               |                |
|         |               | Sponsor Website      |   |               |                |
|         |               | Program URL          | <a href="#">Link to program URL</a>   |               |                |
|         |               | Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021   |               |                |
|         |               | Synopsis             | <p>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus. This FOA will use the NIH Research Project (R01) award mechanism.</p> |               |                |

|        |   |  |           |             |               |
|--------|---|--|-----------|-------------|---------------|
| 077707 | <a href="#">Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PA-18-937 | 05-Jun-2021 | Not Specified |
|--------|---|--|-----------|-------------|---------------|

|  |                      |  |  |  |  |
|--|----------------------|--|--|--|--|
|  | Contact Name         | Michael L. Oshinsky, Ph.D.   |  |  |  |
|  | Contact Telephone    | 301-451-4460   |  |  |  |
|  | Contact Email        | <a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>   |  |  |  |
|  | Sponsor Website      |  |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>  |  |  |  |
|  | Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021  |  |  |  |
|  | Synopsis             | <p>National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain</p> |  |  |  |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| conditions. This FOA will use the NIH Research Project (R01) award mechanism.

|        |  |  |            |             |               |
|--------|--|--|------------|-------------|---------------|
| 086932 | <a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 - Clinical Trial Required)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-20-050 | 07-May-2021 | Not Specified |
|--------|--|--|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Stephen Korn, PhD   |
| Contact Telephone    |   |
| Contact Email        | <a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023   |
| Synopsis             | The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049). |

|        |   |  |           |             |             |
|--------|---|--|-----------|-------------|-------------|
| 071757 | <a href="#">Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (R21 Clinical Trial Not Allowed)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PA-18-623 | 07-May-2021 | 275,000 USD |
|--------|---|--|-----------|-------------|-------------|

|                   |  |
|-------------------|--|
| Contact Name      | Jill A. Morris, Ph.D.  |
| Contact Telephone | 301-496-5745   |
| Contact Email     | <a href="mailto:jill.morris@nih.gov">jill.morris@nih.gov</a> |
| Sponsor Website   |  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications that propose to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. The primary objective of this FOA is to remove barriers to hydrocephalus research that are due to scarcity of tools to investigate both the disease mechanisms and alternative therapies (non-shunt) in a rigorous manner. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>   |  |                |               |                |
| 079593  | <a href="#">Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)</a>   | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-19-171     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Adam L. Hartman, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email <a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 18-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered)). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p> |  |                |               |                |
| 100306  | <a href="#">NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</a>  | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-21-032     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Stephen Korn, Ph.D.</p> <p>Contact Telephone 301-496-4188</p>   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of “mentored training” within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p> |              |                |               |                |

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
| 072892  | <a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)</a>   | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-18-710     | 12-Jun-2021   | Not Specified  |
|         | <p>Contact Name Stephen Korn, Ph.D.</p> <p>Contact Telephone 301-496-4188</p> <p>Contact Email <a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 12-Jun-2021</p> |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | Synopsis   | National Institute of Neurological Disorders and Stroke (NINDS) invites applications to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K22 Career Transition Award mechanism.  |                |               |                |
| 072904  | <a href="#">Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)</a>                                   | National Institute of Neurological Disorders and Stroke/NIH/DHHS  | PAR-18-711     | 12-Jun-2021   | Not Specified  |
|         | Contact Name   | Stephen Korn, Ph.D.   |                |               |                |
|         | Contact Telephone  | 301-496-4188  |                |               |                |
|         | Contact Email  | <a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 12-Jun-2021   |                |               |                |
|         | Synopsis   | National Institute of Neurological Disorders and Stroke (NINDS) invites applications to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K22 Career Transition Award mechanism. |                |               |                |
| 097476  | <a href="#">NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS  | PAR-20-285     | 18-Jun-2021   | Not Specified  |
|         | Contact Name   | Claudia Scala Moy, PhD  |                |               |                |
|         | Contact Telephone  | 301-496-9135  |                |               |                |
|         | Contact Email  | <a href="mailto:moyc@ninds.nih.gov">moyc@ninds.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 18-Jun-2021 , 14-Oct-2021 , 22-Feb-2022 , 20-Jun-2022 , 18-Oct-2022 , 14-Feb-2023 , 14-Jun-2023   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |          |   |  |  |  |
|--|----------|---|--|--|--|
|  | Synopsis | <p>This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. NINDS intends that all multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet and that only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this program. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this FOA. This FOA uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement mechanism. Awards made under this FOA will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase.</p> |  |  |  |
|--|----------|---|--|--|--|

|        |  |  |               |             |               |
|--------|--|--|---------------|-------------|---------------|
| 097731 | <a href="#">Notice of Special Interest (NOSI): Platform Trials of Thrombectomy in Acute Stroke Treatment</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | NOT-NS-20-095 | 18-Jun-2021 | Not Specified |
|--------|--|--|---------------|-------------|---------------|

|  |                      |   |
|--|----------------------|---|
|  | Contact Name         | Claudia Scala Moy, PhD  |
|  | Contact Telephone    | 301-496-9135  |
|  | Contact Email        | <a href="mailto:moyc@ninds.nih.gov">moyc@ninds.nih.gov</a>  |
|  | Sponsor Website      |   |
|  | Program URL          | <a href="#">Link to program URL</a>   |
|  | Deadline Dates (ALL) | 18-Jun-2021   |
|  | Synopsis             | The NINDS is issuing this Notice of Special Interest in applications to establish a master protocol to conduct platform trials for treatments of ischemic stroke due to large vessel occlusion. Master protocols should incorporate advanced clinical trial methodologies such as, but not limited to, Bayesian modeling, response adaptive randomization, shared controls, and the ability for treatment arms to enter, leave, or be combined. Master protocols must be designed to allow future addition of |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | <p>trial questions. Strong representation of expertise from the neurology, neurosurgery, and interventional communities is required for such a multi-disciplinary approach and will be expected of applicants.</p>  |                |               |                |
| 086471  | <a href="#">NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</a>       | National Institute of Neurological Disorders and Stroke/NIH/DHHS  | PAR-20-021     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>      | <p>Stephen Korn, Ph.D.</p> <p>301-496-4188</p> <p><a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023</p> <p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p> |                |               |                |
| 098951  | <a href="#">Notice of Special Interest (NOSI): Administrative Supplements for Connecting Pre-mortem Clinical Information with Post-Mortem Brain Analysis</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS  | NOT-NS-21-001  | 28-Jun-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>  | <p>Debra Babcock, PhD, MD</p> <p>301-496-9964</p> <p><a href="mailto:dbabcock@mail.nih.gov">dbabcock@mail.nih.gov</a></p>   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Jun-2021</p> <p>Synopsis The Lewy Body Dementias (LBD) are frequently misdiagnosed or underdiagnosed during life, and despite the development of diagnostic criteria at multiple expert consensus conferences, the gold standard for diagnosis remains post-mortem brain analysis. Improvement in diagnostic accuracy during life, and the development of good quality diagnostic biomarkers, would be greatly facilitated if comprehensive, longitudinal clinical and biological data obtained on patients during life were regularly linked with detailed post-mortem brain examination. In response to recommendations from the Alzheimer's Disease Related Dementias (ADRD) Summits convened by the NINDS in 2013, 2016, and 2019, longitudinal clinical data and biospecimens are being collected from patients with LBD and shared with the research community through the Parkinson's Disease Biomarker Program (PDBP). The PDBP is an NINDS-funded resource that collects standardized clinical data and biospecimens longitudinally on patients with Parkinson's Disease (PD) and PD-related disorders (including LBD) with the goal of accelerating the pace of biomarkers research. The PDBP currently has data and biospecimens on about 1900 subjects, some of whom have gone to autopsy, though relatively little post-mortem data on these subjects is available in PDBP at this time.</p> |  |                |               |                |
| 100817  | <a href="#">Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)</a>   | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-21-057     | 04-May-2021   | Not Specified  |
|         | <p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email <a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.</p>  |  |                |               |                |
| 102739  | <a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE):</a>   | National Institute of Neurological                               | PAR-21-        | 17-Jun-2021   | 750,000        |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <a href="#">Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)</a>   | Disorders and Stroke/NIH/DHHS                                    | 123            |               | USD            |
|         | <p>Contact Name   Becky Roof, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   17-Jun-2021 , 19-Oct-2021 , 22-Feb-2022 , 21-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 20-Oct-2023 , 20-Feb-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.</p> |  |                |               |                |
| 102747  | <a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)</a>  | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-21-122     | 17-Jun-2021   | 750,000 USD    |
|         | <p>Contact Name   Becky Roof, PhD</p> <p>Contact Telephone   301-496-1779</p> <p>Contact Email   <a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   17-Jun-2021 , 19-Oct-2021 , 22-Feb-2022 , 21-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 20-Oct-2023 , 20-Feb-2024</p> <p>Synopsis   This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further</p>   |  |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.  |                |               |                |
| 100819  | <a href="#">Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS  | PAR-21-059     | 04-May-2021   | Not Specified  |
|         | Contact Name   | Mary Ann Pellemounter, PhD  |                |               |                |
|         | Contact Telephone  | 301-496-1779  |                |               |                |
|         | Contact Email  | <a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023   |                |               |                |
|         | Synopsis   | The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. |                |               |                |
| 103393  | <a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)</a>            | National Institute of Neurological Disorders and Stroke/NIH/DHHS  | PAR-21-153     | 12-Jun-2021   | Not Specified  |
|         | Contact Name   | Michelle Jones-London, Ph.D.  |                |               |                |
|         | Contact Telephone  | 301-451-7966  |                |               |                |
|         | Contact Email  | <a href="mailto:jonemiche@ninds.nih.gov">jonemiche@ninds.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
| 103392  | <a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)</a> | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-21-152     | 12-Jun-2021   | Not Specified  |

**Synopsis** | The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-152).

**Contact Name** | Michelle Jones-London, Ph.D.  
**Contact Telephone** | 301-451-7966  
**Contact Email** | [jonesmiche@ninds.nih.gov](mailto:jonesmiche@ninds.nih.gov)  
**Sponsor Website** |  
**Program URL** | [Link to program URL](#)  
**Deadline Dates (ALL)** | 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024

**Synopsis** | The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-153).

## NIH Funding Opportunities

| SPIN ID              | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
|----------------------|---|--|----------------|---------------|----------------|--------------|----------------------------|-------------------|--------------|---------------|--|-----------------|--|-------------|-------------------------------------|----------------------|---|----------|---|
| 083919               | <a href="#">Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)</a>   | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PAR-19-315     | 07-May-2021   | Not Specified  |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Mary Ann Pellemounter, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-496-1779</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.</td> </tr> </table> |  |                |               |                | Contact Name | Mary Ann Pellemounter, PhD | Contact Telephone | 301-496-1779 | Contact Email | <a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a> | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 07-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 | Synopsis | The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies. |
| Contact Name         | Mary Ann Pellemounter, PhD  |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Contact Telephone    | 301-496-1779  |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Contact Email        | <a href="mailto:mary.pellemounter@nih.gov">mary.pellemounter@nih.gov</a>  |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Sponsor Website      |   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Program URL          | <a href="#">Link to program URL</a>   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Deadline Dates (ALL) | 07-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Synopsis             | The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| 077714               | <a href="#">Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)</a>  | National Institute of Neurological Disorders and Stroke/NIH/DHHS | PA-18-939      | 16-Jun-2021   | 275,000 USD    |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Michael L. Oshinsky, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-4460</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Jun-2021 , 16-Oct-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying</td> </tr> </table>   |  |                |               |                | Contact Name | Michael L. Oshinsky, Ph.D. | Contact Telephone | 301-451-4460 | Contact Email | <a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>   | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021   | Synopsis | National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying   |
| Contact Name         | Michael L. Oshinsky, Ph.D.  |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Contact Telephone    | 301-451-4460  |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Contact Email        | <a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>  |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Sponsor Website      |   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Program URL          | <a href="#">Link to program URL</a>   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Synopsis             | National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying   |  |                |               |                |              |                            |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

|        |   |   |            |             |             |
|--------|---|---|------------|-------------|-------------|
| 078414 | <a href="#">Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS | PAR-19-058 | 07-May-2021 | 275,000 USD |
|--------|---|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Lynn S. Adams, Ph.D.  |
| Contact Telephone    | 301-594-8911  |
| Contact Email        | <a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022   |
| Synopsis             | The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities. |

|        |   |   |           |             |               |
|--------|---|---|-----------|-------------|---------------|
| 078636 | <a href="#">Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS | PA-19-073 | 07-May-2021 | Not Specified |
|--------|---|---|-----------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Lois A. Tully, PhD   |
| Contact Telephone    | 301-594-5968   |
| Contact Email        | <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |
| Synopsis             | The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount  |
|---------|---|--|----------------|---------------|---|
|         |   |  |                |               | telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies. |
| 077974  | <a href="#">Addressing Caregiver Symptoms through Technological Tools (R21 Clinical Trial Optional)</a>   | National Institute of Nursing Research/NIH/DHHS  | PA-19-024      | 07-May-2021   | 275,000 USD   |
|         | Contact Name  | Augie Diana, Ph.D.   |                |               |   |
|         | Contact Telephone   | 301-402-6423   |                |               |   |
|         | Contact Email   | <a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a>   |                |               |   |
|         | Sponsor Website   |  |                |               |   |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |   |
|         | Deadline Dates (ALL)  | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |                |               |   |
|         | Synopsis  | The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers. |                |               |   |
| 078635  | <a href="#">Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS  | PA-19-074      | 07-May-2021   | Not Specified   |
|         | Contact Name  | Lois A. Tully, PhD   |                |               |   |
|         | Contact Telephone   | 301-594-5968   |                |               |   |
|         | Contact Email   | <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>   |                |               |   |
|         | Sponsor Website   |  |                |               |   |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |   |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022  |                |               |   |
|         | Synopsis  | The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of  |                |               |   |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 079184 | <a href="#">Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)</a> | National Institute of Nursing Research/NIH/DHHS | PAR-19-135 | 07-May-2021 | 300,000 USD |
|--------|--|---|------------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Michelle R.J. Hamlet, PhD  |
| Contact Telephone    | 301-496-9623   |
| Contact Email        | <a href="mailto:hamletm@mail.nih.gov">hamletm@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Oct-2021 , 07-Jan-2022  |
| Synopsis             | <p>The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions (e.g., the university or college with a unique identifier number (such as DUNS) and a unique NIH Institutional Profile File (IPF) number)) must award NIH-relevant baccalaureate or advanced degrees in health professions and have received no more than \$6 million per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by the institution as a whole (meaning all schools and colleges within an institution). In other words, the funding for all the institution's health professional schools, graduate schools, and colleges and all the institution's non-health professional schools and colleges that are part of the institution are considered together and summed as total NIH funding when determining institutional eligibility. For institutions with multiple campuses, eligibility can be considered for each individual campus (e.g. main, satellite, etc.) only if a unique identifier number or NIH IPF number is established for each campus. For institutions that use one identifier number or NIH IPF number for all campuses, eligibility is determined for all campuses (e.g. main, satellite, etc.) together. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not</p> |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
| 079185 | <a href="#">End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS | PAR-19-136 | 07-May-2021 | Not Specified |
|--------|---|---|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Lynn S. Adams, Ph.D.   |
| Contact Telephone    | 301-594-8911   |
| Contact Email        | <a href="mailto:lynn.adams@nih.gov">lynn.adams@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022  |
| Synopsis             | The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers. |

|        |  |   |            |             |               |
|--------|--|---|------------|-------------|---------------|
| 084549 | <a href="#">Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS | PAR-19-321 | 07-May-2021 | Not Specified |
|--------|--|---|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Karen A. Kehl, PhD, RN, FPCN  |
| Contact Telephone    | 301-594-8010  |
| Contact Email        | <a href="mailto:karen.kehl@mail.nih.gov">karen.kehl@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022   |
| Synopsis             | The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and |





## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                    | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Name   Lynn S. Adams, Ph.D.</p> <p>Contact Telephone   301-594-8911</p> <p>Contact Email   <a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.</p> |   |                |               |                |
| 077788  | <a href="#">Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)</a>  | National Institute of Nursing Research/NIH/DHHS | PA-18-945      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Martha Matocha, PhD</p> <p>Contact Telephone   301-594-2775</p> <p>Contact Email   <a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.</p>   |   |                |               |                |
| 077972  | <a href="#">Addressing Caregiver Symptoms through Technological Tools (R01 Clinical Trial Optional)</a>  | National Institute of Nursing Research/NIH/DHHS | PA-19-023      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Augie Diana, Ph.D.</p> <p>Contact Telephone   301-402-6423</p> <p>Contact Email   <a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |          |   |  |  |  |
|--|----------|---|--|--|--|
|  | Synopsis | <p>The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.</p> |  |  |  |
|--|----------|---|--|--|--|

|        |  |   |           |             |               |
|--------|--|---|-----------|-------------|---------------|
| 074459 | <a href="#">Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS | PA-18-776 | 07-May-2021 | Not Specified |
|--------|--|---|-----------|-------------|---------------|

|  |                      |  |  |  |  |
|--|----------------------|--|--|--|--|
|  | Contact Name         | Sung Sug (Sarah) Yoon, PhD, RN   |  |  |  |
|  | Contact Telephone    | 301-402-6959   |  |  |  |
|  | Contact Email        | <a href="mailto:sungsug.yoon@nih.gov">sungsug.yoon@nih.gov</a>   |  |  |  |
|  | Sponsor Website      |  |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>  |  |  |  |
|  | Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021  |  |  |  |
|  | Synopsis             | <p>National Institute of Nursing Research (NINR) and Office of Dietary Supplements (ODS) invite applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and subsequently fetal development and the health of the newborn. This FOA will use the NIH Research Project (R01) award mechanism.</p> |  |  |  |

|        |   |   |           |             |             |
|--------|---|---|-----------|-------------|-------------|
| 077787 | <a href="#">Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS | PA-18-943 | 07-May-2021 | 275,000 USD |
|--------|---|---|-----------|-------------|-------------|

|  |                      |  |  |  |  |
|--|----------------------|--|--|--|--|
|  | Contact Name         | Lois A. Tully, PhD   |  |  |  |
|  | Contact Telephone    | 301-594-5968   |  |  |  |
|  | Contact Email        | <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>   |  |  |  |
|  | Sponsor Website      |  |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>  |  |  |  |
|  | Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |  |  |  |
|  | Synopsis             | <p>The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on</p> |  |  |  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount  |
|---------|---|--|----------------|---------------|---|
|         |   |  |                |               | the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness. |
| 077789  | <a href="#">Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)</a>                     | National Institute of Nursing Research/NIH/DHHS  | PA-18-946      | 07-May-2021   | 275,000 USD   |
|         | Contact Name  | Martha Matocha, PhD  |                |               |   |
|         | Contact Telephone   | 301-594-2775   |                |               |   |
|         | Contact Email   | <a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a>   |                |               |   |
|         | Sponsor Website   |  |                |               |   |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |   |
|         | Deadline Dates (ALL)  | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |                |               |   |
|         | Synopsis  | The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.   |                |               |   |
| 079344  | <a href="#">End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS  | PAR-19-153     | 07-May-2021   | 275,000 USD   |
|         | Contact Name  | Lynn S. Adams, Ph.D.   |                |               |   |
|         | Contact Telephone   | 301-594-8911   |                |               |   |
|         | Contact Email   | <a href="mailto:lynn.adams@nih.gov">lynn.adams@nih.gov</a>   |                |               |   |
|         | Sponsor Website   |  |                |               |   |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |   |
|         | Deadline Dates (ALL)  | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |                |               |   |
|         | Synopsis  | The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers. |                |               |   |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                    | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
| 076050  | <a href="#">Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)</a>   | National Institute of Nursing Research/NIH/DHHS | PA-18-850      | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name: Mary C. Roary, Ph.D.</p> <p>Contact Telephone: 301-594-2154</p> <p>Contact Email: <a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis: National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p> |   |                |               |                |
| 085884  | <a href="#">Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)</a>   | National Institute of Nursing Research/NIH/DHHS | PAR-19-382     | 07-May-2021   | 400,000 USD    |
|         | <p>Contact Name: Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone: 301-594-5970</p> <p>Contact Email: <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 16-Jul-2021 , 07-Sep-2021 , 16-Feb-2022 , 16-Mar-2022 , 07-May-2022 , 16-Jun-2022 , 16-Jul-2022 , 07-Sep-2022 , 16-Feb-2023 , 16-Mar-2023 , 07-May-2023</p> <p>Synopsis: The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>   |   |                |               |                |
| 085882  | <a href="#">Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)</a>   | National Institute of Nursing Research/NIH/DHHS | PAR-19-381     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name: Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone: 301-594-5970</p> <p>Contact Email: <a href="mailto:hussk@mail.nih.gov">hussk@mail.nih.gov</a></p>  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                    | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 05-Jul-2021 , 07-Sep-2021 , 05-Feb-2022 , 05-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>   |   |                |               |                |
| 102700  | <a href="#">Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards</a>  | National Institute of Nursing Research/NIH/DHHS | NOT-NR-21-001  | 25-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-May-2021 , 12-Jun-2021 , 08-Aug-2021 , 07-Sep-2021 , 25-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 25-Jan-2022 , 12-Feb-2022 , 08-Apr-2022 , 07-May-2022 , 25-May-2022 , 12-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 12-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 12-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 12-Jun-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The National Institute of Nursing Research (NINR) is committed to training the next generation of nurse scientists at all levels of education and encouraging training in important new areas of nursing research.</p> |   |                |               |                |
| 084550  | <a href="#">Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)</a>   | National Institute of Nursing Research/NIH/DHHS | PAR-19-320     | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name Karen A. Kehl, PhD, RN, FPCN</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email <a href="mailto:karen.kehl@mail.nih.gov">karen.kehl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | Synopsis  | The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care. |                |               |                |
| 076049  | <a href="#">Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)</a>                                    | National Institute of Nursing Research/NIH/DHHS  | PA-18-849      | 07-May-2021   | Not Specified  |
|         | Contact Name  | Mary C. Roary, Ph.D.   |                |               |                |
|         | Contact Telephone   | 301-594-2154   |                |               |                |
|         | Contact Email   | <a href="mailto:mary.roary@nih.gov">mary.roary@nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021  |                |               |                |
|         | Synopsis  | National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH Research Project (R01) award mechanism.   |                |               |                |
| 078362  | <a href="#">End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)</a> | National Institute of Nursing Research/NIH/DHHS  | PAR-19-044     | 07-May-2021   | 275,000 USD    |
|         | Contact Name  | Karen A. Kehl, Ph.D.   |                |               |                |
|         | Contact Telephone   | 301-594-8010   |                |               |                |
|         | Contact Email   | <a href="mailto:kehlka@nih.gov">kehlka@nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |                |               |                |
|         | Synopsis  | The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.   |                |               |                |
| 077785  | <a href="#">Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)</a>                                       | National Institute of Nursing Research/NIH/DHHS  | PA-18-944      | 07-May-2021   | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Contact Name   Lois A. Tully, PhD</p> <p>Contact Telephone   301-594-5968</p> <p>Contact Email   <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.</p> |                                      |                |                                     |                |
| 101126  | <a href="#">RFA-AG-22-002 -- Aging Effects on Osteoimmunology (R01 Clinical Trials Not Allowed)</a>  | National Institute on Aging/NIH/DHHS | RFA-AG-22-002  | 15-May-2021 [Optional][LOI/Pre-App] | 1,500,000 USD  |
|         | <p>Contact Name   John P. Williams, Ph.D.</p> <p>Contact Telephone   301-496-6403</p> <p>Contact Email   <a href="mailto:williamsj6@nih.nih.gov">williamsj6@nih.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA), issued by the National Institute on Aging (NIA) of the National Institutes of Health, solicits grant applications that will examine the role of aging in the interactions between the immune systems and skeletal systems in animal models. Research projects that will determine the mechanisms involved in how both aging of the bone marrow niche and immunosenescence impact these interactions, leading to pathological conditions in bone homeostasis, are the focus of this FOA.</p>  |                                      |                |                                     |                |
| 101456  | <a href="#">RFA-AG-22-006 -- New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)</a>  | National Institute on Aging/NIH/DHHS | RFA-AG-22-006  | 17-May-2021 [Optional][LOI/Pre-App] | 2,500,000 USD  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Name   Amanda DiBattista, Ph.D.</p> <p>Contact Telephone   301-827-3342</p> <p>Contact Email   <a href="mailto:amanda.dibattista@nih.gov">amanda.dibattista@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   17-May-2021 [Optional][LOI/Pre-App], 17-Jun-2021</p> <p>Synopsis   The goal of this Funding Opportunity Announcement is to support research on novel approaches and/or innovative expansion of existing approaches to identify the presence of neurogenesis and study its dynamics in brain aging and AD/ADRD.</p>   |                                      |                |               |                |
| 101790  | <a href="#">NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)</a>   | National Institute on Aging/NIH/DHHS | PAR-21-106     | 12-Jun-2021   | Not Specified  |
|         | <p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:NIAttraining@nih.gov">NIAttraining@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis   The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.</p> |                                      |                |               |                |
| 087474  | <a href="#">Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)</a>   | National Institute on Aging/NIH/DHHS | PAR-20-070     | 16-Jun-2021   | 1,775,000 USD  |
|         | <p>Contact Name   Winifred K. Rossi</p> <p>Contact Telephone   301-496-3836</p> <p>Contact Email   <a href="mailto:rossiw@mail.nih.gov">rossiw@mail.nih.gov</a></p>   |                                      |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.</p>  |                                      |                |                                     |                |
| 101921  | <a href="#">RFA-AG-22-008 -- The Cellular Scale Connectome in Aging and Alzheimer's Disease (U01 Clinical Trial Not Allowed)</a>   | National Institute on Aging/NIH/DHHS | RFA-AG-22-008  | 15-May-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name Mirosław 'Mack' Mackiewicz, Ph.D.</p> <p>Contact Telephone 301-594-7636</p> <p>Contact Email <a href="mailto:miroslaw.mackiewicz@nih.gov">miroslaw.mackiewicz@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-May-2021 [Optional][LOI/Pre-App], 15-Jun-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that will: (1) promote the development of a comprehensive characterization of brain circuits susceptible to Alzheimer's disease type pathology and/or neurodegeneration in mouse models of Alzheimer's disease (AD), (2) share data on the cell connectome in the aging and AD brain in a common reference brain cell atlas that integrates both molecular and anatomical annotations, and (3) complement and extend research on vulnerable cell types to include the mapping of connectivity changes between cells in aging and AD and provide a greater understanding of the mechanisms underlying resilience and vulnerability in AD.</p> |                                      |                |                                     |                |
| 084767  | <a href="#">Limited Competition: Renewals of, and Revisions and Resubmissions to, the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cooperative Agreement (U01 Clinical Trial Not Allowed)</a>  | National Institute on Aging/NIH/DHHS | PAR-19-338     | 05-Jun-2021                         | Not Specified  |
|         | <p>Contact Name John K. Hsiao, M.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:jhsiao@mail.nih.gov">jhsiao@mail.nih.gov</a></p>  |                                      |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--------------------------------------|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis This FOA invites revision, resubmission, or renewal applications to the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cooperative Agreement. Revision applications may not request funding beyond the project end date of the Parent award.</p>   |                                      |                |               |                |
| 075498  | <a href="#">Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)</a>   | National Institute on Aging/NIH/DHHS | PAR-18-820     | 07-May-2021   | 5,000,000 USD  |
|         | <p>Contact Name Lorenzo M. Refolo, Ph.D.</p> <p>Contact Telephone 301-594-7576</p> <p>Contact Email <a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Aging's (NIA) invites applications for pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</p> |                                      |                |               |                |
| 075524  | <a href="#">Analyses of Adherence Strategies and Data Sets from CALERIE to Explore Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R01 Clinical Trial Not Allowed)</a>   | National Institute on Aging/NIH/DHHS | PA-18-825      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Giovanna Zappalà, Ph.D., M.P.H.</p> <p>Contact Telephone 301-827-6240</p>  |                                      |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis<br/>National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals. This FOA will use the NIH Research Project (R01) award mechanism.</p> |                                      |                |               |                |
| 075519  | <a href="#">Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R01 Clinical Trial Not Allowed)</a>  | National Institute on Aging/NIH/DHHS | PA-18-823      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Giovanna Zappalà, Ph.D., M.P.H.</p> <p>Contact Telephone 301-827-6240</p> <p>Contact Email <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis<br/>National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans. This FOA will use the NIH Research Project (R01) award mechanism.</p>  |                                      |                |               |                |
| 083316  | <a href="#">Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional)</a>  | National Institute on Aging/NIH/DHHS | PAR-19-298     | 05-Jun-2021   | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Name   Kristina McLinden</p> <p>Contact Telephone   301-827-2563</p> <p>Contact Email   <a href="mailto:kristina.mclinden@nih.gov">kristina.mclinden@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis   The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination interventions are allowed, provided the focus and innovative component is neurostimulation. Applications that seek to develop devices, tools, or invasive techniques are outside the scope of this FOA.</p> |                                      |                |               |                |
| 083523  | <a href="#">NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)</a>  | National Institute on Aging/NIH/DHHS | PAR-19-302     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Sergei Romashkan, M.D., Ph.D.</p> <p>Contact Telephone   301-435-3047</p> <p>Contact Email   <a href="mailto:romashks@mail.nih.gov">romashks@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</p>  |                                      |                |               |                |
| 076719  | <a href="#">Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project: Opportunity for Revision Requests for Active Cooperative Agreements (U01 Clinical Trial Not Allowed)</a>   | National Institute on Aging/NIH/DHHS | PAR-18-890     | 05-Jun-2021   | 2,500,000 USD  |
|         | <p>Contact Name   Marilyn Miller, Ph.D.</p> <p>Contact Telephone   301-496-9350</p>   |                                      |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis<br/>National Institute on Aging (NIA) invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.</p> |                                      |                |               |                |
| 076590  | <a href="#">Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)</a>   | National Institute on Aging/NIH/DHHS | PAR-18-878     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Laurie Ryan</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis<br/>National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism.</p>  |                                      |                |               |                |
| 076587  | <a href="#">Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)</a>  | National Institute on Aging/NIH/DHHS | PAR-18-877     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Laurie Ryan</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website</p>   |                                      |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--------------------------------------|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement early stage (Phase I or II) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) to stimulate studies to enhance trial design and methods. This FOA will use the NIH Research Project (R01) award mechanism.</p> |                                      |                |               |                |
| 076718  | <p><a href="#">Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed)</a></p>   | National Institute on Aging/NIH/DHHS | PAR-18-889     | 05-Jun-2021   | 2,500,000 USD  |
|         | <p>Contact Name Marilyn Miller, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) invites the NIA Alzheimer's Disease Genetics Consortium to submit revision and/or renewal applications in the area of the genetics of Alzheimer's Disease. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.</p>  |                                      |                |               |                |
| 081010  | <p><a href="#">Pragmatic Clinical Trial on Efficacy of Managing Reduced Iron Stores on Risk of Clinically Important Events in Older Adults with Heart Failure and Anemia (U01 Clinical Trial Required)</a></p>   | National Institute on Aging/NIH/DHHS | PA-19-230      | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Sergei Romashkan, MD, Ph.D.</p> <p>Contact Telephone 301-435-3047</p> <p>Contact Email <a href="mailto:romashks@nia.nih.gov">romashks@nia.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis This FOA invites applications for a pragmatic clinical trial to establish efficacy of managing reduced iron stores on risk of</p>  |                                      |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| clinically important events in older adults with heart failure and anemia.

|        |  |                                      |            |             |               |
|--------|--|--------------------------------------|------------|-------------|---------------|
| 083551 | <a href="#">Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)</a> | National Institute on Aging/NIH/DHHS | PAR-19-305 | 16-Jun-2021 | Not Specified |
|--------|--|--------------------------------------|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Chhanda Dutta, Ph.D.   |
| Contact Telephone    | 301-496-4161   |
| Contact Email        | <a href="mailto:duttac@nia.nih.gov">duttac@nia.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022  |
| Synopsis             | <p>This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. This FOA provides support for up to two years (R21, milestone-driven exploratory phase) for preliminary, proof-of-concept studies, which is followed by up to three years of support (R33 phase) for further/expanded preclinical development of the candidate therapeutic. Applicants may request funds for the development of assays and other methodologies required for translational studies in the project budget for the R21 and/or R33 phases. Funding for the R33 phase will be contingent on successful completion of established milestones in the R21 phase. The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement. Applications using only the R21 mechanism will not be accepted under this FOA.</p> |

|        |  |                                      |            |             |               |
|--------|--|--------------------------------------|------------|-------------|---------------|
| 083550 | <a href="#">Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional)</a> | National Institute on Aging/NIH/DHHS | PAR-19-304 | 16-Jun-2021 | 1,500,000 USD |
|--------|--|--------------------------------------|------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Chhanda Dutta, Ph.D.                                       |
| Contact Telephone | 301-496-4161   |
| Contact Email     | <a href="mailto:duttac@nia.nih.gov">duttac@nia.nih.gov</a> |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |                      |  |  |  |  |
|--|----------------------|--|--|--|--|
|  | Sponsor Website      |  |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>  |  |  |  |
|  | Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022  |  |  |  |
|  | Synopsis             | <p>This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets. The R33 mechanism is intended to provide milestone-driven support (up to 5 years) for innovative exploratory and developmental research activities originally initiated under the R21 mechanism. Awardees from NIA's R21 T1 translational aging research program are encouraged to apply to this FOA to expand upon the translation of their candidate pharmacological interventions from prior studies. Other applicants with sufficient and strong preliminary/proof-of-concept data (equivalent to that achievable under a R21) for a novel drug target, new compound(s), or for a potential new clinical indication for an FDA-approved drug for age-related conditions are also eligible to apply to this FOA. The scope of early-stage T1 translational research activities to be conducted under the R33 is expected to vary with the stage of translation of the candidate therapeutic. Nevertheless, the R33 support should advance the experimental intervention closer to human testing (if warranted). The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement.</p> |  |  |  |

|        |   |                                      |               |             |               |
|--------|---|--------------------------------------|---------------|-------------|---------------|
| 097636 | <a href="#">Notice of Special Interest (NOSI): Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimer's Disease and Related Dementias (AD/ADRD)</a> | National Institute on Aging/NIH/DHHS | NOT-AG-20-040 | 07-May-2021 | Not Specified |
|--------|---|--------------------------------------|---------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Janine Simmons, M.D., Ph.D.  |
| Contact Telephone | 301-480-8959   |
| Contact Email     | <a href="mailto:janine.simmons@nih.gov">janine.simmons@nih.gov</a> |
| Sponsor Website   |  |
| Program URL       | <a href="#">Link to program URL</a>                                |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   This Notice of Special Interest (NOSI) is intended to underscore NIA’s continued commitment to psychological and neuroscientific research on affective, motivational, and social functions in midlife and aging. NIA supports research to further clarify the changes in and trajectories of these processes in adults who are aging normally and/or in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). NIA also seeks to understand how changes in the structure and function of neurobiological and neuromodulatory systems mediate or moderate affective, motivational, and social behaviors and interact with other psychological functions, including cognition. NIA’s goals are three-fold: (1) to advance understanding of normative maturational changes in affective, motivational, and social processes, their role in behavior and cognition, and their underlying integrative neural-behavioral mechanisms; (2) to elucidate how dysfunction in these processes might manifest in MCI and the early stages of AD/ADRD; and/or (3) to determine how dysfunction in these processes might account for any of the Behavioral and Psychological Symptoms of Dementia (BPSD) observed in AD/ADRD. Such studies may identify novel targets for preventative or therapeutic interventions to promote social, emotional, and cognitive well-being; facilitate adaptive function in aging; normalize social or emotional dysregulation; and/or strengthen social or emotional resilience at different stages of the life course and at different disease stages in AD/ADRD.</p> |                                      |                |               |                |
| 100297  | <p><a href="#">Notice of Special Interest (NOSI): Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging</a></p>  | National Institute on Aging/NIH/DHHS | NOT-AG-21-012  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Luci Roberts, Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:roberlu@mail.nih.gov">roberlu@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform applicants of NIA’s interest in research on the neural mechanisms underlying fundamental affective processes in aging. Grant applications are encouraged to 1) extend research on neural mechanisms underlying affective processes into aging models; and/or 2) seek to “reverse translate” clinical research results on affective processes in aging into model systems that support elucidation of fundamental neural mechanisms. NIA also wishes to encourage collaboration among cognitive and affective neuroscientists and/or investigators working at different levels of neurobiological and behavioral analysis.</p>   |                                      |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|        |  |                                      |           |             |             |
|--------|--|--------------------------------------|-----------|-------------|-------------|
| 075525 | <a href="#">Exploratory Analyses of Adherence Strategies and Data Sets from CALERIE to Investigate Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R21 Clinical Trial Not Allowed)</a> | National Institute on Aging/NIH/DHHS | PA-18-826 | 16-Jun-2021 | 275,000 USD |
|--------|--|--------------------------------------|-----------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Giovanna Zappalà, Ph.D., M.P.H.   |
| Contact Telephone    | 301-827-6240  |
| Contact Email        | <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 16-Jun-2021   |
| Synopsis             | National Institute on Aging (NIA) invites applications for exploratory research projects (R21) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals. This FOA will use the NIH Research Project (R01) award mechanism. |

|        |  |                                      |           |             |             |
|--------|--|--------------------------------------|-----------|-------------|-------------|
| 075522 | <a href="#">Exploratory Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R21 Clinical Trial Not Allowed)</a> | National Institute on Aging/NIH/DHHS | PA-18-824 | 16-Jun-2021 | 275,000 USD |
|--------|--|--------------------------------------|-----------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Giovanna Zappalà, Ph.D., M.P.H.  |
| Contact Telephone    | 301-827-6240   |
| Contact Email        | <a href="mailto:Giovanna.Zappala@nih.gov">Giovanna.Zappala@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 16-Jun-2021  |
| Synopsis             | National Institute on Aging (NIA) invites applications for exploratory research projects (R21) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         |   | Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.  |                |               |                |
| 087500  | <a href="#">Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)</a> | National Institute on Aging/NIH/DHHS   | PAR-20-071     | 16-Jun-2021   | 2,495,000 USD  |
|         | Contact Name  | Winifred K. Rossi  |                |               |                |
|         | Contact Telephone   | 301-496-3836   |                |               |                |
|         | Contact Email   | <a href="mailto:rossiw@mail.nih.gov">rossiw@mail.nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022  |                |               |                |
|         | Synopsis  | This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. |                |               |                |
| 086469  | <a href="#">Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)</a>   | National Institute on Aging/NIH/DHHS   | PAR-19-394     | 07-May-2021   | Not Specified  |
|         | Contact Name  | Shahrooz Vahedi, Ph.D.   |                |               |                |
|         | Contact Telephone   | 301-496-9322   |                |               |                |
|         | Contact Email   | <a href="mailto:shahrooz.vahedi@nih.gov">shahrooz.vahedi@nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | Synopsis   | The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA's strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.  |                |               |                |
| 086252  | <a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)</a>  | National Institute on Aging/NIH/DHHS  | PAS-19-393     | 16-Jun-2021   | 200,000 USD    |
|         | Contact Name   | Alison Yao, Ph.D.   |                |               |                |
|         | Contact Telephone  | 301-496-9350  |                |               |                |
|         | Contact Email  | <a href="mailto:alison.yao@nih.gov">alison.yao@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022   |                |               |                |
|         | Synopsis   | This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support. |                |               |                |
| 086244  | <a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed)</a> | National Institute on Aging/NIH/DHHS  | PAS-19-391     | 16-Jun-2021   | 200,000 USD    |
|         | Contact Name   | Partha Bhattacharyya, Ph.D.   |                |               |                |
|         | Contact Telephone  | 301-496-3136  |                |               |                |
|         | Contact Email  | <a href="mailto:bhattacharyyap@mail.nih.gov">bhattacharyyap@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |                 |  |  |  |  |
|--|-----------------|--|--|--|--|
|  | <p>Synopsis</p> | <p>This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.</p> |  |  |  |
|--|-----------------|--|--|--|--|

|        |   |                                      |            |             |             |
|--------|---|--------------------------------------|------------|-------------|-------------|
| 086248 | <p><a href="#">Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Basic Science (R03 Clinical Trials Not Allowed)</a></p> | National Institute on Aging/NIH/DHHS | PAS-19-392 | 16-Jun-2021 | 200,000 USD |
|--------|---|--------------------------------------|------------|-------------|-------------|

|  |   |   |  |  |  |
|--|---|---|--|--|--|
|  | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Lisa Opanashuk, Ph.D.</p> <p>301-807-5422</p> <p><a href="mailto:lisa.opanashuk@nih.gov">lisa.opanashuk@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.</p> |  |  |  |
|--|---|---|--|--|--|

|        |  |                                      |               |  |               |
|--------|--|--------------------------------------|---------------|--|---------------|
| 102870 | <p><a href="#">RFA-AG-22-012 -- High-Priority Behavioral and Social Research Networks in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R24 Clinical Trial Optional)</a></p> | National Institute on Aging/NIH/DHHS | RFA-AG-22-012 | 23-May-2021<br>[Optional][LOI/Pre-App] | 1,250,000 USD |
|--------|--|--------------------------------------|---------------|--|---------------|

|  |                     |                                 |  |  |  |
|--|---------------------|---------------------------------|--|--|--|
|  | <p>Contact Name</p> | <p>John W. R. Phillips, PhD</p> |  |  |  |
|--|---------------------|---------------------------------|--|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|--------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Contact Telephone   301- 827-4137</p> <p>Contact Email   <a href="mailto:John.Phillips@nih.gov">John.Phillips@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure via networks for behavioral and social research on Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD); attract new researchers into behavioral and social research on AD/ADRD; infuse a focus on health disparities into AD/ADRD research; and address ongoing needs for harmonization and biomarker collection in large population panel studies to support AD/ADRD research as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: decision neuroscience and aging; measurement for dementia care in home and community-based services (HCBS); the dementia care workforce; and education and AD/ADRD.</p> |                                      |                |                                     |                |
| 102872  | <p><a href="#">RFA-AG-22-013 -- High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional)</a></p>  | National Institute on Aging/NIH/DHHS | RFA-AG-22-013  | 23-May-2021 [Optional][LOI/Pre-App] | 1,250,000 USD  |
|         | <p>Contact Name   John W. R. Phillips, Ph.D.</p> <p>Contact Telephone   301- 827-4137</p> <p>Contact Email   <a href="mailto:John.Phillips@nih.gov">John.Phillips@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: midlife reversibility of biobehavioral risk associated with early life adversity; harmonization of Health and Retirement Study (HRS) international aging studies; biomarker collection in population studies;</p>  |                                      |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

and innovation in longitudinal aging studies.

|        |  |                                      |               |             |               |
|--------|--|--------------------------------------|---------------|-------------|---------------|
| 101997 | <a href="#">RFA-AG-22-011 -- Early-Phase Clinical Trials of Novel Interventions to Prevent, Delay, or Treat Aging-Related Conditions by Targeting Aging-Related Mechanisms (U01 Clinical Trial Required)</a> | National Institute on Aging/NIH/DHHS | RFA-AG-22-011 | 17-Jun-2021 | Not Specified |
|--------|--|--------------------------------------|---------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Irina Sazonova, Ph.D.  |
| Contact Telephone    | 301-435-3048   |
| Contact Email        | <a href="mailto:irina.sazonova@nih.gov">irina.sazonova@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 17-Jun-2021  |
| Synopsis             | NIA invites applications for Phase 1, 2a, and 2b clinical trials of new compounds or re-purposed existing drugs, biologics (except stem cells), or supplements to treat multiple chronic conditions by modulating fundamental aging-related mechanisms as well as to test compounds that could affect the individual diseases and conditions disproportionately affecting older adults. This FOA is not intended to provide support for definitive efficacy and safety trials. |

|        |   |                                      |               |             |               |
|--------|---|--------------------------------------|---------------|-------------|---------------|
| 102443 | <a href="#">Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration</a> | National Institute on Aging/NIH/DHHS | NOT-AG-21-016 | 05-Jun-2021 | Not Specified |
|--------|---|--------------------------------------|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Miroslaw Mackiewicz, Ph.D.  |
| Contact Telephone    | 301-496-9350  |
| Contact Email        | <a href="mailto:miroslaw.mackiewicz@nih.gov">miroslaw.mackiewicz@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023   |
| Synopsis             | The purpose of this Notice of Special Interest (NOSI) is to inform applicants to the National Institute on Aging (NIA) of NIA's interest in basic and clinical mechanistic research on neurological and neurocognitive sequelae originating from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and Coronavirus Disease 2019 (COVID-19) in aging and age- |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--------------------------------------|----------------|---------------|----------------|
|         |  |                                      |                |               |                |
|         | related neurodegeneration.   |                                      |                |               |                |
| 102978  | <a href="#">Limited Competition: Alzheimer's Disease Sequencing Project Follow-Up Study 2.0 (ADSP FUS 2.0): The Diverse Population Initiative (U01 Clinical Trial Not Allowed)</a>   | National Institute on Aging/NIH/DHHS | PAR-21-212     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name: Marilyn Miller, Ph.D.</p> <p>Contact Telephone: 301-496-9350</p> <p>Contact Email: <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, data calling, data sharing, data harmonization, and analysis that will support the generation of data from multi-ethnic cohorts for the Alzheimer's Disease Sequencing Project Follow-Up Study 2.0: The Diverse Population Initiative (ADSP FUS 2.0).</p> |                                      |                |               |                |
| 100902  | <a href="#">Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)</a>  | National Institute on Aging/NIH/DHHS | PAR-20-309     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name: Laurie Ryan, Ph.D.</p> <p>Contact Telephone: 301-496-9350</p> <p>Contact Email: <a href="mailto:ryanl@mail.nih.gov">ryanl@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.</p>  |                                      |                |               |                |
| 091505  | <a href="#">Translational Bioinformatics Approaches to Advance Drug</a>  | National Institute on Aging/NIH/DHHS | PAR-20-        | 05-Jun-2021   | Not            |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount   |
|---------|---|--------------------------------------|----------------|---------------|------------------|
|         | <a href="#">Repositioning and Combination Therapy Development for Alzheimer's Disease (R01 Clinical Trial Optional)</a>   |                                      |                |               | 156<br>Specified |
|         | <p>Contact Name   Jean Yuan, Ph.D.</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:yuanx4@mail.nih.gov">yuanx4@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.</p> |                                      |                |               |                  |
| 081131  | <a href="#">Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed) Activity Code)</a>   | National Institute on Aging/NIH/DHHS | PAR-19-234     | 05-Jun-2021   | Not Specified    |
|         | <p>Contact Name   Marilyn Miller, Ph.D.</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.</p>   |                                      |                |               |                  |
| 082123  | <a href="#">Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)</a>  | National Institute on Aging/NIH/DHHS | PAR-19-269     | 05-Jun-2021   | Not Specified    |
|         | <p>Contact Name   Marilyn Miller, Ph.D.</p> <p>Contact Telephone   301-496-9350</p>   |                                      |                |               |                  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.</p>   |   |                |               |                |
| 101160  | <a href="#">Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)</a>  | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | PAR-21-098     | 17-Jun-2021   | Not Specified  |
|         | <p>Contact Name William Dunty, PhD</p> <p>Contact Telephone 301-443-7351</p> <p>Contact Email <a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022 , 17-Jun-2022 , 18-Oct-2022 , 17-Feb-2023 , 19-Jun-2023 , 17-Oct-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider FOA (PAR-21-097, the R34 option).</p> |   |                |               |                |
| 101159  | <a href="#">Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)</a>  | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | PAR-21-097     | 17-Jun-2021   | 450,000 USD    |
|         | <p>Contact Name William Dunty, PhD</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-443-7351</p> <p>Contact Email   <a href="mailto:duntyw@mail.nih.gov">duntyw@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022 , 17-Jun-2022 , 18-Oct-2022 , 17-Feb-2023 , 19-Jun-2023 , 17-Oct-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-098, the R61/R33 option).</p> |   |                |               |                |
| 076319  | <a href="#">Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R01 - Clinical Trial Optional)</a>   | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | PA-18-863      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Robert Freeman, Ph.D.</p> <p>Contact Telephone   301-443-8820</p> <p>Contact Email   <a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL  </p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.</p>   |   |                |               |                |
| 101405  | <a href="#">RFA-AA-21-001 -- Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional)</a>   | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | RFA-AA-21-001  | 07-May-2021   | 2,500,000 USD  |
|         | <p>Contact Name   Laura E. Kwako, Ph.D.</p> <p>Contact Telephone   301-451-8507</p> <p>Contact Email   <a href="mailto:laura.kwako@nih.gov">laura.kwako@nih.gov</a></p>  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications on health disparities and health services-related research focusing on: 1.) access to treatment; 2.) making treatment more appealing; 3.) costs; 4.) dissemination and implementation. All Applications are expected to emphasize health disparities in addition to the other four areas of focus mentioned above.</p>  |   |                |               |                |
| 076324  | <a href="#">Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R21 - Clinical Trial Optional)</a>  | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | PA-18-862      | 07-May-2021   | 275,000 USD    |
|         | <p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email <a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p> |   |                |               |                |
| 076327  | <a href="#">Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)</a>  | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | PA-18-861      | 07-May-2021   | 100,000 USD    |
|         | <p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email <a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID              | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|----------------------|---|--|----------------|---------------|----------------|
| Synopsis             |   | National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R03 Small Grant Program award mechanism.  |                |               |                |
| 083915               | <a href="#">Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)</a>                             | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  | PAR-19-311     | 07-May-2021   | 1,775,000 USD  |
| Contact Name         |   | Elizabeth M Powell, PhD  |                |               |                |
| Contact Telephone    |   | 301-443-0786   |                |               |                |
| Contact Email        |   | <a href="mailto:elizabeth.powell3@nih.gov">elizabeth.powell3@nih.gov</a>   |                |               |                |
| Sponsor Website      |   |  |                |               |                |
| Program URL          |   | <a href="#">Link to program URL</a>  |                |               |                |
| Deadline Dates (ALL) |   | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022  |                |               |                |
| Synopsis             |   | This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660). |                |               |                |
| 097916               | <a href="#">Notice of Special Interest (NOSI): Secondary Analyses of Existing Alcohol Research Data</a> | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  | NOT-AA-20-018  | 07-May-2021   | Not Specified  |
| Contact Name         |   | Wenxing Zha, Ph.D.   |                |               |                |
| Contact Telephone    |   | 301-443-0633   |                |               |                |
| Contact Email        |   | <a href="mailto:zhaw@mail.nih.gov">zhaw@mail.nih.gov</a>   |                |               |                |
| Sponsor Website      |   |  |                |               |                |
| Program URL          |   | <a href="#">Link to program URL</a>  |                |               |                |
| Deadline Dates (ALL) |   | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | Synopsis  | <p>2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023</p> <p>The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research.</p> |                |               |                |
| 098270  | <a href="#">Notice of Special Interest (NOSI): Alcohol and Aging</a>  | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  | NOT-AA-20-019  | 07-May-2021   | Not Specified  |
|         | Contact Name  | Andras Orosz, Ph.D.  |                |               |                |
|         | Contact Telephone   | 301-443-2193   |                |               |                |
|         | Contact Email   | <a href="mailto:orosza@mail.nih.gov">orosza@mail.nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023  |                |               |                |
|         | Synopsis  | <p>The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. The following broad research areas will be encouraged: 1) Basic and clinical research defining the effects of alcohol consumption on lifespan, health span, and age-related diseases depending on level of alcohol consumption, drinking pattern, and duration of drinking; 2) Research to inform evidence-based guidance for identifying risk for alcohol use disorder (AUD) among older adults as well as prevention, diagnosis, and treatment of AUD in this population; and 3) Research to extend the health span of older adults who drink and decrease the health care burden of age-related diseases associated with alcohol use.</p>                             |                |               |                |
| 100945  | <a href="#">Notice of Special Interest (NOSI): Advances in Research for the Treatment, Services, and Recovery of Alcohol Use Disorder</a> | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  | NOT-AA-20-022  | 07-May-2021   | Not Specified  |
|         | Contact Name  | Brett T. Hagman, Ph.D.   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-443-0638</p> <p>Contact Email   <a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to advance research on various topics that fall within NIAAA's Division of Treatment and Recovery Research (DTRR). DTRR's research interests are wide-ranging and encompass broad categories such as health services, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for alcohol use disorder (AUD) treatment and sustaining recovery. Other areas of interest include topics focusing on special-emphasis and underserved populations, including NIH-designated U.S. health disparity populations, as well as those with co-occurring disorders; and fetal alcohol spectrum disorders (FASD). In all studies, at all levels from FASD to elderly, efforts will be made to include participants that reflect the diversity of the population at large.</p> |   |                |               |                |
| 101458  | <a href="#">Notice of Special Interest (NOSI): Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)</a>  | National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS | NOT-AA-20-024  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Li Lin</p> <p>Contact Telephone   301-827-7749</p> <p>Contact Email   <a href="mailto:linli@mail.nih.gov">linli@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants of the NIAAA's special interest in research project applications studying the harmful effects of alcohol on the body's tissues, organs, and systems in diverse populations across the lifespan.</p>   |   |                |               |                |
| 099940  | <a href="#">RFA-DC-20-002 -- NIDCD's Mentored Research Pathway for</a>  | National Institute on Deafness and                          | RFA-DC-        | 10-Jun-2021   | 2,499,990      |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name | Sponsor Number  | Deadline Date         | Funding Amount |
|---------|--|--------------|---|-----------------------|----------------|
|         | <a href="#">Otolaryngology Residents and Medical Students (R25 - Clinical Trial Not Allowed)</a>   |              | Other Communication Disorders/NIH/DHHS                                    | 20-002                | USD            |
|         | <p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jun-2021 , 10-Feb-2022 , 11-Oct-2022 , 13-Jun-2023</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDCD R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. In particular, this FOA seeks applications from institutional programs that can provide outstanding educational activities to medical students and resident-investigators in otolaryngology and foster their ability to transition to individual career development research awards. The program will support institutions to create a pathway in otolaryngology research careers through structured programs for medical students and resident-investigators with defined program milestones. Program participants are expected to continue in the next appropriate step to prepare for a research career, which may include an appointment to an institutional training grant or career development award, fellowship, or individual career development award.</p> |              |   |                       |                |
| 078368  | <a href="#">Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional)</a>   |              | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | PA-19-046 07-May-2021 | 275,000 USD    |
|         | <p>Contact Name Lana Shekim, Ph.D.</p> <p>Contact Telephone 301-496-5061</p> <p>Contact Email <a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This funding opportunity announcement (FOA) solicits Research Project Grants (R21) applications on augmentative and</p>   |              |   |                       |                |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.

|        |  |   |           |             |               |
|--------|--|---|-----------|-------------|---------------|
| 078310 | <a href="#">Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional)</a> | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | PA-19-047 | 07-May-2021 | Not Specified |
|--------|--|---|-----------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Lana Shekim, Ph.D.   |
| Contact Telephone    | 301-496-5061   |
| Contact Email        | <a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022  |
| Synopsis             | This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational. |

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
| 101155 | <a href="#">NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)</a> | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | PAR-21-063 | 07-May-2021 | 2,499,995 USD |
|--------|---|---|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Trinh T. Ly, M.D.   |
| Contact Telephone    | 301-435-4085  |
| Contact Email        | <a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|          |  |
|----------|--|
| Synopsis | <p>The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-064, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.</p> |
|----------|--|

|        |   |   |            |             |               |
|--------|---|---|------------|-------------|---------------|
| 101736 | <a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)</a> | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | PAR-21-096 | 07-May-2021 | Not Specified |
|--------|---|---|------------|-------------|---------------|

|   |  |
|---|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> | <p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p> <p><a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2021 , 08-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p>   |
| Synopsis  | <p>The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under PAR-21-094 "NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)" Applicants not planning an independent clinical trial or basic</p> |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA PAR-21-095 "NIDCD Research Career Enhancement Award for Established Investigators (K18Independent Clinical Trial Not Allowed)". |                |               |                |
| 101734  | <a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)</a>   | National Institute on Deafness and Other Communication Disorders/NIH/DHHS   | PAR-21-095     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone   301-496-1804</p> <p>Contact Email   <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 08-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study or an ancillary study to a clinical trial. proposing to serve as the lead investigator of an independent clinical trial, as part of their research and career development. Those planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-094 or for PAR-21-096 for Independent Basic Experimental Studies with Humans Required.</p> |   |                |               |                |
| 101733  | <a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)</a>  | National Institute on Deafness and Other Communication Disorders/NIH/DHHS   | PAR-21-094     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone   301-496-1804</p> <p>Contact Email   <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   07-May-2021 , 08-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-095). Applicants not planning an independent clinical trial, but planning a basic experimental study with humans, must apply to companion FOA PAR-21-096 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)</p> |   |                |               |                |
| 076005  | <a href="#">RFA-DC-19-001 -- NIDCD Hearing Healthcare for Adults: Improving Access and Affordability (R21/R33 Clinical Trials Optional)</a>   | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | RFA-DC-19-001  | 04-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Kelly King, Au.D., Ph.D.</p> <p>Contact Telephone   301-402-3458</p> <p>Contact Email   <a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   04-Jun-2021</p> <p>Synopsis   National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for research and/or infrastructure needs in emerging scientific areas leading to more accessible and affordable hearing health care for adults with mild to moderate hearing loss. The proposed research aims should be milestone-driven and lead to better hearing healthcare, targeting enhanced access and affordability, in an effort to improve outcomes for adults with hearing loss. The total project period for an application submitted in response to this FOA may not exceed five years. This FOA provides support for up to two years (R21 phase) for preliminary/developmental studies, followed by possible transition of up to four years of expanded research and development support (R33), although the total duration of the award may not exceed five years. This FOA requires measurable R21 milestones. This program will use the NIH R21/R33 Phased Innovation Award grant mechanism.</p>  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
| 101157  | <a href="#">NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)</a>  | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | PAR-21-064     | 10-Jun-2021   | Not Specified  |
|         | <p>Contact Name: Trinh T. Ly, M.D.</p> <p>Contact Telephone: 301-435-4085</p> <p>Contact Email: <a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 10-Jun-2021 , 13-Oct-2021 , 10-Feb-2022 , 10-Jun-2022 , 11-Oct-2022 , 10-Feb-2023 , 09-Jun-2023 , 10-Oct-2023</p> <p>Synopsis: The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well- designed and well- executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this FOA. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-21-063.</p> |   |                |               |                |
| 102240  | <a href="#">Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability</a>  | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | NOT-DC-21-001  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name: Kelly King, Au.D, Ph.D.</p> <p>Contact Telephone: 301-402-3458</p> <p>Contact Email: <a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 05-Jun-2021 , 16-Jun-2021 , 05-Sep-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  |   |                |               |                |
|         |  |   |                |               |                |
|         |  |   |                |               |                |
|         |  |   |                |               |                |
|         |  |   |                |               |                |
| 101085  | <a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)</a> | National Institute on Deafness and Other Communication Disorders/NIH/DHHS   | PAR-21-087     | 07-May-2021   | 315,000 USD    |
|         | Contact Name   | Alberto L. Rivera-Rentas, Ph.D.   |                |               |                |
|         | Contact Telephone  | 301-496-1804  |                |               |                |
|         | Contact Email  | <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024   |                |               |                |
|         | Synopsis   | <p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Independent Clinical Trial Required’ (PAR-21-085). Applicants not planning an independent clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion ‘Independent Clinical Trial Not Allowed’ (PAR-21-086) FOA.</p> |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
| 101080  | <a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)</a>   | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | PAR-21-086     | 07-May-2021   | 315,000 USD    |
|         | <p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..</p> |   |                |               |                |
| 101078  | <a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)</a>  | National Institute on Deafness and Other Communication Disorders/NIH/DHHS | PAR-21-085     | 07-May-2021   | 315,000 USD    |
|         | <p>Contact Name Alberto L. Rivera-Rentas, Ph.D.</p> <p>Contact Telephone 301-496-1804</p> <p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Synopsis</p> <p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-086). Observational Studies involving humans should submit under PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required).</p> |   |                |               |                |
| 079193  | <a href="#">NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional)</a>   | National Institute on Deafness and Other Communication Disorders/NIH/DHHS   | PAR-19-137     | 06-Jun-2021   | 7,500,000 USD  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>  | <p>Lana Shekim, Ph.D.</p> <p>301-496-5061</p> <p><a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>06-Jun-2021 , 06-Oct-2021</p> <p>The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a clinical trial but are not required to (optional).</p> |                |               |                |
| 101297  | <a href="#">NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)</a>   | National Institute on Deafness and Other Communication Disorders/NIH/DHHS   | PAR-21-107     | 24-Jun-2021   | 375,000 USD    |
|         | <p>Contact Name</p>  | <p>Bracie Watson, Jr.</p>   |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Contact Telephone    | 301-402-3458  |
| Contact Email        | <a href="mailto:watsonb@nidcd.nih.gov">watsonb@nidcd.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 24-Jun-2021 , 28-Oct-2021 , 24-Feb-2022 , 23-Jun-2022 , 27-Oct-2022 , 23-Feb-2023 , 29-Jun-2023 , 26-Oct-2023   |
| Synopsis             | The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application. |

| SPIN ID | Program Title  | Sponsor Name                              | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
| 101829  | <a href="#">Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection</a> | National Institute on Drug Abuse/NIH/DHHS | NOT-DA-21-011  | 05-Jun-2021   | Not Specified  |

|                      |   |
|----------------------|---|
| Contact Name         | Raul Mandler, MD; FAAN; FANA  |
| Contact Telephone    | 301-480-2541  |
| Contact Email        | <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 |
| Synopsis             | The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

of NOT-DA-20-084.

|        |   |   |           |             |             |
|--------|---|---|-----------|-------------|-------------|
| 094123 | <a href="#">Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional)</a> | National Institute on Drug Abuse/NIH/DHHS | PA-20-208 | 07-May-2021 | 100,000 USD |
|--------|---|---|-----------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Aria Crump, Sc.D.  |
| Contact Telephone    | 301-435-0881   |
| Contact Email        | <a href="mailto:acrump@nida.nih.gov">acrump@nida.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023  |
| Synopsis             | The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here ( <a href="https://www.drugabuse.gov/funding/funding-priorities">https://www.drugabuse.gov/funding/funding-priorities</a> ) or within the NIDA Strategic Plan ( <a href="https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan">https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan</a> ). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). |

|        |  |   |               |             |               |
|--------|--|---|---------------|-------------|---------------|
| 100294 | <a href="#">Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders</a> | National Institute on Drug Abuse/NIH/DHHS | NOT-DA-20-046 | 07-May-2021 | Not Specified |
|--------|--|---|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Roger G Sorensen, Ph.D., MPA  |
| Contact Telephone    | 301-443-3205  |
| Contact Email        | <a href="mailto:rsorensen@nida.nih.gov">rsorensen@nida.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 25-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 01-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | Synopsis  | The purpose of this notice is to encourage research project submissions examining the role of neuroimmune signaling in the CNS in relation to: the trajectory (i.e. initiation, escalation, and maintenance) of drug misuse; consequences of chronic exposure to misused drugs; abstinence and withdrawal from prolonged use; and relapse or reinstatement of drug taking at molecular, cellular, circuit, or behavioral levels.   |                |               |                |
| 085474  | <a href="#">Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)</a>  | National Institute on Drug Abuse/NIH/DHHS  | PAR-19-368     | 07-May-2021   | 2,499,995 USD  |
|         | Contact Name  | Marsha F. Lopez, Ph.D., M.H.S.   |                |               |                |
|         | Contact Telephone   | 301-443-6504   |                |               |                |
|         | Contact Email   | <a href="mailto:marsha.lopez@nih.gov">marsha.lopez@nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021  |                |               |                |
|         | Synopsis  | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance use and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. |                |               |                |
| 101989  | <a href="#">Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders</a> | National Institute on Drug Abuse/NIH/DHHS  | NOT-DA-21-018  | 07-May-2021   | Not Specified  |
|         | Contact Name  | Raul Mandler, MD   |                |               |                |
|         | Contact Telephone   | 301-480-2541   |                |               |                |
|         | Contact Email   | <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date  | Funding Amount |
|---------|---|---|----------------|--|----------------|
|         |   |   |                | 2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 |                |
|         | Synopsis  | NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.   |                |  |                |
| 102016  | <a href="#">Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19</a> | National Institute on Drug Abuse/NIH/DHHS   | NOT-DA-21-017  | 07-May-2021  | Not Specified  |
|         | Contact Name  | Raul Mandler, MD  |                |  |                |
|         | Contact Telephone   | 301-480-2541  |                |  |                |
|         | Contact Email   | <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>  |                |  |                |
|         | Sponsor Website   |   |                |  |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |  |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 |                |  |                |
|         | Synopsis  | NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.  |                |  |                |
| 078460  | <a href="#">Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)</a>  | National Institute on Drug Abuse/NIH/DHHS   | PAR-19-064     | 08-Jun-2021  | 275,000 USD    |
|         | Contact Name  | Marsha F. Lopez, PhD, MHS   |                |  |                |
|         | Contact Telephone   | 301-443-6504  |                |  |                |
|         | Contact Email   | <a href="mailto:lopezmar@mail.nih.gov">lopezmar@mail.nih.gov</a>  |                |  |                |
|         | Sponsor Website   |   |                |  |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |  |                |
|         | Deadline Dates (ALL)  | 08-Jun-2021 , 08-Oct-2021   |                |  |                |
|         | Synopsis  | This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 7 priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular  |                |  |                |

## NIH Funding Opportunities

| SPIN ID              | Program Title  | Sponsor Name                              | Sponsor Number | Deadline Date | Funding Amount |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
|----------------------|--|---|----------------|---------------|----------------|--------------|-----------------------|-------------------|--------------|---------------|--|-----------------|--|-------------|-------------------------------------|----------------------|---|----------|---|
|                      | <p>community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service;6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis); 7) research collecting and examining data on the risks and outcomes associated with substance use and COVID-19 infection in the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).</p>  |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| 090993               | <a href="#">NIDA Small Research Grant Program (R03 Clinical Trial Required)</a>  | National Institute on Drug Abuse/NIH/DHHS | PA-20-146      | 07-May-2021   | 100,000 USD    |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
|                      | <table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Katrina L Foster, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-827-5815</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:fosterkl@nih.gov">fosterkl@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.</td> </tr> </table> |   |                |               |                | Contact Name | Katrina L Foster, PhD | Contact Telephone | 301-827-5815 | Contact Email | <a href="mailto:fosterkl@nih.gov">fosterkl@nih.gov</a> | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 | Synopsis | The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA. |
| Contact Name         | Katrina L Foster, PhD  |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Contact Telephone    | 301-827-5815   |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Contact Email        | <a href="mailto:fosterkl@nih.gov">fosterkl@nih.gov</a>   |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Sponsor Website      |  |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Program URL          | <a href="#">Link to program URL</a>  |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023  |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Synopsis             | The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.  |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| 102120               | <a href="#">Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders</a>  | National Institute on Drug Abuse/NIH/DHHS | NOT-DA-21-019  | 07-May-2021   | Not Specified  |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
|                      | <table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Raul Mandler, MD</td> </tr> </table>   |   |                |               |                | Contact Name | Raul Mandler, MD      |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |
| Contact Name         | Raul Mandler, MD   |   |                |               |                |              |                       |                   |              |               |  |                 |  |             |                                     |                      |   |          |   |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                              | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-480-2541</p> <p>Contact Email   <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) inviting research applications to explore and develop telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and Substance Use Disorder (SUD).</p> |   |                |               |                |
| 077343  | <a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)</a>  | National Institute on Drug Abuse/NIH/DHHS | PAR-18-918     | 07-May-2021   | 150,000 USD    |
|         | <p>Contact Name   Steven Grant, Ph.D.</p> <p>Contact Telephone   301-443-4877</p> <p>Contact Email   <a href="mailto:sgrant@nida.nih.gov">sgrant@nida.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   National Institute on Drug Abuse (NIDA) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources. This program will use the NIH Small Research Grant (R03) award mechanism.</p>   |   |                |               |                |
| 083682  | <a href="#">Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)</a>   | National Institute on Drug Abuse/NIH/DHHS | PAR-19-310     | 07-May-2021   | 75,000 USD     |
|         | <p>Contact Name   Holly Moore, Ph.D.</p> <p>Contact Telephone   301-827-7376</p>   |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                              | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|---|----------------|-------------------------------------|----------------|
|         | <p>Contact Email <a href="mailto:holly.moore@nih.gov">holly.moore@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.</p> |   |                |                                     |                |
| 103015  | <a href="#">Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects</a>  | National Institute on Drug Abuse/NIH/DHHS | NOT-DA-21-028  | 05-Jun-2021                         | Not Specified  |
|         | <p>Contact Name Pamela G. Fleming</p> <p>Contact Telephone 301-480-1159</p> <p>Contact Email <a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in research on chemistry, pharmacology, biological targets and biochemical mechanisms that contribute to the effects of synthetic psychoactive substances.</p>   |   |                |                                     |                |
| 094254  | <a href="#">RFA-DA-21-019 --Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)</a>   | National Institute on Drug Abuse/NIH/DHHS | RFA-DA-21-019  | 20-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                              | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <p>Contact Name   John Satterlee, Ph.D.</p> <p>Contact Telephone   301-435-1020</p> <p>Contact Email   <a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021</p> <p>Synopsis   The purpose of this FOA is to support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder.</p>  |   |                |               |                |
| 103071  | <a href="#">Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain</a>  | National Institute on Drug Abuse/NIH/DHHS | NOT-DA-21-001  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Shang-Yi Anne Tsai, Ph.D</p> <p>Contact Telephone   301-827-5842</p> <p>Contact Email   <a href="mailto:stsai@nih.gov">stsai@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 16-Jun-2021 , 25-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.</p> |   |                |               |                |
| 102446  | <a href="#">Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning</a>   | National Institute on Drug Abuse/NIH/DHHS | NOT-DA-21-007  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Richard A. Jenkins PhD</p> <p>Contact Telephone   301-443-1923</p>   |   |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                              | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to increase the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions, as well as other publicly available data including those provided by government bodies, data warehouses and commercial data sources. Existing data may include data from completed projects as well as those that are ongoing. Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public policy. NIDA is particularly interested in research that integrates substance use considerations into program planning and policy to increase the quality of HIV services and their responsiveness to substance using populations.</p> |   |                |               |                |
| 102988  | <p><a href="#">Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology</a></p>  | National Institute on Drug Abuse/NIH/DHHS | NOT-DA-21-033  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Pamela G. Fleming</p> <p>Contact Telephone 301-480-1159</p> <p>Contact Email <a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in basic research on fentanyl and synthetic fentanyl analogs. Of particular interest is research that is focused on elucidating chemical,</p>  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         |  | cellular, signaling, and neurobiological mechanisms underlying abuse potential, physical dependence, addiction liability and deaths due to overdose of fentanyl and fentanyl analogs.  |                |               |                |
| 077321  | <a href="#">Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)</a>                                      | National Institute on Drug Abuse/NIH/DHHS  | PA-18-917      | 07-May-2021   | Not Specified  |
|         | Contact Name   | David Thomas, PhD  |                |               |                |
|         | Contact Telephone  | 301-435-1313   |                |               |                |
|         | Contact Email  | <a href="mailto:dthomas1@nida.nih.gov">dthomas1@nida.nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021  |                |               |                |
|         | Synopsis   | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. This FOA will use the NIH Research Project (R01) award mechanism.   |                |               |                |
| 082221  | <a href="#">Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)</a> | National Institute on Drug Abuse/NIH/DHHS  | PAR-19-278     | 24-Jun-2021   | Not Specified  |
|         | Contact Name   | John Satterlee Ph.D.   |                |               |                |
|         | Contact Telephone  | 301-435-1020   |                |               |                |
|         | Contact Email  | <a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 24-Jun-2021 , 17-Dec-2021  |                |               |                |
|         | Synopsis   | The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies. |                |               |                |
| 101618  | <a href="#">Pilot and Feasibility Studies in Preparation for Substance Use</a>   | National Institute on Drug Abuse/NIH/DHHS  | PA-21-110      | 07-May-2021   | 450,000        |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                              | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <a href="#">Prevention Trials (R34 Clinical Trial Optional)</a>   | Abuse/NIH/DHHS                            |                |               | USD            |
|         | <p>Contact Name   Amy B. Goldstein, PhD</p> <p>Contact Telephone   301-827-4124</p> <p>Contact Email   <a href="mailto:amy.goldstein@nih.gov">amy.goldstein@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this FOA include a reduction in negative sequelae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.</p> |   |                |               |                |
| 079379  | <a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)</a>  | National Institute on Drug Abuse/NIH/DHHS | PAR-19-162     | 07-May-2021   | 1,250,000 USD  |
|         | <p>Contact Name   Karen Sirocco</p> <p>Contact Telephone   301-451-8661</p> <p>Contact Email   <a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community</p>  |   |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page ([www.abcdstudy.org](http://www.abcdstudy.org)).

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 079380 | <a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)</a> | National Institute on Drug Abuse/NIH/DHHS | PAR-19-163 | 07-May-2021 | 275,000 USD |
|--------|--|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Karen Sirocco   |
| Contact Telephone    | 301-451-8661  |
| Contact Email        | <a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021   |
| Synopsis             | The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page ( <a href="http://www.abcdstudy.org">www.abcdstudy.org</a> ). |

|        |  |   |            |             |             |
|--------|--|---|------------|-------------|-------------|
| 091370 | <a href="#">NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)</a> | National Institute on Minority Health and Health Disparities/NIH/DHHS | PAR-20-150 | 07-May-2021 | 275,000 USD |
|--------|--|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         |   |
| Contact Telephone    | 301-402-1366  |
| Contact Email        | <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 |
| Synopsis             | NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.   |                |               |                |
| 103482  | <a href="#">RFA-MD-21-007 -- Centers for Multiple Chronic Diseases Associated with Health Disparities: Prevention, Treatment, and Management (P50 Clinical Trial Required)</a> | National Institute on Minority Health and Health Disparities/NIH/DHHS   | RFA-MD-21-007  | 08-May-2021   | 15,000,000 USD |
|         | Contact Name   | Jennifer Alvidrez, PhD  |                |               |                |
|         | Contact Telephone  | 301-594-9567  |                |               |                |
|         | Contact Email  | <a href="mailto:jennifer.alvidrez@nih.gov">jennifer.alvidrez@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 08-May-2021 , 10-Jun-2021   |                |               |                |
|         | Synopsis   | The purpose of this initiative is to support regional comprehensive research centers on the prevention, treatment, and management of chronic diseases associated with health disparities.   |                |               |                |
| 103484  | <a href="#">RFA-MD-21-008 -- NIMHD Multiple Chronic Disease Disparities Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed)</a>                                | National Institute on Minority Health and Health Disparities/NIH/DHHS   | RFA-MD-21-008  | 11-May-2021   | 15,000,000 USD |
|         | Contact Name   | Nathan Stinson, Jr, PhD, MD   |                |               |                |
|         | Contact Telephone  | 301-594-8704  |                |               |                |
|         | Contact Email  | <a href="mailto:stinsonn@mail.nih.gov">stinsonn@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 11-May-2021 , 11-Jun-2021   |                |               |                |
|         | Synopsis   | NIMHD invites applications from eligible institutions to establish a Research Coordinating Center (RCC) to support NIMHD P50 comprehensive research centers on prevention, treatment, and management of comorbid chronic diseases associated with health disparities authorized in Public Law 116-260, the Consolidated Appropriations Act of 2021. The RCC will coordinate activities across all of the chronic disease centers, including data collection; promoting collaboration and communication among investigators and the broader research community; promoting skills development of early stage investigators; coordinating and managing in-person and/or virtual meetings; and facilitating community engagement efforts. |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
| 077869  | <a href="#">Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS | PAR-18-952     | 07-Jun-2021   | 100,000 USD    |
|         | <p>Contact Name   Alice Chen, M.D.</p> <p>Contact Telephone   301-827-2015</p> <p>Contact Email   <a href="mailto:alice.chen2@nih.gov">alice.chen2@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jun-2021 , 25-Oct-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.</p> |                                    |                |               |                |
| 097262  | <a href="#">Notice of Special Interest (NOSI): Improving Methods to Assess Body Composition in Infants and Young Children</a>  | National Institutes of Health/DHHS | NOT-DK-20-036  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Voula Osganian, M.D., Sc.D., M.P.H.</p> <p>Contact Telephone   301-827-6939</p> <p>Contact Email   <a href="mailto:voula.osganian@nih.gov">voula.osganian@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Sep-2021 , 05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in research to improve methods to assess body composition in infants and young children ages birth through 5 years.</p>  |                                    |                |               |                |
| 101780  | <a href="#">Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease</a>  | National Institutes of Health/DHHS | NOT-AT-21-002  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Wen G. Chen, M.MSc, Ph.D.</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-451-3989</p> <p>Contact Email   <a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this NOSI is to promote innovative and rigorous research on interoception and its impact on health and disease. This initiative is broadly supported by many participating NIH institutes, centers, and offices (ICOs). For this NOSI, interoception includes the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself and represents its internal states. This NOSI encourages basic and clinical research projects that 1) combine diverse expertise; 2) develop and use innovative technologies and approaches to delineate interoceptive mechanisms at the molecular, cellular, circuit, functional, and/or behavioral levels; 3) assess pathophysiological processes of interoception in the context of diseases and disorders; 4) determine the impact of interventions and therapies to manipulate interoceptive processes on health and/or disease; and 5) develop and validate predictive biomarkers, computational models, or artificial intelligence models relevant to interoception and its impact on health and disease.</p> |                                    |                |               |                |
| 101814  | <p><a href="#">Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers</a></p>   | National Institutes of Health/DHHS | NOT-CA-21-028  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Natalie Abrams, PhD</p> <p>Contact Telephone   240-474-7336</p> <p>Contact Email   <a href="mailto:natalie.abrams@nih.gov">natalie.abrams@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This Notice encourages applications proposing multi-institutional collaborative AI</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         |  | development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data. |                |               |                |
| 102071  | <a href="#">Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS   | PAR-21-125     | 01-Jun-2021   | 250,000 USD    |
|         | <p>Contact Name   Alena Horska, PhD</p> <p>Contact Telephone   301-435-0772</p> <p>Contact Email   <a href="mailto:SIG@mail.nih.gov">SIG@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2021</p> <p>Synopsis   The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of \$250,001 or greater in any of the Federal fiscal years 2018-2020. The minimum award is \$25,000. There is no maximum price limit for the instrument; however, the maximum award is \$250,000. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.</p> |  |                |               |                |
| 102075  | <a href="#">Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS   | PAR-21-127     | 01-Jun-2021   | 600,000 USD    |
|         | <p>Contact Name   Alena Horska, PhD</p> <p>Contact Telephone   301-435-0772</p> <p>Contact Email   <a href="mailto:SIG@mail.nih.gov">SIG@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2021</p> <p>Synopsis   The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is \$50,000. There is no maximum price limit for the instrument; however, the maximum award is \$600,000. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear</p>  |  |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  | magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.   |                |               |                |
| 094033  | <a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS  | PA-20-195      | 07-May-2021   | 275,000 USD    |
|         | Contact Name   |   |                |               |                |
|         | Contact Telephone  |   |                |               |                |
|         | Contact Email  | <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023   |                |               |                |
|         | Synopsis   | The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding. |                |               |                |
| 094050  | <a href="#">NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</a>                     | National Institutes of Health/DHHS  | PA-20-200      | 07-May-2021   | 100,000 USD    |
|         | Contact Name   |   |                |               |                |
|         | Contact Telephone  |   |                |               |                |
|         | Contact Email  | <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023   |                |               |                |
|         | Synopsis   | The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

|        |   |                                    |           |             |             |
|--------|---|------------------------------------|-----------|-------------|-------------|
| 094032 | <a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)</a> | National Institutes of Health/DHHS | PA-20-194 | 07-May-2021 | 275,000 USD |
|--------|---|------------------------------------|-----------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         |   |
| Contact Telephone    |   |
| Contact Email        | <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023   |
| Synopsis             | <p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. See Related Notices section below. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Mental Health (NIMH) Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p> |

|        |   |                                    |           |             |         |
|--------|---|------------------------------------|-----------|-------------|---------|
| 094034 | <a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21)</a> | National Institutes of Health/DHHS | PA-20-196 | 07-May-2021 | 275,000 |
|--------|---|------------------------------------|-----------|-------------|---------|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

[Basic Experimental Studies with Humans Required\)](#)

USD

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br><br>Synopsis | 301-496-4000<br><a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a><br><br><a href="#">Link to program URL</a><br>07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023<br><br>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding. |
|--|--|

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 095691 | <a href="#">Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (P12 CARBON) (R03 Clinical Trials Not Allowed)</a> | National Institutes of Health/DHHS | PAR-20-228 | 07-May-2021 | 100,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

|                   |  |
|-------------------|--|
| Contact Name      |  |
| Contact Telephone |  |
| Contact Email     |  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis<br/>The purpose of this funding opportunity announcement (FOA) is to support collaborative pilot research projects focused on potential effects relevant to human health of chemically complex natural products and/or the causal, molecular mechanisms underlying such effects. A critical element of each proposed project must be collaboration with one or more of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (CARBON). More specifically, letters of support describing collaboration with one or more of the U19 Botanical Dietary Supplements Research Centers awarded pursuant to RFA OD-19-001 by July, 2020, must be included at the time of submission. Each proposed pilot project must, with agreement of its collaborating Center(s), leverage products used in those Centers to extend understanding of their biological effects, or of their causal, molecular mechanisms of action, or increase understanding of other chemically complex natural products through use of methods developed and used in the Centers. Research approaches may range from bench through in vitro and non-human animal models to, where feasible and appropriate, obtaining additional feasibility or outcome information from the clinical trials being performed by the CARBON awardees, either through inclusion of additional measures or through secondary analysis of data or specimens</p> |                                    |                |               |                |
| 088011  | <p><a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)</a></p>   | National Institutes of Health/DHHS | PAR-20-055     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name David M. Panchision, Ph.D.</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis<br/>This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA(PAR-20-082).

|        |  |                                    |           |             |             |
|--------|--|------------------------------------|-----------|-------------|-------------|
| 078546 | <a href="#">Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PA-19-066 | 07-May-2021 | 275,000 USD |
|--------|--|------------------------------------|-----------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Timothy A. Gondré-Lewis, Ph.D.  |
| Contact Telephone    | 240-627-3566  |
| Contact Email        | <a href="mailto:tglewis@niaid.nih.gov">tglewis@niaid.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022   |
| Synopsis             | This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines. |

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 088090 | <a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PAR-20-037 | 07-May-2021 | 825,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Enrique Michelotti, Ph.D.   |
| Contact Telephone    | 301-443-5415  |
| Contact Email        | <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023   |
| Synopsis             | This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to |

## NIH Funding Opportunities

| SPIN ID          | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|------------------|---|------------------------------------|----------------|-------------------------------------|----------------|
| FOA PAR-20-038 . |   |                                    |                |                                     |                |
| 102069           | <a href="#">Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)</a>   | National Institutes of Health/DHHS | PAR-21-115     | 05-Jun-2021                         | Not Specified  |
|                  | <p>Contact Name   Melissa Parisi, MD, PhD</p> <p>Contact Telephone   301-435-6880</p> <p>Contact Email   <a href="mailto:parisima@mail.nih.gov">parisima@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023</p> <p>Synopsis   This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.</p> |                                    |                |                                     |                |
| 102332           | <a href="#">RFA-DK-21-005 -- Immune Cell Engineering For Targeted Therapy And Disease Monitoring in Type 1 Diabetes (R01 Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS | RFA-DK-21-005  | 22-May-2021 [Optional][LOI/Pre-App] | 3,000,000 USD  |
|                  | <p>Contact Name   Olivier Blondel, Ph.D.</p> <p>Contact Telephone   301-451-7334</p> <p>Contact Email   <a href="mailto:blondelol@niddk.nih.gov">blondelol@niddk.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>  |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Deadline Dates (ALL)   22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021</p> <p>Synopsis   This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and/or to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.</p>   |                                    |                |                                     |                |
| 099865  | <a href="#">RFA-NS-21-010 -- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)</a>  | National Institutes of Health/DHHS | RFA-NS-21-010  | 14-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name   Michael Oshinsky</p> <p>Contact Telephone   301-496-9964</p> <p>Contact Email   <a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 15-Sep-2021 [Optional][LOI/Pre-App], 15-Oct-2021 , 16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) <a href="https://heal.nih.gov/research/clinical-research/eppic-net">https://heal.nih.gov/research/clinical-research/eppic-net</a> or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.</p> |                                    |                |                                     |                |
| 088012  | <a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)</a>   | National Institutes of Health/DHHS | PAR-20-082     | 07-May-2021                         | 275,000 USD    |
|         | <p>Contact Name   David M. Panchision, Ph.D.</p> <p>Contact Telephone   301-443-5288</p> <p>Contact Email   <a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a></p>  |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-20-NNN).</p>   |                                    |                |                                     |                |
| 093908  | <a href="#">NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)</a>   | National Institutes of Health/DHHS | PA-20-185      | 07-May-2021                         | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p> |                                    |                |                                     |                |
| 097189  | <a href="#">Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01)</a>  | National Institutes of Health/DHHS | PAR-20-271     | 05-May-2021 [Optional][LOI/Pre-App] | Not Specified  |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Name   Suzanne Forry, Ph.D.</p> <p>Contact Telephone   240-276-5922</p> <p>Contact Email   <a href="mailto:forryscs@mail.nih.gov">forryscs@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-May-2021 [Optional][LOI/Pre-App], 07-May-2021 , 05-Jun-2021 , 05-Sep-2021 [Optional][LOI/Pre-App], 07-Sep-2021 , 05-Oct-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 07-Jan-2022 , 05-Feb-2022 , 05-May-2022 [Optional][LOI/Pre-App], 07-May-2022 , 05-Jun-2022 , 05-Sep-2022 [Optional][LOI/Pre-App], 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.</p> |                                    |                |               |                |
| 096053  | <p><a href="#">Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required)</a></p>   | National Institutes of Health/DHHS | PAR-20-235     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Andrew Rossi</p> <p>Contact Telephone   301-443-1576</p> <p>Contact Email   <a href="mailto:rossia@mail.nih.gov">rossia@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages research to develop task-based behavioral measures that are shown to engage brain systems relevant to anhedonia using neuroimaging or other brain measures with similar spatial resolution. The goal is to identify behavioral tasks that can be used as quantitative tools in future studies of the functional constructs associated with anhedonia and in treatment development. This FOA is for basic science experimental studies involving human participants that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

(i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of brain function in healthy individuals or those with disorders. These mechanistic studies are expected to be appropriate for the Basic Experimental Studies With Humans (BESH) FOAs <https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-006.html> since they are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.

|        |   |                                    |               |             |               |
|--------|---|------------------------------------|---------------|-------------|---------------|
| 097158 | <a href="#">Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations</a> | National Institutes of Health/DHHS | NOT-HL-20-788 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|---------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Lawrence J. Fine, MD, DrPH   |
| Contact Telephone    | 301-435-0305   |
| Contact Email        | <a href="mailto:Lawrence.Fine@NIH.gov">Lawrence.Fine@NIH.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023  |
| Synopsis             | The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Environmental Health Sciences (NIEHS) have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in air pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes. This notice specifically encourages intervention studies or clinical trials that examine the efficacy of personal air pollution interventions to reduce the adverse cardiopulmonary effects of Particulate Matter (PM) <2.5 µm in diameter (PM2.5) in high risk or vulnerable participants. |

|        |  |                                    |               |             |               |
|--------|--|------------------------------------|---------------|-------------|---------------|
| 097215 | <a href="#">Notice of Special Interest (NOSI): Fundamental and Translational Research on Decision Making in Aging and/or Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD)</a> | National Institutes of Health/DHHS | NOT-AG-20-039 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|---------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Luke Stoeckel, Ph.D.   |
| Contact Telephone | 202-570-9388   |
| Contact Email     | <a href="mailto:luke.stoeckel@nih.gov">luke.stoeckel@nih.gov</a> |
| Sponsor Website   |  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Notice of Special Interest (NOSI) underscores NIA's continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest. This NOSI also encourages preclinical and applied research on decision making that may facilitate the design of decision-supportive interventions for midlife and older adults with and without MCI and AD/ADRD. Specific opportunities include the development of decision-support interventions to leverage cognitive, emotional, social, and motivational strengths of these populations; tools to assess decisional capacities; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). The use of animal models to explore the neural basis of affective, cognitive, social, and motivational parameters as they relate to age-related changes in decision making is also invited.</p> |                                    |                |               |                |
| 078543  | <a href="#">Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed)</a>   | National Institutes of Health/DHHS | PA-19-067      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Timothy A. Gondré-Lewis, Ph.D.</p> <p>Contact Telephone 240-627-3566</p> <p>Contact Email <a href="mailto:tglewis@niaid.nih.gov">tglewis@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
| 093636  | <a href="#">Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)</a>  | National Institutes of Health/DHHS | PAR-20-179     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   David L. Tilley, MPH, MS, CPH</p> <p>Contact Telephone   301-827-6014</p> <p>Contact Email   <a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs. Prospective applicants whose research interests relate to studies that identify shared mechanisms or development of innovative interventions to address MCCs should see PAR-20-180.</p> |                                    |                |               |                |
| 092568  | <a href="#">Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)</a>   | National Institutes of Health/DHHS | PAR-20-165     | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Vicky Whittemore, PhD</p> <p>Contact Telephone   301-496-1917</p> <p>Contact Email   <a href="mailto:vicky.whittemore@nih.gov">vicky.whittemore@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |          |  |  |  |  |
|--|----------|--|--|--|--|
|  | Synopsis | <p>This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.</p> |  |  |  |
|--|----------|--|--|--|--|

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 093035 | <a href="#">Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PA-20-172 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|  |                      |   |  |  |  |
|--|----------------------|---|--|--|--|
|  | Contact Name         | Larissa Avilés-Santa, MD, MPH   |  |  |  |
|  | Contact Telephone    | 301-827-6924  |  |  |  |
|  | Contact Email        | <a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a>  |  |  |  |
|  | Sponsor Website      |   |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>   |  |  |  |
|  | Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023   |  |  |  |
|  | Synopsis             | <p>The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.</p> |  |  |  |

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 091506 | <a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-157 | 05-Jun-2021 | Not Specified |
|--------|---|------------------------------------|------------|-------------|---------------|

|  |                   |                      |
|--|-------------------|----------------------|
|  | Contact Name      | Jovier D. Evans, PhD |
|  | Contact Telephone | 301-443-1369         |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This FOA uses the R01 mechanism, while the companion announcement PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p> |                                    |                |               |                |
| 098071  | <a href="#">Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities</a>  | National Institutes of Health/DHHS | NOT-MD-20-025  | 05-Jun-2021   | Not Specified  |
|         | <p>Contact Name Rada Dagher, Ph.D., M.P.H.</p> <p>Contact Telephone 301-451-2187</p> <p>Contact Email <a href="mailto:rada.dagher@nih.gov">rada.dagher@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.</p>   |                                    |                |               |                |
| 100289  | <a href="#">Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS | PAR-21-029     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name Enrique L. Michelotti, Ph.D.</p> <p>Contact Telephone 301-443 5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).</p> |                                    |                |               |                |
| 099859  | <p><a href="#">Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)</a></p>   | National Institutes of Health/DHHS | NOT-HL-20-814  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Guofei Zhou, PhD</p> <p>Contact Telephone   301-827-7825</p> <p>Contact Email   <a href="mailto:guofei.zhou@nih.gov">guofei.zhou@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).</p>   |                                    |                |               |                |
| 101245  | <p><a href="#">Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities</a></p>  | National Institutes of Health/DHHS | NOT-MD-21-008  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Deborah E. Linares, Ph.D., M.A.</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   301-402-2516</p> <p>Contact Email   <a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis   This Notice of Special Interest (NOSI) highlights the need for research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US.* Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.</p> |                                    |                |               |                |
| 097708  | <a href="#">Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)</a>   | National Institutes of Health/DHHS | PAR-20-286     | 18-Jun-2021   | 10,000,000 USD |
|         | <p>Contact Name   Joel Sherrill, Ph.D.</p> <p>Contact Telephone   301-443-2477</p> <p>Contact Email   <a href="mailto:jsherril@mail.nih.gov">jsherril@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   18-Jun-2021 , 18-Feb-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications for research centers to support integrated programs of high-impact, practice-based research with near-term potential to address NIMH suicide prevention priorities and help achieve the National Action Alliance for Suicide Prevention goals of reducing the rate of suicide in the US. The Centers are intended to support transdisciplinary teams of clinical and mental health services researchers, behavioral/social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) engaged in transdisciplinary programs of research that could not be achieved using standard research project grant mechanisms. Research Centers will support the rapid development, refinement, and testing of effective and scalable approaches for intervening at key intercepts in the chain of</p>   |                                    |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

care: for identifying high-risk individuals, for promoting continuity across key care transitions (e.g., following identification in the emergency department or discharge from inpatient care), and for intervening (including prevention strategies and treatment for acute risk). Support will be provided for individual research projects and for cores that are critical for the integration across Center components. The Centers are expected to provide plans for rapid, widespread sharing of relevant data, methods, and resources that will promote near-term improvements in clinical practice, and to accelerate research in suicide prevention. A strong vision of how the Center will advance the field beyond the goals of the individual projects is essential for successful applications. Recognizing that advancing suicide prevention depends on a diversity of scientific perspectives and contributions from a diverse research workforce, these Centers are also expected to provide opportunities for new transdisciplinary collaborations and for research education and training for graduate students, postdoctoral scholars, and investigators in early stages of independent careers, to help ensure a well-trained, diverse research workforce. Applicants interested in submitting applications to support transdisciplinary programs of research focused on other topics consistent with the priorities of NIMH are directed to ALACRITY ("Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY)") Research Centers FOA (see NOT-MH-20-070).

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 088091 | <a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-038 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Enrique Michelotti, Ph.D.  |
| Contact Telephone    | 301-443-5415   |
| Contact Email        | <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023  |
| Synopsis             | This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion FOA PAR-20-037 . |

|        |   |                                    |         |             |     |
|--------|---|------------------------------------|---------|-------------|-----|
| 080193 | <a href="#">Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not</a> | National Institutes of Health/DHHS | PAR-19- | 05-Jun-2021 | Not |
|--------|---|------------------------------------|---------|-------------|-----|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <a href="#">Allowed</a> )   |                                    | 193            |               | Specified      |
|         | <p>Contact Name   Avi Rasooly, PhD</p> <p>Contact Telephone   240-276-6196</p> <p>Contact Email   <a href="mailto:rasoolya@mail.nih.gov">rasoolya@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis   The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaeobacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies. This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants applying to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy. Complex microbial-tumor interactions are best addressed with a team approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.</p> |                                    |                |               |                |
| 100769  | <a href="#">Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS | PAR-21-080     | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Deborah Linares, Ph.D.</p> <p>Contact Telephone   301-402-2516</p> <p>Contact Email   <a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023   |                |               |                |
|         | Synopsis  | The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. |                |               |                |
| 100780  | <a href="#">Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS  | PAR-21-081     | 07-May-2021   | Not Specified  |
|         | Contact Name  | Deborah Linares, Ph.D.  |                |               |                |
|         | Contact Telephone   | 301-402-2516  |                |               |                |
|         | Contact Email   | <a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a>  |                |               |                |
|         | Sponsor Website   |   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023   |                |               |                |
|         | Synopsis  | The purpose of this initiative is to support research to design and implement effective interventions to enhance health advantages and reduce the health disparities among US immigrant populations.  |                |               |                |
| 100758  | <a href="#">Notice of Special Interest (NOSI): Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program</a>   | National Institutes of Health/DHHS  | NOT-OD-21-021  | 07-May-2021   | Not Specified  |
|         | Contact Name  | Sarah Scharf, MPA   |                |               |                |
|         | Contact Telephone   | 301-496-4784  |                |               |                |
|         | Contact Email   | <a href="mailto:sarah.scharf@nih.gov">sarah.scharf@nih.gov</a>  |                |               |                |
|         | Sponsor Website   |   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024                         |                |               |                |
|         | Synopsis  | The purpose of this Notice of Special Interest (NOSI) is to alert the community about this opportunity and disseminate knowledge and information on a program designed to foster the expansion of U.S.-Finland biomedical and behavioral research collaboration.    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
| 092569  | <a href="#">Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)</a>   | National Institutes of Health/DHHS | PAR-20-168     | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name   Vicky Whittemore, PhD</p> <p>Contact Telephone   301-496-1917</p> <p>Contact Email   <a href="mailto:vicky.whittemore@nih.gov">vicky.whittemore@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Applications submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.</p> |                                    |                |               |                |
| 094250  | <a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)</a>  | National Institutes of Health/DHHS | PA-20-206      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
|         | <p>Synopsis</p>  | <p>2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |                |               |                |
| 094234  | <a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)</a> | National Institutes of Health/DHHS   | PA-20-202      | 07-May-2021   | Not Specified  |

|   |  |
|---|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p></p> <p>301-496-8580</p> <p><a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not</p> |
|---|--|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 094248 | <a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PA-20-205 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         |  |
| Contact Telephone    |  |
| Contact Email        | <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023  |
| Synopsis             | The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged. |

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 094040 | <a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)</a> | National Institutes of Health/DHHS | PA-20-198 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|                   |                                     |
|-------------------|-------------------------------------|
| Contact Name      |                                     |
| Contact Telephone |                                     |
| Contact Email     |                                     |
| Sponsor Website   |                                     |
| Program URL       | <a href="#">Link to program URL</a> |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis   The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |                                    |                |               |                |
| 094233  | <a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)</a>  | National Institutes of Health/DHHS | PA-20-201      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|  |          |   |  |  |  |
|--|----------|---|--|--|--|
|  | Synopsis | <p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |  |  |  |
|--|----------|---|--|--|--|

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 094235 | <a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PA-20-203 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|  |                      |   |  |  |  |
|--|----------------------|---|--|--|--|
|  | Contact Name         |   |  |  |  |
|  | Contact Telephone    | 301-496-8580  |  |  |  |
|  | Contact Email        | <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>  |  |  |  |
|  | Sponsor Website      |   |  |  |  |
|  | Program URL          | <a href="#">Link to program URL</a>   |  |  |  |
|  | Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023   |  |  |  |
|  | Synopsis             | <p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to</p> |  |  |  |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 094244 | <a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)</a> | National Institutes of Health/DHHS | PA-20-204 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         |  |
| Contact Telephone    |  |
| Contact Email        |  |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023  |
| Synopsis             | The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 094044 | <a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PA-20-199 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         |   |
| Contact Telephone    |   |
| Contact Email        | <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023   |
| Synopsis             | <p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-20-197). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 097475 | <a href="#">Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-257 | 17-Jun-2021 | 100,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

|                   |              |
|-------------------|--------------|
| Contact Name      | Joy Boyer    |
| Contact Telephone | 301-402-4997 |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022 , 17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.</p> |              |                |               |                |

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 093214 | <a href="#">Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)</a> | National Institutes of Health/DHHS | PA-20-173 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|  |  |  |  |  |  |
|--|--|--|--|--|--|
|  | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with</p> |  |  |  |  |
|--|--|--|--|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 093210 | <a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)</a> | National Institutes of Health/DHHS | PA-20-171 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|  |   |
|--|---|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis</p> | <p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.</p> |
|--|---|

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 093225 | <a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PA-20-174 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|  |  |
|--|--|
| <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> |  |
|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis   The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA.</p>   |                                    |                |               |                |
| 099505  | <a href="#">Notice of Special Interest (NOSI): Advancing the Science of Geriatric Palliative Care</a>   | National Institutes of Health/DHHS | NOT-AG-20-041  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name   Basil Eldadah, M.D., Ph.D.</p> <p>Contact Telephone   301-496-6761</p> <p>Contact Email   <a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis   This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in geriatric populations. This NOSI covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, long-term care facilities, hospices, and other healthcare or community settings. This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure is encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.</p> |                                    |                |               |                |
| 100292  | <a href="#">Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21</a>  | National Institutes of Health/DHHS | PAR-21-        | 07-May-2021   | 275,000        |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <a href="#">Clinical Trial Not Allowed</a>  |                                    |                | 028           | USD            |
|         | <p>Contact Name: Enrique L. Michelotti, Ph.D.</p> <p>Contact Telephone: 301-443 5415</p> <p>Contact Email: <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI and/or NIA; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism, (PAR-21-029).</p> |                                    |                |               |                |
| 099801  | <p><a href="#">Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design Notice Number:</a></p>  | National Institutes of Health/DHHS | NOT-AI-20-071  | 07-May-2021   | Not Specified  |
|         | <p>Contact Name: Que Dang, PhD</p> <p>Contact Telephone: 240-292-6181</p> <p>Contact Email: <a href="mailto:que.dang@nih.gov">que.dang@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis: The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB)</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         |   | <p>disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.</p> |                |               |                |
| 100050  | <a href="#">Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19</a>                              | National Institutes of Health/DHHS   | NOT-HD-20-031  | 07-May-2021   | Not Specified  |
|         | Contact Name  | Theresa Cruz, PhD.   |                |               |                |
|         | Contact Telephone   | 301-496-9233   |                |               |                |
|         | Contact Email   | <a href="mailto:cruzth@mail.nih.gov">cruzth@mail.nih.gov</a>   |                |               |                |
|         | Sponsor Website   |  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023  |                |               |                |
|         | Synopsis  | <p>The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of survivors of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the National Center for Medical Rehabilitation Research (NCMRR) at NICHD.</p>  |                |               |                |
| 100734  | <a href="#">Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS   | PAR-21-077     | 16-Jun-2021   | Not Specified  |
|         | Contact Name  | Xiaoli Zhao, Ph.D.   |                |               |                |
|         | Contact Telephone   |  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:xiaoli.zhao@nih.gov">xiaoli.zhao@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis<br/>                     The purpose of this funding opportunity announcement (FOA) is to support efficient collection, banking, and sharing of biospecimens and associated clinical data from critically ill patients, ultimately for use in mechanistic research on sepsis. The goals of this FOA are to determine the scientific value of existing or newly collected sepsis human biospecimen sets as testbeds for studies on human sepsis and to provide guidance on the best practices for collecting, utilizing, and analyzing human biospecimens, thus maximizing their value for the entire sepsis research community. This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. Studies should focus on: 1) assessment of the utility of existing biospecimen repositories from critically ill and septic patients for future mechanistic research; or 2) development of improved methods for de novo collection and analysis of biospecimens from critically ill patients, ultimately for mechanistic studies of sepsis. The proposed studies should be information-gathering and useful for hypothesis generation; the final results should be data and approaches that can ultimately form the basis for future mechanistic studies and biospecimen collection efforts. Mechanistic studies based on testable hypotheses already formed should be submitted to other opportunities for research grants (e.g., R01 or R35 applications). Applications to solely support novel technology development should be submitted for the Technology Development program. Interventional studies that meet the NIH definition for a clinical trial, or studies including animal models of sepsis, will not be accepted. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to an two additional years of scaled-up, expanded, or confirmatory research support (R33 phase). Ideally, in the R21 phase, applicants should test new methods for biospecimen acquisition and/or verify the quality of those or existing biospecimens, and identify assays useful for future mechanistic research. The R33 phase should focus on scale-up activities to generate data useable to formulate testable hypotheses of the prediction, development, complexity, and resolution of sepsis in humans. The total project period for an application may not exceed four years. This FOA requires applicant-identified measurable R21 phase milestones, which will be used to determine whether an award transitions to the R33 phase. Transition to the R33 phase is not automatic, and NIGMS anticipates that about half of the funded R21 phase awards may progress to the R33 phase award.</p> |                                    |                |               |                |
| 101300  | <a href="#">Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis</a>  | National Institutes of Health/DHHS | NOT-MH-21-075  | 07-May-2021   | Not Specified  |



## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
| 101367  | <p><a href="#">Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis</a></p> | National Institutes of Health/DHHS | NOT-MH-21-175  | 07-May-2021   | Not Specified  |

|                      |  |
|----------------------|--|
| Contact Name         | Yvonne Bennett, Ph.D.  |
| Contact Telephone    | 301-222-7094   |
| Contact Email        | <a href="mailto:yvonne.bennett@nih.gov">yvonne.bennett@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024  |
| Synopsis             | NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: <a href="https://www.humanconnectome.org/">https://www.humanconnectome.org/</a> and at the NIMH Data Archive (NDA) <a href="http://www.nda.nih.gov">www.nda.nih.gov</a> . |

|                      |   |
|----------------------|---|
| Contact Name         | Yvonne Bennett, Ph.D.   |
| Contact Telephone    | 301-222-7094  |
| Contact Email        | <a href="mailto:yvonne.bennett@nih.gov">yvonne.bennett@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Synopsis NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: <https://www.humanconnectome.org/> and at the NIMH Data Archive (NDA) [www.nda.nih.gov](http://www.nda.nih.gov).

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 098640 | <a href="#">Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PAR-20-258 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Deborah Philp, Ph.D.  |
| Contact Telephone    | 301-761-7766  |
| Contact Email        | <a href="mailto:deborah.philp@nih.gov">deborah.philp@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023   |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. |

|        |   |                                    |           |             |     |
|--------|---|------------------------------------|-----------|-------------|-----|
| 094015 | <a href="#">Mentored Research Scientist Development Award (Parent K01 -</a> | National Institutes of Health/DHHS | PA-20-176 | 07-May-2021 | Not |
|--------|---|------------------------------------|-----------|-------------|-----|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

[Independent Clinical Trial Required](#)

Specified

|   |  |
|---|--|
| Contact Name<br>Contact Telephone<br>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a><br>Sponsor Website<br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023<br><br>Synopsis | The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-20-190). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged. |
|---|--|

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 094038 | <a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)</a> | National Institutes of Health/DHHS | PA-20-197 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|   |  |
|---|--|
| Contact Name<br>Contact Telephone<br>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a><br>Sponsor Website<br>Program URL <a href="#">Link to program URL</a> |  |
|---|--|

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL)   07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis   The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |                                    |                |               |                |
| 094020  | <a href="#">Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS | PA-20-190      | 07-May-2021   | Not Specified  |

|                      |  |
|----------------------|--|
| Contact Name         |  |
| Contact Telephone    |  |
| Contact Email        | <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023  |
| Synopsis             | The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 093955 | <a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)</a> | National Institutes of Health/DHHS | PA-20-193 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         |   |
| Contact Telephone    |   |
| Contact Email        | <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023   |
| Synopsis             | <p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 094026 | <a href="#">Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)</a> | National Institutes of Health/DHHS | PA-20-191 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

Contact Name

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis<br/>                     The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |                                    |                |               |                |
| 093953  | <a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS | PA-20-186      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |                                    |                |               |                |
| 093954  | <a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Basic Experimental Studies with Humans Required)</a>  | National Institutes of Health/DHHS | PA-20-192      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

|        |   |                                    |               |             |               |
|--------|---|------------------------------------|---------------|-------------|---------------|
| 087104 | <a href="#">RFA-NS-19-043 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | RFA-NS-19-043 | 09-Jun-2021 | Not Specified |
|--------|---|------------------------------------|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Edmund (Ned) Talley, PhD  |
| Contact Telephone    | 301-496-1917  |
| Contact Email        | <a href="mailto:BRAINDIVERSITYK99R00@nih.gov">BRAINDIVERSITYK99R00@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 09-Jun-2021 , 06-Oct-2021 , 10-Feb-2022 , 08-Jun-2022 , 11-Oct-2022   |
| Synopsis             | The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA RFA-NS-19-044 . |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
| 087107  | <a href="#">RFA-NS-19-044 -- BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)</a> | National Institutes of Health/DHHS | RFA-NS-19-044  | 09-Jun-2021   | Not Specified  |

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | Edmund (Ned) Talley, PhD<br>301-496-1917<br><a href="mailto:BRAINDIVERSITYK99R00@nih.gov">BRAINDIVERSITYK99R00@nih.gov</a><br><br><a href="#">Link to program URL</a><br>09-Jun-2021 , 06-Oct-2021 , 10-Feb-2022 , 08-Jun-2022 , 11-Oct-2022<br>The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (RFA-NS-19-043) |
|--|--|

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 097436 | <a href="#">Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-254 | 17-Jun-2021 | Not Specified |
|--------|--|------------------------------------|------------|-------------|---------------|

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | Joy Boyer<br>301-402-4997<br><a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a><br><br><a href="#">Link to program URL</a><br>17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022 , 17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023<br>This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the |
|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

|        |  |                                    |            |             |             |
|--------|--|------------------------------------|------------|-------------|-------------|
| 097437 | <a href="#">Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-255 | 17-Jun-2021 | 275,000 USD |
|--------|--|------------------------------------|------------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Joy Boyer  |
| Contact Telephone    | 301-402-4997   |
| Contact Email        | <a href="mailto:boyerj@mail.nih.gov">boyerj@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022 , 17-Jun-2022 , 19-Oct-2022 , 17-Feb-2023 , 19-Jun-2023  |
| Synopsis             | This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. |

|        |  |                                    |               |                                     |               |
|--------|--|------------------------------------|---------------|-------------------------------------|---------------|
| 097523 | <a href="#">RFA-HG-20-048 -- Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | RFA-HG-20-048 | 08-Jun-2021 [Optional][LOI/Pre-App] | 2,000,000 USD |
|--------|--|------------------------------------|---------------|-------------------------------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Nicole Lockhart   |
| Contact Telephone    | 301-385-1622  |
| Contact Email        | <a href="mailto:lockhani@mail.nih.gov">lockhani@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021  |
| Synopsis             | The purpose of this initiative is to support investigator-initiated research on genetic counseling processes and practices in |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|--|----------------|-------------------------------------|----------------|
|         |   | <p>genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Applications will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems; and the challenges of effective and efficient communication of genomic findings to clinicians, patients, and families.</p>   |                |                                     |                |
| 091783  | <a href="#">RFA-NS-20-029 -- BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trials Optional)</a>           | National Institutes of Health/DHHS   | RFA-NS-20-029  | 15-Jun-2021                         | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> | <p>Karen K David, Ph.D.</p> <p>301-496-9964</p> <p><a href="mailto:BRAINCircuits@nih.gov">BRAINCircuits@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>15-Jun-2021</p> <p>This funding opportunity announcement (FOA) is designed to support teams of investigators that seek to cross boundaries of interdisciplinary collaboration to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications are encouraged to propose adventurous and challenging goals that can only be tackled by a synergistic team-based approach and have the potential to be transformative and/or to enable significant advances. These studies at the exploratory stage are intended for the development of experimental capabilities and/or theoretical frameworks in preparation for a future competition for larger-scale or extended efforts, including the BRAIN TargetedBCP R01 or the multi-component, Team-Research BRAIN Circuit Programs (U19). The overall goal of this FOA is to enable a large-scale analysis of neural systems and circuits within the context and during the simultaneous measurement of an ethologically relevant behavior. Toward this end, teams are expected to assemble and leverage multi-disciplinary expertise, and to integrate experimental with computational and theoretical approaches. Teams are expected to bridge fields by incorporating rich information on cell-types, on circuit functionality and connectivity, in conjunction with sophisticated analyses of an ethologically relevant behavior of an organism or a well-defined neural system. Teams are also expected to aim for a mechanistic understanding of the circuits of the central nervous system (CNS) by applying cutting-edge methods such as those for large-scale recording, manipulation, and analysis of neural circuits across multiple regions of the CNS.</p> |                |                                     |                |
| 097805  | <a href="#">RFA-MH-20-600 -- BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional)</a>                                 | National Institutes of Health/DHHS   | RFA-MH-20-600  | 14-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Name   Ming Zhan, Ph.D.</p> <p>Contact Telephone   301-827-3678</p> <p>Contact Email   <a href="mailto:ming.zhan@nih.gov">ming.zhan@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 14-Jun-2022 [Optional][LOI/Pre-App], 14-Jul-2022 , 14-Jun-2023 [Optional][LOI/Pre-App], 14-Jul-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this FOA. The data archives will use appropriate standards to describe the data, but the creation of such standards is not part of this FOA. A goal of this program is to advance research by creating a community resource data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research.</p>  |                                    |                |               |                |
| 093907  | <a href="#">Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)</a>  | National Institutes of Health/DHHS | PA-20-184      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name  </p> <p>Contact Telephone   301-496-4000</p> <p>Contact Email   <a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis   The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or</p> |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                   | Funding Amount |
|---------|--|---|----------------|---------------------------------|----------------|
|         | <p>products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' or 'Clinical Trial Optional' FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p> |   |                |                                 |                |
| 103023  | <a href="#">Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)</a>  | National Institutes of Health/DHHS  | PAR-21-166     | 05-Jun-2021                     | 2,495,000 USD  |
|         | Contact Name   | Miguel Ossandon MS  |                |                                 |                |
|         | Contact Telephone  | 240-276-5714  |                |                                 |                |
|         | Contact Email  | <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a>  |                |                                 |                |
|         | Sponsor Website  |   |                |                                 |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |                                 |                |
|         | Deadline Dates (ALL)   | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023   |                |                                 |                |
|         | Synopsis   | <p>The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines "innovation" as likelihood to deliver a new capability to end users.</p> |                |                                 |                |
| 087977  | <a href="#">RFA-NS-20-006 -- BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)</a>  | National Institutes of Health/DHHS  | RFA-NS-20-006  | 02-May-2021 [Optional][LOI/Pre- | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

App]

|  |   |
|--|---|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | Sahana N. Kukke, PhD<br>301-496-1447<br><a href="mailto:BRAIN-FOAs@nih.gov">BRAIN-FOAs@nih.gov</a><br><br><a href="#">Link to program URL</a><br>02-May-2021 [Optional][LOI/Pre-App], 01-Jun-2021 , 02-Jan-2022 [Optional][LOI/Pre-App], 01-Feb-2022 , 03-Sep-2022 [Optional][LOI/Pre-App], 03-Oct-2022<br>A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system. This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed. |
|--|---|

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 097095 | <a href="#">Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-266 | 02-Jun-2021 | 1,750,000 USD |
|--------|---|------------------------------------|------------|-------------|---------------|

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL) | Wen G. Chen, Ph.D.<br>301-451-3989<br><a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a><br><br><a href="#">Link to program URL</a><br>02-Jun-2021 , 17-Jun-2021 , 04-Oct-2021 , 19-Oct-2021 , 02-Jun-2022 , 17-Jun-2022 , 03-Oct-2022 , 19-Oct-2022 , 02-Jun-2023 , 19-Jun-2023 |
|--|--|

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their mechanisms of action and clinical applications for the treatment of many diseases, disorders, and conditions. Given the emphasis on innovation, little or no preliminary data are needed to apply under this FOA. Because of the need for a multidisciplinary approach, collaborations among basic researchers, translational science researchers, music intervention experts, other clinical researchers, music health professionals, and technology development researchers are encouraged. The FOA utilizes a phased R61/R33 funding mechanism to support mechanistic research and to evaluate the clinical relevance of music interventions. The R61 phase will provide funding to either investigate the biological mechanisms or behavioral processes underlying music interventions in relevant animal models, healthy human subjects, and/or clinical populations, or can be used to develop innovative technology or approaches to enhance music intervention research. The second R33 phase will provide support for further mechanistic investigations in human subjects or animal models, intervention development, or pilot clinical studies. The pilot clinical studies may focus on intervention optimization/refinement, feasibility, adherence, and/or identification of appropriate outcome measures to inform future clinical research. Transition from the R61 to the R33 phase of the award will depend on successful completion of pre-specified milestones established in the R61.

|        |  |                                    |               |                                     |               |
|--------|--|------------------------------------|---------------|-------------------------------------|---------------|
| 102357 | <a href="#">RFA-HL-22-007 -- Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Clinical Centers (Collaborative UG3/UH3 Clinical Trial Required)</a> | National Institutes of Health/DHHS | RFA-HL-22-007 | 11-May-2021 [Optional][LOI/Pre-App] | Not Specified |
|--------|--|------------------------------------|---------------|-------------------------------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Charlotte A. Pratt, MS, PhD  |
| Contact Telephone    | 301-435-0382   |
| Contact Email        | <a href="mailto:charlotte.pratt@mail.nih.gov">charlotte.pratt@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 11-May-2021 [Optional][LOI/Pre-App], 11-Jun-2021   |
| Synopsis             | This Funding Opportunity Announcement (FOA) invites applications for clinical or community sites to be part of a multi-center group- or cluster-randomized trial under the Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program. ENRICH will aim to test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

(CVH) and address CVH disparities in both mothers and children (0-5 years old) who are of low socio-economic status (SES), live in low-resource rural or urban communities, or who are in diverse geographic regions of the U.S. with high burden of cardiovascular disease (CVD) risk factors. Specifically, this initiative will support multi-site interventions designed to determine if a CVH module delivered within the context of a home visiting program can enhance maternal and early childhood CVH. This FOA uses the bi-phasic, milestone-driven cooperative agreement mechanism (UG3/UH3) and runs in parallel with a companion FOA (RFA-HL-22-008) that encourages applications for a collaborating Resource Coordinating Center (RCC). Awards made under this FOA will support a milestone driven planning phase including feasibility studies and pilot activities for up to 2 years (UG3), with possible transition to an implementation phase (UH3) for up to five additional years. Only UG3 trials that meet the scientific milestones and award requirements of the UG3 may transition to the UH3 phase. Applications submitted to this FOA must address both the UG3 and UH3 phases. Applications must also include plans for project management, subject recruitment and retention, scientific conduct of the trial including study design, intervention, measurement and data analysis, and performance milestones for each phase.

|        |  |                                    |               |  |               |
|--------|--|------------------------------------|---------------|--|---------------|
| 102358 | <a href="#">RFA-HL-22-008 -- Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Resource and Coordinating Center (U24 Clinical Trial Required)</a> | National Institutes of Health/DHHS | RFA-HL-22-008 | 11-May-2021<br>[Optional][LOI/Pre-App] | Not Specified |
|--------|--|------------------------------------|---------------|--|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Charlotte A. Pratt, MS, PhD  |
| Contact Telephone    | 301-435-0382   |
| Contact Email        | <a href="mailto:charlotte.pratt@mail.nih.gov">charlotte.pratt@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 11-May-2021 [Optional][LOI/Pre-App], 11-Jun-2021   |
| Synopsis             | <p>This Funding Opportunity Announcement (FOA) invites applications for a Resource and Coordinating Center (RCC) for the Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) program, a new NIH multi-center group- or cluster- randomized trial with clinical or community sites to be supported under the companion RFA-HL-22-007. The RCC will coordinate and provide support for the clinical or community sites that propose to test the effectiveness of an implementation-ready intervention designed to promote cardiovascular health (CVH) and address CVH</p> |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

disparities in both mothers and children (0-5 years of age) who are of low socio-economic status (SES), live in low-resource rural or urban communities, or are in diverse geographic regions of the U.S. with a high burden of cardiovascular disease (CVD) risk factors. Applicants should propose activities that include the following: Plan and support study coordinating structure and functions, including efforts to promote communication and collaborations among study investigators, training of staff on study protocols, convening of meetings, evaluating the data collected from the ENRICH clinical/community sites , and coordinating ancillary studies that leverage the ENRICH research platform Facilitate the development of a common intervention protocol for the UH3 phase, including the study design, analytic plan, sample size, and use of common elements and measures across studies, to be reviewed by the NHLBI-appointed DSMB and approved by the NHLBI prior to UH3 phase for the clinical or community sites Develop and implement data collection procedures, facilitate the collection of biomedical data, establish a central database, provide additional biostatistical expertise, conduct data analysis of data across study sites, and facilitate reporting of trial results, including process, impact, and outcomes measures. Involve and develop the skills of Early Stage Investigators (ESIs) and home-visiting staff professionals in early CVH promotion and implementation strategies to foster the next generation of researchers in promoting maternal and child CVH. Coordinate the development of public access data files to be made available in a data repository as designated by the NHLBI. This U24 cooperative agreement initiative is administered by the NHLBI but includes extensive participation and funding contributions from a coalition of Institutes, Centers, and Offices (ICOs) at the National Institutes of Health (NIH) as well as the Health Resources and Services Administration (HRSA) and the Administration for Children and Families (ACF). HRSA and ACF will provide the infrastructure and in-kind support to awardee investigators to gain access to evidence-based home visiting programs already being supported by HHS. HRSA and ACF staff, along with NIH staff will provide staff-level scientific and technical input for ENRICH. HRSA and ACF staff along with NIH staff may serve as project scientists on the Steering Committee and various subcommittees (e.g., intervention, measurement, publications, ancillary studies subcommittees). .

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 093897 | <a href="#">Research Project Grant (Parent R01 Clinical Trial Required)</a> | National Institutes of Health/DHHS | PA-20-183 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      |  |
| Contact Telephone |  |
| Contact Email     | <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a> |
| Sponsor Website   |  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023

Synopsis The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. NOTE: The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. National Heart, Lung, and Blood Institute (NHLBI) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) National Center for Complementary and Integrative Health (NCCIH) National Institute of Mental Health (NIMH)

|        |  |                                    |               |             |               |
|--------|--|------------------------------------|---------------|-------------|---------------|
| 102735 | <a href="#">RFA-NS-21-015 -- HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | RFA-NS-21-015 | 27-Apr-2021 | 7,500,000 USD |
|--------|--|------------------------------------|---------------|-------------|---------------|

Contact Name Michael L. Oshinsky, PhD

Contact Telephone 301-496-9964

Contact Email [michael.oshinsky@nih.gov](mailto:michael.oshinsky@nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 27-Apr-2021 , 28-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 13-Sep-2021 [Optional][LOI/Pre-App], 13-Oct-2021 , 10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 10-Sep-2023 [Optional][LOI/Pre-App], 10-Oct-2023

Synopsis This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is encouraged. The goal of each 5-year U19 application should be to identify candidate therapeutic(s) that will be ready to be submitted to RFA-NS-21-010 for further optimization.

|        |   |                                    |               |             |               |
|--------|---|------------------------------------|---------------|-------------|---------------|
| 102738 | <a href="#">RFA-NS-21-016 -- HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | RFA-NS-21-016 | 27-Apr-2021 | 1,000,000 USD |
|--------|---|------------------------------------|---------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Michael L. Oshinsky, PhD   |
| Contact Telephone    | 301-496-9964   |
| Contact Email        | <a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 27-Apr-2021 , 28-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 13-Sep-2021 [Optional][LOI/Pre-App], 13-Oct-2021 , 10-May-2022 [Optional][LOI/Pre-App], 09-Jun-2022 , 11-Sep-2022 [Optional][LOI/Pre-App], 11-Oct-2022 , 10-May-2023 [Optional][LOI/Pre-App], 09-Jun-2023 , 10-Sep- |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

2023 [Optional][LOI/Pre-App], 10-Oct-2023

Synopsis The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 084924 | <a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PAR-19-343 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Kenneth D. Gibbs, Jr., Ph.D.  |
| Contact Telephone    |   |
| Contact Email        | <a href="mailto:kenneth.gibbs@nih.gov">kenneth.gibbs@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022   |
| Synopsis             | The purpose of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions at research-intensive institutions. The MOSAIC K99/R00 program will |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         |  |   |                |               |                |
|         | <p>provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p> |   |                |               |                |
| 102638  | <a href="#">New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)</a>   | National Institutes of Health/DHHS  | PAS-21-150     | 05-Jun-2021   | 600,000 USD    |
|         | Contact Name   | Shilpa Hattangadi, M.D.   |                |               |                |
|         | Contact Telephone  | 301-594-7726  |                |               |                |
|         | Contact Email  | <a href="mailto:shilpam.hattangadi@nih.gov">shilpam.hattangadi@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024   |                |               |                |
|         | Synopsis   | <p>This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.</p> |                |               |                |
| 102694  | <a href="#">Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health</a>   | National Institutes of Health/DHHS  | NOT-HD-20-032  | 05-Jun-2021   | Not Specified  |
|         | Contact Name   | Regina M. Bures, Ph.D.  |                |               |                |
|         | Contact Telephone  | 301-496-9485  |                |               |                |
|         | Contact Email  | <a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a>  |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024

Synopsis The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support multi-disciplinary scientific teams proposing research using systems science approaches to address persistent public health challenges. Systems science refers to multi-level methodologies addressing complex behavioral and social phenomena. This initiative encourages applications for both basic and applied research, including methodological and measurement development, with a focus on human behavioral and/or social science. This initiative also seeks to promote interdisciplinary collaboration among health researchers and experts in mathematical modelling.

|        |  |                                    |               |             |               |
|--------|--|------------------------------------|---------------|-------------|---------------|
| 103050 | <a href="#">Notice of Special Interest (NOSI): Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS)</a> | National Institutes of Health/DHHS | NOT-HL-21-008 | 05-Jun-2021 | Not Specified |
|--------|--|------------------------------------|---------------|-------------|---------------|

Contact Name Denis Buxton, PhD

Contact Telephone 301-435-0515

Contact Email [buxtond@nhlbi.nih.gov](mailto:buxtond@nhlbi.nih.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024

Synopsis Postural Orthostatic Tachycardia Syndrome (POTS) can be a debilitating condition that affects routine activities such as working or attending school. POTS primarily affects women of child-bearing age, with most studies reporting 80-90% female predominance. The peak incidence is at age 14 years, but half of all individuals with POTS develop it in adulthood. While there are no precise data on the prevalence of POTS, it is estimated to affect 0.2-1% of the U.S. population. There is thus a compelling need to stimulate research to understand the causes of POTS in order to inform the development of treatments.

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|--|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Improving the diagnosis of POTS through the development of biomarkers or improved diagnostic tools represents another major need. Translational studies and mechanistic clinical trials to guide the development of better treatments are also important goals. This NOSI signals interest in this important area with the goal of stimulating research applications to address these critical needs.</p>   |                                    |                |                                     |                |
| 102531  | <a href="#">RFA-AG-22-020 -- Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional)</a>  | National Institutes of Health/DHHS | RFA-AG-22-020  | 23-May-2021 [Optional][LOI/Pre-App] | 2,500,000 USD  |
|         | <p>Contact Name: Melissa S. Gerald, Ph.D.<br/>           Contact Telephone: 301-496-3136<br/>           Contact Email: <a href="mailto:melissa.gerald@nih.gov">melissa.gerald@nih.gov</a><br/>           Sponsor Website:<br/>           Program URL: <a href="#">Link to program URL</a><br/>           Deadline Dates (ALL): 23-May-2021 [Optional][LOI/Pre-App], 23-Jun-2021</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) invites applications focused on triadic interactions and interpersonal processes between individuals with Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD), clinicians, and care partners. NIA seeks to increase our understanding of the impact of such interactions on patient health and well-being outcomes. The goal of this initiative is to identify targets for the development of behavioral interventions to optimize interactions in clinical settings and help build and preserve strong and supportive caregiving relationships throughout all stages of AD/ADRD and across the continuum of care. To these ends, this FOA solicits basic research and Stage I behavioral intervention development clinical trials in two high-priority areas: (1) triadic communication and interpersonal relationships between patients, clinicians, and care partners; and (2) the clinical significance of dyadic processes in caregiving relationships between patients and care partners in the context of patient-caregiver-clinician encounters.</p> |                                    |                |                                     |                |
| 102925  | <a href="#">Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromeE)</a>  | National Institutes of Health/DHHS | NOT-OD-20-024  | 07-May-2021                         | Not Specified  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

[Project](#)

|                      |   |
|----------------------|---|
| Contact Name         |   |
| Contact Telephone    |   |
| Contact Email        |   |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022   |
| Synopsis             | The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science). |

|        |  |                                    |               |                                     |               |
|--------|--|------------------------------------|---------------|-------------------------------------|---------------|
| 102984 | <a href="#">RFA-AT-21-006 -- Neural Mechanisms of Force-Based Manipulations: High Priority Research Networks (U24 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | RFA-AT-21-006 | 14-Jun-2021 [Optional][LOI/Pre-App] | 2,000,000 USD |
|--------|--|------------------------------------|---------------|-------------------------------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Merav Sabri, Ph.D.  |
| Contact Telephone    | 301-496-2583  |
| Contact Email        | <a href="mailto:merav.sabri@nih.gov">merav.sabri@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021  |
| Synopsis             | This Funding Opportunity Announcement (FOA) solicits applications that focus on developing resources to refine and test key concepts that will advance and further support study on the neural mechanisms and biomechanics of force-based manipulations. This grant funding initiative will support resources and activities such as research network meetings, conferences, small-scale pilot research, multidisciplinary cross training (e.g., intensive workshops, summer institutes, or visiting scholar programs), and information dissemination to foster the growth and development of research on the neural mechanisms and biomechanics of force-based manipulations. Further details and a description of |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

| priority areas are provided in this FOA.

|        |  |                                    |               |  |               |
|--------|--|------------------------------------|---------------|--|---------------|
| 103124 | <a href="#">RFA-AI-21-025 -- Prevention Strategies to End the HIV Epidemic (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | RFA-AI-21-025 | 30-Jun-2021<br>[Optional][LOI/Pre-App] | Not Specified |
|--------|--|------------------------------------|---------------|--|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Dale Burwen, MD, MPH  |
| Contact Telephone    | 240-669-2867  |
| Contact Email        | <a href="mailto:dale.burwen@nih.gov">dale.burwen@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV. Research funded under this FOA will support the goals of the DIAGNOSE and PREVENT pillars of the Ending the HIV Epidemic: A Plan for America (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities. |

|        |   |                                    |           |             |             |
|--------|---|------------------------------------|-----------|-------------|-------------|
| 103183 | <a href="#">Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PA-21-199 | 16-Jun-2021 | 100,000 USD |
|--------|---|------------------------------------|-----------|-------------|-------------|

|                      |  |
|----------------------|--|
| Contact Name         | Lisa Gilotty, Ph.D.  |
| Contact Telephone    | 301-443-3825   |
| Contact Email        | <a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). An R03 grant |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

supports small, discrete, well-defined projects that can be completed in two years and that require limited resources. R03 applications may include development of new research methodologies or technology, secondary analysis of existing data, and pilot or feasibility studies. Preliminary data are not required, particularly in applications proposing pilot or feasibility studies. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.

|        |  |                                    |               |             |               |
|--------|--|------------------------------------|---------------|-------------|---------------|
| 103220 | <a href="#">Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children</a> | National Institutes of Health/DHHS | NOT-MH-21-225 | 05-Jun-2021 | Not Specified |
|--------|--|------------------------------------|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Susan Borja, PhD  |
| Contact Telephone    | 301-443-1252  |
| Contact Email        | <a href="mailto:susan.borja@nih.gov">susan.borja@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022   |
| Synopsis             | NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 - 12. Particularly, we are interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios. |

|        |   |                                    |               |  |               |
|--------|---|------------------------------------|---------------|--|---------------|
| 103117 | <a href="#">RFA-AI-21-023 -- Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | RFA-AI-21-023 | 30-Jun-2021<br>[Optional][LOI/Pre-App] | Not Specified |
|--------|---|------------------------------------|---------------|--|---------------|

|              |                      |
|--------------|----------------------|
| Contact Name | Rosemary McKaig, PhD |
|--------------|----------------------|

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone 240-627-3214</p> <p>Contact Email <a href="mailto:rmckaig@niaid.nih.gov">rmckaig@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021</p> <p>Synopsis<br/>The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.</p>   |                                    |                |               |                |
| 103180  | <a href="#">Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)</a>  | National Institutes of Health/DHHS | PA-21-200      | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name Lisa Gilotty, Ph.D.</p> <p>Contact Telephone 301-443-3825</p> <p>Contact Email <a href="mailto:gilottyl@mail.nih.gov">gilottyl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024</p> <p>Synopsis<br/>The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Exploratory, novel studies that break new ground or extend previous discoveries toward new directions are appropriate for this mechanism. No preliminary data are required but may be included if available. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199 . Applicants pursuing larger studies in established scientific areas where preliminary data are expected should consider the companion R01 FOA, PA-21-201.</p> |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID              | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                          | Funding Amount |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|----------------------|---|------------------------------------|----------------|--|----------------|--------------|------------------------|-------------------|--------------|---------------|--|-----------------|--|-------------|-------------------------------------|----------------------|---|----------|--|
| 103168               | <a href="#">Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)</a>   | National Institutes of Health/DHHS | PA-21-201      | 05-Jun-2021                            | Not Specified  |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Lisa Gilotty, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-443-3825</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:gilotty@mail.nih.gov">gilotty@mail.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The Research Project Grant (R01) mechanism supports discrete, specified projects based in scientific areas that represent the investigators' specific interests and competencies, and that fall within the mission of the participating NIH Institutes and Centers (ICs). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions, and preliminary data are generally expected. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199.</td> </tr> </table> |                                    |                |  |                | Contact Name | Lisa Gilotty, Ph.D.    | Contact Telephone | 301-443-3825 | Contact Email | <a href="mailto:gilotty@mail.nih.gov">gilotty@mail.nih.gov</a>       | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024 | Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The Research Project Grant (R01) mechanism supports discrete, specified projects based in scientific areas that represent the investigators' specific interests and competencies, and that fall within the mission of the participating NIH Institutes and Centers (ICs). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions, and preliminary data are generally expected. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199. |
| Contact Name         | Lisa Gilotty, Ph.D.   |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Telephone    | 301-443-3825  |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Email        | <a href="mailto:gilotty@mail.nih.gov">gilotty@mail.nih.gov</a>  |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Sponsor Website      |   |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Program URL          | <a href="#">Link to program URL</a>   |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023 , 05-Feb-2024   |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). The Research Project Grant (R01) mechanism supports discrete, specified projects based in scientific areas that represent the investigators' specific interests and competencies, and that fall within the mission of the participating NIH Institutes and Centers (ICs). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions, and preliminary data are generally expected. Applicants pursuing exploratory/developmental research to support early and conceptual stages of project development should consider the companion R21 FOA, PA-21-200. Applicants pursuing secondary analysis of existing data, and pilot or feasibility studies that can be completed with limited budgets should consider the companion R03 FOA, PA-21-199.  |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| 103216               | <a href="#">RFA-AR-21-016 -- Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)</a>   | National Institutes of Health/DHHS | RFA-AR-21-016  | 15-Jun-2021<br>[Optional][LOI/Pre-App] | Not Specified  |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Ricardo Cibotti, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-5888</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> </table>   |                                    |                |  |                | Contact Name | Ricardo Cibotti, Ph.D. | Contact Telephone | 301-451-5888 | Contact Email | <a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a> | Sponsor Website |  | Program URL | <a href="#">Link to program URL</a> |                      |   |          |  |
| Contact Name         | Ricardo Cibotti, Ph.D.  |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Telephone    | 301-451-5888  |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Contact Email        | <a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a>  |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Sponsor Website      |   |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |
| Program URL          | <a href="#">Link to program URL</a>   |                                    |                |  |                |              |                        |                   |              |               |  |                 |  |             |                                     |                      |   |          |  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date                       | Funding Amount |
|---------|---|------------------------------------|----------------|-------------------------------------|----------------|
|         | <p>Deadline Dates (ALL) 15-Jun-2021 [Optional][LOI/Pre-App], 15-Jul-2021</p> <p>Synopsis The purpose of this FOA is to establish Technology and Analytic Cores (TACs) and a Research Management Unit (RMU) for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. The TACs include the Technology Cores and the specialized Tissue Repository and Systems Biology Cores. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. TACs will work together to test, optimize and apply state-of-the-art and next-generation high-dimensional, high-resolution technologies to interrogate and analyze human biopsy tissue and biosamples from patients with rheumatoid arthritis, lupus, psoriatic spectrum disease and Sjögren's syndrome. The RMU will provide centralized management and operational support to the network including clinical monitoring for the entire AMP AIM program. All Cores and the RMU will work collaboratively with the Disease Teams (RFA-AR-21-015) to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue involvement in relevant patient populations.</p> |                                    |                |                                     |                |
| 103215  | <p><a href="#">RFA-AR-21-015 -- Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren's Syndrome (UC2 Clinical Trial Optional)</a></p>  | National Institutes of Health/DHHS | RFA-AR-21-015  | 15-Jun-2021 [Optional][LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name Ricardo Cibotti, Ph.D.</p> <p>Contact Telephone 301-451-5888</p> <p>Contact Email <a href="mailto:ricardo.cibotti@nih.gov">ricardo.cibotti@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021 [Optional][LOI/Pre-App], 15-Jul-2021</p> <p>Synopsis The purpose of this FOA is to establish Disease Teams for the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) Program. Disease Teams (DTs) will focus on one of the following diseases: rheumatoid arthritis, lupus, psoriatic spectrum disease, or Sjögren's syndrome. The goal of the AMP AIM Program is to gain a comprehensive understanding of cellular and molecular disease pathways and to identify novel targets for intervention. Disease Teams will lead the research efforts to define the most significant scientific opportunities that can be addressed with state</p>  |                                    |                |                                     |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

of the art and next-generation tissue interrogation technologies in the context of disease de- and reconstruction approaches of AMP AIM. DTs will work collaboratively to identify molecular and cellular pathways of disease by probing the structural, functional and molecular complexities of end organ tissue in relevant patient populations with state-of the art and next generation analytics provided by the Technical and Analytic Cores (RFA-AR-21-016). DTs will work to harmonize, integrate and optimize all aspects of the data generation pipeline, from tissue collection to data analysis and interpretation.

|        |   |                                    |            |             |             |
|--------|---|------------------------------------|------------|-------------|-------------|
| 102740 | <a href="#">Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PAR-21-124 | 17-Jun-2021 | 750,000 USD |
|--------|---|------------------------------------|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Becky Roof, PhD   |
| Contact Telephone    | 301-496-1779  |
| Contact Email        | <a href="mailto:rebecca.roof@nih.gov">rebecca.roof@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 17-Jun-2021 , 19-Oct-2021 , 22-Feb-2022 , 21-Jun-2022 , 18-Oct-2022 , 21-Feb-2023 , 20-Jun-2023 , 20-Oct-2023 , 20-Feb-2024   |
| Synopsis             | This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs. |

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 095409 | <a href="#">Enhancing Science, Technology, Engineering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)</a> | National Institutes of Health/DHHS | PAR-20-223 | 24-Jun-2021 | Not Specified |
|--------|--|------------------------------------|------------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Zeynep Erim, Ph.D.   |
| Contact Telephone | 301-451-4797   |
| Contact Email     | <a href="mailto:erimz@mail.nih.gov">erimz@mail.nih.gov</a> |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 24-Jun-2021 , 24-Jun-2022</p> <p>Synopsis</p> <p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences for undergraduate freshmen and sophomores from diverse backgrounds, including those from groups underrepresented in bioengineering or STEM fields relevant to bioengineering, such as engineering or the physical/computational sciences, which play key roles in biomedical technologies and innovation. The ESTEEMED program is intended to expose students to bioengineering research early in their college careers and interest them in potentially pursuing advanced studies in bioengineering or a related field. It will prepare students to join, in their junior and senior years, an honors program, supported by federal or institutional funds, that promotes STEM and entrance into a Ph.D. program. The ultimate goal is for the participants to pursue a Ph.D. or M.D./Ph.D. degree and a subsequent research career integrating engineering and the physical sciences with medicine and biology in academia or industry.</p> |                                    |                |               |                |
| 101555  | <p><a href="#">Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)</a></p>  | National Institutes of Health/DHHS | PAR-21-109     | 16-Jun-2021   | 275,000 USD    |
|         | <p>Contact Name Manuel Moro, DVM, Ph.D.</p> <p>Contact Telephone 301-480-1796</p> <p>Contact Email <a href="mailto:manuel.moro@nih.gov">manuel.moro@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023 , 16-Oct-2023 , 16-Feb-2024</p> <p>Synopsis</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support research using nonhuman primate (NHP) models performed by early-stage investigators who are within 10 years of their terminal</p>  |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

degree or residency training and have at least two years of postdoctoral experience. This FOA is designed specifically for applicants proposing to develop new research directions using NHP models in basic science or translational research.

|        |  |                                    |               |  |               |
|--------|--|------------------------------------|---------------|--|---------------|
| 103354 | <a href="#">RFA-AI-21-013 -- Understanding HIV Reservoir Dynamics (P01 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | RFA-AI-21-013 | 30-Jun-2021<br>[Optional][LOI/Pre-App] | 5,000,000 USD |
|--------|--|------------------------------------|---------------|--|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Leia Novak, Ph.D.   |
| Contact Telephone    | 301- 761-7825   |
| Contact Email        | <a href="mailto:Leia.novak@nih.gov">Leia.novak@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding changes in the HIV reservoir over time in different cell types and tissues. A better understanding of the mechanisms that govern HIV reservoir dynamics over time is essential to inform the development of strategies to cure HIV or control viral infection to overcome the need for life-long antiretroviral therapy. |

|        |  |                                    |               |             |               |
|--------|--|------------------------------------|---------------|-------------|---------------|
| 099392 | <a href="#">Notice of Special Interest (NOSI): Optimizing Precision Treatment of Gynecologic, Reproductive and Obstetrical Outcomes in Adolescents and Adults with PCOS and Associated Comorbid Conditions (Clinical Trial Optional)</a> | National Institutes of Health/DHHS | NOT-HD-20-026 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Esther Eisenberg, MD MPH  |
| Contact Telephone    | 301-496-6516  |
| Contact Email        | <a href="mailto:esther.eisenberg@nih.gov">esther.eisenberg@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16- |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023

Synopsis The National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) to announce the opportunity for investigators to apply for funding to optimize treatments of comorbid conditions in adolescents and reproductive age women with a diagnosis of Polycystic Ovary Syndrome (PCOS). The goals of this initiative are to stimulate interdisciplinary scientific collaboration between gynecologists/reproductive endocrinologists/obstetricians and subspecialists in diverse medical fields, including cardiologists, endocrinologists, gastroenterologists, psychiatrists, mental health professionals, pulmonologists, among others, to: 1) advance individualized treatments consistent with gynecologic, reproductive and obstetrical needs and desires; 2) promote translational and clinical research to increase knowledge and understanding of interaction of various therapies on gynecologic, reproductive and obstetric outcomes; and 3) discover and develop novel safe and more effective therapies for adolescents and women with PCOS with underlying comorbid conditions. Ultimately, this research would advance precision therapeutics for adolescents and adults with PCOS who have concomitant medical conditions.

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 076698 | <a href="#">New Paradigms in Tissue Communication-from mediators to metabolic function (RC2 Clinical Trials Optional)</a> | National Institutes of Health/DHHS | PAR-18-886 | 01-Jun-2021 | Not Specified |
|--------|---|------------------------------------|------------|-------------|---------------|

Contact Name Olivier Blondel, Ph.D.  
 Contact Telephone 301-451-7334  
 Contact Email [blondelol@niddk.nih.gov](mailto:blondelol@niddk.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 01-Jun-2021

Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to generate scientific advancements that are focused on identifying new signals and regulatory networks that mediate metabolic cross talks within and between organs that play a role in the development of diabetes and obesity. The interdisciplinary approaches proposed should be designed to foster novel synergies that will accelerate conceptual and technical breakthroughs in science related to metabolic tissue communication. This FOA will use the NIH RC2 High Impact Research and Research Infrastructure Programs award mechanism.

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date                          | Funding Amount |
|---------|--|------------------------------------|----------------|--|----------------|
| 102794  | <a href="#">RFA-OD-21-005 -- Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 - Independent Clinical Trial Not Allowed)</a>   | National Institutes of Health/DHHS | RFA-OD-21-005  | 04-May-2021<br>[Optional][LOI/Pre-App] | 800,000<br>USD |
|         | <p>Contact Name   Erica L. Spotts, Ph.D.</p> <p>Contact Telephone   301-594-2105</p> <p>Contact Email   <a href="mailto:spottse@od.nih.gov">spottse@od.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   04-May-2021 [Optional][LOI/Pre-App], 04-Jun-2021 , 07-Sep-2021</p> <p>Synopsis   The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development</p> |                                    |                |  |                |
| 103244  | <a href="#">Notice of Special Interest (NOSI): Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01, R21)</a>  | National Institutes of Health/DHHS | NOT-HD-21-024  | 05-Jun-2021                            | Not Specified  |
|         | <p>Contact Name   Robert Tamburro, MD, MSc</p> <p>Contact Telephone   301-451-4295</p> <p>Contact Email   <a href="mailto:robert.tamburro@nih.gov">robert.tamburro@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 06-Feb-2023 , 07-May-2023</p> <p>Synopsis   The purpose of this Notice of Scientific Interest (NOSI) is to continue a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome</p>   |                                    |                |  |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

(MODS). MODS is a clinical condition commonly encountered in the pediatric intensive care unit that is associated with significant morbidity and mortality. It is characterized by the failure or dysfunction of a consistent group of body organs or organ systems. It is triggered by a wide range of disease processes and clinical insults, most notably sepsis and trauma, and is frequently associated with uncontrolled inflammation. Despite its high prevalence and unfavorable outcomes, this clinical entity remains poorly understood. First described over 40 years ago, it still can only be described as a “syndrome,” a constellation of symptoms, rather than as a specific pathologic entity with a distinguishable cause. The current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Applications may include any appropriate study design ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research solicited through this NOSI, outcomes will improve both in terms of the prevention and treatment of MODS in children. Applicants planning to submit an application in response to this NOSI are strongly encouraged to contact the NICHD scientific/programmatic contact(s) listed on this NOSI in advance of the application due date.

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 103252 | <a href="#">Short-term Mentored Research Career Enhancement Award to Promote Diversity (K18 No Independent Clinical Trials)</a> | National Institutes of Health/DHHS | PA-21-214 | 12-Jun-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Luis Cubano, Ph.D.   |
| Contact Telephone    | 301-480-3435   |
| Contact Email        | <a href="mailto:luis.cubano@nih.gov">luis.cubano@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 12-Jun-2021 , 12-Feb-2022 , 12-Feb-2023  |
| Synopsis             | The objective of this Career Enhancement Award (K18) is to provide support for scientists from diverse backgrounds, including underrepresented groups, (NOT-OD-20-031) who wish either to expand their genomic competencies or to change their research careers by acquiring new genomics research knowledge or skills. This FOA provides short-term (3 person-months up to a maximum of 12 person-months) career development experiences to faculty members from diverse backgrounds, including underrepresented groups, that would result in strengthening their ability to perform independent research in genomics. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 076238 | <a href="#">Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PA-18-856 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Mary Evans, Ph.D.   |
| Contact Telephone    | 301-594-4578  |
| Contact Email        | <a href="mailto:evansmary@nidDK.nih.gov">evansmary@nidDK.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021   |
| Synopsis             | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH Research Project (R01) award mechanism. |

|        |   |                                    |               |  |               |
|--------|---|------------------------------------|---------------|--|---------------|
| 103292 | <a href="#">RFA-NS-21-013 -- BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | RFA-NS-21-013 | 07-Jun-2021<br>[Optional][LOI/Pre-App] | Not Specified |
|--------|---|------------------------------------|---------------|--|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Karen K David, PhD  |
| Contact Telephone    | 301-496-9964  |
| Contact Email        | <a href="mailto:BRAINcircuits@NIH.GOV">BRAINcircuits@NIH.GOV</a>                                    |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-Jun-2021 [Optional][LOI/Pre-App], 07-Jul-2021 , 11-Oct-2021 [Optional][LOI/Pre-App], 10-Nov-2021 |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                          | Funding Amount |
|---------|--|---|----------------|--|----------------|
|         | <p style="text-align: center;">Synopsis</p> <p>This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles.</p> |   |                |  |                |
| 103295  | <p><a href="#">RFA-NS-21-014 -- BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)</a></p>   | National Institutes of Health/DHHS  | RFA-NS-21-014  | 07-Jun-2021<br>[Optional][LOI/Pre-App] | Not Specified  |
|         | <p style="text-align: center;">Synopsis</p> <p>This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-21-013). Applications should be adventurous exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.</p>   | <p>Contact Name: Karen K David, PhD</p> <p>Contact Telephone: 301-496-9964</p> <p>Contact Email: <a href="mailto:BRAINcircuits@NIH.GOV">BRAINcircuits@NIH.GOV</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jun-2021 [Optional][LOI/Pre-App], 07-Jul-2021, 11-Oct-2021 [Optional][LOI/Pre-App], 10-Nov-2021</p> |                |  |                |
| 090374  | <p><a href="#">In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01)</a></p>   | National Institutes of Health/DHHS  | PAR-20-137     | 05-Jun-2021                            | 2,499,995 USD  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

[Clinical Trial Not Allowed](#)

|                      |   |
|----------------------|---|
| Contact Name         | Mahua Mukhopadhyay, PhD   |
| Contact Telephone    | 301-435-6886  |
| Contact Email        | <a href="mailto:mukhopam@mail.nih.gov">mukhopam@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Jun-2022 , 05-Oct-2022   |
| Synopsis             | <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. As of November 2019, the IMPC-KOMP2 KO mouse phenotyping effort has generated mutants in 9,051 mouse genes, completed phenotypes of 7153 lines, and released data for 6255 lines corresponding to 5861 mutant genes. Overall, the IMPC hopes to achieve broad-based phenotyping of roughly 20,000 KO strains. About 30% of these strains either are expected to be embryonic or perinatal lethal, or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.</p> |

|        |   |                                    |            |             |               |
|--------|---|------------------------------------|------------|-------------|---------------|
| 087955 | <a href="#">Surgical Disparities Research (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-079 | 05-Jun-2021 | Not Specified |
|--------|---|------------------------------------|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Benyam Hailu, MD, MPH  |
| Contact Telephone    | 301-594-8696   |
| Contact Email        | <a href="mailto:Benyam.Hailu@nih.gov">Benyam.Hailu@nih.gov</a>                             |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 05-Jun-2021 , 05-Jun-2022  |
| Synopsis             | The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level.

|        |  |                                    |               |             |                |
|--------|--|------------------------------------|---------------|-------------|----------------|
| 103245 | <a href="#">Notice of Special Interest (NOSI): Illuminating the Druggable Genome (IDG) Initiative: Request for Administrative Supplements to Existing Grants for incorporating single cell data into the IDG</a> | National Institutes of Health/DHHS | NOT-RM-21-019 | 15-Jun-2021 | 175,000<br>USD |
|--------|--|------------------------------------|---------------|-------------|----------------|

Contact Name  
 Contact Telephone  
 Contact Email [DruggableGenome@mail.nih.gov](mailto:DruggableGenome@mail.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 15-Jun-2021

Synopsis This Notice is part of the Common Fund Program "Illuminating the Druggable Genome" (IDG; <https://commonfund.nih.gov/idg/index>), an initiative that aims to catalyze research to improve our understanding of the properties and functions of proteins that are currently not well studied within commonly drug-targeted protein families. The IDG Program is inviting investigators with relevant active research project grants and cooperative agreements to submit administrative supplements, according to PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) for funded projects to incorporate and present single-cell data within the IDG Pharos (<https://pharos.nih.gov>) resource. Pharos and the underlying infrastructure manage knowledge about human proteins by accruing, abstracting, data and information available in the primary literature, databases, and other resources around the world to create an integrated resource. A major goal of the resource is to help the community prioritize and study understudied targets to determine its relevance in human health and disease. It is crucial to remember is that Pharos does not store primary data only processed and abstracted data. Currently, a significant and highly useful datatype missing in Pharos is single-cell data. Supplement awarded under this Notice will help to enhance the utility of Pharos by adding this new datatype to the Pharos databases and undertake research to identify the best ways to display and use this data to further the underlying goal of the IDG program—namely, incentivize the study of understudied targets. This Notice will only accept

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

supplement requests that do not propose clinical trials.

|        |  |                                    |               |  |               |
|--------|--|------------------------------------|---------------|--|---------------|
| 103421 | <a href="#">Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | RFA-AG-21-035 | 09-May-2021<br>[Optional][LOI/Pre-App] | Not Specified |
|--------|--|------------------------------------|---------------|--|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | John W.R. Phillips, Ph.D.   |
| Contact Telephone    | 301-496-3136  |
| Contact Email        | <a href="mailto:John.Phillips@nih.gov">John.Phillips@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 09-May-2021 [Optional][LOI/Pre-App], 09-Jun-2021  |
| Synopsis             | The purpose of this Cooperative Resource-Related Research Project FOA is to establish a coordinating center to support and develop research, dissemination, and various data sharing activities for social, behavioral, and economic research on COVID-19. The Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (SBECCC) will foster innovation, collaboration, and synergies across researchers funded through the Social, Behavioral and Economic Research on COVID-19 Consortium (U01) program and other relevant NIH-funded studies by supporting networking activities intended to advance research in the field; supporting the development and use of harmonized COVID-19 data constructs for primary and secondary data to support comparability and replicability; assisting in efficient and enhanced sharing/discoverability of data; and disseminating findings to the research community and the public. |

|        |   |                                    |               |  |               |
|--------|---|------------------------------------|---------------|--|---------------|
| 102840 | <a href="#">RFA-DK-21-004 -- The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | RFA-DK-21-004 | 22-May-2021<br>[Optional][LOI/Pre-App] | 2,500,000 USD |
|--------|---|------------------------------------|---------------|--|---------------|

|                   |  |
|-------------------|--|
| Contact Name      | Salvatore Sechi, Ph.D.                           |
| Contact Telephone | 301-594-8814                                     |
| Contact Email     | <a href="mailto:sechi@nih.gov">sechi@nih.gov</a> |
| Sponsor Website   |  |
| Program URL       | <a href="#">Link to program URL</a>              |



## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL) 22-May-2021 [Optional][LOI/Pre-App], 22-Jun-2021 , 09-Feb-2022 [Optional][LOI/Pre-App], 09-Mar-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications from institutions and organizations proposing original research aimed at the characterization of the function of neoepitopes and neoantigens in type 1 diabetes. This includes the function that post-translational modifications might have in the humoral and cell mediated autoimmune responses and overall in the etiology and pathophysiology of type 1 diabetes. Applications that include the discovery of neoantigens or neoepitopes are within the scope of this solicitation, but should propose a plan for integrating these discoveries with the present knowledge on established epitopes and antigens (e.g. autoantibodies for insulin, GAD65, IA-2, and ZnT8). In the long-term the goals of this initiative are to facilitate the development of better tools to monitor disease progression and treatment, and potentially to facilitate the development of personalized therapeutics.</p>  |                                    |                |               |                |
| 103305  | <a href="#">Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)</a>   | National Institutes of Health/DHHS | PAR-21-213     | 09-Jun-2021   | Not Specified  |
|         | <p>Contact Name John W.R. Phillips, Ph.D.</p> <p>Contact Telephone 301-496-3136</p> <p>Contact Email <a href="mailto:John.Phillips@nih.gov">John.Phillips@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2021 , 08-Nov-2021</p> <p>Synopsis The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations. To address these questions, this FOA aims to form a research consortium to access, extract, integrate, share, and analyze existing data from various sources with broad population coverage including underserved and vulnerable populations. Examples of existing data include public health data; personal digital data; economic, labor, and commerce data; electronic health records (EHRs); claims data; and ongoing health, demographic, and social surveys. This FOA solicits applications for individual population research projects that will be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBCECC) to foster collaboration and synergies across consortium</p> |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

member projects. Investigators will work with the SBECCC to enhance as well as share data resources used in proposed research both within the consortium as well as with others for health research purposes. The SBECCC will organize annual meetings of the consortium investigators to share results, foster harmonization among measures collected, identify new opportunities for interaction/collaboration, and share results with NIH and the public. Further, the SBECCC will support the development of reports and analyses summarizing and integrating the findings/products of the consortium.

|        |   |                                    |            |             |             |
|--------|---|------------------------------------|------------|-------------|-------------|
| 091508 | <a href="#">Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-159 | 16-Jun-2021 | 275,000 USD |
|--------|---|------------------------------------|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Jovier D. Evans, PhD  |
| Contact Telephone    | 301-443-1369  |
| Contact Email        | <a href="mailto:jevans1@mail.nih.gov">jevans1@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023   |
| Synopsis             | The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementia (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. PAR-20-157 uses the R01 grant mechanism, while PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. |

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 090366 | <a href="#">Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical Trial Required)</a> | National Institutes of Health/DHHS | PAR-20-133 | 08-Jun-2021 | 1,775,000 USD |
|--------|--|------------------------------------|------------|-------------|---------------|

Contact Name | Padma Maruvada, PhD

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Contact Telephone | 301-594-8884

Contact Email | [padma.maruvada@nih.gov](mailto:padma.maruvada@nih.gov)

Sponsor Website

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 08-Jun-2021

Synopsis | The purpose of this Funding Opportunity Announcement is to support the development of tools/devices for sampling or monitoring of diet- gastro-intestinal (GI)(contents and mucosa) and microbial interactions (GI- Microbiome Explorer). It is anticipated that successful completion of the projects completed under this FOA will yield implementable devices/tools for gastroenterological research or other clinical applications, along with monitoring and sampling of GI contents and/or mucosa to examine diet-host-microbiome interactions for clinical research or diagnostic applications.

|        |   |                                    |               |             |               |
|--------|---|------------------------------------|---------------|-------------|---------------|
| 103419 | <a href="#">Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health</a> | National Institutes of Health/DHHS | NOT-OD-21-100 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|---------------|-------------|---------------|

Contact Name | Wendy Nelson, PhD, MPH

Contact Telephone | 240-276-6971

Contact Email | [nelsonw@mail.nih.gov](mailto:nelsonw@mail.nih.gov)

Sponsor Website

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 15-Jun-2021 , 16-Jun-2021 , 10-Aug-2021 , 07-Sep-2021 , 05-Oct-2021 , 15-Oct-2021 , 16-Oct-2021 , 14-Dec-2021 , 07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 14-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024

Synopsis | This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.

|        |  |                                    |               |             |             |
|--------|--|------------------------------------|---------------|-------------|-------------|
| 103418 | <a href="#">Notice of Special Interest (NOSI): Limited Competition to Support Mentorship of Junior Investigators</a> | National Institutes of Health/DHHS | NOT-NS-21-026 | 14-Jun-2021 | 300,000 USD |
|--------|--|------------------------------------|---------------|-------------|-------------|

Contact Name | Laura Dover Wandner, PhD  
 Contact Telephone | 301-318-8070  
 Contact Email | [Laura.Wandner@nih.gov](mailto:Laura.Wandner@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 14-Jun-2021

Synopsis | This Notice of Special Interest (NOSI) provides an opportunity for researchers funded by the Helping to End Addiction Long-Term (HEAL) initiative to devote more time to patient-oriented research and mentoring. For the purposes of the K24 award, patient-oriented research is defined as research conducted with human subjects for which an investigator (or colleague) directly interacts with human subjects. This area of research includes: 1) therapeutic interventions, and 2) clinical trials. NIH ICs participating in HEAL are issuing this notice to highlight their interest in receiving applications from HEAL investigators for a K24 award.

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 091413 | <a href="#">Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-155 | 05-Jun-2021 | Not Specified |
|--------|--|------------------------------------|------------|-------------|---------------|

Contact Name | Christopher M. Hartshorn, Ph.D.  
 Contact Telephone | 240-781-3315  
 Contact Email | [christopher.hartshorn@nih.gov](mailto:christopher.hartshorn@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

|        |   |                                    |               |                                     |               |
|--------|---|------------------------------------|---------------|-------------------------------------|---------------|
| 103055 | <a href="#">RFA-TW-21-001 -- Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | RFA-TW-21-001 | 08-Jun-2021 [Optional][LOI/Pre-App] | Not Specified |
|--------|---|------------------------------------|---------------|-------------------------------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Christine M. Jessup, Ph.D.   |
| Contact Telephone    | 301-496-1653   |
| Contact Email        | <a href="mailto:Christine.Jessup@nih.gov">Christine.Jessup@nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021   |
| Synopsis             | This Funding Opportunity Announcement (FOA) solicits applications for research projects in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research must be harmonized with a linked application for research training under RFA-TW-21-002 “Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)”. This research FOA is intended to support collaborative research that contributes to the long-term goals of 1) building and strengthening sustainable research capacity in LMICs to address environmental and occupational health, and 2) developing a research foundation to inform evidence-based policy related to environmental and occupational health. Clinical research (<https://grants.nih.gov/grants/glossary.htm#ClinicalResearch>), clinical trials (<https://grants.nih.gov/grants/glossary.htm#ClinicalTrial>), and human subjects research (<https://humansubjects.nih.gov/>) are allowed under this FOA. Examples of the types of NIH-defined clinical trials that could be proposed include (but are not limited to) technology interventions, behavioral interventions, etc. This FOA will NOT support studies whose purpose is to evaluate safety clinical efficacy, effectiveness, and management and/or implementation of new or established pharmacological agents. For the NIH definition of clinical research versus clinical trials, please see <https://grants.nih.gov/policy/clinical-trials/definition.htm>. Please use the clinical trial tool (<https://grants.nih.gov/ct-decision/index.htm>) to determine whether your proposed study is a clinical trial. For additional information please refer to the NIH Clinical Trials Requirements and Fogarty information on human subjects research and clinical trials. Applicants desiring to conduct NIH-defined clinical trials should contact the FIC prior to submission to review the scope of the proposed clinical trial with the program contact. Applicants are strongly encouraged to review the NOT-OD-15-103 on enhancing the reproducibility of NIH-supported research through rigor and transparency and to incorporate appropriate features into the proposed research plans.

|        |  |                                    |               |  |               |
|--------|--|------------------------------------|---------------|--|---------------|
| 103058 | <a href="#">RFA-TW-21-002 -- Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research Training (Collaborative U2R Clinical Trial Optional)</a> | National Institutes of Health/DHHS | RFA-TW-21-002 | 08-Jun-2021<br>[Optional][LOI/Pre-App] | Not Specified |
|--------|--|------------------------------------|---------------|--|---------------|

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name           | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------|----------------|---------------|----------------|
|         | <p>Contact Name   Christine M. Jessup, Ph.D.</p> <p>Contact Telephone   301-496-1653</p> <p>Contact Email   <a href="mailto:Christine.Jessup@nih.gov">Christine.Jessup@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Jun-2021 [Optional][LOI/Pre-App], 08-Jul-2021</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits applications for research training activities in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts. Hubs are supported by two coordinated linked awards to 1) a LMIC institution for research and 2) a U.S. institution for research training. Both applications must demonstrate a commitment to extensive coordination between these two awards to meet goals of the GEOHealth program. An application submitted in response to this FOA for research training must be harmonized with a linked application for related research under RFA-TW-21-001 “Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)”. This research training FOA is intended to support research training of LMIC investigators, provide mentored research training opportunities in the partner LMIC, and strengthen the capacity of the partner LMIC institution to conduct environmental and occupational health research. This Funding Opportunity Announcement (FOA) allows appointment of Trainees proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.</p> |                        |                |               |                |
| 090063  | <a href="#">Native American Research Centers for Health</a>   | National Institutes of | PAR-20-125     | 24-Jun-2021   | 4,000,000      |

## NIH Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | <a href="#">(NARCH) (S06 Clinical Trials Optional)</a>   | Health/DHHS   |                | USD           |                |
|         | Contact Name   | Sheila A. Caldwell, PhD   |                |               |                |
|         | Contact Telephone  |   |                |               |                |
|         | Contact Email  | <a href="mailto:caldwells@mail.nih.gov">caldwells@mail.nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 24-Jun-2021 , 23-Jul-2021   |                |               |                |
|         | Synopsis   | <p>The National Institute of General Medical Sciences, in conjunction with the Institutes/Centers of the National Institutes of Health (NIH) listed above in the "Components of Participating Organizations" section and the Indian Health Service (IHS), invites applications from federally recognized Tribes and Tribal organizations for the Native American Research Centers for Health (NARCH) initiative. The objective of the NARCH initiative is to support biomedical research and career enhancement opportunities to meet health needs prioritized by American Indian/Alaska Native (AI/AN) communities. The NARCH initiative also supports research capacity building and the development of research infrastructure to enhance the biomedical research capabilities of AI/AN communities.</p> |                |               |                |
| 103492  | <a href="#">Notice of Special Interest (NOSI): Administrative Supplement for Modifiable Factors Potentially affecting the Cost of Cancer Treatment</a> | National Institutes of Health/DHHS  | NOT-CA-21-055  | 18-Jun-2021   | Not Specified  |
|         | Contact Name   | Michael T. Halpern, MD, PhD   |                |               |                |
|         | Contact Telephone  | 240-276-5818  |                |               |                |
|         | Contact Email  | <a href="mailto:michael.halpern@nih.gov">michael.halpern@nih.gov</a>  |                |               |                |
|         | Sponsor Website  |   |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)   | 18-Jun-2021   |                |               |                |
|         | Synopsis   | <p>This Notice of Special Interest (NOSI) informs current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on modifiable factors affecting costs of cancer treatment in the context of improving health outcomes. This includes factors associated with the cost of cancer treatment paid by individuals diagnosed with cancer (i.e., "out-of-pocket costs") and/or factor associated with the cost of treatment to healthcare systems</p>   |                |               |                |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

or organizations.

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 090369 | <a href="#">Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones (R21/R33 Clinical Trial Required)</a> | National Institutes of Health/DHHS | PAR-20-134 | 08-Jun-2021 | 1,775,000 USD |
|--------|--|------------------------------------|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Padma Maruvada, PhD   |
| Contact Telephone    | 301-594-8884  |
| Contact Email        | <a href="mailto:padma.maruvada@nih.gov">padma.maruvada@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 08-Jun-2021   |
| Synopsis             | The purpose of this Funding Opportunity Announcement is to develop tools and devices that can continuously monitor a broader range of nutrients, metabolites and/or metabolic signals for advancing precision nutrition, microbiome, and circadian metabolism research. |

|        |   |                                    |            |             |             |
|--------|---|------------------------------------|------------|-------------|-------------|
| 080196 | <a href="#">Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PAR-19-194 | 16-Jun-2021 | 550,000 USD |
|--------|---|------------------------------------|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Avi Rasooly, PhD  |
| Contact Telephone    | 240-276-6196  |
| Contact Email        | <a href="mailto:rasoolya@mail.nih.gov">rasoolya@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022   |
| Synopsis             | The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaeobacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

tumor, and immune system. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies. This FOA will support basic, mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants responding to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy. The FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy.

|        |  |                                    |            |             |               |
|--------|--|------------------------------------|------------|-------------|---------------|
| 093638 | <a href="#">Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)</a> | National Institutes of Health/DHHS | PAR-20-180 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | David L. Tilley, MPH, MS, CPH   |
| Contact Telephone    | 301-827-6014  |
| Contact Email        | <a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 |

Synopsis This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs. Prospective applicants whose research interests relate to developing improved measures and methods for understanding multimorbidity, including but not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways and identification and initial evaluation of MCC shared signatures, should see PAR-20-179.

|        |   |                                    |               |  |               |
|--------|---|------------------------------------|---------------|--|---------------|
| 103426 | <a href="#">RFA-CA-21-029 -- Centers on Telehealth Research for Cancer-Related Care (P50 Clinical Trial Required)</a> | National Institutes of Health/DHHS | RFA-CA-21-029 | 20-Jun-2021<br>[Optional][LOI/Pre-App] | 4,000,000 USD |
|--------|---|------------------------------------|---------------|--|---------------|

Contact Name  
 Contact Telephone  
 Contact Email  
 Sponsor Website  
 Program URL  
 Deadline Dates (ALL)

[Link to program URL](#)

20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to fund P50 Centers dedicated to advancing a national telehealth research agenda focused on improving cancer-related care and outcomes across the cancer control continuum in a rapidly changing healthcare, policy, technology, and communication environment. Centers are expected to generate and disseminate a robust evidence base for patient-centered, sustainable telehealth models of cancer care delivery. Centers will foster innovations to improve cancer care delivery by researching real-time, patient-provider telehealth communication using new tools, research methods, and technologies. Each Center will focus on one overarching cancer-focused telehealth research theme that will frame the Center’s scientific activities. Each Center will leverage a clinical practice network able to support multiple cancer-focused telehealth research studies, including two rapid-cycle pilot projects and one large-scale pragmatic randomized control trial. A centerpiece of each Center, the pragmatic trial will evaluate the integration of telehealth-delivered cancer care into a real-world clinical environment, evaluating improvements in patient access, quality of care, patient-provider communication, and health outcomes. Centers will disseminate evidence-based approaches to telehealth-focused cancer care to the broader clinical care and cancer control communities. Collectively, the P50 Centers on Telehealth Research for Cancer-

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Related Care will represent a national initiative at the forefront of cancer-related telehealth research committed to improving access to care, care quality, patient-provider communication, and health outcomes across the cancer control continuum.

|        |   |                                    |               |             |               |
|--------|---|------------------------------------|---------------|-------------|---------------|
| 103312 | <a href="#">Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being</a> | National Institutes of Health/DHHS | NOT-OD-21-087 | 05-Jun-2021 | Not Specified |
|--------|---|------------------------------------|---------------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Bramaramba Kowtha MS, RDN, LDN  |
| Contact Telephone    | 301-435-8052  |
| Contact Email        | <a href="mailto:bramaramba.kowtha@nih.gov">bramaramba.kowtha@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024   |
| Synopsis             | The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary feasibility studies, as well as expanded feasibility work for a discrete, specified, circumscribed project that is based on well-established theory, existing data and evidence-based interventions. |

|        |   |                                    |           |             |               |
|--------|---|------------------------------------|-----------|-------------|---------------|
| 093932 | <a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)</a> | National Institutes of Health/DHHS | PA-20-188 | 07-May-2021 | Not Specified |
|--------|---|------------------------------------|-----------|-------------|---------------|

|                   |  |
|-------------------|--|
| Contact Name      |  |
| Contact Telephone |  |

## NIH Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                       | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p> |                                    |                |               |                |
| 093935  | <a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)</a>  | National Institutes of Health/DHHS | PA-20-189      | 07-May-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p>   |                                    |                |               |                |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Synopsis

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

|        |  |                                    |           |             |               |
|--------|--|------------------------------------|-----------|-------------|---------------|
| 093931 | <a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)</a> | National Institutes of Health/DHHS | PA-20-187 | 07-May-2021 | Not Specified |
|--------|--|------------------------------------|-----------|-------------|---------------|

|                      |   |
|----------------------|---|
| Contact Name         |   |
| Contact Telephone    |   |
| Contact Email        | <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Synopsis | The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

|        |   |                                       |            |  |               |
|--------|---|---------------------------------------|------------|--|---------------|
| 078618 | <a href="#">Data Science Research: Personal Health Libraries for Consumers and Patients (R01 Clinical Trial Optional)</a> | National Library of Medicine/NIH/DHHS | PAR-19-072 | 30-Jun-2021<br>[Optional][LOI/Pre-App] | 1,000,000 USD |
|--------|---|---------------------------------------|------------|--|---------------|

|                      |   |
|----------------------|---|
| Contact Name         | Alan VanBiervliet, Ph.D.  |
| Contact Telephone    | 301-594-4882  |
| Contact Email        | <a href="mailto:vanbiervlietag@mail.nih.gov">vanbiervlietag@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021  |
| Synopsis             | The National Library of Medicine seeks applications for novel informatics and data science approaches that can help individuals gather, manage and use data and information about their personal health. A goal of this program is to advance research and application by patients and the research community through broadly sharing the results via publication, and through open source mechanisms for data or resource sharing. |

|        |   |                                       |            |             |               |
|--------|---|---------------------------------------|------------|-------------|---------------|
| 099844 | <a href="#">Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)</a> | National Library of Medicine/NIH/DHHS | PAR-20-304 | 07-May-2021 | 1,000,000 USD |
|--------|---|---------------------------------------|------------|-------------|---------------|

|                   |                        |
|-------------------|------------------------|
| Contact Name      | Alan VanBiervliet, PhD |
| Contact Telephone | 301-594-4882           |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |  |
|----------------------|--|
| Contact Email        | <a href="mailto:vanbiervlietaq@mail.nih.gov">vanbiervlietaq@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023  |
| Synopsis             | National Library of Medicine (NLM) wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes. |

|        |  |                                       |            |             |               |
|--------|--|---------------------------------------|------------|-------------|---------------|
| 076848 | <a href="#">NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)</a> | National Library of Medicine/NIH/DHHS | PAR-18-896 | 07-May-2021 | 1,000,000 USD |
|--------|--|---------------------------------------|------------|-------------|---------------|

|                      |  |
|----------------------|--|
| Contact Name         | Dr. Hua-Chuan Sim  |
| Contact Telephone    | 301-594-4882   |
| Contact Email        | <a href="mailto:simh@mail.nih.gov">simh@mail.nih.gov</a>   |
| Sponsor Website      |  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 07-May-2021 , 05-Jun-2021 , 07-Sep-2021  |
| Synopsis             | National Library of Medicine (NLM) offers support for innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. Biomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology. NIH defines data science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This FOA will use the NIH Research Project (R01) award mechanism. |



## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|        |   |   |            |             |             |
|--------|---|---|------------|-------------|-------------|
| 079634 | <a href="#">Methods Development for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R21 Clinical Trial Not Allowed)</a> | Office of Research Infrastructure Programs/NIH/DHHS | PAR-19-176 | 07-May-2021 | 275,000 USD |
|--------|---|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Sige Zou, Ph.D.   |
| Contact Telephone    | 301-435-0749  |
| Contact Email        | <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022   |
| Synopsis             | This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish. |

|        |   |   |            |             |             |
|--------|---|---|------------|-------------|-------------|
| 102835 | <a href="#">Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)</a> | Office of Research Infrastructure Programs/NIH/DHHS | PAR-21-167 | 16-Jun-2021 | 275,000 USD |
|--------|---|---|------------|-------------|-------------|

|                      |   |
|----------------------|---|
| Contact Name         | Sige Zou, Ph.D.   |
| Contact Telephone    | 301-435-0749  |
| Contact Email        | <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>  |
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 |
| Synopsis             | This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better  |

## NIH Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.

## National Science Foundation (NSF) Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                | Sponsor Number | Deadline Date             | Funding Amount |
|---------|---|-----------------------------|----------------|---------------------------|----------------|
| 101709  | <a href="#">Enabling Quantum Leap: Quantum Interconnect Challenges for Transformational Advances in Quantum Systems (QuIC-TAQS)</a>   | National Science Foundation | 21-553         | 14-Jun-2021               | 2,500,000 USD  |
|         | <p>Contact Name</p> <p>Contact Telephone 703-292-2980</p> <p>Contact Email <a href="mailto:quic@nsf.gov">quic@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jun-2021</p> <p>Synopsis</p> <p>The Quantum Interconnect Challenges for Transformational Advances in Quantum Systems (QuIC - TAQS) program is designed to support interdisciplinary teams that will explore highly innovative, original, and potentially transformative ideas for developing and applying quantum science, quantum computing, and quantum engineering in the specific area of quantum interconnects. Quantum interconnects are an integral part of all aspects of quantum information science. Proposals should have the potential to deliver new concepts, new platforms, and/or new approaches that will implement the transfer of quantum states efficiently across platforms and over large length scales. Progress in the area of quantum interconnects will enable breakthroughs in quantum sensing, quantum communications, quantum simulations, and quantum computing systems. This Quantum Interconnect Challenges solicitation will support the process of translating such ideas into reality. This solicitation calls for proposals focused on interdisciplinary research that enhances the development of quantum interconnects (QuIC) that would allow the transfer of quantum states between different physical states and/or different physical systems. Proposals must articulate how the project leverages and/or promotes advances in quantum interconnects. Proposals should be innovative and must focus on quantum functionality and must result in experimental demonstrations and/or transformative advances towards quantum systems and/or proof-of-concept validations. Competitive proposals will come from an interdisciplinary research team led by at least three investigators who collectively contribute synergistic expertise from expertise from a subset of the following domains: engineering, mathematics, computational science, computer/information science, physical, chemical, biological, material science. Proposals will be judged on how likely the integrated effort is to lead to transformative advances in quantum interconnection.</p> |                             |                |                           |                |
| 102893  | <a href="#">NSF Convergence Accelerator Phases I and II for the 2021 Cohort</a>   | National Science Foundation | 21-572         | 05-May-2021 [LOI/Pre-App] | Not Specified  |
|         | <p>Contact Name Linda Molnar</p> <p>Contact Telephone 703-292-8316</p>  |                             |                |                           |                |

## National Science Foundation (NSF) Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|-----------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:lmolnar@nsf.gov">lmolnar@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-May-2021 [LOI/Pre-App], 14-Jun-2021 , 25-May-2022</p> <p>Synopsis The NSF Convergence Accelerator program addresses national-scale societal challenges through use-inspired convergence research. Using a convergence approach and innovation processes like human-centered design, user discovery, and team science and integration of multidisciplinary research, the Convergence Accelerator program seeks to transition basic research and discovery into practice—to solve high-impact societal challenges aligned with specific research themes (tracks). NSF Convergence Accelerator tracks are chosen in concordance with the themes identified during the program’s ideation process that have the potential for significant national impact. The NSF Convergence Accelerator implements a two-phase program. Both phases are described in this solicitation and are covered by this single solicitation and corresponding Broad Agency Announcement. The link to the Broad Agency Announcement can be found here. The purpose of this parallel activity is to provide increased opportunities for proposals that are led by non-academic entities. Proposals that are led by Institutions of Higher Education (IHEs), non-profits, independent museums, observatories, research labs, professional societies and similar organizations should respond to this solicitation. Proposals led by for-profit or similar organizations should respond to the BAA. Phase I awardees receive significant resources to further develop their convergence research ideas and to identify important partnerships and resources to accelerate their projects, leading to deliverable research prototypes in Phase II.</p> |                             |                |               |                |
| 072693  | <a href="#">Tribal Colleges and Universities Program (TCUP)</a>  | National Science Foundation | 18-546         | 04-Jun-2021   | Not Specified  |
|         | <p>Contact Name Jody Chase</p> <p>Contact Telephone 703-292-8640</p> <p>Contact Email <a href="mailto:jchase@nsf.gov">jchase@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-Jun-2021 , 10-Jun-2021 , 06-Sep-2021 , 09-Sep-2021 , 20-Sep-2021 , 10-Dec-2021 , 30-Dec-2021</p> <p>Synopsis The Tribal Colleges and Universities Program (TCUP) provides awards to Tribal Colleges and Universities, Alaska Native-serving institutions, and Native Hawaiian-serving institutions to promote high quality science (including sociology, psychology, anthropology, economics, statistics, and other social and behavioral sciences as well as natural sciences), technology, engineering and mathematics (STEM) education, research, and outreach. Support is available to TCUP-eligible</p>   |                             |                |               |                |

## National Science Foundation (NSF) Funding Opportunities

| SPIN ID              | Program Title  | Sponsor Name                | Sponsor Number | Deadline Date | Funding Amount |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
|----------------------|--|-----------------------------|----------------|---------------|----------------|--------------|---------------|-------------------|--------------|---------------|--|-----------------|---|-------------|-------------------------------------|----------------------|--|----------|---|
|                      | <p>institutions for transformative capacity-building projects through Instructional Capacity Excellence in TCUP Institutions (ICE-TI), Targeted STEM Infusion Projects (TSIP), TCU Enterprise Advancement Centers (TEA Centers), and Preparing for TCUP Implementation (Pre-TI). Collaborations that involve multiple institutions of higher education led by TCUP institutions are supported through Partnerships for Geoscience Education (PAGE) and Partnerships for Documentary Linguistics Education (PADLE). Finally, research studies that further the scholarly activity of individual faculty members are supported through Small Grants for Research (SGR) and Science Education Alliance Phage Hunters Advancing Genomics and Evolutionary Science in Tribal Colleges and Universities (SEA-PHAGES in TCUs). Through the opportunities highlighted above, as well as collaborations with other National Science Foundation (NSF) units and other organizations, TCUP aims to increase Native individuals' participation in STEM careers and improve the quality of STEM programs at TCUP-eligible institutions. TCUP strongly encourages the inclusion of activities that will benefit veterans.</p>  |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| 094021               | <a href="#">Industry/University Cooperative Research Centers</a>   | National Science Foundation | 20-570         | 09-Jun-2021   | Not Specified  |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
|                      | <table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Prakash Balan</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>703-292-5341</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:pbalan@nsf.gov">pbalan@nsf.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>09-Jun-2021 , 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.</td> </tr> </table> |                             |                |               |                | Contact Name | Prakash Balan | Contact Telephone | 703-292-5341 | Contact Email | <a href="mailto:pbalan@nsf.gov">pbalan@nsf.gov</a> | Sponsor Website | <a href="#">Link to sponsor website</a> | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 09-Jun-2021 , 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021 | Synopsis | The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce. |
| Contact Name         | Prakash Balan  |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Contact Telephone    | 703-292-5341   |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Contact Email        | <a href="mailto:pbalan@nsf.gov">pbalan@nsf.gov</a>   |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Sponsor Website      | <a href="#">Link to sponsor website</a>  |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Program URL          | <a href="#">Link to program URL</a>  |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Deadline Dates (ALL) | 09-Jun-2021 , 08-Sep-2021 [LOI/Pre-App], 08-Dec-2021   |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Synopsis             | The IUCRC program catalyzes breakthrough pre-competitive research by enabling close and sustained engagement between industry innovators, world-class academic teams, and government agencies. IUCRCs help industry partners and government agencies connect directly and efficiently with university researchers to achieve three primary objectives: 1) Conduct high-impact research to meet shared and critical industrial needs in companies of all sizes; 2) Enhance U.S. global leadership in driving innovative technology development, and 3) Identify, mentor and develop a diverse, highly skilled science and engineering workforce.  |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| 102799               | <a href="#">AMENDMENT -- NSF Convergence Accelerator Broad Agency Announcement</a>   | National Science Foundation | NSFBAA-CA21-01 | 14-Jun-2021   | Not Specified  |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
|                      | <table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Keith Boyea</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:kboyea@nsf.gov">kboyea@nsf.gov</a></td> </tr> </table>  |                             |                |               |                | Contact Name | Keith Boyea   | Contact Telephone |              | Contact Email | <a href="mailto:kboyea@nsf.gov">kboyea@nsf.gov</a> |                 |   |             |                                     |                      |  |          |   |
| Contact Name         | Keith Boyea  |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Contact Telephone    |  |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |
| Contact Email        | <a href="mailto:kboyea@nsf.gov">kboyea@nsf.gov</a>   |                             |                |               |                |              |               |                   |              |               |  |                 |   |             |                                     |                      |  |          |   |

## National Science Foundation (NSF) Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Sponsor Website      |   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 14-Jun-2021   |
| Synopsis             | Convergence accelerator Broad Agency Announcement (BAA). See attached BAA document. |

## Other Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--|----------------|---------------|----------------|
| 057648  | <a href="#">Large Research Projects for Prevention of Healthcare-Associated Infections (R01)</a>     | Agency for Healthcare Research and Quality/DHHS  | PA-17-008      | 05-Jun-2021   | 2,500,000 USD  |
|         | Contact Name   | James I. Cleeman, M.D.   |                |               |                |
|         | Contact Telephone  | 301-427-1330   |                |               |                |
|         | Contact Email  | <a href="mailto:james.cleeman@ahrq.hhs.gov">james.cleeman@ahrq.hhs.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 05-Jun-2021  |                |               |                |
|         | Synopsis   | Agency for Healthcare Research and Quality (AHRQ) invites applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects This FOA will utilize the AHRQ R01 Research Project Grant award mechanism.   |                |               |                |
| 057071  | <a href="#">Developing Measures of Shared Decision Making (R01)</a>                                  | Agency for Healthcare Research and Quality/DHHS  | PA-16-424      | 05-Jun-2021   | 1,500,000 USD  |
|         | Contact Name   | Monique D. Cohen, PhD, MPH   |                |               |                |
|         | Contact Telephone  | 301-427-1630   |                |               |                |
|         | Contact Email  | <a href="mailto:Monique.Cohen@ahrq.hhs.gov">Monique.Cohen@ahrq.hhs.gov</a>   |                |               |                |
|         | Sponsor Website  |  |                |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)   | 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022  |                |               |                |
|         | Synopsis   | Shared decision making (SDM) is a collaborative process in which patients and members of their clinical team work together to make health care decisions informed by scientific evidence as well as patients' own values and preferences. SDM has proven difficult to measure, and the literature points to significant gaps and limitations in the measurement of SDM. Agency for Healthcare Research and Quality (AHRQ) invites applications to develop, test, and evaluate measures of SDM that can be used to conduct research in clinical settings. This FOA will use the Research Project (R01) award mechanism. |                |               |                |
| 061542  | <a href="#">Health Information Technology (IT) to Improve Health Care Quality and Outcomes (R21)</a> | Agency for Healthcare Research and Quality/DHHS  | PA-17-246      | 16-Jun-2021   | 300,000 USD    |
|         | Contact Name   | Bryan B. Kim, Ph.D.  |                |               |                |

## Other Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                              | Sponsor Number           | Deadline Date | Funding Amount |
|---------|---|---|--------------------------|---------------|----------------|
|         | <p>Contact Telephone   301-427-1505</p> <p>Contact Email   <a href="mailto:HealthITFunding@ahrq.hhs.gov">HealthITFunding@ahrq.hhs.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021</p> <p>Synopsis   Agency for Healthcare Research and Quality (AHRQ) invites applications for funding to conduct exploratory and developmental research grants (R21) for projects in the early and conceptual stages of development that will contribute to the evidence base of how health information technology (IT) improves health care quality and outcomes. This program will use the Exploratory/Developmental (R21) grant mechanism.</p>  |   |                          |               |                |
| 102834  | <a href="#">Department of Defense Space University Research Initiative</a>  | Air Force Office of Scientific Research   | FOA-AFRL-AFOSR-2021-0004 | 16-Jun-2021   | Not Specified  |
|         | <p>Contact Name   Bhawana Sharma</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:bhawana.sharma@us.af.mil">bhawana.sharma@us.af.mil</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   16-Jun-2021</p> <p>Synopsis   This is a special Funding Opportunity Announcement (FOA) in support of the research objectives the Department of Defense (DoD) Space University Research Initiative (SURI), sponsored by the Air Force Office of Scientific Research (AFOSR) and the Air Force Research Laboratory (AFRL) Chief Technologist Office. DOD's SURI program is focused on directing basic research toward applications that meet US Space Force (USSF) needs and challenges. The program was initiated as a pilot to foster engagements between various DoD agencies and the academic community in a developing USSF University Consortium, with the goal of improving the transition of critical concepts from the academic sector into revolutionary new military technologies. Key to the program's success is the close management of the SURI projects by DoD agency program officers, and their role in providing research guidance and supporting transition of research products into DoD applications.</p> |   |                          |               |                |
| 096161  | <a href="#">Defense Sciences Office (DSO) Office-Wide Broad Agency Announcement</a>   | Defense Advanced Research Projects Agency | HR001120S0048            | 11-Jun-2021   | Not Specified  |
|         | Contact Name  |   |                          |               |                |



## Other Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name           | Sponsor Number      | Deadline Date | Funding Amount |
|---------|--|------------------------|---------------------|---------------|----------------|
|         | <p>Contact Telephone</p> <p>Contact Email <a href="mailto:HR001120S0048@darpa.mil">HR001120S0048@darpa.mil</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jun-2021</p> <p>Synopsis<br/>The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security. In support of this mission, the DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: (1) Frontiers in Math, Computation and Design, (2) Limits of Sensing and Sensors, (3) Complex Social Systems, and (4) Anticipating Surprise. Each of these thrust areas is described below and includes a list of example research topics that highlight several (but not all) potential areas of interest. Proposals must investigate innovative approaches that enable revolutionary advances. DSO is explicitly not interested in approaches or technologies that primarily result in evolutionary improvements to the existing state of practice.</p> |                        |                     |               |                |
| 101002  | <a href="#">One Planet: Environment, Health, and Science</a>   | Department of State    | DOSRUS21GR004       | 01-Jun-2021   | 200,000 USD    |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:GrantsRussia@state.gov">GrantsRussia@state.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021</p> <p>Synopsis<br/>The U.S. Embassy Moscow's Public Affairs Section (PAS) is announcing "One Planet: Environment, Health, and Science" grant, which supports the promotion of environmental, health, and scientific issues in Russia of strategic importance to U.S. and global priorities. Funding for this program is now available through the PAS grants office. This call for proposals outlines the funding priorities, strategic themes, and the procedure for submitting funding requests. Applicants may apply for funding for any amount up to \$200,000.</p>  |                        |                     |               |                |
| 101519  | <a href="#">Breast Cancer Research Program--Breakthrough Award Level 4</a>   | Department of the Army | W81XWH-21-BCRP-BTA4 | 23-Jun-       | Not Specified  |

## Other Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

2021

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL) | 301-682-5507<br><a href="mailto:help@eBRAP.org">help@eBRAP.org</a><br><br><a href="#">Link to program URL</a><br>23-Jun-2021<br><br>Synopsis<br>The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. |
|--|--|

|        |  |                        |                      |             |               |
|--------|--|------------------------|----------------------|-------------|---------------|
| 101521 | <a href="#">Breast Cancer Research Program--Innovator Awards</a> | Department of the Army | W81XWH-21-BCRP-INNOV | 23-Jun-2021 | Not Specified |
|--------|--|------------------------|----------------------|-------------|---------------|

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL) | 301-682-5507<br><a href="mailto:help@eBRAP.org">help@eBRAP.org</a><br><br><a href="#">Link to program URL</a><br>23-Jun-2021 , 25-Jun-2021<br><br>Synopsis<br>The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. |
|--|--|

## Other Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number      | Deadline Date | Funding Amount |
|---------|--|--|---------------------|---------------|----------------|
|         |  | <p>Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer.</p>  |                     |               |                |
| 101514  | <a href="#">Breast Cancer Research Program--Breakthrough Award Level 3</a>   | Department of the Army   | W81XWH-21-BCRP-BTA3 | 23-Jun-2021   | Not Specified  |
|         | Contact Name   |  |                     |               |                |
|         | Contact Telephone  | 301-682-5507   |                     |               |                |
|         | Contact Email  | <a href="mailto:help@eBRAP.org">help@eBRAP.org</a>   |                     |               |                |
|         | Sponsor Website  |  |                     |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                     |               |                |
|         | Deadline Dates (ALL)   | 23-Jun-2021  |                     |               |                |
|         | Synopsis   | <p>The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.</p> |                     |               |                |
| 103065  | <a href="#">Measurement and Monitoring Methods for Air Toxics and Contaminants of Emerging Concern in the Atmosphere</a> | Environmental Protection Agency  | EPA-G2021-STAR-C1   | 02-Jun-2021   | 800,000 USD    |
|         | Contact Name   | Ron Josephson  |                     |               |                |

## Other Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                    | Sponsor Number    | Deadline Date | Funding Amount |
|---------|--|---------------------------------|-------------------|---------------|----------------|
|         | Contact Telephone 202-564-7823<br>Contact Email <a href="mailto:josephson.ron@epa.gov">josephson.ron@epa.gov</a><br>Sponsor Website<br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 02-Jun-2021<br>Synopsis The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research to advance air measurement and monitoring methods for air toxics and contaminants of emerging concern in the atmosphere. Funding is up to \$800,000 for regular awards.                                    |                                 |                   |               |                |
| 103066  | <a href="#">Early Career: Measurement and Monitoring Methods for Air Toxics and Contaminants of Emerging Concern in the Atmosphere</a>   | Environmental Protection Agency | EPA-G2021-STAR-C2 | 02-Jun-2021   | 400,000 USD    |
|         | Contact Name Ron Josephson<br>Contact Telephone 202-564-7823<br>Contact Email <a href="mailto:josephson.ron@epa.gov">josephson.ron@epa.gov</a><br>Sponsor Website<br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 02-Jun-2021<br>Synopsis The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research to advance air measurement and monitoring methods for air toxics and contaminants of emerging concern in the atmosphere. Funding is up to \$400,000 for early career awards. |                                 |                   |               |                |
| 100207  | <a href="#">Loan Repayment Program for Repayment of Health Professions Educational Loans</a>   | Indian Health Service/DHHS      |                   | 15-May-2021   | Not Specified  |
|         | Contact Name Ms. Jacqueline K. Santiago<br>Contact Telephone 301-443-3396<br>Contact Email<br>Sponsor Website<br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 15-May-2021 , 15-Jun-2021 , 15-Jul-2021 , 15-Aug-2021 , 15-Sep-2021 , 30-Sep-2021   |                                 |                   |               |                |

## Other Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|          |  |
|----------|--|
| Synopsis | <p>The Indian Health Service (IHS) estimated budget for fiscal year (FY) 2021 includes \$34,800,000 for the IHS Loan Repayment Program (LRP) for health professional educational loans (undergraduate and graduate) in return for full-time clinical service as defined in the IHS LRP policy.</p> |
|----------|--|

## Non Federal Funding Opportunities

| SPIN ID | Program Title                             | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
| 024799  | <a href="#">'A' Award Grant</a>           | Alex's Lemonade Stand  |                | 18-Jun-2021   | 800,000 USD    |
|         | Contact Name                              | Gina Dyer, Grant Coordinator   |                |               |                |
|         | Contact Telephone                         |  |                |               |                |
|         | Contact Email                             | <a href="mailto:Grants@AlexsLemonade.org">Grants@AlexsLemonade.org</a>   |                |               |                |
|         | Sponsor Website                           | <a href="#">Link to sponsor website</a>  |                |               |                |
|         | Program URL                               | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)                      | 18-Jun-2021  |                |               |                |
|         | Synopsis                                  | <p>The purpose of the 'A' Award Grant is to advance ALSF's mission to find cures and better treatments for childhood cancers by providing support to early career scientists who want to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. A mentor is required, and a career development plan must be included. The 'A' Award is a four-year grant, with the possibility of a 5th year of funding.</p> |                |               |                |
| 053808  | <a href="#">Foundation Research Award</a> | American Academy of Otolaryngic Allergy Foundation   |                | 01-Jun-2021   | 10,000 USD     |
|         | Contact Name                              | Elisabeth Herzfeld-Rice  |                |               |                |
|         | Contact Telephone                         | 202-955-5010 x600  |                |               |                |
|         | Contact Email                             | <a href="mailto:foundation@aaoallergy.org">foundation@aaoallergy.org</a>   |                |               |                |
|         | Sponsor Website                           | <a href="#">Link to sponsor website</a>  |                |               |                |
|         | Program URL                               | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)                      | 01-Jun-2021  |                |               |                |
|         | Synopsis                                  | <p>The AAOA Foundation seeks to advance allergy research and knowledge for the treatment of otolaryngic conditions by inviting applications for grants to conduct research in the pathogenesis, pathophysiology, diagnosis, prevention, or</p>   |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID              | Program Title  | Sponsor Name                                     | Sponsor Number | Deadline Date | Funding Amount   |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
|----------------------|--|--|----------------|---------------|------------------|--------------|--------------|-------------------|--------------------|---------------|--|-----------------|---|-------------|-------------------------------------|----------------------|-------------|----------|---|
|                      | treatment of otolaryngic allergy. Funds are available to support multiple projects each year; each project may have total direct costs of \$10,000.  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| 064695               | <a href="#">Dr. James T. Mellonig Regeneration Research Award</a>  | American Academy of Periodontology<br>Foundation |                | 01-Jun-2021   | 10,000 USD       |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; border-right: 1px solid black;">Contact Name</td> <td>Robert Vitas</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>800-282-4867 x3256</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td><a href="mailto:bob@perio.org">bob@perio.org</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>01-Jun-2021</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The \$10,000 Dr. James T. Mellonig Regeneration Research Award recognizes excellence in original research by a resident or recent graduate in the specialty of periodontics that advances clinical therapies in periodontal regeneration.</td> </tr> </table> |  |                |               |                  | Contact Name | Robert Vitas | Contact Telephone | 800-282-4867 x3256 | Contact Email | <a href="mailto:bob@perio.org">bob@perio.org</a> | Sponsor Website | <a href="#">Link to sponsor website</a> | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 01-Jun-2021 | Synopsis | The \$10,000 Dr. James T. Mellonig Regeneration Research Award recognizes excellence in original research by a resident or recent graduate in the specialty of periodontics that advances clinical therapies in periodontal regeneration. |
| Contact Name         | Robert Vitas   |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Contact Telephone    | 800-282-4867 x3256   |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Contact Email        | <a href="mailto:bob@perio.org">bob@perio.org</a>   |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Sponsor Website      | <a href="#">Link to sponsor website</a>  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Program URL          | <a href="#">Link to program URL</a>  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Deadline Dates (ALL) | 01-Jun-2021  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Synopsis             | The \$10,000 Dr. James T. Mellonig Regeneration Research Award recognizes excellence in original research by a resident or recent graduate in the specialty of periodontics that advances clinical therapies in periodontal regeneration.  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| 032751               | <a href="#">Eva King Killiam Research Award</a>  | American College of<br>Neuropsychopharmacology   |                | 24-Jun-2021   | Not<br>Specified |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
|                      | <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>615-324-2360</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td><a href="mailto:acnp@acnp.org">acnp@acnp.org</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>24-Jun-2021</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>The American College of Neuropsychopharmacology (ACNP) presents the Eva King Killam Award to an early career researcher on the basis of outstanding translational research contributions to neuropsychopharmacology. Award</td> </tr> </table>                                  |  |                |               |                  | Contact Name |              | Contact Telephone | 615-324-2360       | Contact Email | <a href="mailto:acnp@acnp.org">acnp@acnp.org</a> | Sponsor Website | <a href="#">Link to sponsor website</a> | Program URL | <a href="#">Link to program URL</a> | Deadline Dates (ALL) | 24-Jun-2021 | Synopsis | The American College of Neuropsychopharmacology (ACNP) presents the Eva King Killam Award to an early career researcher on the basis of outstanding translational research contributions to neuropsychopharmacology. Award                |
| Contact Name         |  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Contact Telephone    | 615-324-2360   |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Contact Email        | <a href="mailto:acnp@acnp.org">acnp@acnp.org</a>   |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Sponsor Website      | <a href="#">Link to sponsor website</a>  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Program URL          | <a href="#">Link to program URL</a>  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Deadline Dates (ALL) | 24-Jun-2021  |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |
| Synopsis             | The American College of Neuropsychopharmacology (ACNP) presents the Eva King Killam Award to an early career researcher on the basis of outstanding translational research contributions to neuropsychopharmacology. Award   |  |                |               |                  |              |              |                   |                    |               |  |                 |   |             |                                     |                      |             |          |   |

## Non Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

recipients will be announced at the ACNP Annual Meeting during the President's Plenary.

|        |   |   |  |             |               |
|--------|---|---|--|-------------|---------------|
| 072617 | <a href="#">Joel Elkes Research Award</a> | American College of Neuropsychopharmacology |  | 24-Jun-2021 | Not Specified |
|--------|---|---|--|-------------|---------------|

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | 615-324-2360<br><a href="mailto:ancp@acnp.org">ancp@acnp.org</a><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>24-Jun-2021<br>The American College of Neuropsychopharmacology (ACNP) presents the Joel Elkes Research Award to a young scientist in recognition of an outstanding clinical contribution to neuropsychopharmacology. |
|--|--|

|        |  |                            |  |             |               |
|--------|--|----------------------------|--|-------------|---------------|
| 092352 | <a href="#">Harry Goldblatt New Investigator Award</a> | American Heart Association |  | 21-Jun-2021 | Not Specified |
|--------|--|----------------------------|--|-------------|---------------|

|  |  |
|--|--|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | 214-706-1181<br><a href="mailto:council.awards@heart.org">council.awards@heart.org</a><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>21-Jun-2021 , 23-Jun-2021 , 25-Jun-2021<br>The Harry Goldblatt Award for New Investigators recognizes a new independent investigator working in hypertension or cardiovascular research who has significantly contributed to our understanding of the causes of hypertension and related cardiovascular disease. The awardee will be selected by the Council's Awards Committee from applicants who have submitted abstracts accepted for presentation at the Hypertension Scientific Sessions, along with other |
|--|--|



## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | materials.  |   |                |               |                |
| 092353  | <a href="#">Stephanie Watts Career Development Award</a>            | American Heart Association  |                | 21-Jun-2021   | Not Specified  |
|         | Contact Name  |   |                |               |                |
|         | Contact Telephone   | 214-706-1240  |                |               |                |
|         | Contact Email   | <a href="mailto:council.awards@heart.org">council.awards@heart.org</a>  |                |               |                |
|         | Sponsor Website   | <a href="#">Link to sponsor website</a>   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 21-Jun-2021 , 23-Jun-2021 , 25-Jun-2021   |                |               |                |
|         | Synopsis  | This award supports early career investigators working in hypertension and cardiovascular research who show exceptional promise but may be currently unfunded or have limited access to extramural funding. |                |               |                |
| 005950  | <a href="#">Marvin Moser Clinical Hypertension Award</a>            | American Heart Association  |                | 23-Jun-2021   | 2,000 USD      |
|         | Contact Name  |   |                |               |                |
|         | Contact Telephone   | 212-696-9099  |                |               |                |
|         | Contact Email   | <a href="mailto:council.awards@heart.org">council.awards@heart.org</a>  |                |               |                |
|         | Sponsor Website   | <a href="#">Link to sponsor website</a>   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 23-Jun-2021 , 25-Jun-2021   |                |               |                |
|         | Synopsis  | This award recognizes a qualified Hypertension Clinician for their dedication to the treatment and care of hypertensive patients.   |                |               |                |
| 003146  | <a href="#">Novartis Excellence Award for Hypertension Research</a> | American Heart Association  |                | 21-Jun-2021   | Not Specified  |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------------------------------|----------------|---------------|----------------|
|         | Contact Name<br>Contact Telephone<br>Contact Email <a href="mailto:council.awards@heart.org">council.awards@heart.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 21-Jun-2021 , 23-Jun-2021 , 25-Jun-2021<br>Synopsis This award honors excellence in research and discoveries in the field of hypertension as well as a researcher's contributions. The selection committee assesses the candidates' impact on their fields throughout their productive careers as well as any single discovery. |                                      |                |               |                |
| 102829  | <a href="#">Mitchell A. Baran Achievement Award for Clinical Excellence in Aerosol and Airway Clearance Therapies</a>   | American Respiratory Care Foundation |                | 01-Jun-2021   | 2,500 USD      |
|         | Contact Name Crystal Maldonado<br>Contact Telephone 972-243-2272<br>Contact Email<br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021<br>Synopsis This award is given to recognize and honor those individuals demonstrating clinical excellence and leadership in advocating and promoting the use of evidence-based, clinically sound practices for the delivery of aerosolized medications and/or the application of non-pharmacologic airway clearance therapies.                             |                                      |                |               |                |
| 068798  | <a href="#">Thomas L. Petty, MD Invacare Award for Excellence in Home Respiratory Care</a>  | American Respiratory Care Foundation |                | 01-Jun-2021   | Not Specified  |
|         | Contact Name Crystal Maldonado  |                                      |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                         | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|--------------------------------------|----------------|---------------|----------------|
|         | Contact Telephone 972-243-2272<br>Contact Email<br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021<br>Synopsis This award recognizes outstanding individual achievement in home respiratory care.   |                                      |                |               |                |
| 068800  | <a href="#">H. Frederic Helmholtz, Jr., MD Educational Research Fund</a>   | American Respiratory Care Foundation |                | 01-Jun-2021   | 5,000 USD      |
|         | Contact Name<br>Contact Telephone 972-243-2272<br>Contact Email<br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021<br>Synopsis The National Board for Respiratory Care/Applied Measurement Professionals, Inc. has provided an endowment to the American Respiratory Care Foundation to support up to \$5,000 for educational or credentialing research. A Master's Thesis, or Doctoral Dissertation with practical value to the respiratory care profession are acceptable submissions by a candidate. |                                      |                |               |                |
| 068786  | <a href="#">Forrest M. Bird, MD, PhD, ScD Lifetime Scientific Achievement Award</a>  | American Respiratory Care Foundation |                | 01-Jun-2021   | Not Specified  |
|         | Contact Name Crystal Maldonado<br>Contact Telephone 972-243-2272<br>Contact Email<br>Sponsor Website <a href="#">Link to sponsor website</a>   |                                      |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                              | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|---|----------------|---------------|----------------|
|         | Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021<br>Synopsis This award acknowledges outstanding individual scientific contributions in the area of respiratory care of cardiopulmonary disorders.  |   |                |               |                |
| 097671  | <a href="#">Hector Leon Garza, MD International Achievement Award</a>  | American Respiratory Care Foundation      |                | 01-Jun-2021   | Not Specified  |
|         | Contact Name Crystal Maldonado<br>Contact Telephone 972-243-2272<br>Contact Email <a href="mailto:crystal.maldonado@aacrc.org">crystal.maldonado@aacrc.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021<br>Synopsis The Hector Leon Garza, MD International Achievement Award recognizes respiratory therapists, physicians, and other health care providers who have had a profound impact on the development of international respiratory care. |   |                |               |                |
| 075269  | <a href="#">Cutting Edge Research Grant Program</a>  | American Society for Dermatologic Surgery |                | 30-Jun-2021   | 20,000 USD     |
|         | Contact Name<br>Contact Telephone 847-956-9139<br>Contact Email <a href="tel:847-956-0900">847-956-0900</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 30-Jun-2021<br>Synopsis The Cutting Edge Research Grant Program (CERG) awards grants of up to \$20,000 in order to stimulate a broad scope of research relevant to dermatologic surgeons and the dermatology specialty at large.   |   |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID  | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |  |   |
|--|---|---|----------------|---------------|----------------|--|---|
| 033695   | <a href="#">ASPEN Rhoads Research Foundation Annual Grants</a>  | American Society for Parenteral and Enteral Nutrition |                | 16-Jun-2021   | Not Specified  |  |   |
| <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">                     Contact Name<br/>                     Contact Telephone<br/>                     Contact Email<br/>                     Sponsor Website<br/>                     Program URL<br/>                     Deadline Dates (ALL)<br/>                     Synopsis                 </td> <td style="border-left: 1px solid black; padding-left: 5px;">                     301-587-6315<br/> <a href="mailto:foundation@nutritioncare.org">foundation@nutritioncare.org</a><br/> <a href="#">Link to sponsor website</a><br/> <a href="#">Link to program URL</a><br/>                     16-Jun-2021<br/>                     The A.S.P.E.N. Rhoads Research Foundation awards a grant of up to \$25,000 renewable for a second year of funding, assuming satisfactory progress, to assist nutrition investigators by providing preliminary funding for promising new research in the fields of nutrition and metabolic support and related areas of clinical nutrition.                 </td> </tr> </table> |   |   |                |               |                | Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | 301-587-6315<br><a href="mailto:foundation@nutritioncare.org">foundation@nutritioncare.org</a><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>16-Jun-2021<br>The A.S.P.E.N. Rhoads Research Foundation awards a grant of up to \$25,000 renewable for a second year of funding, assuming satisfactory progress, to assist nutrition investigators by providing preliminary funding for promising new research in the fields of nutrition and metabolic support and related areas of clinical nutrition. |
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis   | 301-587-6315<br><a href="mailto:foundation@nutritioncare.org">foundation@nutritioncare.org</a><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>16-Jun-2021<br>The A.S.P.E.N. Rhoads Research Foundation awards a grant of up to \$25,000 renewable for a second year of funding, assuming satisfactory progress, to assist nutrition investigators by providing preliminary funding for promising new research in the fields of nutrition and metabolic support and related areas of clinical nutrition. |   |                |               |                |  |   |
| 011252   | <a href="#">Fellowship Research Award</a>   | American Surgical Association Foundation              |                | 15-Jun-2021   | 75,000 USD     |  |   |
| <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">                     Contact Name<br/>                     Contact Telephone<br/>                     Contact Email<br/>                     Sponsor Website<br/>                     Program URL<br/>                     Deadline Dates (ALL)<br/>                     Synopsis                 </td> <td style="border-left: 1px solid black; padding-left: 5px;">                     978-927-8330<br/> <br/> <a href="#">Link to sponsor website</a><br/> <a href="#">Link to program URL</a><br/>                     15-Jun-2021<br/>                     The purpose of the ASAF Fellowship is to support and encourage gifted young surgeons who choose careers in investigation and academic surgery. Fellows will be supported in an initial year; the Fellowship can be renewed by review of the Fellowship Committee for a succeeding year.                 </td> </tr> </table>  |   |   |                |               |                | Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | 978-927-8330<br><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>15-Jun-2021<br>The purpose of the ASAF Fellowship is to support and encourage gifted young surgeons who choose careers in investigation and academic surgery. Fellows will be supported in an initial year; the Fellowship can be renewed by review of the Fellowship Committee for a succeeding year.  |
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis   | 978-927-8330<br><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>15-Jun-2021<br>The purpose of the ASAF Fellowship is to support and encourage gifted young surgeons who choose careers in investigation and academic surgery. Fellows will be supported in an initial year; the Fellowship can be renewed by review of the Fellowship Committee for a succeeding year.  |   |                |               |                |  |   |
| 019022   | <a href="#">Department of Urology - Endourology Fellowship at Northwestern</a>  | American Urological Association                       |                | 28-May-2021   | Not Specified  |  |   |

## Non Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|                      |   |
|----------------------|---|
| Contact Name         | Debra Caridi, Fellowship Coordinator  |
| Contact Telephone    | 516-520-1226  |
| Contact Email        | <a href="mailto:debra@endourologysociety.com">debra@endourologysociety.com</a>  |
| Sponsor Website      | <a href="#">Link to sponsor website</a>   |
| Program URL          | <a href="#">Link to program URL</a>   |
| Deadline Dates (ALL) | 28-May-2021 , 21-Jun-2021   |
| Synopsis             | The endourology fellowship is a program with clinical, operative and research components. Previous fellows have gone on to successful careers in both academic and specialized private practice settings. |

|        |  |                                     |  |             |           |
|--------|--|-------------------------------------|--|-------------|-----------|
| 082545 | <a href="#">Walter P. de Groot, MD Educational Scholarship</a> | American Vein and Lymphatic Society |  | 30-Jun-2021 | 1,000 USD |
|--------|--|-------------------------------------|--|-------------|-----------|

|                      |  |
|----------------------|--|
| Contact Name         |  |
| Contact Telephone    | 510-346-6800   |
| Contact Email        | <a href="mailto:Education@myavls.org">Education@myavls.org</a>   |
| Sponsor Website      | <a href="#">Link to sponsor website</a>  |
| Program URL          | <a href="#">Link to program URL</a>  |
| Deadline Dates (ALL) | 30-Jun-2021  |
| Synopsis             | This award recognizes the significant contribution of Dr. Walter P. de Groot in advancing the specialty of venous and lymphatic disease by providing access for physicians seeking to advance their training in venous and lymphatic disease. The award provides an educational grant to attend the American Vein & Lymphatic Society Annual Congress. |

|        |  |                                     |  |             |           |
|--------|--|-------------------------------------|--|-------------|-----------|
| 002899 | <a href="#">Walter P. de Groot, MD Educational Scholarship</a> | American Vein and Lymphatic Society |  | 30-Jun-2021 | 1,500 USD |
|--------|--|-------------------------------------|--|-------------|-----------|

|                   |  |
|-------------------|--|
| Contact Name      |  |
| Contact Telephone | 510-346-6800   |
| Contact Email     | <a href="mailto:education@myavls.org">education@myavls.org</a> |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount   |
|---------|--|--|----------------|---------------|------------------|
|         | Sponsor Website  | <a href="#">Link to sponsor website</a>  |                |               |                  |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                  |
|         | Deadline Dates (ALL)   | 30-Jun-2021  |                |               |                  |
|         | Synopsis   | <p>The purpose of this award is to continue Dr. DeGroot’s mission of promoting the sharing and exchange of venous and lymphological knowledge. The award provides an educational grant to attend the American Vein &amp; Lymphatic Society Annual Congress, which includes complimentary conference registration and \$1,500 towards travel expenses. Additionally, the recipient will receive a one-year membership in the AVLS. Successful applicants will also be honored at the meeting with their name and training institution recognized during the meeting. They will also be invited to the Presidential Reception and New Members Reception.</p> |                |               |                  |
| 005624  | <a href="#">BIAL Award in Biomedicine</a>                      | Bial Foundation  |                | 30-Jun-2021   | 357,000<br>USD   |
|         | Contact Name   |  |                |               |                  |
|         | Contact Telephone  | +351 22 986 6100   |                |               |                  |
|         | Contact Email  | <a href="mailto:fundacao@bial.com">fundacao@bial.com</a>   |                |               |                  |
|         | Sponsor Website  | <a href="#">Link to sponsor website</a>  |                |               |                  |
|         | Program URL  | <a href="#">Link to program URL</a>  |                |               |                  |
|         | Deadline Dates (ALL)   | 30-Jun-2021  |                |               |                  |
|         | Synopsis   | BIAL Merit Award in Medical Sciences is designed to distinguish an intellectual work written specifically for this purpose, on any freely chosen medical topic, representing a work of high quality and scientific relevance.  |                |               |                  |
| 061628  | <a href="#">Robert A. Pritzker Distinguished Lecture Award</a> | Biomedical Engineering Society   |                | 30-Jun-2021   | Not<br>Specified |
|         | Contact Name   |  |                |               |                  |
|         | Contact Telephone  | 301-459-1999   |                |               |                  |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:membership@bmes.org">membership@bmes.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021</p> <p>Synopsis The Pritzker Distinguished Lecture Award is awarded each year to individuals who have demonstrated impactful leadership and accomplishments in biomedical engineering science and practice. This recipient receives complimentary registration for the 2022 Annual Meeting, a plaque, an honorarium of \$12,000, and travel expenses up to \$1,250.</p>                       |                                |                |               |                |
| 061633  | <a href="#">Rita Schaffer Young Investigator Award</a>  | Biomedical Engineering Society |                | 30-Jun-2021   | 5,000 USD      |
|         | <p>Contact Name</p> <p>Contact Telephone 301-459-1999</p> <p>Contact Email <a href="mailto:membership@bmes.org">membership@bmes.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021</p> <p>Synopsis The Rita Schaffer Young Investigator Award recognizes early stage, independent PIs for the highest level of originality and ingenuity in scientific work in biomedical engineering. The winner will receive a crystal plaque, complimentary registration for the annual meeting, and an honorarium for \$5,000.</p> |                                |                |               |                |
| 089931  | <a href="#">PhD Fellowships</a>   | Boehringer Ingelheim Fonds     |                | 01-Jun-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone +49 (0)6131 2750 80</p> <p>Contact Email <a href="mailto:secretariat@bifonds.de">secretariat@bifonds.de</a></p>  |                                |                |               |                |



## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name               | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|----------------------------|----------------|---------------|----------------|
|         | Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021 , 01-Oct-2021<br>Synopsis The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships of 2 to 3.5 years to outstanding junior scientists worldwide who wish to pursue an ambitious PhD project in basic biomedical research in an internationally leading laboratory.   |                            |                |               |                |
| 002586  | <a href="#">Grants Program</a>   | Cure Parkinsons Trust      |                | 04-Jun-2021   | Not Specified  |
|         | Contact Name<br>Contact Telephone 020 7487 3892<br>Contact Email <a href="mailto:leah@cureparkinsons.org.uk">leah@cureparkinsons.org.uk</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 04-Jun-2021 , 01-Oct-2021<br>Synopsis The aim of CPT is to fund, facilitate and encourage research which leads to a cure for Parkinson's, with urgency for people currently living with Parkinson's. |                            |                |               |                |
| 006883  | <a href="#">Research Grants</a>  | Cure Starts Now Foundation |                | 01-Jun-2021   | 100,000 USD    |
|         | Contact Name Keith Desserich<br>Contact Telephone 513-772-9006<br>Contact Email <a href="mailto:keith@thecurestartsnow.org">keith@thecurestartsnow.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a>   |                            |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name               | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|----------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL) 01-Jun-2021</p> <p>Synopsis The Cure Starts Now annually awards research grants to institutions and medical professionals whose research focuses on cancers that present the greatest opportunities for a homerun cancer cure.</p>   |                            |                |               |                |
| 074665  | <a href="#">Clinical Research Scholars Program Award</a>   | Cystic Fibrosis Foundation |                | 09-Jun-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email <a href="mailto:grants@cff.org">grants@cff.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jun-2021</p> <p>Synopsis The Cystic Fibrosis Foundation (CFF) and the Therapeutics Development Network (TDN) announce the Cystic Fibrosis Clinical Research Scholars Program (CRSP) Award. The CRSP Award will enable outstanding early-career pediatricians and internists to enhance their clinical research proficiency and develop the necessary clinical research capabilities to become independent investigators who formulate and lead multi-center, clinical research studies.</p> |                            |                |               |                |
| 047975  | <a href="#">Global Giving Grants</a>   | Edwards Lifesciences       |                | 25-Jun-2021   | Not Specified  |
|         | <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jun-2021</p>  |                            |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID  | Program Title  | Sponsor Name                    | Sponsor Number | Deadline Date | Funding Amount |
|--|--|---------------------------------|----------------|---------------|----------------|
| Synopsis   The Edwards Lifesciences Foundation supports health- and community-focused programs through grants to non-profit organizations.   |  |                                 |                |               |                |
| 030970   | <a href="#">Eppendorf &amp; Science Prize for Neurobiology</a> | Eppendorf AG                    |                | 15-Jun-2021   | 25,000 USD     |
| Contact Name<br>Contact Telephone 202-326-6550<br>Contact Email <a href="mailto:eppendorfscienceprize@aaas.org">eppendorfscienceprize@aaas.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 15-Jun-2021<br>Synopsis   The International Eppendorf & Science Prize for Neurobiology is awarded annually to one young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by him/her during the past three years, as described in a 1,000-word entrance essay. The essays are rated in two areas: scientific quality and significance, and clarity and style of the writing. |  |                                 |                |               |                |
| 057307   | <a href="#">Research Grants</a>                                | Fibrolamellar Cancer Foundation |                | 01-Jun-2021   | Not Specified  |
| Contact Name<br>Contact Telephone 203-3400-7800<br>Contact Email <a href="mailto:grants@fibrofoundation.org">grants@fibrofoundation.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021 , 01-Oct-2021<br>Synopsis   The Fibrolamellar Cancer Foundation (FCF) is a public, nonprofit organization established primarily to support the funding of research related to Fibrolamellar Carcinoma. The FCF is also committed to raising awareness about this   |  |                                 |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

disease through education and marketing across all stakeholders, as well as fostering a global community of patients and caregivers for all suffering from, and caring for, this rare liver cancer.

|        |  |                                      |  |             |            |
|--------|--|--------------------------------------|--|-------------|------------|
| 081859 | <a href="#">Clinician-Scientist Emerging Leader (CSEL) Award</a> | Foundation Fighting Blindness Canada |  | 01-Jun-2021 | 47,400 USD |
|--------|--|--------------------------------------|--|-------------|------------|

Contact Name | Larissa Moniz  
 Contact Telephone | 416-360-4200 x238  
 Contact Email | [research@fightingblindness.ca](mailto:research@fightingblindness.ca)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 01-Jun-2021

Synopsis | Fighting Blindness Canada's (FBC's) Clinician-Scientist Emerging Leader (CSEL) Award aims to strengthen the community of clinician-scientists with ophthalmological expertise, who are ready to collaborate with key stakeholders and researchers across the vision research community. Clinician-scientists in training face pivotal challenges because they must balance new clinical responsibilities with their developing research interests.

|        |   |   |  |             |            |
|--------|---|---|--|-------------|------------|
| 007245 | <a href="#">Henry G. Friesen International Prize in Health Research</a> | Friends of Canadian Institutes of Health Research |  | 01-Jun-2021 | 27,650 USD |
|--------|---|---|--|-------------|------------|

Contact Name |  
 Contact Telephone | 416-506-1597  
 Contact Email | [fcibr@fcibr.ca](mailto:fcibr@fcibr.ca)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 01-Jun-2021

Synopsis | The Henry G. Friesen International Prize in Health Research is awarded to individuals who have had an impact in health research and health research policy at an international level. The prize supports an annual Public Lecture at a

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         |   | <p>major Canadian academic institution. Through the partnership of CBC Radio One “Ideas”, a recorded interview is broadcast nationally to reach the broadest possible audience. A manuscript is also published in the “Friesen Prize Lecture” series.</p>  |                |               |                |
| 033250  | <a href="#">TECNIOspring INDUSTRY</a>   | Generalitat de Catalunya   |                | 15-Jun-2021   | Not Specified  |
|         | Contact Name  |  |                |               |                |
|         | Contact Telephone   | (+34) 93 552 40 88   |                |               |                |
|         | Contact Email   | <a href="mailto:tecniospring.accio@gencat.cat">tecniospring.accio@gencat.cat</a>   |                |               |                |
|         | Sponsor Website   | <a href="#">Link to sponsor website</a>  |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>  |                |               |                |
|         | Deadline Dates (ALL)  | 15-Jun-2021  |                |               |                |
|         | Synopsis  | <p>Tecniospring INDUSTRY provides financial support to individual mobility proposals presented by experienced researchers in liaison with a company based in Catalonia, a TECNIO accredited organisation or a Catalan Technology Centre. The duration of the projects is 2 years. Experienced researchers applying to this action need to develop an applied research project with a focus on technology transfer for the total duration of the project that will enable them to progress in the development of their careers. The project is expected to be part of a structured, long-term personal career development plan that is coherent with past achievements and clearly defines the future aims of the researcher.</p> |                |               |                |
| 058073  | <a href="#">University of Toronto Integrated Neonatal-Perinatal Fellowship Training Program</a> | Hospital for Sick Children Foundation/Sick Kids Foundation   |                | 30-Jun-2021   | Not Specified  |
|         | Contact Name  | Tara Dwomoh, Education Administrative Coordinator, Neonatology Fellowship Programs   |                |               |                |
|         | Contact Telephone   | 416-813-7654 x 228902  |                |               |                |
|         | Contact Email   | <a href="mailto:diana.soares@sickkids.ca">diana.soares@sickkids.ca</a>   |                |               |                |
|         | Sponsor Website   | <a href="#">Link to sponsor website</a>  |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID  | Program Title                                     | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|--|---|---|----------------|---------------|----------------|
| <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021</p> <p>Synopsis The University of Toronto Training Program in Neonatal-Perinatal Medicine provides two years of neonatal-perinatal training to paediatricians.</p> </div> <div style="width: 65%;"></div> </div>   |   |   |                |               |                |
| 075540   | <a href="#">John J. Bonica Trainee Fellowship</a> | International Association for the Study of Pain                 |                | 01-Jun-2021   | 100,000 USD    |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <p>Contact Name</p> <p>Contact Telephone 202-856-7400</p> <p>Contact Email <a href="mailto:grants@iasp-pain.org">grants@iasp-pain.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021</p> <p>Synopsis The John J. Bonica Trainee Fellowship supports training in all aspects of pain research.</p> </div> <div style="width: 65%;"></div> </div>  |   |   |                |               |                |
| 057310   | <a href="#">ACT for FOP Grant Program</a>         | International Fibrodysplasia Ossificans Progressiva Association |                | 04-Jun-2021   | Not Specified  |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <p>Contact Name</p> <p>Contact Telephone 407-365-4194</p> <p>Contact Email <a href="mailto:grants@ifopa.org">grants@ifopa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-Jun-2021</p> <p>Synopsis The IFOPA offers the ACT (Accelerating Cures and Treatments) for FOP grant program to help enable the research and development of safe and transformative therapies for fibrodysplasia ossificans progressiva (FOP). The research grant</p> </div> <div style="width: 65%;"></div> </div> |   |   |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID  | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                | Funding Amount |
|--|---|--|----------------|------------------------------|----------------|
| program provides, through a competitive application process, funding to scientists conducting research on FOP. |   |  |                |                              |                |
| 058306   | <a href="#">Operating Grants</a>                                      | International Organization For the Study of Inflammatory Bowel Disease   |                | 30-Jun-2021                  | 59,500 USD     |
|  | Contact Name  | Marischka Konings  |                |                              |                |
|  | Contact Telephone   | +31 35 5426745   |                |                              |                |
|  | Contact Email   | <a href="mailto:ioibd@mkproducties.nl">ioibd@mkproducties.nl</a>   |                |                              |                |
|  | Sponsor Website   | <a href="#">Link to sponsor website</a>  |                |                              |                |
|  | Program URL   | <a href="#">Link to program URL</a>  |                |                              |                |
|  | Deadline Dates (ALL)  | 30-Jun-2021  |                |                              |                |
|  | Synopsis  | The IOIBD attaches great importance to the ethical acceptability of experiments involving human subjects. It is recognized that the investigator has a professional responsibility in this respect, and that the institution in which the research will be conducted must also make certain that the experiments are conducted in an ethical way. The IOIBD examines the ethical considerations as part of its review of each proposal, and funds will not be provided unless the protocol is entirely satisfactory. |                |                              |                |
| 066688   | <a href="#">Clinical Research Grants for Robotic-Assisted Surgery</a> | Intuitive Surgical Inc.  |                | 11-Jun-2021<br>[LOI/Pre-App] | 60,000 USD     |
|  | Contact Name  |  |                |                              |                |
|  | Contact Telephone   |  |                |                              |                |
|  | Contact Email   | <a href="mailto:grants@intuitive-foundation.org">grants@intuitive-foundation.org</a>   |                |                              |                |
|  | Sponsor Website   | <a href="#">Link to sponsor website</a>  |                |                              |                |
|  | Program URL   | <a href="#">Link to program URL</a>  |                |                              |                |
|  | Deadline Dates (ALL)  | 11-Jun-2021 [LOI/Pre-App], 10-Sep-2021   |                |                              |                |
|  | Synopsis  | The purpose of these grants is to support clinical research in the field of robotic-assisted surgery. Successful proposals   |                |                              |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                | Funding Amount |
|---------|---|--|----------------|------------------------------|----------------|
|         |   | will address important clinical questions or support clinically relevant technology development. Grants will be awarded to researchers at non-profit institutions worldwide. |                |                              |                |
| 066689  | <a href="#">Technology Research Grants</a>  | Intuitive Surgical Inc.  |                | 11-Jun-2021<br>[LOI/Pre-App] | 60,000 USD     |
|         | <p>Contact Name</p> <p>Contact Telephone 408-523-2100</p> <p>Contact Email <a href="mailto:grants@intusurg.com">grants@intusurg.com</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jun-2021 [LOI/Pre-App], 10-Sep-2021</p> <p>Synopsis The purpose of these grants is to support technology research in the field of surgical robotics, or related fields. Successful proposals will address clinically-relevant technology development. Grants will be awarded to researchers at non-profit academic institutions worldwide. Awards will be conferred on a competitive basis by submission of a grant application.</p> |  |                |                              |                |
| 036282  | <a href="#">LEO Foundation Awards</a>   | LEO Foundation   |                | 18-Jun-2021                  | 100,000 USD    |
|         | <p>Contact Name</p> <p>Contact Telephone + 45 32 72 51 10</p> <p>Contact Email <a href="mailto:applications@leo-foundation.org">applications@leo-foundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jun-2021 , 10-Sep-2021</p> <p>Synopsis The LEO Foundation Awards constitute a global recognition and are given annually to outstanding young scientists</p>  |  |                |                              |                |



## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         |   | <p>whose work represent extraordinary contributions to dermatology research. There will be three awards of 100.000 USD, one in each of the Americas, EMEA (Europe/Middle East/Africa) and Asia-Pacific regions.</p> |                |               |                |
| 061336  | <a href="#">Research Grant Program</a>  | LGS Foundation  |                | 01-Jun-2021   | Not Specified  |
|         | <p>Contact Name Tracy Dixon-Salazar<br/>           Contact Telephone 718-374-3800<br/>           Contact Email <a href="mailto:Tracy@LGSfoundation.org">Tracy@LGSfoundation.org</a><br/>           Sponsor Website <a href="#">Link to sponsor website</a><br/>           Program URL <a href="#">Link to program URL</a><br/>           Deadline Dates (ALL) 01-Jun-2021<br/>           Synopsis The LGS Foundation's seed grant program awards one-year research grants up to \$30,000 and two-year grants up to \$50,000 (the LGS Foundation does not permit indirect costs) to young investigators, physician residents, and clinicians who are interested in studying Lennox-Gastaut Syndrome.</p> |   |                |               |                |
| 082247  | <a href="#">Lupus Innovation Award</a>  | Lupus Research Alliance   |                | 15-Jun-2021   | 300,000 USD    |
|         | <p>Contact Name Dr. Shayla Shorter, Scientific Program Manager<br/>           Contact Telephone 1-646-884-6015<br/>           Contact Email <a href="mailto:shorter@lupusresearch.org">shorter@lupusresearch.org</a><br/>           Sponsor Website <a href="#">Link to sponsor website</a><br/>           Program URL <a href="#">Link to program URL</a><br/>           Deadline Dates (ALL) 15-Jun-2021<br/>           Synopsis The Lupus Research Alliance seeks to fund biomedical research that will discover better diagnostics, improve medical treatments and advance translational and clinical research that will ultimately lead to a cure for lupus. The Lupus</p>                         |   |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date                | Funding Amount   |
|---------|--|--|----------------|------------------------------|------------------|
|         |  | Innovation Award provides support for pioneering, high-risk, high-reward approaches to major challenges in lupus research. Funding is up to \$150,000 per year for total costs for up to 2 years.  |                |                              |                  |
| 002595  | <a href="#">Distinguished Innovator Award (DIA)</a>  | Lupus Research Alliance  |                | 01-Jun-2021<br>[LOI/Pre-App] | 1,000,000<br>USD |
|         | Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL) | Dr. Hoang Nguyen, Senior Scientific Program Manager<br>646-884-6015<br><a href="mailto:hnguyen@lupusresearch.org">hnguyen@lupusresearch.org</a><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>01-Jun-2021 [LOI/Pre-App]   |                |                              |                  |
|         | Synopsis   | The Distinguished Innovator Award is intended to attract exceptionally creative scientists from all relevant scientific disciplines and to provide them with robust and sustained support to explore bold and paradigm shifting ideas that could lead to ground-breaking discoveries in lupus research. Investigators working in areas outside of lupus are strongly encouraged to apply. The D IA provides outstanding scientists with substantial support (up to \$250,000 per year for up to four years). |                |                              |                  |
| 022414  | <a href="#">Fellowship Program</a>   | Matsumae International Foundation  |                | 30-Jun-2021                  | Not Specified    |
|         | Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL) | <br><br><br><a href="mailto:contact@mif-japan.org">contact@mif-japan.org</a><br><a href="#">Link to sponsor website</a><br><a href="#">Link to program URL</a><br>30-Jun-2021  |                |                              |                  |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | Synopsis  | The Matsumae International Foundation offers fellowships of three to six months in duration to doctorate degree holders who have never been to Japan.   |                |               |                |
| 057820  | <a href="#">Rotavirus Merck MISP Grant</a>  | Merck   |                | 05-Jun-2021   | Not Specified  |
|         | Contact Name  | Patty Williams  |                |               |                |
|         | Contact Telephone   | 267-305-5410  |                |               |                |
|         | Contact Email   | <a href="mailto:patricia_williams@msd.com">patricia_williams@msd.com</a>  |                |               |                |
|         | Sponsor Website   | <a href="#">Link to sponsor website</a>   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |
|         | Deadline Dates (ALL)  | 05-Jun-2021 , 11-Aug-2021   |                |               |                |
|         | Synopsis  | Effective December 2020, the Rotavirus Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to June 5, 2021. This is a competitive process that will be conducted by the Rotavirus MISP in 2021. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups. |                |               |                |
| 057824  | <a href="#">Measles, Mumps, Rubella &amp; Varicella Merck Investigator Studies Program (MISP) Grant</a> | Merck   |                | 05-Jun-2021   | Not Specified  |
|         | Contact Name  | Sara Chybinski  |                |               |                |
|         | Contact Telephone   | 732-594- 7970   |                |               |                |
|         | Contact Email   | <a href="mailto:sara_chybinski@merck.com">sara_chybinski@merck.com</a>  |                |               |                |
|         | Sponsor Website   | <a href="#">Link to sponsor website</a>   |                |               |                |
|         | Program URL   | <a href="#">Link to program URL</a>   |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number | Deadline Date                | Funding Amount |
|---------|--|---|----------------|------------------------------|----------------|
|         | Deadline Dates (ALL)   | 05-Jun-2021   |                |                              |                |
|         | Synopsis   | The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications. The Measles, Mumps, Rubella & Varicella Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest. |                |                              |                |
| 058805  | <a href="#">Investigator Studies Program (MISP) -- Surgery -- Anesthesia</a> | Merck   |                | 01-May-2021                  | Not Specified  |
|         | Contact Name   | Lisa Mount  |                |                              |                |
|         | Contact Telephone  | 267-305-1258  |                |                              |                |
|         | Contact Email  | <a href="mailto:lisa_mount@merck.com">lisa_mount@merck.com</a>  |                |                              |                |
|         | Sponsor Website  | <a href="#">Link to sponsor website</a>   |                |                              |                |
|         | Program URL  | <a href="#">Link to program URL</a>   |                |                              |                |
|         | Deadline Dates (ALL)   | 01-May-2021 , 18-Jun-2021 , 01-Sep-2021 , 19-Oct-2021   |                |                              |                |
|         | Synopsis   | The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.   |                |                              |                |
| 075001  | <a href="#">Interdisciplinary Translational Project (ITP) Program</a>        | Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM)  |                | 01-Jun-2021<br>[LOI/Pre-App] | 300,000<br>USD |
|         | Contact Name   | Mutsumi Yoshida   |                |                              |                |
|         | Contact Telephone  | 734-764-4622  |                |                              |                |
|         | Contact Email  | <a href="mailto:yoshidam@umich.edu">yoshidam@umich.edu</a>  |                |                              |                |
|         | Sponsor Website  | <a href="#">Link to sponsor website</a>   |                |                              |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                  | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [LOI/Pre-App], 27-Aug-2021</p> <p>Synopsis The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center is one of the two national Resource Centers established by the National Institute of Dental and Craniofacial Research (NIDCR)'s Dental Oral and Craniofacial Tissue Regeneration Consortium (DOCTRC) initiative. With the overarching goal of developing clinical trial-ready tissue engineering/ regenerative medicine products and protocols, the DOCTRC initiative is providing funding and resources through the Interdisciplinary Translational Project (ITP) program administered by the two national Resource Centers. The MPWRM Resource Center brings together a multi-disciplinary team of clinicians, engineers, scientists, and technology commercialization and regulatory experts from academia and industry to support the regenerative medicine research community by providing resources and expertise to guide innovations that address unmet clinical needs for the regeneration or restoration of DOC tissues.</p> |   |                |               |                |
| 102571  | <a href="#">Request for Applications--Global Seed Investigator Grants</a>   | Multiple System Atrophy Coalition             |                | 15-Jun-2021   | 100,000 USD    |
|         | <p>Contact Name Pam Bower</p> <p>Contact Telephone 1-866-737-4999</p> <p>Contact Email <a href="mailto:pbower@msacoalition.org">pbower@msacoalition.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021</p> <p>Synopsis The Multiple System Atrophy Coalition requests pre-proposal grant applications for research relevant to the improved treatment of Multiple System Atrophy. Applications are accepted from anywhere in the world. The maximum seed grant amount up to \$50,000 for a one year term with option to renew upon satisfactory review and submission of a year 2 research plan.</p>   |   |                |               |                |
| 061146  | <a href="#">High Impact Clinical Research and Scientific Pilot Projects on Myasthenia Gravis and Related Neuromuscular</a>  | Myasthenia Gravis Foundation of America, Inc. |                | 22-Jun-2021   | 100,000 USD    |

## Non Federal Funding Opportunities

| SPIN ID                            | Program Title  | Sponsor Name         | Sponsor Number | Deadline Date                | Funding Amount |
|------------------------------------|--|----------------------|----------------|------------------------------|----------------|
| <a href="#">Junction Disorders</a> |  |                      |                |                              |                |
|                                    | <p>Contact Name</p> <p>Contact Telephone 212-297-2156</p> <p>Contact Email <a href="mailto:MGFA@myasthenia.org">MGFA@myasthenia.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 22-Jun-2021</p> <p>Synopsis The Myasthenia Gravis Foundation of America requests submission of proposals to support high impact clinical research and scientific pilot studies that are focused and innovative. A clear plan of how success will be assessed is mandatory. High Impact clinical research proposals should focus on patient outcome measurements or alteration in clinical or research practices that aid in present treatment paradigm. Scientific pilot projects will require a clear plan that will lead to new federal, pharmaceutical, or private foundation supported investigations.</p> |                      |                |                              |                |
| 067593                             | <a href="#">Pilot Project Grants</a>   | Myositis Association |                | 01-May-2021<br>[LOI/Pre-App] | 100,000<br>USD |
|                                    | <p>Contact Name Chrissy Thornton</p> <p>Contact Telephone 703-553-2631</p> <p>Contact Email <a href="mailto:chrissy@myositis.org">chrissy@myositis.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-May-2021 [LOI/Pre-App], 30-Jun-2021</p> <p>Synopsis Pilot Grants are designed to fund new and innovative research projects in the hope that they will attract funding from other sources (such as NIH). A competitive application will clearly delineate how this pilot funding will lead to future grant support. In addition, a competitive application will clearly distinguish itself from the investigator's existing research program. Any industry partnership must be clearly disclosed and a letter of support from the industry partner</p>                                    |                      |                |                              |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

must be included. Pilot grants will be awarded for one or two years and up to a maximum of \$100,000 annually, subject to satisfactory progress.

|        |   |                      |  |             |             |
|--------|---|----------------------|--|-------------|-------------|
| 067591 | <a href="#">Mentored Research Fellowships</a> | Myositis Association |  | 01-May-2021 | 100,000 USD |
|--------|---|----------------------|--|-------------|-------------|

Contact Name | Chrissy Thornton  
 Contact Telephone | 703-553-2631  
 Contact Email | [Chrissy@myositis.org](mailto:Chrissy@myositis.org)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 01-May-2021 , 30-Jun-2021

Synopsis | Mentored Research Fellowships are designed to help promising junior investigators (MDs and PhDs) for a period of two years, subject to satisfactory progress, at the salary level approved by the participating institution, to a maximum received annually of \$50,000. Candidates should have completed residency or fellowship training or have received a PhD within the three years prior to commencing the Fellowship and be performing research under the supervision of an established mentor. Recipients must devote at least 50% of their time to research, but may include some study and clinical experience in allied fields. There should be limited supplementation of salary from outside sources.

|        |   |                          |  |             |            |
|--------|---|--------------------------|--|-------------|------------|
| 078566 | <a href="#">Research Grants Program</a> | National Rosacea Society |  | 18-Jun-2021 | 15,000 USD |
|--------|---|--------------------------|--|-------------|------------|

Contact Name |  
 Contact Telephone | 847-382-8971  
 Contact Email | [info@rosacea.org](mailto:info@rosacea.org)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 18-Jun-2021

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number       | Deadline Date | Funding Amount |
|---------|--|--|----------------------|---------------|----------------|
|         | Synopsis   | The National Rosacea Society awards grants of up to \$15,000, or higher in special cases, for research on rosacea.   |                      |               |                |
| 096282  | <a href="#">Graduate Research Fellowships</a>        | National Swimming Pool Foundation  |                      | 01-Jun-2021   | 1,000 USD      |
|         | Contact Name   |  |                      |               |                |
|         | Contact Telephone                                    |  |                      |               |                |
|         | Contact Email  | <a href="mailto:dolores.malocsay@phta.org">dolores.malocsay@phta.org</a>   |                      |               |                |
|         | Sponsor Website                                      | <a href="#">Link to sponsor website</a>  |                      |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                      |               |                |
|         | Deadline Dates (ALL)                                 | 01-Jun-2021  |                      |               |                |
|         | Synopsis   | The National Swimming Pool Foundation provides support for fellowships to encourage and support graduate students and post-doctoral fellows who focus research in two areas associated with aquatic venues that are treated to maintain a sanitary condition (e.g., swimming pools, spas/hot tubs, therapy pools, water parks, etc). |                      |               |                |
| 088263  | <a href="#">Marco Cabrera Student Research Award</a> | North American Society for Pediatric Exercise Medicine   |                      | 01-Jun-2021   | 1,500 USD      |
|         | Contact Name   | Dr Daniela Rubin   |                      |               |                |
|         | Contact Telephone                                    |  |                      |               |                |
|         | Contact Email  | <a href="mailto:drubin@fullerton.edu">drubin@fullerton.edu</a>   |                      |               |                |
|         | Sponsor Website                                      | <a href="#">Link to sponsor website</a>  |                      |               |                |
|         | Program URL  | <a href="#">Link to program URL</a>  |                      |               |                |
|         | Deadline Dates (ALL)                                 | 01-Jun-2021  |                      |               |                |
|         | Synopsis   | It is a priority of the North American Society for Pediatric Exercise Medicine (NASPEM) to support applied, and clinical research.   |                      |               |                |
| 103510  | <a href="#">CDC Analytical Chemistry Fellowship</a>  | Oak Ridge Institute for Science and Education  | CDC-NCEZID-2021-0062 | 30-Jun-2021   | Not Specified  |



## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                                  | Sponsor Number   | Deadline Date | Funding Amount |
|---------|---|---|------------------|---------------|----------------|
|         | Contact Name<br>Contact Telephone<br>Contact Email <a href="mailto:ORISE.CDC.NCEZID@orau.org">ORISE.CDC.NCEZID@orau.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 30-Jun-2021<br>Synopsis A research opportunity is currently available with the Biotechnology Core Facility Branch (BCFB) in the Division of Scientific Resources (DSR) at the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. |   |                  |               |                |
| 103516  | <a href="#">CDC Data and Reporting Fellowship</a>   | Oak Ridge Institute for Science and Education | CDC-OD-2021-0040 | 01-Jun-2021   | Not Specified  |
|         | Contact Name<br>Contact Telephone<br>Contact Email <a href="mailto:ORISE.CDC.NCEZID@orau.org">ORISE.CDC.NCEZID@orau.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021<br>Synopsis A research opportunity is currently available with the Office of the Associate Director for Communication (OADC) within the Office of the Director (OD) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.  |   |                  |               |                |
| 021106  | <a href="#">Research Grants</a>   | Oncology Nursing Society Foundation           |                  | 08-Jun-2021   | 50,000 USD     |
|         | Contact Name<br>Contact Telephone 866-257-4667<br>Contact Email <a href="mailto:info@onfgivesback.org">info@onfgivesback.org</a>  |   |                  |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                                | Sponsor Number | Deadline Date                | Funding Amount |
|---------|--|---|----------------|------------------------------|----------------|
|         | Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 08-Jun-2021<br>Synopsis Oncology Nursing Society Foundation offers General Research grants to support rigorous scientific oncology nursing research. Research projects may include investigator-initiated research, pilot or feasibility studies, supplements to current funded projects, or developing a new aspect of a program of research. Funding is \$50,000 over two years.  |   |                |                              |                |
| 067690  | <a href="#">Total Joint Replacement Research Grant</a>   | Orthopaedic Research & Education Foundation |                | 08-Jun-2021<br>[LOI/Pre-App] | 300,000<br>USD |
|         | Contact Name<br>Contact Telephone 847-430-5109<br>Contact Email <a href="mailto:grants@oref.org">grants@oref.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 08-Jun-2021 [LOI/Pre-App], 24-Aug-2021<br>Synopsis OREF encourages investigator-initiated research proposals focused on total joint replacement. Areas of research focus may include: New surgical techniques, devices, joint implant designs, joint implant materials, or the biology of disease and repair. |   |                |                              |                |
| 015267  | <a href="#">ORS Collaborative Exchange Grant</a>   | Orthopaedic Research Society                |                | 19-Jun-2021                  | Not Specified  |
|         | Contact Name<br>Contact Telephone 847-238-5770<br>Contact Email <a href="mailto:ors@ors.org">ors@ors.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a>  |   |                |                              |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                               | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 19-Jun-2021<br>Synopsis The ORS Collaborative Exchange Grant provides investigators at any stage of their career an opportunity to visit a research lab for the purpose of collaboration and knowledge exchange.  |  |                |               |                |
| 082015  | <a href="#">Philip J. Boyne Junior Faculty Award</a>  | Osteo Science Foundation                   |                | 01-Jun-2021   | 50,000 USD     |
|         | Contact Name<br>Contact Telephone 215-977-2877<br>Contact Email <a href="mailto:info@osteoscience.org">info@osteoscience.org</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 01-Jun-2021 , 01-Dec-2021<br>Synopsis The Philip J. Boyne Junior Faculty Award is exclusively designated for an Oral and Maxillofacial surgeon in a junior faculty position in a CODA/CDAC accredited Oral and Maxillofacial Program – with an aim to inspire their pursuit of advancing the field of tissue regeneration. The maximum award is \$25,000 per year, with a one or two-year project duration, totaling a maximum of \$50,000 (inclusive of indirect costs, which are capped at 10%). |  |                |               |                |
| 011837  | <a href="#">Junior and Senior WO Neitz Medals</a>   | Parasitological Society of Southern Africa |                | 30-Jun-2021   | Not Specified  |
|         | Contact Name Dr Kgomotso P. Sibeko-Matjila<br>Contact Telephone +27 (0)12 529 8402<br>Contact Email <a href="mailto:kgomotso.sibeko@up.ac.za">kgomotso.sibeko@up.ac.za</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 30-Jun-2021  |  |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Synopsis | The Parasitological Society of Southern Africa confers two awards annually for a postgraduate (MSc and PhD) thesis focussed on parasitology.

|        |  |  |  |                              |                  |
|--------|--|--|--|------------------------------|------------------|
| 066563 | <a href="#">Implementation of Effective Shared Decision Making Approaches in Practice Settings</a> | Patient-Centered Outcomes Research Institute (PCORI) |  | 22-Jun-2021<br>[LOI/Pre-App] | 1,500,000<br>USD |
|--------|--|--|--|------------------------------|------------------|

Contact Name  
 Contact Telephone 202-827-7700  
 Contact Email [info@pcori.org](mailto:info@pcori.org)  
 Sponsor Website [Link to sponsor website](#)  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 22-Jun-2021 [LOI/Pre-App], 31-Aug-2021

Synopsis | This PCORI Funding Announcement (PFA) is intended to promote the targeted implementation and systematic uptake of shared decision making (SDM) in healthcare settings, in line with PCORI's goal of supporting patients in making informed decisions about their care. For this PFA, PCORI defines an SDM strategy as an intervention or approach that draws on and presents evidence to inform patients of available treatment options and their risks and benefits, and either engages patients in a decision-making process with their clinician or promotes their ability to engage in such a process.

|        |  |  |  |                              |                  |
|--------|--|--|--|------------------------------|------------------|
| 088268 | <a href="#">Assessment of Prevention, Diagnosis, and Treatment Options Program</a> | Patient-Centered Outcomes Research Institute (PCORI) |  | 01-Jun-2021<br>[LOI/Pre-App] | 5,000,000<br>USD |
|--------|--|--|--|------------------------------|------------------|

Contact Name  
 Contact Telephone 202-627-1885  
 Contact Email [pfa@pcori.org](mailto:pfa@pcori.org)  
 Sponsor Website  
 Program URL [Link to program URL](#)

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|--|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL) 01-Jun-2021 [LOI/Pre-App], 31-Aug-2021 , 05-Oct-2021 [LOI/Pre-App], 11-Jan-2022</p> <p>Synopsis The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Health Systems. Applications should address needs of patients, caregivers, clinicians, and other healthcare stakeholders in making personalized clinical decisions across a wide range of conditions, populations, and treatments.</p>   |  |                |               |                |
| 030477  | <a href="#">Broad PCORI Funding</a>   | Patient-Centered Outcomes Research Institute (PCORI) |                | 04-May-2021   | 3,000,000 USD  |
|         | <p>Contact Name</p> <p>Contact Telephone 202-827-7700</p> <p>Contact Email <a href="mailto:info@pcori.org">info@pcori.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 04-May-2021 , 01-Jun-2021 [LOI/Pre-App], 31-Aug-2021</p> <p>Synopsis The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas outlined in PCORI’s National Priorities for Research and Research Agenda: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Healthcare Systems. These broad areas encompass the patient-centered comparative CER we support.</p> |  |                |               |                |
| 081961  | <a href="#">Antimicrobial Stewardship Fellowship Award</a>  | Pediatric Infectious Diseases Society                |                | 07-Jun-2021   | Not Specified  |
|         | Contact Name  |  |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name           | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|------------------------|----------------|---------------|----------------|
|         | <p>Contact Telephone   703-299-6764</p> <p>Contact Email   <a href="mailto:pids@idsociety.org">pids@idsociety.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jun-2021</p> <p>Synopsis   The goal of this award is to support the development of future researchers in pediatric antimicrobial stewardship by providing mentorship to complete a scholarly research project in a timely manner during fellowship or residency. Applicants may propose any type of study focusing on antimicrobial stewardship. The project should be able to be completed in one year, and the award will provide travel funds for awardees to present their work at the annual Pediatric Antimicrobial Stewardship Conference in St. Louis in June of 2022.</p> |                        |                |               |                |
| 089570  | <a href="#">Competitive Grant Program: Growth Hormone Research</a>  | Pfizer Pharmaceuticals |                | 01-Jun-2021   | 100,000 USD    |
|         | <p>Contact Name   Amanda Stein</p> <p>Contact Telephone   212-733-2323</p> <p>Contact Email   <a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2021</p> <p>Synopsis   Pfizer Global Medical Grants (GMG) issuing this Request for Proposals (RFP) for research projects that will advance the medical knowledge of short stature. Individual projects requesting up to \$100,000 will be considered.</p>   |                        |                |               |                |
| 102502  | <a href="#">Competitive Grant Program: Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease</a>   | Pfizer Pharmaceuticals |                | 01-Jun-2021   | 150,000 USD    |

## Non Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

Contact Name | Amanda Stein  
 Contact Telephone | 212-733-2323  
 Contact Email | [amanda.j.stein@pfizer.com](mailto:amanda.j.stein@pfizer.com)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 01-Jun-2021  
 Synopsis | Pfizer is issuing this Request for Proposals (RFP) to support the delivery of gene therapies to patients with rare diseases. The estimated total available budget related to this RFP is \$150,000.

|        |   |                        |  |             |            |
|--------|---|------------------------|--|-------------|------------|
| 103344 | <a href="#">Competitive Grant Program: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research – U.S.</a> | Pfizer Pharmaceuticals |  | 09-Jun-2021 | 75,000 USD |
|--------|---|------------------------|--|-------------|------------|

Contact Name | Amanda Stein, Grant Officer  
 Contact Telephone |  
 Contact Email | [amanda.j.stein@pfizer.com](mailto:amanda.j.stein@pfizer.com)  
 Sponsor Website | [Link to sponsor website](#)  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 09-Jun-2021  
 Synopsis | Pfizer is issuing this Request for Proposals (RFP) for research related to Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the United States. Individual projects requesting up to \$75,000 will be considered.

|        |  |                        |  |             |            |
|--------|--|------------------------|--|-------------|------------|
| 102068 | <a href="#">Transthyretin Cardiac Amyloidosis Fellowship</a> | Pfizer Pharmaceuticals |  | 15-Jun-2021 | 80,000 USD |
|--------|--|------------------------|--|-------------|------------|

Contact Name | Amanda Stein  
 Contact Telephone | 212-733-2323  
 Contact Email | [amanda.j.stein@pfizer.com](mailto:amanda.j.stein@pfizer.com)

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name           | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------|----------------|---------------|----------------|
|         | Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 15-Jun-2021<br>Synopsis Pfizer is accepting applications to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grant funding is available to support one fellow for up to a year at \$80,000.  |                        |                |               |                |
| 102547  | <a href="#">Medical Education Grants: Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain</a>   | Pfizer Pharmaceuticals |                | 18-Jun-2021   | 200,000 USD    |
|         | Contact Name Jessica Romano<br>Contact Telephone 212-733-2323<br>Contact Email <a href="mailto:jessica.romano@pfizer.com">jessica.romano@pfizer.com</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a><br>Deadline Dates (ALL) 18-Jun-2021 , 20-Aug-2021<br>Synopsis Pfizer is issuing this Request for Proposals (RFP) to support virtual and potentially live programs and other innovative digital medical education for HCPs. The typical grant maximum under this RFP will be up to \$200,000. |                        |                |               |                |
| 101765  | <a href="#">Competitive Grant Program: Pediatric Endocrinology Fellowship</a>  | Pfizer Pharmaceuticals |                | 01-Jun-2021   | 75,000 USD     |
|         | Contact Name Amanda Stein, Grant Officer<br>Contact Telephone 212-733-2323<br>Contact Email <a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a><br>Sponsor Website <a href="#">Link to sponsor website</a><br>Program URL <a href="#">Link to program URL</a>   |                        |                |               |                |



## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name           | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|------------------------|----------------|---------------|----------------|
|         | <p>Deadline Dates (ALL) 01-Jun-2021</p> <p>Synopsis Pfizer Global Medical Grants (GMG) is issuing this Request for Proposals (RFP) to support institutions with fellowship programs for Pediatric Endocrinologists that have a strong focus on clinical practice, research, and education to further the understanding of short stature/growth failure.</p>  |                        |                |               |                |
| 101768  | <a href="#">Competitive Grant Program: Acromegaly</a>  | Pfizer Pharmaceuticals |                | 01-Jun-2021   | 100,000 USD    |
|         | <p>Contact Name Amanda Stein</p> <p>Contact Telephone 212-733-2323</p> <p>Contact Email <a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021</p> <p>Synopsis Pfizer Global Medical Grants (GMG) is issuing this Request for Proposals (RFP) for research involving Growth Hormone Excess. Individual projects requesting up to \$100,000 will be considered.</p> |                        |                |               |                |
| 103345  | <a href="#">Competitive Grant Program: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator</a>  | Pfizer Pharmaceuticals |                | 15-Jun-2021   | Not Specified  |
|         | <p>Contact Name Amanda Stein, Grant Officer</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021</p> <p>Synopsis Pfizer is issuing this Request for Proposals (RFP) for projects focused on supporting the development of nurse</p>  |                        |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name   | Sponsor Number | Deadline Date                | Funding Amount |
|---------|--|--|----------------|------------------------------|----------------|
|         |  | navigator programs, including training, in order to improve the quality of care for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) patients. |                |                              |                |
| 103497  | <a href="#">Quality Improvement Grant Request for Proposals (RFP) Addressing Social Health Needs in Chronic and Preventative Disease</a>   | Pfizer Pharmaceuticals   | 2020VAC1       | 03-Jun-2021                  | 250,000 USD    |
|         | <p>Contact Name   Jessica Romano, Grant Officer</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:jessica.romano@pfizer.com">jessica.romano@pfizer.com</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jun-2021</p> <p>Synopsis   Pfizer is partnering with the Institute for Healthcare Improvement to issue this Request for Proposals (RFP) to encourage proposals to join a Learning and Action Network (LAN) to support the journey of health care organizations seeking to integrate social care into health care delivery in pursuit of improved health, well-being, and equity for their populations. The LAN will focus on the social care integration work of 3-5 integrated delivery networks (IDNs) in the United States, also known as health systems - organizations that own and operate a network of one or more health care facilities. Each selected IDN will set 12-month goals specific to their contexts. Participants will test social care integration strategies with their patient populations and share their results both with one another and stakeholders in their own IDNs to enhance the rate of learning and improvement. This LAN will be convened by IHI and funded by Pfizer. Individual projects requesting up to \$250,000 will be considered.</p> |  |                |                              |                |
| 070888  | <a href="#">RPB Stein Innovation Awards</a>  | Research to Prevent Blindness  |                | 15-Jun-2021<br>[LOI/Pre-App] | 300,000 USD    |
|         | <p>Contact Name   Pattie Moran</p> <p>Contact Telephone   646-892-9566</p>   |  |                |                              |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                  | Sponsor Number | Deadline Date             | Funding Amount |
|---------|--|-------------------------------|----------------|---------------------------|----------------|
|         | <p>Contact Email <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021 [LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis The RPB Stein Innovation (SI) Awards provide funds to two groups of researchers, both with a common goal of understanding the visual system and the diseases that compromise its function. These SI Awards are intended to provide seed money to proposed high-risk/high-gain vision science research which is innovative, cutting-edge, and demonstrates out-of-the-box thinking.</p>  |                               |                |                           |                |
| 039600  | <a href="#">Catalyst Award for Stem Cell Research Approaches for Age-Related Macular Degeneration</a>  | Research to Prevent Blindness |                | 15-Jun-2021               | 300,000 USD    |
|         | <p>Contact Name Pattie Moran</p> <p>Contact Telephone 212-752-4333ex223</p> <p>Contact Email <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021 , 01-Jul-2021</p> <p>Synopsis Research to Prevent Blindness (RPB) is partnering with: American Macular Degeneration Foundation (AMDF) Dr. H. James and Carole Free International Retinal Research Foundation (IRRF) to co-fund up to three (3) Catalyst Awards for Innovative Research Approaches for Age-Related Macular Degeneration (AMD). One (1) award will be made in partnership with AMDF, one (1) award with Dr. H. James and Carole Free, and one (1) award with IRRF. The \$300,000 grant is payable for up to three (3) years upon approval of a 14-month substantive progress report.</p> |                               |                |                           |                |
| 006942  | <a href="#">Career Development Awards</a>  | Research to Prevent Blindness |                | 15-Jun-2021 [LOI/Pre-App] | 350,000 USD    |
|         | Contact Name   |                               |                |                           |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                  | Sponsor Number | Deadline Date                | Funding Amount |
|---------|---|-------------------------------|----------------|------------------------------|----------------|
|         | <p>Contact Telephone   646-892-9566</p> <p>Contact Email   <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2021 [LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis   The RPB Career Development Award (CDA) helps RPB-supported ophthalmology Chairs recruit promising young researchers to ophthalmology and support junior faculty who have demonstrated their potential for independent research. The \$350,000 grant is payable for up to four (4) years.</p>                             |                               |                |                              |                |
| 006939  | <a href="#">Physician-Scientist Award</a>   | Research to Prevent Blindness |                | 15-Jun-2021<br>[LOI/Pre-App] | 300,000<br>USD |
|         | <p>Contact Name   Pattie Moran</p> <p>Contact Telephone   212-752-4333</p> <p>Contact Email   <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jun-2021 [LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis   The RPB Physician-Scientist Award promotes the clinical and/or basic research of clinicians, recognizing that the clinical scientist has difficulty competing against basic scientists for national-level grant support. The maximum award is \$300,000, payable in two payments.</p> |                               |                |                              |                |
| 070892  | <a href="#">RPB International Research Collaborators Award</a>  | Research to Prevent Blindness |                | 15-Jun-2021<br>[LOI/Pre-App] | 75,000 USD     |
|         | <p>Contact Name   Pattie Moran</p> <p>Contact Telephone   646-892-9566</p>  |                               |                |                              |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                     | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|----------------------------------|----------------|---------------|----------------|
|         | <p>Contact Email <a href="mailto:pmoran@rpbusa.org">pmoran@rpbusa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021 [LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis The RPB International Research Collaborators Award promotes international collaborations through which collaborating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international collaborations have the potential to accelerate the development of treatments for blinding disorders, positively affecting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers from any institution of higher education in the United States. A three- to six-month stay in the other country is expected by each researcher, with a minimum stay of three months.</p> |                                  |                |               |                |
| 001730  | <a href="#">Physician and Public Awareness Proposals</a>   | ResMed Foundation                |                | 15-Jun-2021   | 10,000 USD     |
|         | <p>Contact Name Kristi Burlingame, Executive Director</p> <p>Contact Telephone 858-361-0755</p> <p>Contact Email <a href="mailto:kristib@resmedfoundation.org">kristib@resmedfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jun-2021 , 15-Dec-2021</p> <p>Synopsis The Foundation's goal in this funding category is to further the awareness and knowledge of the inherent dangers of untreated sleep disordered breathing, its symptoms, diagnosis and treatment with sleep specialists, primary care physicians, educators and the general public.</p>   |                                  |                |               |                |
| 095002  | <a href="#">Innovative Research Award For Community Practitioners</a>  | Rheumatology Research Foundation |                | 01-Jun-2021   | 400,000 USD    |
|         | Contact Name   |                                  |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID   | Program Title                               | Sponsor Name                     | Sponsor Number | Deadline Date                | Funding Amount |
|---|---|----------------------------------|----------------|------------------------------|----------------|
| <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <p>Contact Telephone   404-365-1373</p> <p>Contact Email   <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2021 , 02-Aug-2021</p> </div> <div style="width: 65%;"> <p>Synopsis   The Rheumatology Research Foundation (Foundation) recognizes the unique potential for research performed by rheumatologists and rheumatology professionals in community-based environments to advance our understanding of rheumatic diseases, their treatment and how to improve patient outcomes. The award amount is up to \$50,000 to \$200,000 per year, for up to two years.</p> </div> </div>  |   |                                  |                |                              |                |
| 095001  | <a href="#">Innovative Research Award</a>   | Rheumatology Research Foundation |                | 01-Jun-2021                  | 400,000 USD    |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <p>Contact Name  </p> <p>Contact Telephone   404-365-1373</p> <p>Contact Email   <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   01-Jun-2021 , 01-Jul-2021</p> </div> <div style="width: 65%;"> <p>Synopsis   The Innovative Research Award provides independent academic investigators with the funding they need to pursue ideas that could lead to important breakthroughs in discovering new treatments and, one day, a cure. This award provides essential support for innovative studies focused on generating new insights into the cause, progression, treatment, and outcomes of rheumatic and musculoskeletal diseases. The award amount is up to \$400,000 for two years (maximum \$200,000 per year).</p> </div> </div> |   |                                  |                |                              |                |
| 000622  | <a href="#">Scientist Development Award</a> | Rheumatology Research Foundation |                | 01-Jun-2021<br>[LOI/Pre-App] | 50,000 USD     |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                     | Sponsor Number | Deadline Date                | Funding Amount |
|---------|--|----------------------------------|----------------|------------------------------|----------------|
|         | <p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [LOI/Pre-App], 01-Jul-2021</p> <p>Synopsis This award is designed for individuals in the early stages of their career (typically Fellows) or those without significant prior research experience who plan to embark on careers in rheumatic diseases. The purpose of this award is to provide support for a structured research training program for rheumatologists or health professionals in the field of rheumatology.</p> |                                  |                |                              |                |
| 063212  | <a href="#">Marshall J. Schiff, MD Memorial Fellow Research Award</a>  | Rheumatology Research Foundation |                | 01-Jun-2021<br>[LOI/Pre-App] | 1,500 USD      |
|         | <p>Contact Name</p> <p>Contact Telephone 404-365-1373</p> <p>Contact Email <a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021 [LOI/Pre-App], 02-Aug-2021</p> <p>Synopsis The Marshall J. Schiff, MD Memorial Fellow Research Award was established with the aim of supporting outstanding scholarship in the field of rheumatology research and to recognize and celebrate fellows presenting an abstract at the ACR Convergence.</p>  |                                  |                |                              |                |
| 071837  | <a href="#">Research Grants</a>  | SENS Research Foundation         |                | 16-Jun-2021                  | Not Specified  |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name   | Sponsor Number | Deadline Date                | Funding Amount |
|---------|---|----------------|----------------|------------------------------|----------------|
|         | <p>Contact Name</p> <p>Contact Telephone 650-336-1780</p> <p>Contact Email <a href="mailto:foundation@sens.org">foundation@sens.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Jun-2021 , 18-Aug-2021 , 01-Nov-2021</p> <p>Synopsis SRF is uniquely focused on a damage repair approach to treating the diseases of aging. This approach has amazing potential to positively affect the human condition by giving people interventions and treatments that yield more years of healthy, productive life.</p>  |                |                |                              |                |
| 060678  | <a href="#">Dr. Ernest J. Ring Academic Development Grant</a>   | SIR Foundation |                | 30-Jun-2021<br>[LOI/Pre-App] | 100,000<br>USD |
|         | <p>Contact Name</p> <p>Contact Telephone 703-691-1805</p> <p>Contact Email <a href="mailto:grants@sirfoundation.org">grants@sirfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 [LOI/Pre-App], 15-Jan-2022</p> <p>Synopsis The Dr. Ernest J. Ring Academic Development Grant program is designed to provide support to junior interventional radiology faculty members early in their academic careers to allow time for the conduct of research. The goal of this program is to have grant recipients subsequently obtain additional funding from other sources, such as National Institutes of Health (NIH) grants.</p> |                |                |                              |                |
| 060679  | <a href="#">Academic Transition Grant</a>   | SIR Foundation |                | 30-Jun-2021<br>[LOI/Pre-App] | 25,000 USD     |



## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name                        | Sponsor Number | Deadline Date | Funding Amount |
|---------|--|-------------------------------------|----------------|---------------|----------------|
|         | <p>Contact Name</p> <p>Contact Telephone 703-691-1805</p> <p>Contact Email <a href="mailto:grants@sirfoundation.org">grants@sirfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jun-2021 [LOI/Pre-App], 15-Oct-2021 [LOI/Pre-App], 15-Jan-2022</p> <p>Synopsis The Academic Transition Grant is designed for interventional radiologists over the age of 40 who have recently begun academic careers after spending several years in non-academic practice. The grant is intended to facilitate the establishment of a record of independent research by the investigator in order to promote a successful academic career.</p> |                                     |                |               |                |
| 016255  | <a href="#">SOPHE/CDC Student Fellowship in Injury Prevention</a>  | Society for Public Health Education |                | 01-Jun-2021   | 2,000 USD      |
|         | <p>Contact Name</p> <p>Contact Telephone 202-408-9804</p> <p>Contact Email <a href="mailto:info@sophe.org">info@sophe.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 01-Jun-2021</p> <p>Synopsis The SOPHE/CDC Student Fellowship in Injury Prevention recognizes, assists and trains students working on research or practice-based projects in either unintentional injury prevention or violence prevention from the perspective of health education or the behavioral sciences.</p>   |                                     |                |               |                |
| 066849  | <a href="#">Mentored Clinical Scientist Research Career Development Award (K08)</a>  | Society for Vascular Surgery        |                | 12-Jun-2021   | Not Specified  |
|         | Contact Name Jane D. Scott   |                                     |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title  | Sponsor Name  | Sponsor Number  | Deadline Date | Funding Amount |
|---------|--|---|-----------------|---------------|----------------|
|         | <p>Contact Telephone   301-435-0535</p> <p>Contact Email   <a href="mailto:scottj2@nhlbi.nih.gov">scottj2@nhlbi.nih.gov</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Jun-2021 , 12-Oct-2021</p> <p>Synopsis   The SVS Foundation offers this award in partnership with the NHLBI as a means to facilitate the research career development of individuals pursuing a career in vascular research. This award provides financial support over and above that offered by the NHLBI K08 mechanism.</p>   |   |                 |               |                |
| 091553  | <a href="#">Student Scholarship Program</a>  | Society of Diagnostic Medical Sonography Foundation |                 | 30-Jun-2021   | 2,500 USD      |
|         | <p>Contact Name  </p> <p>Contact Telephone   214-473-8057</p> <p>Contact Email   <a href="mailto:scholarship@sdmsfoundation.org">scholarship@sdmsfoundation.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jun-2021 , 31-Dec-2021</p> <p>Synopsis   The SDMS Foundation Sonography Student Scholarship provides provides a \$2,500 scholarship to a deserving sonography student who has been accepted or is currently enrolled in an educational program in diagnostic medical sonography or cardiovascular technology which has been accredited by the Commission on Accreditation of Allied Health Educational Programs (CAAHEP).</p> |   |                 |               |                |
| 103413  | <a href="#">Transit Cooperative Research Program (TCRP) - COVID-19 and Transit Air Quality Protections (Insight Event)</a>   | Transportation Research Board                       | TCRP E-13 [RFP] | 03-Jun-2021   | 120,000 USD    |
|         | Contact Name   Mariela Garcia-Colberg  |   |                 |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title   | Sponsor Name                            | Sponsor Number | Deadline Date | Funding Amount |
|---------|---|---|----------------|---------------|----------------|
|         | <p>Contact Telephone   202-334-2361</p> <p>Contact Email   <a href="mailto:mgarciacolberg@nas.edu">mgarciacolberg@nas.edu</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   03-Jun-2021</p> <p>Synopsis   The Transportation Research Board's Transit Cooperative Research Program (TCRP) has issued a request for proposals (RFP) to invite proposals that will assist TCRP in conducting an Insight Event to understand how air quality inside transit vehicles might contribute to the spread of infections. The purpose of this convening event is to allow transit and stakeholders to share their knowledge about the issue of air quality inside vehicles, and help identify possible solutions to the problem and/or areas of research to be undertaken in a future TCRP project.</p> |   |                |               |                |
| 096603  | <a href="#">Vilcek Prize for Creative Promise in Biomedical Science</a>   | Vilcek Foundation                       |                | 11-Jun-2021   | 50,000 USD     |
|         | <p>Contact Name  </p> <p>Contact Telephone   212-472-2500</p> <p>Contact Email   <a href="mailto:info@vilcek.org">info@vilcek.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   11-Jun-2021</p> <p>Synopsis   The Vilcek Foundation will award three Creative Promise Prizes of \$50,000 each to young foreign-born biomedical scientists who demonstrate outstanding early achievement. Eligible work may be creative, independent research in basic, applied, and/or translational biomedical science.</p>  |   |                |               |                |
| 001134  | <a href="#">Requests for Proposals in Leukemia Research</a>   | When Everyone Survives Foundation, Inc. |                | 01-Jun-2021   | 50,000 USD     |
|         | <p>Contact Name  </p> <p>Contact Telephone   770-595-3573</p>   |   |                |               |                |

## Non Federal Funding Opportunities

| SPIN ID | Program Title | Sponsor Name | Sponsor Number | Deadline Date | Funding Amount |
|---------|---------------|--------------|----------------|---------------|----------------|
|---------|---------------|--------------|----------------|---------------|----------------|

|   |  |
|---|--|
| Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | <p><a href="mailto:contact@wheneveryonesurvives.org">contact@wheneveryonesurvives.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>01-Jun-2021</p> <p>This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Leukemia Research Foundation) to solicit innovative research in leukemia. Grants of \$50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia.</p> |
|---|--|

|        |                                      |                                |  |             |               |
|--------|--------------------------------------|--------------------------------|--|-------------|---------------|
| 000604 | <a href="#">Research Fellowships</a> | Whitney (Helen Hay) Foundation |  | 15-Jun-2021 | Not Specified |
|--------|--------------------------------------|--------------------------------|--|-------------|---------------|

|  |   |
|--|---|
| Contact Name<br>Contact Telephone<br>Contact Email<br>Sponsor Website<br>Program URL<br>Deadline Dates (ALL)<br>Synopsis | <p></p> <p>845-639-6799</p> <p><a href="mailto:office@hhwf.org">office@hhwf.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>15-Jun-2021</p> <p>The Helen Hay Whitney Foundation supports early postdoctoral research training in all basic biomedical sciences. To attain its ultimate goal of increasing the number of imaginative, well-trained and dedicated medical scientists, the Foundation grants financial support of sufficient duration to help further the careers of young men and women engaged in biological or medical research.</p> |
|--|---|